

Funding Opportunities Monthly Edition May 2025 Due Dates

<u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in May 2025.

The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 below for assistance or questions.

128420 Context of Non-communicable Dis Countries and US Tribal Population	seases in Low- and Middle-Income Fogarty International Center/NIH/DHHS PAR- 07-May-2025	Not Specified
Contact Name	Brad Newsome, Ph.D.	
Contact Telephone	301-480-8389	
Contact Email	<u>brad.newsome@nih.gov</u>	
Sponsor Website		
Program URL	Link to program URL	
Deadline Dates (ALL)	07-May-2025 , 06-Oct-2025 [Optional][LOI/Pre-App], 05-Nov-2025 , 07-Jan-2026	
	The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with Alliance for Chronic Diseases (GACD), invite applications for implementation research that aims to improve the of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (Ninnovative approaches to identifying, understanding, developing, and implementing strategies for overcoming adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and addition, studies to advance dissemination and implementation research methods and measures into applications must be within the scope of the mission of one of the Institutes/Centers listed about "Components of Participating Organizations," excluding the Fogarty International Center which manages this produces not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions on	availability ble long-term l/or within OFO) supports parriers to the and guidelines. ation are we (see cogram but
Implementation Research for Mul 128421 Context of Non-communicable Dis Countries and US Tribal Population	DVA-	Not Specified
Contact Name	Brad Newsome, Ph.D.	
Contact Telephone	301-480-8389	
Contact Email	brad.newsome@nih.gov	
Sponsor Website		
Program URL	Link to program URL	

Deadline Dates (ALL) 07-May-2025 , 06-Oct-2025 [Optional][LOI/Pre-App], 05-Nov-2025 , 07-Jan-2026

The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research that aims to improve the availability of effective, equitable, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. Synopsis In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. This NOFO uses the bi-phasic, milestone driven R61/R33 grant mechanism. Awards made under this NOFO will initially support a one-year milestone-driven initiation (R61) phase, with possible transition to an implementation (R33) phase of up to four additional years. Only projects that meet the scientific milestones and award requirements of the R61 phase may transition to the R33 phase. Applications submitted in response to this NOFO must address both the R61 and R33 phases. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only.

Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

25-106

05-May-2025

2,375,000 USD

Contact Name Piotr Grodzinski, Ph.D.

Contact Telephone 240-781-3305

Contact Email grodzinp@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-May-2025, 03-Nov-2025, 04-May-2026

Through this Notice of Funding Opportunity (NOFO) entitled "Innovative Research in Cancer Nanotechnology (IRCN)", the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address overcoming major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these

	interventions is outside of scope of the	his NOFO.			
RFA-CA-25-013 Discovery and 117092 Cancer Interception and Prevent Allowed)	Development of Natural Products for ion (UG3/UH3 Clinical Trial Not	National Cancer Institute/NIH/DHHS	RFA- CA-25- 013	14-May-2025 [Optional][LOI/Pre-App]	Not Specified
Contact Nam	e Altaf Mohammed, PhD				
Contact Telephon	e 240-276-6082				
Contact Ema	il wynne.norton@nih.gov				
Sponsor Websit	е				
Program UF	L Link to program URL				
Deadline Dates (AL	_) 14-May-2025 [Optional][LOI/Pre-App	o], 13-Jun-2025			
Synops	development of novel natural product UG3 phase will provide up to three years clinical samples and preclinical in vivo target toxicity screening, and pilot sc scale screening, identification of activity.	ertunity (NOFO), the National Cancer Institute that are safe, non-toxic, and efficaciou ears of support for milestone-driven initial studies, assay development, and/or assareening of natural agents. If UG3 milestorive natural compounds, full-scale evaluation and in vivo, and determining the optimal designation.	s for cance I target se By validations Bes are me Bon of scree	er interception and prever election, verification of th on for target activity, as we et, support may be provid ened individual agents, as	ention. The le target in well as on- led for a full- ssessment of
113074 The Metastasis Research Netwo (U01 Clinical Trial Not Allowed)	rk (MetNet): MetNet Research Projects	National Cancer Institute/NIH/DHHS	PAR- 25-130	21-May-2025 [Optional][LOI/Pre-App]	2,500,000 USD
Contact Nam	e Joanna M. Watson, Ph.D.				
Contact Telephon	e 240-276-6206				
Contact Ema	il watsonjo@mail.nih.gov				
Sponsor Websit	e				
Program UF	L Link to program URL				
Deadline Dates (ALI	21-May-2025 [Optional][LOI/Pre-App	o], 20-Jun-2025			
Synops		Metastasis Research Network (MetNet) in the stounderstand pressing questions in m			

advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Funding Opportunity Announcement (FOA), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.

National Cancer Institute Program Project Applications for the Years PAR-Not 114681 National Cancer Institute/NIH/DHHS 07-May-2025 23-059 2023, 2024, and 2025 (P01 Clinical Trial Optional) Specified

Contact Name Referral Officer Contact Telephone 240-276-6390

Contact Email ncirefof@dea.nci.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 25-May-2025, 07-Sep-2025, 25-Sep-2025, 07-Jan-2026, 25-Jan-2026, 07-May-2026

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

121672

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

PAR-23-276

07-May-2025

1,500,000 USD

Contact Name Sergey Radaev, Ph.D.

Contact Telephone 240-276-5630

Contact Email sradaev@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025 , 25-May-2025 , 07-Sep-2025 , 25-Sep-2025 , 07-Jan-2026 , 25-Jan-2026 , 07-May-2026 , 25-May-2026 , 07-Sep-2026 , 25-Sep-2026 , 07-Jan-2027

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this notice of funding opportunity (NOFO) will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from c

Cancer Research Education Grants Program - Research Experiences (R25 121504 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

07-May-2025 23-277

1,500,000 USD

Contact Name Sergey Radaev, Ph.D.

Contact Telephone 240-276-5630

Contact Email sradaev@mail.nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 25-May-2025, 07-Sep-2025, 25-Sep-2025, 07-Jan-2026, 25-Jan-2026, 07-May-2026, 25-May-2026, 07-Sep-Deadline Dates (ALL) 2026, 25-Sep-2026, 07-Jan-2027

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Research Experiences NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 Synopsis program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this notice of funding opportunity (NOFO) will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

121506 Cancer Research Education Grant Development (R25 Clinical Trial N	s Program - Curriculum or Methods ot Allowed)	National Cancer Institute/NIH/DHHS	PAR- 23-278	07-May-2025	300,000 USD
Contact Name	Sergey Radaev, PhD				
Contact Telephone	240-276-5630				
Contact Email	sradaev@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 07-Sep 2026 , 25-Sep-2026 , 07-Jan-2027	o-2025 , 25-Sep-2025 , 07-Jan-2026 , 25-Ja	n-2026 , 0	07-May-2026 , 25-May	-2026 , 07-Sep-
Synopsis	overarching goal of this R25 program workforce to meet the nation's biom goal, this NOFO will support education Research Education Program (R25) so goal of this NCI R25 program is to support to meet the nation's biomedical, behaviore of funding opportunity (NOFO Methods Development. Applications	in (R25) supports research education activities that of its to support educational activities that of its to support educational activities that of its to support educational and clinical research neonal activities with a primary focus on: Cut supports research education activities in the poort educational activities that complementary and clinical research needs. To activitie are encouraged that propose innovative, the to advance the NCI mission.	compleme eeds. To ad rriculum of the mission ent and/of complish the es with a state-of-t	nt and/or enhance the complish the stated or Methods Developm areas of the NIH. The or enhance the training the stated over-arching primary focus on Curhe-art programs that	e training of a over-arching ent The NIH e overarching g of a workforce g goal, this riculum or address the
106890 Cancer Center Support Grants (CC Centers (P30 Clinical Trial Options		National Cancer Institute/NIH/DHHS	PAR- 21-321	25-May-2025	Not Specified
Contact Name					
Contact Telephone	240-276-5600				
Contact Email	ncicenters-r@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-May-2025 , 25-Sep-2025				
Synopsis	This Funding Opportunity Announce	ment (FOA) invites applications for P30 Ca	incer Cent	er Support Grants (CC	SGs) to support

NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae 128629 and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS

PAR-06-May-2025 Not 25-145 [Optional][LOI/Pre-App] Specified

Contact Name Kelly Filipski PhD, MPH

Contact Telephone 240-276-6841

Contact Email Kelly.Filipski@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025, 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Sep-2026 [Optional][LOI/Pre-App], 05-Jun-2026 [Optional][LOI/Pre-Ap App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027

The purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects. This NOFO supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-

Synopsis induced adverse sequelae, clinically characterize the adverse sequelae, and translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. The scope of research projects includes mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes or combined elements) for future use in clinical trials that will

evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae. This Notice of Funding
Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).						
128619 Molecular Imaging of Inflammatic Allowed)	on in Cancer (R01 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR- 24-311	06-May-2025 [Optional][LOI/Pre-App]	2,499,995 USD	
Contact Name	Charles Lin , Ph.D.					
Contact Telephone	240-276-6108					
Contact Email	linp3@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	[Optional][LOI/Pre-App], 05-Feb-2026], 05-Jun-2025 , 05-Sep-2025 [Optional][L0 5 , 06-May-2026 [Optional][LOI/Pre-App], 0 ional][LOI/Pre-App], 05-Feb-2027 , 06-Ma , 05-Oct-2027	05-Jun-20	026 , 05-Sep-2026 [Option	nal][LOI/Pre-	
Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites research grant applications (RO1) for the development and application of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is the recognition that much of the current imaging research on inflammation in cancer relies heavily on in vitro and ex vivo methods. These approaches have limited potential to provide significant insights into the dynamic interactions between cancer and inflammation. Utilizing molecular imaging probes in pre-clinical and clinical investigations allows for precise temporal resolution at molecular and cellular levels. This information is valuable for identifying and characterizing in vivo inflammatory cellular physiology in cancer and for detecting molecular changes in response to treatment. This NOFO encourages applications focused on developing integrated imaging approaches to investigate the role of inflammation in cancer through strong cross-discipline collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance the science and understanding of cancer inflammation interactions.				ntal insights ging potential to maging vels. This or detecting ed imaging	
128621 Integration of Imaging and Fluid-E Therapy (R01 Clinical Trial Options	Based Tumor Monitoring in Cancer al)	National Cancer Institute/NIH/DHHS	PAR- 25-175	06-May-2025 [Optional][LOI/Pre-App]	499,999 USD	

Contact Name Shane Woodward
Contact Telephone 240-276-6624
Contact Email woodwars@mail.nih.gov

Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 07-May-2025, 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025, 05-Oct-2025, 06-Jan-2026 [Optional][LOI/Pre-App], 07-Jan-2026, 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 07-May-2026, 05-Jun-2026, 05-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026, 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 07-Jan-2027, 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 07-May-2027, 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 07-Jan-2028			
Synopsis	National Cancer Institute (NCI) invites applications for research projects th monitoring (liquid biopsy) assays during cancer therapy in patients to determine the characterization of therapy response and/or emergence of resistance. This mechanism.	mine the op	timal use of those	modalities in the
1/3/153	gator-Initiated Early Phase Clinical viagnosis (R01 Clinical Trial Required) National Cancer Institute/NIH/DHHS	PAR- 25-081	07-May-2025	2,499,995 USD
Contact Name	Lori A. Henderson, Ph.D.			
Contact Telephone	240-276-5930			
Contact Email	hendersonlori@mail.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05- 2026 , 05-Oct-2026 , 07-Jan-2027	Feb-2026 , 0	07-May-2026 <i>,</i> 05-Jเ	un-2026 , 07-Sep-
Synopsis	Through this Notice of Funding Opportunity (NOFO), the National Cancer In implement early phase (Phase 0, I, and II) investigator-initiated clinical trials therapeutic interventions of direct relevance to the research mission of DCT at least 1 clinical trial related to the scientific interests of one or more of the Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, R Alternative Medicine Program and/or the HIV and AIDS Malignancies Resea an early phase trial by itself, or in combination with another research aim(s) III clinical trials.	focused on TD and OHA e following I adiation Res	n cancer-targeted di M. The proposed p research programs: search Program, Co ns. Applicants may p	agnostic and roject must involve Cancer Therapy mplementary and propose to conduct
123051 Cancer Prevention and Control Clinical Trial Required)	inical Trials Grant Program (R01 National Cancer Institute/NIH/DHHS	PAR- 25-167	07-May-2025	Not Specified

Contact Name Jessica Faupel-Badger, Ph.D., M.P.H.

cancer diagnosis and/or oncologic therapy in patients.

Contact Telephone 240-276-7296

Contact Email badgerje@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 05-Jan-2027

Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or Synopsis survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this NOFO and the application instructions. This NOFO does not and will not support clinical trials for studies of

<u>Dissemination and Implementation Research in Health (R01 Clinical Trial</u> Optional)

National Cancer Institute/NIH/DHHS

07-May-2025 25-144

Not Specified

Contact Name Gila Neta, Ph.D.

Contact Telephone 240-276-6785

Contact Email gila.neta@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027, 05-Feb-2027, 07-May-2027, 05-Jun-2027, 07-Sep-2027, 05-Oct-2027, 07-Jan-2028

The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidencebased interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based

interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant.

127772 Mechanisms that Impact Cancer F Trial Optional)	Risk after Bariatric Surgery (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR- 25-043	06-May-2025 [Optional][LOI/Pre-App]	2,500,000 USD
Contact Name	Edward R. Sauter, M.D., Ph.D.				
Contact Telephone	240-276-7657				
Contact Email	edward.sauter@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	[Optional][LOI/Pre-App], 05-Feb-2026	, 05-Jun-2025 , 05-Sep-2025 [Optional][L0 , 06-May-2026 [Optional][LOI/Pre-App], onal][LOI/Pre-App], 05-Feb-2027 , 06-Ma 05-Oct-2027	05-Jun-20	026 , 05-Sep-2026 [Option	nal][LOI/Pre-
Synopsis	of investigator-initiated studies addre	nouncement (FOA), the National Cancer I ssing mechanisms by which bariatric surg surgery to investigate its effects on canc	ery impa	cts cancer risk, and seeks	to draw in
113232 Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR- 22-242	05-Mar-2025	Not Specified
Contact Name	Rao Divi, Ph.D.				
Contact Telephone	240-276-6913				
Contact Email	divir@mail.nih.gov				

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Mar-2025, 07-May-2025, 05-Jun-2025, 05-Jul-2025, 07-Sep-2025

Synopsis	The purpose of this funding opportunity that: 1) apply a multidisciplinary bioengi optimize, validate, translate or accelerate and address specific research or clinical enhancing our understanding of health a design-directed, developmental, discoverapplying an integrative approach to increscience.	ineering approach to the solution of a bete adoption of promising tools, method problem in basic, translational, and/or and disease, and/or c) improve practice ery-driven, or hypothesis-driven researce.	piomedical problem; and 2) d Is and techniques: a) that fulf clinical science and practice, e of medicine. Applications m ch, and this FOA is appropriat	evelop, integrate, fill an unmet need b) capable of ay propose te for small teams
113233 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR- 22-243 05-Mar-2025	Not Specified
Contact Name	Rao Divi, Ph.D.			
Contact Telephone	240-276-6913			
Contact Email	divir@mail.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	05-Mar-2025 , 07-May-2025 , 05-Jun-20	25 , 05-Jul-2025 , 07-Sep-2025		
Synopsis	The purpose of this funding opportunity that: 1) apply a multidisciplinary bioengic validate, translate or otherwise accelerator clinical problem in basic, translational developmental, discovery-driven, or hypapproach to increase our understanding support clinical trials that test functional conventional clinical trials that lack translany area of research are not sought by a commercial production.	ineering approach to the solution of a bate the adoption of promising tools, me I, or clinical science and practice. An appothesis-driven research and is approprig of and solve problems in biological, clility or validate performance in the chost slation as the primary motivation. Appl	piomedical problem; and 2) in othods, and techniques for a sopplication may propose designate for small teams applying inical, or translational science sen setting. This FOA is not in lications that propose phase I	ntegrate, optimize, specific research n-directed, g an integrative e. This FOA will stended to support
129351 Toward Translation of Nanotechn (R01 Clinical Trial Not Allowed)	ology Cancer Interventions (TTNCI)	National Cancer Institute/NIH/DHHS	PAR- 25-336 19-May-2025	1,900,000 USD

Contact Name Piotr Grodzinski, Ph.D.

Contact Telephone 240-781-3305

Contact Email grodzinp@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 19-May-2025, 17-Nov-2025, 18-May-2026, 16-Nov-2026, 17-May-2027, 15-Nov-2027 This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature Synopsis experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs. NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 100,000 National Cancer Institute/NIH/DHHS 24-Feb-2025 25-078 Clinical Trial Optional) USD Contact Name Crystal Wolfrey Contact Telephone 240-276-6277 Contact Email wolfrevc@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025, 20-Jun-2025, 07-Sep-2025, 17-Oct-2025, 07-Jan-2026 This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. NOT-Notice of Special Interest (NOSI): Basic Mechanisms of Cannabis and Not National Cancer Institute/NIH/DHHS CA-22- 07-May-2025 Cannabinoid Action in Cancer

Contact Name Ron Johnson, Ph.D.

085

Specified

Contact Telephone	240-276-6250			
Contact Email	rjohnso2@mail.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
	2026 , 05-Feb-2026 , 12-Feb-2026 , 1	2025 , 16-Jun-2025 , 07-Sep-2025 , 05-Oc 6-Feb-2026 , 07-May-2026 , 05-Jun-2026 6 , 07-Jan-2027 , 05-Feb-2027 , 12-Feb-20	, 12-Jun-2026 , 16-Jun-2026 , 07-	-
		Interest (NOSI) is to promote research in ncer biology, cancer interception, cancer t		
115306 Notice of Special Interest (NOSI): Interest (NOSI)	Research on the Etiology, Early ion of Early-Onset Colorectal Cancer	National Cancer Institute/NIH/DHHS	NOT- CA-23- 07-May-2025 018	Not Specified
Contact Name	Gary Della'Zanna			
Contact Telephone	240-276-7042			
Contact Email	Gary.DellaZanna@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025			
Synopsis	mitigating risk factors, identifying bio	Interest (NOSI) is to solicit applications di markers for early detection, best screeni), defined as occurring before 50 years of	ng modalities, and preventive int	
115117 Notice of Special Interest (NOSI): A	Adaptive Biomaterials for Cancer	National Cancer Institute/NIH/DHHS	NOT- CA-23- 07-May-2025 030	Not Specified
Contact Name	Eric M. Johnson Chavarria, Ph.D.			
Contact Telephone	240-276-7416			

Contact Email eric.johnsonchavarria@nih.gov

	1			
Sponsor Website				
_	Link to program URL			
Deadline Dates (ALL)	07-May-2025			
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to promote research for integration of innovative biomaterials for cancer biology. The applications of the insights into basic cancer research.		• • • •	<u>-</u>
128547 Dissemination and Implementation Optional)	on Research in Health (R21 Clinical Trial National Cancer Institute/NIH/DHHS	PAR- 25-143	07-May-2025	275,000 USD
Contact Name	Gila Neta, Ph.D.			
Contact Telephone	240-276-6785			
Contact Email	gila.neta@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb 2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027,			
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support studies strategies for overcoming barriers to the adoption, adaptation, integration, subased interventions, practices, programs, tools, treatments, guidelines, and poevidence-based interventions). Studies that promote equitable dissemination interventions among underrepresented communities are encouraged. Conversircumstances that create a need to stop or reduce (de-implement) the use of value, or harmful. In addition, studies to advance dissemination and implement encouraged. Applications that focus on re-implementation of evidence-based disasters (e.g., pandemics, climate change) remain relevant. All applications me the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO Perspectives (PEDP).	stainability blicies (her and imple sely, there practices to tation res health serv ust be wit	y, scale-up, and spread rein referred to collective mentation of evidences is a benefit in understathat are ineffective, unpearch methods and methods that may be disruphin the scope of the missing scale.	of evidence- vely as based inding proven, low- asures are pted amidst ssion of one of
128525 Dissemination and Implementation Not Allowed)	on Research in Health (R03 Clinical Trial National Cancer Institute/NIH/DHHS	PAR- 25-233	07-May-2025	100,000 USD

Contact Telephone 240-276-6785

Contact Email gila.neta@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028

The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidencebased interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding Synopsis circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, lowvalue, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant. All applications must be within the scope of the mission of one of

128676 Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS

the Institutes/Centers listed above. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse

PA-25-07-May-2025 253

275,000 USD

Contact Name Mukesh Verma, Ph.D.

Perspectives (PEDP).

Contact Telephone 240-276-6889

Contact Email vermam@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028, 16-Feb-2028, 07-May-2028, 16-Jun-2028, 07-Sep-2028

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on

	development of novel techniques, ag	otential to substantially advance populati ents, methodologies, models, or applicat c, biomedical, behavioral, health care del	ions that could have a major ir	
Notice of Special Interest (NOSI): 113746 Study Designs for Liquid Biopsy As Cancers	Utilization of Cohorts and Prospective ssay Validation for Early Detection of	National Cancer Institute/NIH/DHHS	NOT- CA-23- 01-Mar-2025 004	Not Specified
Contact Name	Matthew Young, Ph.D.			
Contact Telephone	240-276-5846			
Contact Email	matthew.young@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Mar-2025 , 05-Apr-2025 , 07-May-	-2025 , 05-Jun-2025 , 12-Jun-2025 , 01-Ju	l-2025	
Synopsis	biomarker technology developers wit and biorepository researchers. Propo	Interest (NOSI) is to encourage research sich assays for early cancer detection, and pisals that facilitate early cancer biomarked owered retrospective cohorts and/or throngare responsive to this NOSI.	oopulation-based researchers, r assay development, verificati	including cohort ion, qualification,
117714 Notice of Special Interest (NOSI):	RNA Modifications in Cancer Biology	National Cancer Institute/NIH/DHHS	NOT- CA-23- 07-May-2025	Not Specified

Contact Name Stefan Maas, Ph.D. Contact Telephone 240-276-6230

Contact Email stefan.maas@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 12-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 12-Oct-2025, 16-Oct-2025, 07-Jan-2026

Synopsis Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of

060

RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underlie cancer formation and the cancer phenotype.

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated 128271 Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

10-Mar-2025 24-275

Not **Specified**

Contact Name Elizabeth Ginexi, Ph.D.

Contact Telephone 301-827-0160

Contact Email elizabeth.ginexi@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

10-Mar-2025, 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025, 14-Jul-2025, 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026, 17-Mar-2026, 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026, 14-Jul-2026

This notice of funding opportunity (NOFO) encourages applications for investigator-initiated multisite clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH-designated areas of high research priority. Clinical coordinating centers (CCC) should develop and implement the proposed fully powered multisite clinical trial (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. CCC applications are expected to describe plans for project management, Synopsis participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying data coordinating center (DCC) application (U24), submitted under PAR-24-087 and proposing a data analysis and data management plan for the clinical project, is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate Scientific/Research

Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This

		Notice of Funding Opportunity (NOFC)) requires a Plan for Enhancing Diverse P	erspective	es (PEDP).	
110434	NEI Cooperative Agreement for Eathan Minimal Risk (U01 Clinical Tr	arly-Stage Clinical Trials with Greater ial Required)	National Eye Institute/NIH/DHHS	PAR- 22-149	07-May-2025	Not Specified
	Contact Name	Sangeeta Bhargava, PhD				
	Contact Telephone	301-435-8175				
	Contact Email	bhargavas@nei.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2025				
	Synopsis	than minimal risk and typically are Ph oversight and safety monitoring. For p aimed at screening, diagnosing, preve	nent awards to support investigator-initial ase I or II trials. The risk level of the UO1 purposes of this FOA, the proposed study enting, or treating vision disorders. Applianplication with human subjects to determine	trial requi must be i cants are	res appropriate perform ntended to evaluate int strongly advised to cons	nance terventions sult with NEI
	NEI Small Business Innovation Res	search (SBIR) Cooperative Agreement		PAR-		2,000,000
	for Early-Stage Clinical Trials with	Greater than Minimal Risk (U44-	National Eye Institute/NIH/DHHS	24-066	28-May-2025	2,000,000 USD
	<u>Clinical Trial Required)</u>	1				
		Paek Lee, PhD				
	Contact Telephone	301-435-8164				
	Contact Email	paek.lee@nih.gov				
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)	28-May-2025 , 23-Sep-2025 , 24-Jan-2	2026 , 27-May-2026 , 23-Sep-2026			
	Synopsis	The NEI uses this U44 Notice of Funding Opportunity to support SBIR grant applications from small business concerns (SBCs) that propose to implement investigator-initiated, early-stage clinical trials with greater than minimal risk and typically are sis Phase I or II trials. The risk level of the U44 trial requires appropriate performance oversight and safety monitoring. For purposes of this NOFO, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. Applicants are strongly advised to consult with NEI program staff prior to submitting				

	an application with human subjects to	determine the appropriate funding op	portunity.		
118875 NEI Collaborative Clinical Vision R Grant (UG1 Clinical Trial Required	esearch Project: Coordinating Center)	National Eye Institute/NIH/DHHS	PAR- 23-204	07-May-2025	Not Specified
Contact Name	Sangeeta Bhargava, PhD				
Contact Telephone	301-435-8175				
Contact Email	bhargavas@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 07-Sep-	2025 , 25-Sep-2025 , 07-Jan-2026 , 25-Ja	an-2026 , 07	7-May-2026	
Synopsis	transfer, stem cell therapy trials, and of multifaceted and of high public health responsibilities and require careful pe Opportunity (NOFO), the proposed stupreventing, or treating vision disorder UG1-supported studies are typically for Grant, the Coordinating Center, and R	nent awards to support investigator-inition other complex or high resource- or safe of significance requiring clear delineation rformance oversight and monitoring. Fouly must be intended to evaluate intervers, or to compare the effectiveness of two unded as a group of single-component clesource Centers, when appropriate. Speprovides details of the Coordinating Cere	ty-risk clinic of study or or purposes ventions aim vo or more e companion g ecifically, th	al trials. These proganization includir of this Notice of Funed at screening, destablished interversant awards includes NOFO encourage	jects are ag roles and unding iagnosing, entions. The NEI ding the Chair's es applications for
118866 NEI Collaborative Clinical Vision R Grant (UG1 Clinical Trial Required		National Eye Institute/NIH/DHHS	PAR- 23-201	07-May-2025	Not Specified
Contact Name	Sangeeta Bhargava, PhD				
Contact Telephone	301-435-8175				
Contact Email	bhargavas@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 07-Sep-	2025 , 25-Sep-2025 , 07-Jan-2026 , 25-Ja	an-2026 , 07	7-May-2026	
Synopsis	The NEI uses UG1 cooperative agreem transfer, stem cell therapy trials, and o	nent awards to support investigator-inition other complex or high resource- or safe	iated large-s ty-risk clinic	scale clinical trials, al trials. These pro	human gene- jects are

multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this NOFO encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial.

118879 NEI Collaborative Clinical Vision R Trial Required)	esearch: Chair's Grant (UG1-Clinical	National Eye Institute/NIH/DHHS	PAR- 23-209	07-May-2025	Not Specified
Contact Name	Sangeeta Bhargava, PhD				
Contact Telephone	301-435-8175				
Contact Email	bhargavas@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 07-Sep	-2025 , 25-Sep-2025 , 07-Jan-2026 , 25-Jai	n-2026 , 0	7-May-2026	
Synopsis	transfer, stem cell therapy trials, and multifaceted and of high public healt responsibilities and require careful proportunity (NOFO), the proposed structure preventing, or treating vision disorder UG1-supported studies are typically forant, the Coordinating Center, and	ment awards to support investigator-initial other complex or high resource- or safety his significance requiring clear delineation conformance oversight and monitoring. For tudy must be intended to evaluate intervents, or to compare the effectiveness of two funded as a group of single-component conformation of the secource Centers, when appropriate. Specially sims and significations.	y-risk clinic of study of purposes entions air o or more mpanion cifically, th	cal trials. These projects rganization including ro sof this Notice of Fundined at screening, diagn established intervention grant awards including his NOFO encourages againgt a second courages agains agains second courages again	s are les and ng osing, ns. The NEI the Chair's
109678 NEI Regenerative Medicine Clinica Trials Not Allowed)	al Trial Planning Grant (R34 - Clinical	National Eye Institute/NIH/DHHS	PAR- 22-135	07-May-2025	300,000 USD

Contact Name Donald Everett, MA Contact Telephone 301-435-8181

Contact Email everettd@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell Synopsis manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.

Notice of Special Interest (NOSI): Development of Innovative 117409 Informatics and Data Science Technologies, Tools, and Methods for

National Eye Institute/NIH/DHHS

NOT-EY-23- 05-Apr-2025 005

Not Specified

Contact Name James Gao, Ph.D.

Contact Telephone 301-594-6074

Vision Research

Contact Email james.gao@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 2026

05-Apr-2025, 07-May-2025, 16-Jun-2025, 05-Sep-2025, 07-Sep-2025, 16-Oct-2025, 05-Jan-2026, 07-Jan-2026, 16-Feb-

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Eye Institute (NEI) is interested in supporting research to develop innovative informatics and data science methods, algorithms, and tools to Synopsis improve data acquisition, analysis, visualization, annotation, integration, and interpretation. The emphasis will be on innovation and its potential impact on vision research, including discovery biology, population studies, as well as clinical and translational research.

129739 NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial

National Eye Institute/NIH/DHHS

PAR-

07-May-2025

300,000

Not Allowed)		25-358	USD
Contact Name	Donald Everett, MA		
Contact Telephone	301-435-8181		
Contact Email	everettd@mail.nih.gov		
Sponsor Website			
Program URL	Link to program URL		
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-2027 , 07-May-2027 , 16-Jun-2027		
Synopsis	The NEI supports large-scale clinical vision research projects, including rando eye/vision conditions. At the time of submission, applications requesting supdetailed information regarding the study rationale, design, analytic technique environment, organizational structure, and collaborative arrangements. This Procedures (MOP), the development of which represents a costly and timegrant funding opportunity supports applicants in their planning efforts to comay be used to support the development of a MOP, as well as to conduct predocument recruitment potential. The grant must not be used to generate dance NEI FOA is applicable to both epidemiologic and clinical trial research studies.	oport for these activities are exposes, protocols and procedures, fast information is best conveyed in consuming activity. This clinical reduct collaborative clinical reseaseliminary studies to refine study at a on the effects of a proposed	rected to provide acilities and a Manual of research planning arch. The grant y procedures or
129611 NEI Research Grant for Vision-Rel Clinical Trial Not Allowed)	ated Secondary Data Analysis (R21 National Eye Institute/NIH/DHHS	PAR- 25-357 07-May-2025	275,000 USD
Contact Name	Donald Everett, M.A.		
Contact Telephone	301-435-8181		
Contact Email	everettd@mail.nih.gov		
Sponsor Website			
Program URL	Link to program URL		
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2027 , 16-Oct-2027 , 16-Jun-2027		
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to conduct second from humans participating in vision-related clinical trials, epidemiologic, and clinical and health care database resources (e.g., electronic health records).	other clinical research studies of	or represented in

statistical methodologies or test hypotheses using existing data, but this NOFO must not be used to support the collection of new data. This NOFO encourages applications from institutions/organizations that propose to conduct vision-related secondary analyses of data collected from humans. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest.

114386	Secondar	y Analysis	of Existing	Datasets in	Heart, Lung,	and Blood
	Diseases a	and Sleep	Disorders	(R21 Clinical	Trial Not All	owed)

National Heart, Lung, and Blood Institute/NIH/DHHS

PAR-28-Feb-2025 25-056

150.000 USD

Not

Specified

Contact Name Ruth Kirby, RN, BS

Contact Telephone 301-435-0401

Contact Email kirbyr@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 28-Feb-2025, 07-May-2025, 28-Oct-2025, 07-Jan-2026

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute Synopsis (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed.

122581 NHLBI Program Project Applications (P01 Clinical Trials Optional)

National Heart, Lung, and Blood PAR-25-May-2025 Institute/NIH/DHHS 24-065

Contact Name Michelle Olive, Ph.D.

Contact Telephone 301-443-7933

Contact Email NHLBI DCVS500k@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025, 25-Sep-2025, 25-Jan-2026, 25-May-2026, 25-Sep-2026

Synopsis	submission of investigator-initiated Pr relevant to the NHLBI mission includin resources; and sleep disorders. Progra research that addresses the mission of least three related research projects the	OFO), issued by the National Heart, Lung ogram Project (P01) applications. The program Project (P01) applications. The program Project (P01) applications. The program and the project of the heart, he was also include implementation scient from the Institute. Each application submitted that share a common central theme, foculude at least four projects, one of which it	oposed programs may address sci blood vessels, lung, and blood; blo ence, health disparities, and trans ed in response to this NOFO must i s, and/or overall objective. Highe	ientific areas bod Slation include at r budgets may
Notice of Special Interest (NOSI): 115585 to Evaluate Candidate -Omics Var Blood, or Sleep Disease (R01, R41		National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-23- 05-Apr-2025 066	Not Specified
Contact Telephone	Charlene Schramm, Ph.D. 301-402-3793 schrammc@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)		2025 , 05-Jun-2025 , 05-Sep-2025 , 07-Se -Apr-2026 , 07-May-2026 , 05-Jun-2026 ,	•	25 , 05-Jan-
Synopsis	disorders in the following area(s): Dev provide biological validation of candid	cial Interest (NOSI) to highlight interest in elopment and/or application of moderat ate human variants associated with HLBS Development and validation of functional	e- or high-throughput functional a S disorders Defining causal relatio	assays to
116586 Notice of Special Interest (NOSI): TOPMed Data (Parent R01 Clinica	Integrative Omics Analysis of NHLBI I Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-23- 07-May-2025 067	Not Specified
Contact Name	James Luo, Ph.D.			
Contact Telephone	301-435-0533			

Contact Email <u>luoja@nih.gov</u>

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026

The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has created the Trans-omics for Precision Medicine (TOPMed) program, which aims to utilize genomics data to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence (WGS) from over 194,270 well-phenotyped individuals and is currently generating multi-omics data (e.g., over 31,852 RNA sequences, over 44,342 DNA methylation profiles, and 26,124 metabolomics profiles) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource to uncover biological function and disease pathobiology through novel systems biology analyses and the power of artificial intelligence (AI) and Machine Learning (ML). Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks and the gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are essential to move TOPMed to the next phase of discovery.

NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for National Heart, Lung, and Blood HLBS Disorders (R61/R33 Clinical Trial Required)

Institute/NIH/DHHS

PAR-05-May-2025 Not 25-026 [Optional][LOI/Pre-App] Specified

Contact Name Sumita Khatri, MD

Contact Telephone 301-402-9673

125098

Contact Email sumita.khatri@nih.gov

Sponsor Website

Program URL Link to program URL

05-May-2025 [Optional][LOI/Pre-App], 07-May-2025, 04-Jun-2025, 03-Sep-2025 [Optional][LOI/Pre-App], 07-Sep-2025, 02-Deadline Dates (ALL) Oct-2025, 04-Jan-2026 [Optional] [LOI/Pre-App], 07-Jan-2026, 03-Feb-2026, 05-May-2026 [Optional] [LOI/Pre-App], 07-May-2026, 04-Jun-2026, 03-Sep-2026 [Optional][LOI/Pre-App], 07-Sep-2026, 02-Oct-2026, 07-Jan-2027

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

		as stability, shipping studies, and site t	raining.			
125065	NHLBI Early Phase Clinical Trials for HLBS Disorders (R33 CT Required)	or Therapeutics and/or Diagnostics for	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR- 25-025	05-May-2025 [Optional][LOI/Pre-App]	4,545,000 USD
	Contact Name	Sumita Khatri, MD				
	Contact Telephone	301-402-9673				
	Contact Email	sumita.khatri@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	Oct-2025 , 04-Jan-2026 [Optional][LOI	, 07-May-2025 , 04-Jun-2025 , 02-Sep-202 /Pre-App], 07-Jan-2026 , 03-Feb-2026 , 05 :ional][LOI/Pre-App], 07-Sep-2026 , 02-00	5-May-20	026 [Optional][LOI/Pre-Ap	
	Synopsis	diagnostic and therapeutic intervention proposed trial can be single or multi-siclinical trial within the first quarter of (FDA, DSMB, IRB) approvals, and established by the stablished by the	g Opportunity (NOFO) is to support investing for heart, lung, blood, and sleep (HLBS) te. Applicants applying for funding under the project period. Discussion, submission blishment of drug (and placebo, if applicable the time of award. If time and support for ants should consider the companion NOF	i) disorder this NO n, and atole) supp these ar	ers in adults and children. FO should be ready to inite tainment of applicable re lies, and any necessary the and other pre-clinical and/	The tiate the egulatory nird-party or trial
112260	Notice of Special Interest (NOSI): S Pathobiological Mechanisms of Lu Dimensional Cellular Systems (RO	ing Diseases Using Human 3-	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-22- 030	07-May-2025	Not Specified

Contact Name Qing Lu, Ph.D.
Contact Telephone 301-480-9158
Contact Email qing.lu@nih.gov

Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2	2025		
Synopsis	onset and progression of lung disease experimental systems with cellular he will utilize ex vivo preparations (e.g., t	e research characterizing the pathobiolog s at a molecular/cellular level, providing a terogeneity and 3-D architecture. It is exp thin human lung slices) or 3-D multi-cellul multi-omics measures (e.g., spatial or sin ystems of interacting cell types.	a systems-level understanding bected that projects supported lar in vitro systems (e.g., organc	oy studying by this NOSI oids) of human
Notice of Special Interest (NOSI): 114141 and Cardiovascular Disease (R01 Cardiovascul	Advancing Research in Lipoprotein(a) Clinical Trials Allowed) and (R01 No	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-22- 07-May-2025 052	Not Specified
Contact Name	Lijuan Liu, PhD			
Contact Telephone	301-435-0582			
Contact Email	lliu@nhlbi.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2	2025 , 05-Oct-2025 , 07-Jan-2026		
Synopsis	The purpose of this NOSI is to stimula encourage multidisciplinary collaborates	te research on lipoprotein(a) [Lp(a)] and it ions to conduct basic, preclinical, and me	its role in cardiovascular disease echanistic clinical studies on Lp(e (CVD). We (a) and CVD.
107287 Notice of Special Interest (NOSI): Ancillary Studies to Large Ongoing	Heart, Lung, Blood and Sleep Focused g Clinical Studies (Revised)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-21- 07-May-2025 030	Not Specified
Contact Name	Jue Chen, Ph.D.			
Contact Telephone	301-435-0550			
Contact Email	jue.chen@nih.gov			

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) Synopsis	This Notice of Special Interest (NOSI) treatment of diseases within the miss clinical research studies through ancil conduct focused ancillary studies to la	seeks to expand the breadth of scientification of the National Heart, Lung, and Blooklary studies. The purpose of this NOSI is arge ongoing clinical trials (including late) This NOSI also serves as a replacement for	od Institute (NHLBI) by leveragi to invite research project appli -stage T4 implementation clinion	ng ongoing cations to cal trials),
Notice of Special Interest (NOSI): 106202 Cardiometabolic Health in Early Stadolescence Through Adolescence	tages of the Lifecourse: Pre-	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-21- 07-May-2025 015	Not Specified
Contact Name	Alison G.M. Brown, PhD, MS, RDN			
Contact Telephone	301-435-0583			
Contact Email	Alison.brown@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2	2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Fe	b-2026 , 07-May-2026 , 05-Jun-	·2026
Synopsis	during transitionary phases across the young adulthood (19-39 years). This i pathogenesis of cardiometabolic heal phases from pre-adolescence into ado	calls for research to understand and pro e lifecourse, from pre-adolescence (6-10 nitiative would support research to: 1) u th and cardiovascular disease (CVD) risk plescence and adolescence into young ac opulations levels) to address cardiovascu	years) through adolescence (1: nderstand the mechanisms and in vulnerable groups throughoulthood, and 2) develop precis	1-18 years) to I the ut transitionary sion prevention
	Basic and Translational Research on ng, Blood, and Sleep Disorders (R01)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT- HL-22- 07-May-2025 043	Not Specified
Contact Name Contact Telephone	Ravi Balijepalli, Ph.D. 301-435-0504			

Contact Email ravi.balijepalli@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027, 05-Feb-2027, 07-May-2027, 05-Jun-2027, 07-Sep-2027, 05-Oct-2027, 07-Jan-2028

This NOSI aims to stimulate research on understanding how circadian rhythms regulate cell function and metabolism of peripheral tissues, and to find new avenues for the investigation of heart, lung, and blood disease risk, pathogenesis, diagnosis, treatment, and prevention. Basic, translational, and clinical research applications to elucidate circadian-dependent mechanisms contributing to the pathophysiology of HLBS disorders are invited. This NOSI encourages multidisciplinary and multiple investigator teams of experts in heart, lung, and blood research fields to synergistically work with circadian biologists and sleep researchers to provide a comprehensive understanding of the circadian biology in relation to HLBS conditions. The purpose is to facilitate translational research to identify potential applications of circadian science to the diagnosis, prevention and treatment of HLBS conditions. Mechanism-based studies investigating the circadian rhythm dysregulation, clinical markers, and/or therapeutic targets of HLBS conditions are encouraged. Behavioral, physiological, pharmacological, molecular, and genomic studies aimed at elucidating the relationship between circadian-dependent mechanisms and disease are appropriate. Studies to delineate circadian-based mechanisms, therapeutic targets, epidemiological risk and clinical trials

Synopsis

RFA-HL-26-011 -- Leadership and Coordination Center (LACC) for the 129892 MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed)

National Heart, Lung, and Blood Institute/NIH/DHHS

to assess therapeutic safety, efficacy, effectiveness, or implementation may be proposed.

RFA-02-Apr-2025 HL-26-[Optional][LOI/Pre-App] USD 011

12,000,000

Contact Name Dr. Elizabeth Pathak

Contact Telephone

Contact Email beth.pathak@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 02-Apr-2025 [Optional][LOI/Pre-App], 02-May-2025

The purpose of this Notice of Funding Opportunity (NOFO) is to renew the MACS/WIHS Combined Cohort Study of HIV in United States Adults (MWCCS) for a 6-year project period (2026-2032). Continuation of this epidemiological study of middle-Synopsis aged and older people living with HIV (PLWH), along with comparable individuals living without HIV (PLWOH) will enable the continued follow-up of a deeply phenotyped cohort of approximately 5,700 participants from across the United States. This initiative will utilize a populomics approach, i.e., examination of health determinants across multiple scales of influence (e.g.

molecular, cellular, physiological, lifestyle/behavioral, household, neighborhood, environmental, cultural, and sociopolitical) using multi-disciplinary methods to investigate the web of influences impacting the health, quality of life, and survival of adults living with HIV. This NOFO seeks applications to fund a single Leadership and Coordination Center (LACC) for the MWCCS.

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

National Heart, Lung, and Blood Institute/NIH/DHHS

PAR-12-May-2025 22-193

Not Specified

Contact Name Nancy DiFronzo, PhD

Contact Telephone 301-435-0065

Contact Email difronzon@nhlbi.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025, 11-Jun-2025, 11-Sep-2025

This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA PAR-22-192() that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. The application should also describe its approaches to collaborate with the CCC on implementation of the clinical trial community engagement and diversity plans. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

National Heart, Lung, and Blood Institute/NIH/DHHS

11-May-2025 25-028

Not Specified

Contact Name Yves Rosenberg, MD, MPH

Contact Telephone 301-435-1292

Contact Email rosenbey@nhlbi.nih.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 11-May-2025, 11-Jun-2025, 11-Sep-2025

This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to Synopsis consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

National Heart, Lung, and Blood Institute/NIH/DHHS

inequties and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP).

PAR-25-029

12-May-2025

Not Specified

Contact Name Nancy DiFronzo, PhD

Contact Telephone 301-435-0065

112357

Contact Email difronzon@nhlbi.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025, 11-Jun-2025, 11-Sep-2025

This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or Synopsis implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research

priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestonedriven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-193). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The application should also describe its approaches to increasing community engagement and diversity as well as reducing health inequities and disparities. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

	RFA-HL-25-008 Mentored Career Development Award to Promote
125802	Faculty Diversity in Biomedical Research (K01 Independent Clinical Tria
	Required)

National Heart, Lung, and Blood Institute/NIH/DHHS

RFA-HL-25- 07-May-2025 800

Not **Specified**

Contact Name Karin F. Lidman, Ph.D.

Contact Telephone 301-435-0535

Contact Email karin.fredriksson@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025 , 15-Oct-2025 , 07-Jan-2026 , 11-Feb-2026 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2026 , 12-Feb-2027 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2026 , 14-Oct-2026 , 07-Jan-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-Jan-2026 , 07-Jan-2027 , 07-Jan-2028 , 07-Jan-20

This Notice of Funding Opportunity (NOFO) invites applications to provide career development opportunities for a diverse pool of highly trained investigators by providing eligible faculty members with the opportunity to undertake special study and supervised research under an accomplished investigator in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are Synopsis grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This NOFO is designed to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutes to apply to companion NOFO (RFA-HL-25-009).

RFA-HL-25-009 Mentored Caree 125805 Faculty Diversity in Biomedical Re Not Allowed)	er Development Award to Promote search (K01 Independent Clinical Trial	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-25- 07-May-2025 009	Not Specified
Contact Name	Karin F. Lidman, Ph.D.			
Contact Telephone	301-435-0535			
Contact Email	karin.fredriksson@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 15-Oct-2025 , 07-Jan-2 2027	026 , 11-Feb-2026 , 07-May-2026 , 14-Oo	ct-2026 , 07-Jan-2027 , 11-Feb-20	27 , 07-May-
Synopsis	highly trained investigators in resear guidance of an experienced mentor in targeted toward individuals whose ba and experimental approaches needed sleep disorders in the general and heaproposing research that does not involve ancillary clinical trial. Applicants to the	IOFO) invites applications to provide care ch areas of interest to the NHLBI. The can the biomedical, behavioral or clinical scisic, clinical, and translational research in to solve problems related to cardiovascialth disparities populations. This NOFO is olve leading an independent clinical trial, is NOFO are permitted to propose resear clinical trial or an ancillary study to an or panion NOFO (RFA-HL-25-008).	reer development will take place iences leading to research indepeterests are grounded in the advarular, pulmonary, and hematologic designed specifically to support a clinical trial feasibility study, or oth experience in a clinical trial leasibility.	under the ndence. It is need methods diseases and candidates a separate I by a mentor
113729 RFA-HL-25-011 Limited Compet K01/K08/K23/K25 Recipients (R03	ition: Small Grant Program for NHLBI 3 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-25- 07-May-2025 011	150,000 USD
Contact Name	Qing Lu, Ph.D.			
Contact Telephone	301-480-9158			
Contact Email	Qing.Lu@nih.gov			

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 13-Jun-2025, 07-Sep-2025, 15-Oct-2025, 07-Jan-2026

The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status. This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.

Synopsis

122332 NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

National Heart, Lung, and Blood PAR-Institute/NIH/DHHS 25-032 07-May-2025 USD

Contact Name Patrice Desvigne-Nickens, MD

Contact Telephone 301-435-0504

Contact Email desvignp@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027

nnsis

This Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, or sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at Clinical Trial Development Continuum | NHLBI, NIH), the R34 mechanism is intended to

provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application. Plan for Enhancing Diverse Perspectives The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse perspectives include but are not limited to: -Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. - Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduate-focused, minority-serving, community-based). - Individual applications and partnerships that enhance geographic and regional heterogeneity. - Investigators and teams composed of researchers at different career stages. -Participation of individuals from diverse backgrounds, including groups historically underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. - Opportunities to enhance the research environment to benefit early- and mid-career investigators. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

29050 Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 25-300 07-May-2025	Not Specified
---	--	----------------------------	------------------

Contact Name Yan Zhou, Ph.D.

Contact Telephone 240-485-9785

Contact Email zhouy16@niaid.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 07-Sep-2025, 07-Jan-2026, 07-May-2026, 07-Sep-2026, 07-Jan-2027, 07-May-2027, 07-Sep-2027, 07-Jan-2028

The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance

the recognition and elimination of Env-expressing, HIV-1 infected cells. These studies are expected to inform the
development of immunotherapies and targeted vaccines for HIV-1 prevention and cure.

	development of immunotherapies and	d targeted vaccines for HIV-1 prevention	and cure.	•	
117333 Pulmonary Outcomes and Sequela Clinical Trial Optional)	ae after Treatment-TB (POST-TB) (R01	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 23-148	07-May-2025	Not Specified
Contact Name	Robin E. Huebner, Ph.D., M.P.H.				
Contact Telephone	240-627-3216				
Contact Email	rhuebner@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-2	026 , 07-May-2026			
Synopsis	research projects on the long-term cap propose additional testing and data co	Opportunity (NOFO) is to support applicated applicated applicated applicated applicated applicated applicated applicated application in existing cohorts of adult and/outcomes and morbidity associated with	nent for tu or pediatr	uberculosis (TB). Investig	ators should ter
119017 NIAID Clinical Trial Planning Grant	(R34 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 23-206	13-May-2025	150,000 USD
Contact Name	DMID IICT Central Contact Mailbox				
Contact Telephone					
Contact Email	NIAID_DMID_IICT@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	13-May-2025 , 15-Sep-2025 , 13-Jan-2	026 , 13-May-2026			
Synopsis	This Notice of Funding Opportunity (NOFO) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role).				

129203 Role of Defective Proviruses in HI' Allowed)	V Persistence (R01 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PR-25- 330	07-May-2025	2,500,000 USD
Contact Name	Leia Novak, PhD				
Contact Telephone	301-761-7825				
Contact Email	<u>leia.novak@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-2 2028	.026 , 07-May-2026 , 07-Sep-2026 , 07-J	an-2027 , C	07-May-2027 , 07-Sep-20	27 , 07-Jan-
Synopsis	proviruses on mechanisms of HIV pers	opportunity (NOFO) is to support resear sistence and pathogenesis during antiregies and interference with HIV-specific research	troviral tre	atment and their potenti	
129272 RFA-AI-24-080 Broad Spectrum Botulinum Serotypes (R61/R33 CI		National Institute of Allergy and Infectious Diseases/NIH/DHHS		02-Apr-2025 [Optional][LOI/Pre-App	Not Specified
Contact Name	Amir Zeituni, Ph.D.				
Contact Telephone	301-761-6872				
Contact Email	amir.zeituni@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Apr-2025 [Optional][LOI/Pre-App],	02-May-2025			
Synopsis	Botulinum Neurotoxin (BoNT) intoxica	opportunity (NOFO) is to support the destion. Development of products that can milestone-driven research. Transitioning the R61 phase.	reverse B	oNT intoxication are high	ıly
114362 NIAID Resource-Related Research Allowed)	Projects (R24 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 23-065	07-May-2025	Not Specified
Contact Name	Martin Gutierrez, Ph.D.				

Contact Email mgutierrez@niaid.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 25-May-2025, 07-Sep-2025, 25-Sep-2025, 07-Jan-2026

This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will Synopsis occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic

NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)

diseases.

National Institute of Allergy and Infectious Diseases/NIH/DHHS

PAR-25-May-2025 23-282

1,755,000 USD

Contact Name Madelyn Reves, DNP, FAAN

Contact Telephone 301-594-5945

122331

Contact Email AlTrainingHelpDesk@niaid.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025, 27-May-2025, 07-Sep-2025, 25-Sep-2025, 25-Jan-2026, 25-May-2026, 27-May-2026, 07-Sep-2026

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse Synopsis backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with

113395 NIAID Research Opportunities for New and "At-Risk" Investigators to

a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities

National Institute of Allergy and

PAR-

05-Mar-2025

Not

Promote Workforce Diversity (RO:	1 Clinical Trial Optional)	Infectious Diseases/NIH/DHHS	22-241	Specified
Contact Name	Diane Adger-Johnson, MPH			
Contact Telephone				
Contact Email	AlTrainingHelpDesk@niaid.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	05-Mar-2025 , 07-May-2025 , 05-Jun-	-2025 , 05-Jul-2025 , 07-Sep-2025		
Synopsis	mission. This FOA seeks to support ei successfully for substantial, independ support as a PD/PI on a substantial in award in the current fiscal year, will h	nity announcement is to encourage appether (a) a New Investigator (NI), an ind dent funding from NIH, or (b) are an 'Atadependent research award and unless have no substantial research grant fund outpet underrepresented in the health-research grant fundations.	ividual who has not previously or -Risk' investigator, an individual successful in securing a substar ling in the following fiscal year,	competed who had prior atial research grant
129406 Elucidating Immunometabolic Res TB or HBV Risk (R01 Clinical Trial N	sponses to HIV Infection that Increase Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 07-May-2025 25-315	Not Specified
Contact Name	Josh Radke, Ph.D.			
Contact Telephone	301-761-6525			
Contact Email	josh.radke@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan- 2028	2026 , 07-May-2026 , 07-Sep-2026 , 07	-Jan-2027 , 07-May-2027 , 07-Se	ep-2027 , 07-Jan-
Synopsis	immunometabolic alterations, in a ho immune response and increase risk for as Mycobacterium tuberculosis (Mtb	opportunity (NOFO) is to support resent suppressed on combination antiretror poor outcomes due to a second, pot or hepatitis B virus (HBV). This NOFO alism affect immune cell regulation, cell disease progression.	oviral therapy (cART-suppresse entially long-term, infection sucaims to support research to def	d), impact the h ine how HIV-
113281 NIAID Investigator Initiated Progra	am Project Applications (P01 Clinical	National Institute of Allergy and	PAR- 07-May-2025	Not

Trial Not Allowed)		Infectious Diseases/NIH/DHHS	22-225		Specified
Contact Name	Mr. Martin Gutierrez, B.S.				<u> </u>
Contact Telephone	·				
Contact Email	mgutierrez@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 11-Jun-2025 , 07-Sep-2	2025			
Synopsis	This Funding Opportunity Announcem applications. The proposed programs pathogenesis of infectious microbes, development and function across the allergy, asthma, autoimmunity, immutherapeutics, and diagnostics to prevent to this FOA must include at least two overall objective; and an administration	should address scientific areas relevant including HIV; host-microbe interaction lifespan, and in response to infection nodeficiency, or transplant rejection ent and treat infectious and immune- related, synergistic research projects	ant to the NIA ons; mechanisus pathogens; and translation mediated dise	ID mission including: bid sms regulating immune immune dysfunction re onal research to develo eases. Each PO1 applicat common central theme,	ology and system sulting in p vaccines, tion submitted focus, and/or
129890 RFA-AI-24-079 Asthma and Aller Centers (U19 Clinical Trial Optional	rgic Diseases Cooperative Research	National Institute of Allergy and Infectious Diseases/NIH/DHHS		14-May-2025 [Optional][LOI/Pre-App	4,500,000 p] USD
Contact Name	Gang Dong, M.D., Ph.D.				
Contact Telephone	240-627-3508				
Contact Email	gdong@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	14-May-2025 [Optional][LOI/Pre-App	l, 13-Jun-2025			
Synopsis	The purpose of this notice of funding institutions to participate in the Asthr will support centers that integrate clir onset and progression of diseases of i atopic dermatitis, food allergy, and dr pathogenesis of these conditions and	na and Allergic Diseases Cooperative nical and translational research to co nterest, including asthma, rhinitis (al ug allergy. The overarching goal of th	Research Cennduct studies lergic and non ne program is	nters (AADCRC) program on the mechanisms und n-allergic), chronic rhino to improve the underst	n. The program derlying the sinusitis, anding of the

	strategies.				
115065 NIAID Physician-Scientist Pathway Clinical Trial Required)	to Independence Award (K99/R00	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 23-070	07-May-2025	Not Specified
Contact Name		, .			<u> </u>
Contact Telephone					
·	AlTrainingHelpDesk@niaid.nih.gov				
Sponsor Website					
'	Link to program URL				
•	07-May-2025 , 12-Jun-2025 , 07-Sep-2	2025 , 12-Oct-2025 , 07-Jan-2026			
Synopsis	a strong cohort of new and talented in transition of outstanding postdoctoral positions to independent, tenure-trace support during this transition to help thereby help to address the national particles is designed specifically for candidates feasibility study, or a separate ancillar	cientist Pathway to Independence Awandependent physician-scientists. This parent is a line of the competitive of the competitiv	orogram is dedegree from orogram will pedent research This Funding ator of an in and career c	esigned to facilitate mentored, postdoc provide independer ch careers in biomed Opportunity Annodependent clinical development. Those	a timely toral research at NIAID research dical fields and uncement (FOA) trial, a clinical trial e not planning an
115066 NIAID Physician-Scientist Pathway Independent Clinical Trial Not Allo	y to Independence Award (K99/R00 owed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 23-071	07-May-2025	Not Specified
Contact Name					
Contact Telephone	301-594-5945				
Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2	2025 , 12-Oct-2025 , 07-Jan-2026			
Synopsis	The purpose of the NIAID Physician-So	cientist Pathway to Independence Awa	rd (K99/R00)) program is to incre	ease and maintain

a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-23-070).

129070 NIAID Career Transition Award (K. Allowed)	22 Independent Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 25-251	07-May-2025	Not Specified
Contact Name	Jyothi Arikkath, PhD				
Contact Telephone	301-594-5945				
Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb -Feb-2027 , 07-May-2027 , 12-Jun-2027 ,			
Synopsis	assistant professor or equivalent and of Funding Opportunity (NOFO) is des independent clinical trial, a clinical trial	sition Award program is to assist postdoo initiate a successful biomedical career as igned specifically for applicants proposing al feasibility study, or an ancillary clinical clinical trial led by a mentor or co-mento	an indepo g research trial. Und	endent research scientist n that does not involve le	. This Notice ading an
129405 Elucidating Immunometabolic Res TB or HBV Risk (R21 Clinical Trial N	sponses to HIV Infection that Increase Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 25-316	07-May-2025	275,000 USD
Contact Name	Josh Radke, Ph.D.				
Contact Telephone	301-761-6525				

Contact Email josh.radke@nih.gov

Sponsor Website

Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-2 2028	2026 , 07-May-2026 , 07-Sep-2026 , 07-Ja	an-2027 , C	07-May-2027 , 07-Sep-2	2027 , 07-Jan-
Synopsis	immunometabolic alterations, in a ho immune response and increase risk fo as Mycobacterium tuberculosis (Mtb)	opportunity (NOFO) is to support researd st suppressed on combination antiretrower poor outcomes due to a second, potent or hepatitis B virus (HBV). This NOFO air ism affect immune cell regulation, cell-codisease progression.	iral thera itially long ns to supp	oy (cART-suppressed), i -term, infection such ort research to define	impact the
129757 RFA-AI-25-006 Molecular Mech (MMCA) (R01 Clinical Trial Not All		National Institute of Allergy and Infectious Diseases/NIH/DHHS		11-May-2025 [Optional][LOI/Pre-Ap	2,499,995 pp] USD
Contact Name	Ari Joffe, Ph.D.				
Contact Telephone	240-669-5084				
Contact Email	ari.joffe@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	11-May-2025 [Optional][LOI/Pre-App]], 10-Jun-2025			
Synopsis	(combination adjuvants) in order to unmust have previously demonstrated in	g opportunity (NOFO) is to support reseand the mechanisms by which the mmune modulating activity. The long-tendicting the immune profile elicited by controls.	y work in m goal of	concert. All adjuvants on this research program	considered
123709 NIAID SBIR Phase II Clinical Trial In Agreement (U44 Clinical Trial Req		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 24-099	13-May-2025	Not Specified
Contact Name	Natalia Kruchinin, Ph.D.				
Contact Telephone	240-669-2919				
Contact Email	NIAIDU44@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

	This Notice of Funding Opportunity (Namall business concerns (SBCs) that proof the NIAID. This program provides successive or patient risk, but rather definential interventions, administration	2026, 13-May-2026, 14-Sep-2026, 13-Ja JOFO) encourages Small Business Innova ropose to implement investigator-initiate upport for hypothesis-driven, milestone- d, this program encourages high-risk clini nes a study that contains one or more of of an unlicensed product, or administrat so encouraged and may be proposed und	tion Research (SBIR) grant applied clinical trials related to the redriven clinical trials. Although clical studies. High-risk does not if the following unique features:	esearch mission dinical trials not mply human involves non-	
123710 NIAID Clinical Trial Implementation Clinical Trial Required)	n Cooperative Agreement (U01	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 24-100 13-May-2025	Not Specified	
Contact Name	Martin Gutierrez				
Contact Telephone	240-292-4844				
Contact Email	mgutierrez@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	13-May-2025 , 15-Sep-2025 , 13-Jan-2	2026 , 13-May-2026 , 14-Sep-2026 , 13-Ja	an-2027		
This Notice of Funding Opportunity (NOFO) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.					
113565 Notice of Special Interest (NOSI): Arthropod Vector	argeting the Pathogen within the	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT- Al-22- 07-May-2025 074	Not Specified	
Contact Name	Adriana Costero-Saint Denis, Ph.D.				
Contact Telephone	240-292-4184				
Contact Email	acostero@niaid.nih.gov				
Sponsor Website					

Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2	025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oc	t-2025,0	7-Jan-2026	
Synopsis		nvites applications to stimulate multidis ify approaches to prevent pathogen trai			
114374 Notice of Special Interest (NOSI): Immunology	Complement in Fundamental	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT- AI-23- 012	07-May-2025	Not Specified
Contact Name	Ari Joffe, PhD				
Contact Telephone	240-669-5084				
Contact Email	ari.joffe@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2	025 , 07-Sep-2025 , 05-Oct-2025 , 16-Oc	t-2025,0	7-Jan-2026	
	The main objective of this program is to support studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses involved in pathogenic infections, vaccination, post-infection sequelae, autoimmunity, allergy, or transplantation. The results of such studies will inform the development of vaccines or therapeutics that target complement components.				
Synopsis	components and/or receptors in the in pathogenic infections, vaccination, po	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all	quality of lergy, or tr	immune responses in ansplantation. The re	volved in
	components and/or receptors in the in pathogenic infections, vaccination, po	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all	quality of lergy, or tr	immune responses in ansplantation. The re	volved in
109336 Notice of Special Interest (NOSI): Allograft Survival	components and/or receptors in the in pathogenic infections, vaccination, po studies will inform the development of	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all f vaccines or therapeutics that target co	quality of lergy, or tr emplemen NOT- AI-22-	immune responses in ansplantation. The rest components.	volved in sults of such
109336 Notice of Special Interest (NOSI): Allograft Survival	components and/or receptors in the in pathogenic infections, vaccination, postudies will inform the development of the composite Patricia Kehn, Ph.D.	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all f vaccines or therapeutics that target co	quality of lergy, or tr emplemen NOT- AI-22-	immune responses in ansplantation. The rest components.	volved in sults of such
109336 Notice of Special Interest (NOSI): Allograft Survival Contact Name Contact Telephone	components and/or receptors in the in pathogenic infections, vaccination, postudies will inform the development of the composite Patricia Kehn, Ph.D.	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all f vaccines or therapeutics that target co	quality of lergy, or tr emplemen NOT- AI-22-	immune responses in ansplantation. The rest components.	volved in sults of such
109336 Notice of Special Interest (NOSI): Allograft Survival Contact Name Contact Telephone	components and/or receptors in the in pathogenic infections, vaccination, postudies will inform the development of the developm	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all f vaccines or therapeutics that target co	quality of lergy, or tr emplemen NOT- AI-22-	immune responses in ansplantation. The rest components.	volved in sults of such
109336 Notice of Special Interest (NOSI): Allograft Survival Contact Name Contact Telephone Contact Email Sponsor Website	components and/or receptors in the inpathogenic infections, vaccination, postudies will inform the development of the developme	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all f vaccines or therapeutics that target converse National Institute of Allergy and Infectious Diseases/NIH/DHHS	quality of lergy, or tromplemen NOT- AI-22- 023	immune responses in ansplantation. The ret components. 07-May-2025	volved in sults of such Not Specified
109336 Notice of Special Interest (NOSI): Allograft Survival Contact Name Contact Telephone Contact Email Sponsor Website	components and/or receptors in the inpathogenic infections, vaccination, postudies will inform the development of the developme	nitiation, magnitude, maintenance, and st-infection sequelae, autoimmunity, all f vaccines or therapeutics that target co	quality of lergy, or tromplemen NOT- AI-22- 023	immune responses in ansplantation. The ret components. 07-May-2025	volved in sults of such Not Specified

	•	at focus on 1) optimizing treatment and after vascularized composite allotransplaterm VCA acceptance.	-	_	nce of acute
116360 Notice of Special Interest (NOSI): A Develop a Coccidioidomycosis (Va		National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT- AI-23- 031	05-Apr-2025	Not Specified
Contact Name	Dona C. Love, Ph.D.				
Contact Telephone	301-761-7788				
Contact Email	Dona.Love@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025 , 05-Jun-2 2026 , 07-Jan-2026	.025 , 16-Jun-2025 , 05-Sep-2025 , 07-Se	ep-2025 , 05	-Oct-2025 , 16-Oct-202	25 , 05-Jan-
Synopsis	outlined in the NIAID Strategic Plan For clear relevance to the strategic priorit address gaps in Coccidioides basic res	nterest (NOSI) is to highlight NIAID's int or Research To Develop A Valley Fever Nies defined in the strategic plan, which we earch to support the development of a selop and advance vaccines to prevent co	Vaccine. The encompasse vaccine; 2) c	proposed research sho es three major research develop tools and resou	ould have areas: 1)
114290 Notice of Special Interest (NOSI): HIV/AIDS in NIAMS	Promoting Research Opportunities on	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT- AR-23- 004	09-Apr-2025	Not Specified
Contact Name	Heiyoung Park, Ph.D.				
Contact Telephone	301-594-5032				

09-Apr-2025, 07-May-2025, 05-Jun-2025, 16-Jun-2025, 06-Aug-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 05-Dec-

Oct-2026, 07-Jan-2027, 05-Feb-2027, 16-Feb-2027, 07-May-2027, 05-Jun-2027, 16-Jun-2027, 07-Sep-2027, 05-Oct-2027,

Deadline Dates (ALL) 2025, 07-Jan-2026, 05-Feb-2026, 16-Feb-2026, 07-May-2026, 05-Jun-2026, 16-Jun-2026, 07-Sep-2026, 05-Oct-2026, 16-Deadline Dates (ALL)

Contact Email parkh1@mail.nih.gov

Program URL Link to program URL

Sponsor Website

Synopsis		to inform potential applicants to the Na of special interest in HIV/AIDS-associate				
Notice of Special Interest (NOSI): 117716 Exploratory/Developmental Research	 	National Institute of Arthritis and Musculoskeletal and Skin	NOT- AR-23- 09-Apr-2025	Not		
Areas	STEET FOCUSED OF INITIATION COLE INITISSION	Diseases/NIH/DHHS	006	Specified		
Contact Name	Jana Eisenstein					
Contact Telephone	301-594-5032					
Contact Email	jana.eisenstein@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)		2025 , 16-Jun-2025 , 06-Aug-2025 , 07-Se -Feb-2026 , 07-May-2026 , 05-Jun-2026	•	<u>-</u>		
Synopsis	The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community.					
120314 National Centers for Biomedical In (P41 Clinical Trials Optional)	maging and Bioengineering (NCBIB)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHH	PAR- S 23-235 07-May-2025	Not Specified		
Contact Name	Behrouz Shabestari, PhD					
Contact Telephone	301-451-6771					
Contact Email	shabestb@mail.nih.gov					
Sponsor Website						

Program URL Link to program URL

Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 07-Sep- 2026	2025 , 25-Sep-2025 , 07-Jan-2026 , 25-Jan	-2026 , 0	7-May-2026 , 25-May-20	26 , 07-Sep-
Synopsis	Bioengineering (NCBIB). NCBIB are nat that are driven by the needs of basic,	OFO) encourages grant applications for N tional resource centers for conducting restranslational, and/or clinical researchers. If of the research community in the use of the research community in	earch and NCBIB als	d development on new to o make their technologie	echnologies es available
128633 Bioengineering Partnerships with	Industry (U01 Clinical Trial Optional)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR- 24-325	28-Apr-2025 [Optional][LOI/Pre-App]	Not Specified
Contact Name	Guoying Liu, Ph.D.				
Contact Telephone	301-594-5220				
Contact Email	liug@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	Jan-2026 , 27-Apr-2026 [Optional][LOI	07-May-2025 , 28-May-2025 , 07-Sep-202 /Pre-App], 07-May-2026 , 27-May-2026 , , 27-Apr-2027 [Optional][LOI/Pre-App], 27	07-Sep-2	026 , 28-Dec-2026	re-App], 27-
Synopsis	industrial investigators to accelerate to can address important biomedical proscharacterized solutions that fulfill and the practice of medicine. Awards will bioengineering approach to developing	ent (FOA) solicits applications from resear the development and adoption of promising blems. The objectives are to establish the summet need and are capable of enhancing focus on supporting multidisciplinary tean g technologies. The goal of the program is lize meaningful solutions within 5 – 10 year	ng bioeng se tools a our unde ns that ap s to suppo	ineering tools and techno and technologies as robuserstanding of life science oply an integrative, quant	ologies that st, well- processes or titative
117677 Notice of Special Interest (NOSI): Applications	Synthetic Biology for Biomedical	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	NOT- EB-23- 002	05-May-2025	Not Specified
Contact Name Contact Telephone	Hye-Sook Kim, Ph.D. 301-827-6910				

Contact Email hye-sook.kim@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-May-2025, 05-Jun-2025, 16-Jun-2025, 16-Oct-2025

The purpose of this Notice is to announce that the National Center for Complementary and Integrative Health (NCCIH), the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), the National Institute on Aging (NIA), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of General Medical Sciences (NIGMS) are encouraging new applications to advance research activities relevant to synthetic biology.

In-Depth Phenotyping and Research Using IMPC-Generated Knockout 115197 Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)

National Institute of Child Health and Human Development/NIH/DHHS

PAR-06-May-2025 2,499,995 25-140 [Optional][LOI/Pre-App] USD

Contact Name Mahua Mukhopadhyay, PhD

Contact Telephone 301-435-6886

Contact Email mukhopam@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)|06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025

mouse phenotyping effort to perform additional in-depth phenotyping and research.

research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform

127983 NICHD Resource Program Grants (Allowed)	in Bioinformatics (P41 Clinical Trial No	National Institute of Child Health and Human Development/NIH/DHHS	PAR- 24-301	25-Apr-2025 [Optional][LOI/Pre-App	8,750,000	
		numan bevelopment/Nin/Dnns	24-301	[Optional][LOI/Pre-App	ן טאַט	
	Kathryn Stein, PhD					
Contact Telephone	301-402-3528					
Contact Email	kathryn.stein@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	[Optional][LOI/Pre-App], 25-Jan-2026 App], 25-Sep-2026 , 26-Dec-2026 [Op	-Apr-2025 [Optional][LOI/Pre-App], 25-May-2025, 26-Aug-2025 [Optional][LOI/Pre-App], 25-Sep-2025, 26-Dec-2025 ptional][LOI/Pre-App], 25-May-2026, 26-Aug-2026 [Optional][LOI/Pre-App], 25-May-2026, 26-Aug-2026 [Optional][LOI/Pre-p], 25-Sep-2026, 26-Dec-2026 [Optional][LOI/Pre-App], 25-Jan-2027, 25-Apr-2027 [Optional][LOI/Pre-App], 25-May-2027, -Aug-2027 [Optional][LOI/Pre-App], 25-Sep-2027				
Synopsis	dissemination of unique knowledge, of community using animal models of enhancement of the resources, user t	The purpose of this Notice of Funding Opportunity (NOFO) is to support the continued operation, maintenance, and dissemination of unique knowledge, data, and/or bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development and enhancement of the resources, user training and services, provision of community generated data storage and curation, wide dissemination of the tools and/or resources, and expansion of interoperability with other NIH bioinformatics resources.				
128527 Screening and Functional Validation Variants (R01 Clinical Trial Not Allo	on of Human Birth Defects Genomic owed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR- 25-185	06-May-2025 [Optional][LOI/Pre-App	2,499,995 l USD	
	Reiko Toyama, Ph.D.	,,		[0]000000000000000000000000000000000000	,	
Contact Name	• •					
•	ToyamaR@nih.gov					
Sponsor Website	-					
'	Link to program URL					
Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App [Optional][LOI/Pre-App], 05-Feb-2026], 05-Jun-2025 , 05-Sep-2025 [Optional][L 5 , 06-May-2026 [Optional][LOI/Pre-App], ional][LOI/Pre-App], 05-Feb-2027 , 06-Ma , 05-Oct-2027	05-Jun-2	026 , 05-Sep-2026 [Optio	nal][LOI/Pre-	
Synopsis		xt generation sequencing technologies ha y of congenital defects including structur				

developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric congenital anomalies cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of congenital anomaly-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest

	1	р, р					
129571 Early Immune System Developme Optional)	ent and Ontogeny (R01 Clinical Trial	National Institute of Child Health and Human Development/NIH/DHHS	PAR- 25-362	07-May-2025	1,600,000 USD		
Contact Name	Sai Majji, PhD						
Contact Telephone	301-661-9816						
Contact Email	sai.majji@nih.gov						
Sponsor Website							
Program URL	Link to program URL						
Deadline Dates (ALL)	07-May-2025 , 07-Jan-2026 , 07-May- 2029	07-May-2025 , 07-Jan-2026 , 07-May-2026 , 07-Jan-2027 , 07-May-2027 , 07-Jan-2028 , 07-May-2028 , 07-Sep-2028 , 07-Jan- 2029					
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to further elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART). This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.						
116944 Biological Testing Facility (X01 Clin	nical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR- 23-192	02-May-2025	Not Specified		

Contact Name Leigh Allen, Ph.D.

Contact Telephone 301-594-9151

Contact Email <u>leigh.allen@nih.gov</u>

Sponsor Website

Program URL Link to program URL

	I					
Deadline Dates (ALL)	·					
Synopsis	their contraceptive development prog	investigators with a mechanism to reque gram. This FOA aims to position innovativ I to have current NIH funding to apply, bun submission.	e and val	idated methods for futur	re clinical	
128791 NICHD Small Research Grant Prog	ram (R03 Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-25- 125	07-May-2025	100,000 USD	
Contact Name						
Contact Telephone						
Contact Email	NICHDReferral@mail.nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)		2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb -Feb-2027 , 07-May-2027 , 16-Jun-2027 ,				
Synopsis	The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.					
128792 NICHD Small Research Grant Prog	ram (R03 Basic Experimental Studies	National Institute of Child Health and	PA-25-	07-May-2025	100,000	
with Humans Required)		Human Development/NIH/DHHS	126	07-1VIay-2023	USD	
Contact Name						
Contact Telephone						
Contact Email	NICHDReferral@mail.nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)		2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb -Feb-2027 , 07-May-2027 , 16-Jun-2027 ,				

Synopsis	mission. This funding opportunity and in NOT-OD-18-212 as "prospective badefinition of a clinical trial and also minclude studies that prospectively ass variables) and that assess biomedical aspects of phenomena without specifical	gram (Clinical Trial Required) supports of nouncement is for basic science expering sic science studies involving human parties the definition of basic research. Typing human participants to conditions (i.e., or behavioral outcomes in humans for the capplication towards processes or products in mind should submit under the	nental studies involving humans rticipants." These studies fall wit pes of studies that should submine., experimentally manipulate in the purpose of understanding the ducts in mind. Studies conducted	, referred to thin the NIH t under this FOA ndependent ne fundamental ed with specific
128235 Continuation or Revision of NIDC Implementation Cooperative Agr	R Clinical Trial Planning and eement (UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 25-062 07-Mar-2025	Not Specified
Contact Name	Dena Fischer, DDS, MSD, MS	<u> </u>		
Contact Telephone				
Contact Emai	dena.fischer@nih.gov			
Sponsor Website				
Program URI	Link to program URL			
Deadline Dates (ALL		2025 , 04-Sep-2025 , 06-Nov-2025 , 08-J 8-Jan-2027 , 08-Mar-2027 , 06-May-202		
Synopsis	clinical trials supported by the Nation trial through a competing renewal ap or when an extended period of follow supported when there is compelling j encourages applicants to contact the	IOFO) will accept applications for compal Institute of Dental and Craniofacial Replication will be supported when there youp is well justified to assess longer terustification for modifying the scope of the Scientific/Research contact assigned to apetitive revision prior to submitting an	tesearch (NIDCR). Extension of a is need for additional time to come outcomes. Competitive revision the ongoing clinical trial. NIDCR to the ongoing clinical trial for where	n ongoing clinical implete the trial ons will be strongly
117230 NIDCR Research Grants for Analy (Clinical Trial Not Allowed)	ses of Existing Genomics Data (R01)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 25-164 07-May-2025	Not Specified
Contact Name	Noffisat Oki			

Contact Telephone 301-402-6778

Contact Email	noffisat.oki@nih.gov				
Sponsor Website					
'	Link to program URL				
· ·		2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb	-2026 , 07-May-2026		
Synopsis	The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. In addition to analysis of existing data, experimental or in silico work is required to validate the results of the proposed analysis, or to validate a newly developed analytic method. Projects aimed at understanding oral health disparities to inform strategies for improving health for all individuals are a priority. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.				
117461 NIDCR Prospective Observational Cooperative Agreement (U01 Clin	-	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 23-162 07-May-2025	Not Specified	
Contact Name	Lorena Baccaglini, DDS, MS, PhD				
Contact Telephone	301-435-7908				
Contact Email	lorena.baccaglini@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2	2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb	-2026 , 07-May-2026		
Synopsis		ooperative agreement mechanism, investuire prospective collection of data/biospe	_	ıdies or	
NIDCR Predoctoral to Postdoctoral 125295 Dental, Oral and Craniofacial Research	earch Workforce (F99/K00	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 24-139 08-Apr-2025	Not Specified	
Contact Name					

Contact Telephone 301-569-0273

Contact Email Rachel.Sare@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

08-Apr-2025, 07-May-2025, 08-Aug-2025, 07-Sep-2025, 08-Dec-2025, 07-Jan-2026, 08-Apr-2026, 07-May-2026, 08-Aug-2026, 07-Sep-2026, 08-Dec-2026, 07-Jan-2027, 08-Apr-2027, 07-May-2027

The purpose of the NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and Craniofacial (DOC) Research Workforce (F99/K00) is to support graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences, over the transition from predoctoral to postdoctoral research Synopsis training. This phased award program will facilitate completion of graduate PhD or dual degree clinician scientist programs (F99) and smooth transition to mentored postdoctoral positions in DOC research (K00). This Notice of Funding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical 102596 Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

National Institute of Dental and Craniofacial Research/NIH/DHHS

07-May-2025 PAR-Not 25-057 [Optional][LOI/Pre-App] Specified

Contact Name Dena Fischer, DDS, MSD, MS

Contact Telephone 301-594-4876

Contact Email dena.fischer@nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025 [Optional][LOI/Pre-App], 08-May-2025, 06-Jun-2025, 04-Sep-2025, 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025, 06-Jan-2026, 10-Jan-2026 [Optional][LOI/Pre-App], 09-Feb-2026, 08-May-2026, 09-May-2026 [Optional][LOI/Pre-Deadline Dates (ALL) App], 08-Jun-2026, 08-Sep-2026 [Optional] [LOI/Pre-App], 09-Sep-2026, 08-Oct-2026, 08-Jan-2027, 09-Jan-2027 [Optional][LOI/Pre-App], 08-Feb-2027, 06-May-2027, 08-May-2027 [Optional][LOI/Pre-App], 07-Jun-2027, 07-Sep-2027 [Optional][LOI/Pre-App], 08-Sep-2027, 07-Oct-2027, 06-Jan-2028

This Notice of Funding Opportunity (NOFO) will support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR). Studies appropriate for this NOFO are those testing a drug, biologic, device, or procedure to improve dental, oral, or craniofacial diseases or conditions, including trials for any phase of testing for a Food and Drug Administration (FDA)-

regulated product. Awards made under this NOFO will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase (UH3) of up to five years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, NIDCR program priorities, and availability of funds. The UG3/UH3 application must be submitted as a single application with the final design of the UH3 clinical trial including detail about the study population, intervention(s), and outcome(s) described in the application, following the instructions described in this NOFO. The UG3 planning phase permits both scientific and operational planning activities, though the planning phase cannot be used to test for intervention safety or efficacy or assess the study's primary outcome. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial. Applications designed to test behavior change interventions or those used as tools to understand mechanisms of behavior change will not be supported by this NOFO.

NIDCR Behavioral and Social Intervention Clinical Trial Planning and 129024 Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-25-188

08-May-2025

Not Specified

Contact Name Jill Mattia, Ph.D.

Contact Telephone 301-451-7770

Contact Email ill.mattia@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

08-May-2025, 06-Jun-2025, 04-Sep-2025, 07-Oct-2025, 06-Jan-2026, 09-Feb-2026, 08-May-2026, 08-Jun-2026, 09-Sep-2026, 08-Oct-2026, 08-Jan-2027, 08-Feb-2027, 06-May-2027, 08-Jun-2027, 08-Sep-2027, 08-Oct-2027, 08-Jan-2028

The purpose of this Notice of Funding Opportunity (NOFO) is to provide support for the planning and implementation of welldesigned, rigorously conducted, behavioral/biopsychosocial intervention studies relevant to dental, oral, and craniofacial health as well as associated medical and mental health status or comorbidities. A broad range of intervention research projects that meet the NIH Definition of a Clinical Trial are appropriate for this opportunity. Awards made under this NOFO will initially support a milestone-driven planning phase (UG3) for 1 year, with possible transition to a clinical trial implementation phase (UH3) of up to five years. The UG3/UH3 application must be submitted as a single application. Applications that employ traditional methods as well as novel/advanced features (e.g., mobile health, artificial intelligence, telehealth, responsive health system records, multiple assignment randomized trial designs (SMART) or sequential randomization designs), etc., are encouraged. This NOFO will not support the testing of drugs, devices, or biologics regulated by the FDA; the corresponding NOFO for clinical trials in these areas is PAR-25-057.

Short-term Mentored Career Enhance 110993 Craniofacial Research for Mid-Car Independent Clinical Trial Not Allo		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 22-121	07-May-2025	Not Specified	
Contact Name	Leslie A. Frieden, PhD					
Contact Telephone	301-496-4263					
Contact Email	leslie.frieden@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025					
Synopsis	investigators who either wish to expa their research by incorporating DOC r oral, and craniofacial health and disea candidates proposing research that do	ement Award (K18) is to support mentoring or augment their dental, oral, or cran esearch into their research program to a use. This Funding Opportunity Announce pes not involve leading an independent cants to this FOA are permitted to propo	iofacial (D0 dvance fur ment (FOA clinical trial	OC) research program, on the control of the control	or to redirect about dental, y for ty study, or an	
128678 NIDCR Dentist Scientist Career Tra Investigators (K22 Clinical Trial No		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 25-027	07-May-2025	Not Specified	
Contact Name	Leslie A. Frieden, PhD					
Contact Telephone	301-496-4263					
Contact Email	leslie.frieden@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)		2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Fel -Feb-2027 , 07-May-2027 , 12-Jun-2027 ,				
Synopsis	transition of highly qualified dentist so tenure-track or equivalent faculty pos	26, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027, 12-Oct-2027, 07-Jan-2028 e purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to facilitate insition of highly qualified dentist scientists from NIH Intramural postdoctoral research positions to extramural, academic nure-track or equivalent faculty positions at eligible U.S. institutions. The award will provide support for two years of entored postdoctoral research training in the NIH Intramural Research Program, and three years of independent research				

funding at the extramural institution. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (FON).

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
126076	NIDCR Dual Degree Dentist Scient Transition Award (F99/K00 Indep		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25- 021	08-Apr-2025	Not Specified		
	Contact Name	Rachel Sare, Ph.D.						
	Contact Telephone	301-569-0273						
	Contact Email	Rachel.Sare@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025 , 08-Aug-20 2026 , 07-Sep-2026 , 08-Dec-2026 , 07-Ja			08-Apr-2026 , 07-May-202	26 , 08-Aug-		
	Synopsis	The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provi support and mentorship to graduate students enrolled in integrated dual degree dental (DDS/DMD) and PhD programs during the transition from predoctoral student to postdoctoral scholar. This phased award will facilitate completion of						
110754	Notice of Special Interest (NOSI): Harnessing Immune System Plast	Achieving Tissue Robustness Through icity	National Institute of Dental and Craniofacial Research/NIH/DHHS	NOT-DE- 22-005	07-May-2025	Not Specified		

Contact Name Preethi Chander, PhD

Contact Telephone 301-827-4620

61

Contact Ema	preethi.chander@nih.gov				
Sponsor Websit					
Program UR	Link to program URL				
Deadline Dates (ALL	07-May-2025 , 05-Jun-2025 , 16-Jun-2025	, 07-Sep-2025			
Synopsi	NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward protection against episodic recurrence and preventative disease management in a patient-specific manner across the lifespan.				
127032 NIDCR Mentored Career Developarticipation in Research (K01 In		National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25- 022	07-May-2025	Not Specified
Contact Nam	Shoba Thirumangalathu, Ph.D.				
Contact Telephon	301-594-0652				
Contact Ema	nidcrtraining@nidcr.nih.gov				
Sponsor Websit					
Program UR	Link to program URL				
Deadline Dates (ALL	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb				•
Synopsi	The purpose of the NIDCR Mentored Care the dental, oral, and craniofacial research career faculty engaged in these areas of resupport for a sustained period of protecte experienced mentor. This NOFO is designed independent clinical trial, a clinical trial fer permitted to propose research experiences	workforce by expanding the pool esearch This Notice of Funding Opped time for intensive research careed specifically for applicants propoasibility study, or an ancillary study	of well-train portunity (N er developn sing researd y to a clinica	ed postdoctoral fellows OFO) provides salary and nent under the guidance h that does not involve I trial. Applicants to this	and early d research of an eading an
117231 NIDCR Small Research Grants fo Clinical Trial Not Allowed)	Analyses of Existing Genomics Data (R03)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25- 166	07-May-2025	200,000 USD

	Contact Name	Noffisat Oki					
	Contact Telephone	301-402-6778					
	Contact Email	noffisat.oki@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 16-Oct-2025 , 07-Jan-2026 , 16-Feb-2026 , 07-May-2026					
	Synopsis	The purpose of this NOFO is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) biology, and diseases and conditions, through analysis of existing and publicly available genomic data, with or without other types of complementary data, using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the proposed project(s), including methods for data and metadata mining, data integration, and Artificial Intelligence (AI)/Machine Learning (ML)/Deep Learning (DL) methods. Projects focused on investigating and/or characterizing human biological pathways to inform identification of intervention targets or defining the pathogenicity of known genetic variants are encouraged.					
	Notice of Special Interest (NOSI):	NIDCR Support for Research on the	National Institute of Dental and	NOT-DE-		Not	
116699	Physiological Involvement of Oral (COVID-19)	Cavity in Coronavirus Disease 2019	Craniofacial Research/NIH/DHHS	23-004	07-May-2025	Specified	
	Contact Name	Amanda Melillo, Ph.D.					
	Contact Telephone	301-529-7217					
	Contact Email	amanda.melillo@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
		07-May-2025 , 05-Jun-2025 , 16-Jun-202 2026 , 07-May-2026	5 , 07-Sep-2025 , 05-Oct-2025 , 16-0	Oct-2025 , 0	7-Jan-2026 , 05-Feb-2026	5 , 16-Feb-	
	Synopsis	The National Institute of Dental and Crarencourage research studies focused on t CoV-2 and/or Coronavirus Disease 2019	he physiological involvement of ora	_		-	
128813	NIDCR Small Grant Program for N Allowed)	ew Investigators (R03 Clinical Trial Not	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25- 105	07-May-2025	200,000 USD	

		Preethi Chander, PhD					
	Contact Telephone	301-827-4620					
	Contact Email	preethi.chander@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)		07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep- 2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028				
	Synopsis	This NIDCR Small Grant Program for New science conducted by scientists who are This RO3 program supports pilot or feasi sufficient preliminary data for a subsequ	establishing an independent resear bility studies and developmental res	ch career in search proje	dental, oral and craniofacts with the intention of o	cial research. obtaining	
110996	NIDCR Small Research Grants for Methodology Development (R03	Oral Health Data Analysis and Statistical Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-25- 045	07-May-2025	200,000 USD	
	Contact Name	Lorena Baccaglini, DDS, MS, PhD					
	Contact Telephone	301-435-7908					
	Contact Email	lorena.baccaglini@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2025					
		The goal of this Notice of Funding Oppor involve secondary data analyses of exist methodology for analyzing existing dent	ing oral or craniofacial database res				
113070		vestigators (ESIs) Pursuing Research on and Complications (DP1- Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-23- 024	01-Apr-2025 [Optional][LOI/Pre-App]	1,750,000 USD	
	Contact Name Contact Telephone	Peter J. Perrin, Ph.D. 301-451-3759					

Contact Email Peter.Perrin@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 01-Apr-2025 [Optional] [LOI/Pre-App], 01-May-2025

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS research related to coinfections, comorbidities, Synopsis and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere. Projects must be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been described most recently in NOT-OD-20-018.

125109

RFA-DK-25-009 -- Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed)

National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

13-May-2025 [Optional][LOI/Pre-App] USD

RFA-DK-

25-009

650,000

Contact Name Daniel Gossett, Ph.D.

Contact Telephone 301-594-7723

Contact Email daniel.gossett@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences This NOFO encourages applications from institutions that propose to establish research experiences in kidney technology Synopsis development. Successful programs should include a collaborative capstone research or design project(s), innovative and/or ground-breaking technology development, multidisciplinary/interdisciplinary teamwork, education in entrepreneurship, product development and navigating regulatory pathways, and clinical immersion. Applications must include plans to recruit undergraduate students as participants and to engage students from engineering and other quantitative scientific and technical backgrounds, but applicants may also propose the inclusion of medical students, graduate students and/or dual-

RFA-DK-26-001 -- NIDDK Centers for Diabetes Translation Research (P30

National Institute of Diabetes and RFA-DK-26-001 Digestive and Kidney

degree students (e.g., M.D./Ph.D.; Pharm.D./Ph.D.) prior to their qualifying exams and selection of Ph.D. mentor.

12-May-2025

Not [Optional][LOI/Pre-App] Specified

		Diseases/NIH/DHHS			
Contact Name	Shavon Artis Dickerson, DrPH, MPH				
Contact Telephone	301-435-3055				
Contact Email	shavon.artisdickerson@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-May-2025 [Optional][LOI/Pre-App], 1	L0-Jun-2025			
Synopsis	This Notice of Funding Opportunity (NO (CDTR) to support research across the translations, dissemination and implemental diabetes translation to maximize positive offer specialized expertise, tools, educate equity and reduce diabetes-related head of person-centered, community, and postrategies may be adapted to meaningful institutions and diverse organizational control social services, etc.) is expected to fosted the core concept whereby shared resout funded investigators are supported in a Enhancing Diverse Perspectives (PEDP).	ranslational science spectrum (i.e., betion research). The purpose of this Ce impacts of research on population tion, and support. An emphasis on neith disparities is encouraged. Novel repulation health are also encouraged ally inform on disparity-reduction apollaborators (e.g., healthcare system ra Center framework necessary for reces aimed at fostering productivity,	edside to content of the content of	linical practice and cogram is to accelerate ough activities and coods and research to a res designed to imprication of how such fascientific base reflenity organizations, he population health. Cland novel research ide	e innovation of ore services that ddress health ove other aspects indings or ecting academic ealth departments, DTRs are based on eas among the
129705 Priority HIV/AIDS Research within Trial Optional)	the Mission of the NIDDK (R01 Clinical	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-25- 073	07-May-2025	Not Specified
Contact Name	Khoa Dinhdang Nguyen, PharmD				
Contact Telephone	240-743-8995				
Contact Email	khoa.nguyen2@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-202	26 , 07-May-2026 , 07-Sep-2026 , 07-	Jan-2027 ,	07-May-2027 , 07-Se	p-2027 , 07-Jan-

Synopsis	2028 This Funding Opportunity Announcemer Institute of Diabetes and Digestive and & the NIH Office of AIDS Research (OAR). THIV/AIDS Research Priorities and Guideli	Kidney Diseases (NIDDK) that align w These priorities were most recently o	ith the HIV, described in	/AIDS research priorities	outlined by
129703 Pilot Studies of Biological, Behavior to HIV Pathogenesis Within the National Allowed)	oral and Social Mechanisms Contributing Mission of NIDDK (R21 Clinical Trial Not	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-25- 068	07-May-2025	275,000 USD
Contact Name	Khoa Dinhdang Nguyen, PharmD				
Contact Telephone	240-743-8995				
Contact Email	khoa.nguyen2@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-202 2028	26 , 07-May-2026 , 07-Sep-2026 , 07-	-Jan-2027 ,	07-May-2027 , 07-Sep-20)27 , 07-Jan-
This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for sustained viral suppression or elimination of HIV from the body. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.					
130036 RFA-DK-26-009 New Investigated T1D Research (R03 Clinical Trial N	or Gateway Awards for Collaborative lot Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK- 26-009	26-May-2025 [Optional][LOI/Pre-App	200,000] USD
Contact Name Contact Telephone	Olivier Blondel, Ph.D. (for HIRN-related i 301-451-7344	nquiries)			

Contact Email blondelo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 26-May-2025 [Optional] [LOI/Pre-App], 26-Jun-2025, 06-Feb-2026 [Optional] [LOI/Pre-App], 06-Mar-2026

The New Investigator Gateway Award in T1D Research is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. Bringing New and Early Stage Investigators into existing collaborative research networks will also benefit the networks by providing new ideas and perspectives. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

Notice of Special Interest (NOSI): NIDDK National Research Service Award (NRSA) T32 Diversity Administrative Supplement

National Institute of Diabetes and NOT-DK-12-May-2025 Digestive and Kidney 24-038 Diseases/NIH/DHHS

Contact Name Arthur L. Castle, Ph.D.

Contact Telephone 301-594-7719

Contact Email castlea@niddk.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025, 12-May-2026, 12-May-2027

In effort to promote a diverse research workforce in NIDDK fields of research, NIDDK is making available this opportunity for

additional trainee research slots to eligible candidates on a T32 or TL1 when all regularly-awarded positions have been filled. Synopsis NIDDK encourages individuals from diverse backgrounds, including but not limited to those from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds, to work with their institutions to submit an application for support. For more information, see NOT-OD-20-031 "Notice of NIH's Interest in Diversity." Please

Not

Specified

note that NIH does not use the race, ethnicity, or sex of prospective candidates in the application review process or funding decisions. Applicants are encouraged to consult with their General Counsel to ensure all applicable laws and regulations are being followed in the selection of candidates. The NIDDK administratively funds supplemental slots designated specifically for a selected trainee - either predoctoral or postdoctoral - to an existing T32 or TL1 award. That position remains a part of the T32 or TL1 for as long as the named individual is a member of the training program. When the individual no longer receives support from the T32, the funds for the position are removed from the grant. To ensure an appropriate training experience, only predoctoral slots are considered for programs that exclusively support predoctoral training; the same applies to postdoctoral slots. Programs supporting both predoctoral and postdoctoral training may apply for either.

Small R01s for Clinical Trials Targeting Diseases within the Mission of 116589 NIDDK (R01 Clinical Trial Required)

129839

National Institute of Diabetes and PAS-25-102

07-May-2025

600.000 USD

Contact Name Aynur Unalp-Arida, M.D., M.Sc., Ph.D.

Contact Telephone 301-594-8879

Contact Email aynur.unalp-arida@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026

Diseases/NIH/DHHS

Digestive and Kidney

Diseases/NIH/DHHS

This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.

RFA-DK-26-007 -- Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)

National Institute of Diabetes and RFA-DK-Digestive and Kidney

26-007

26-May-2025 [Optional][LOI/Pre-App] USD

3.600.000

Contact Name Beena Akolkar, Ph.D. Contact Telephone 240-593-1733

Contact Email beena.akolkar@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 26-May-2025 [Optional] [LOI/Pre-App], 26-Jun-2025, 06-Feb-2026 [Optional] [LOI/Pre-App], 06-Mar-2026

This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/researchareas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing

Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)

National Institute of Diabetes and PAR-25-Not Digestive and Kidney 11-Mar-2025 312 Specified Diseases/NIH/DHHS

Contact Name Mary Evans, Ph.D.

Contact Telephone 301-594-4578

129740

Contact Email evansmary@mail.nih.gov

Diverse Perspectives (PEDP).

Sponsor Website

Program URL Link to program URL

11-Mar-2025, 10-Apr-2025, 09-May-2025, 10-Jun-2025, 09-Jul-2025, 07-Aug-2025, 09-Sep-2025, 09-Oct-2025, 07-Nov-2025, 09-Dec-2025, 09-Jan-2026, 10-Feb-2026, 10-Mar-2026, 10-Apr-2026, 08-May-2026, 09-Jun-2026, 09-Jul-2026, 11-Deadline Dates (ALL) Aug-2026, 09-Sep-2026, 09-Oct-2026, 10-Nov-2026, 09-Dec-2026, 08-Jan-2027, 09-Feb-2027, 09-Mar-2027, 09-Apr-2027 , 11-May-2027, 09-Jun-2027, 09-Jul-2027, 10-Aug-2027, 09-Sep-2027, 08-Oct-2027, 09-Nov-2027, 09-Dec-2027, 11-Jan-2028

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical Synopsis activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-

related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

129704	Small Grants for New Investigators to Broaden Participation in Health-
	Related Research (R21 Clinical Trial Ontional)

National Institute of Diabetes and PAR-25-375,000 Digestive and Kidney 07-May-2025 097 USD Diseases/NIH/DHHS

Contact Name Katrina J. Serrano, Ph.D.

Contact Telephone 301-480-7855

Contact Email katrina.serrano@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

129738

07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI) or the National Institute of Biomedical Imaging and Bioengineering (NIBIB). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

National Institute of Diabetes and PAR-25-150.000 Digestive and Kidney 07-May-2025 091 USD Diseases/NIH/DHHS

Contact Name Lisa M. Spain, Ph.D. Contact Telephone 301-451-9871

Contact Email SpainL@niddk.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDKsupported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support during the latter years of the award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The RO3 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The RO3 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

Synopsis

Notice of Special Interest (NOSI): Understanding Exposure and Health Effects of Micro and/or Nanoplastics

National Institute of NOT-ES-Not **Environmental Health** 07-May-2025 23-002 Specified Sciences/NIH/DHHS

113566

Contact Name Lingamanaidu V. Ravichandran, Ph.D.

Contact Telephone 984-287-3309

Contact Email lingamanaidu.ravichandran@nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 07-Jan-2026, 05-Feb-2026, 16-Feb-Deadline Dates (ALL) 2026, 07-May-2026, 05-Jun-2026, 16-Jun-2026, 07-Sep-2026, 05-Oct-2026, 16-Oct-2026, 07-Jan-2027, 05-Feb-2027, 16-Feb-2027, 07-May-2027, 05-Jun-2027, 16-Jun-2027, 07-Sep-2027, 05-Oct-2027, 16-Oct-2027

The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Synopsis Environmental Health Sciences (NIEHS), has special interest in applications that investigate exposure to, and health effects of, microplastics (MPs) and nanoplastics (NPs).

124977	Undergraduate Research Training RISE) (T34)	g Initiative for Student Enhancement (U-	National Institute of General Medical Sciences/NIH/DHHS	PAR-24- 137	28-May-2025	Not Specified
	Contact Name	Marie Harton, Ph.D.				
	Contact Telephone					
	Contact Email	marie.harton@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-May-2025 , 27-May-2026				
	Synopsis	The goal of the Undergraduate Research participation in the biomedical research of well-trained students who: Complete focused higher degree programs (such a eligible, domestic organizations to devel undergraduate training and mentoring the full range of perspectives, experiencengage in outreach and recruitment actiprogram. The proposed research training prepare trainees for careers that will have program is limited to applications from the Research Project Grant (RPG) funding and the last three fiscal years (FY)). This Notime independent clinical trial, but does allow	workforce by strengthening reseatheir baccalaureate degree, and is Ph.D. or M.D./Ph.D.). Specifically op and implement effective, evide o support the development of a bit es and backgrounds needed to advities to encourage individuals from a programs will incorporate didactive a significant impact on the health baccalaureate degree-granting researing less than \$7.5 million in to ce of Funding Opportunity (NOFO)	rch training e ransition int this funding ence-informe omedical res vance discove m underrepr tic, research, th-related research-active earch-active otal costs (directions)	environments and expand o and complete biomedic g announcement provided d approaches to biomedic earch workforce that will ery. NIGMS expects orgates esented groups to particity and career development search needs of the nation organizations (that is, thousect and F&A/indirect) per ow appointed Trainees to	ding the pool cal, research-s support to cal benefit from nizations to pate in the elements to n. This ose with NIH ryear over o lead an
115946	IDeA Networks of Biomedical Res Trial Optional)	earch Excellence (INBRE) (P20 Clinical	National Institute of General Medical Sciences/NIH/DHHS	PAR-23- 100	22-May-2025	13,750,000 USD
	Contact Name	Krishan K. Arora, Ph.D.				

Contact Telephone

Sponsor Website

Contact Email arorak@nigms.nih.gov

Program URL Link to program URL

73

Deadline Dates (ALL	The Institutional Development Award (arch institutions in IDeA-eligible sta	ates to build b	oiomedical research	capacity through
114798 Limited Competition: Renewal or Excellence (COBRE) (Phase 2) (P2	<u> Centers of Biomedical Research</u> 20 - Clinical Trial Optional)	National Institute of General Medical Sciences/NIH/DHHS	PAR-23- 063	28-May-2025	7,500,000 USD
Contact Name	Federico Bernal, Ph.D.				
Contact Telephone					
Contact Emai	federico.bernal@nih.gov				
Sponsor Website					
Program UR	Link to program URL				
Deadline Dates (ALL	28-May-2025				
Synopsi	The Centers of Biomedical Research Ex biomedical and behavioral research cen for three sequential five-year phases. T established in Phase 1 through further mass of investigators with shared scien	nters at Institutional Development the purpose of the COBRE Phase 2 improvements to research infrastr	Award (IDeA) award is to st ucture and th)-eligible institutions rengthen successful ne continued develop	through awards centers ment of a critical
124983 Maximizing Access to Research C	Careers (MARC) (T34)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24- 138	28-May-2025	Not Specified
Contact Name	Lameese Akacem, Ph.D.				
Contact Telephone					
Contact Emai	lameese.akacem@nih.gov				
Sponsor Website					
Program UR	Link to program URL				
Deadline Dates (ALL	28-May-2025 , 27-May-2026				
Synopsi	The goal of the Maximizing Access to F research workforce by strengthening re				

Complete their baccalaureate degree, and Transition into and complete biomedical, research-focused higher degree programs (such as Ph.D. or M.D./Ph.D.). Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to biomedical undergraduate training and mentoring to support the development of a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. NIGMS expects organizations to engage in outreach and recruitment activities to encourage individuals from underrepresented groups to participate in the program. The proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation. This program is limited to applications from baccalaureate degree-granting research-intensive organizations (that is, those with NIH Research Project Grant (RPG) funding averaging greater than or equal to \$7.5 million in total costs (direct and F&A/indirect) per year over the last three fiscal years (FY)). This Notice of Funding Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

125769

Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)

National Institute of General Medical Sciences/NIH/DHHS PAR-25-148

25-Feb-2025

375,000 USD

Contact Name Mahua Mukhopadhyay, PhD

Contact Telephone 301-435-6886

Contact Email mukhopam@mail.nih.gov

Sponsor Website

Program URL Link to program URL

25-Feb-2025, 07-May-2025, 25-Jun-2025, 07-Sep-2025, 25-Oct-2025, 07-Jan-2026, 25-Feb-2026, 07-May-2026, 25-Jun-Deadline Dates (ALL) 2026, 07-Sep-2026, 25-Oct-2026, 07-Jan-2027, 25-Feb-2027, 07-May-2027, 25-Jun-2027, 07-Sep-2027, 25-Oct-2027, 07-Jan-2028

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 Synopsis million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. See Part II. Section 3.1 Eligible Organizations for more information. This Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials such as those that do not require FDA oversight, do not intend to formally establish efficacy,

	and have low risks to potentially cause of the participating NIH institutes.	physical or psychological harm, an	d which addr	ess the mission and re	esearch interests
125765 Academic Research Enhancemen Institutions (R15 Clinical Trial Not	t Award for Undergraduate-Focused t Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 134	25-Feb-2025	375,000 USD
Contact Name Contact Telephone	Charles Ansong, Ph.D.				
Contact Email	charles.ansong@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Feb-2025 , 07-May-2025 , 25-Jun-20 2026 , 07-Sep-2026 , 25-Oct-2026 , 07-J Jan-2028	•	-		•
Synopsis	The purpose of this Academic Research small scale research grants at institution providing biomedical research experient applicant institutions. Eligible institution million dollars per year of NIH support composed of multiple schools and collethe non-health professional schools and Organizations for more information.	ns that do not receive substantial faces primarily for undergraduate stans must award baccalaureate scier (in both direct and F&A/indirect coeges, the \$6 million funding limit is	unding from udents, and once degrees a sts) in 4 of the based on the	the NIH, with an emp enhancing the researd nd have received no r he last 7 fiscal years. Fo amount of NIH fundi	hasis on th environment at more than \$6 or institutions ng received by all
124465 Medical Scientist Training Progra	m (T32)	National Institute of General Medical Sciences/NIH/DHHS	PAR-24- 128	25-May-2025	Not Specified
Contact Name	Miles Fabian, Ph.D.				
Contact Telephone					
Contact Email	miles.fabian@nih.gov				
Sponsor Website					
Program URL	Link to program URL				

Deadline Dates (ALL) 25-May-2025 , 25-Sep-2025 , 25-Jan-2026 , 25-May-2026 , 25-Sep-2026 , 25-Jan-2027

The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of well-trained clinician-scientist leaders available to address the nation's biomedical research needs. Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to dualdegree training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise and lead to the completion of both a clinical degree (for example, M.D., D.O., D.V.M., D.D.S., Pharm.D., etc.) and a research doctorate degree (Ph.D.). With the dual qualifications of a rigorous scientist and clinician, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment, and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are optimizing training efficiency, fostering the persistence of alumni in research careers, and enhancing the diversity of the clinician-scientist workforce. NIGMS expects that the proposed research training program will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Synopsis

National Institute of General Medical Sciences Predoctoral Basic 121787 Biomedical Sciences Research Training Program (T32)

National Institute of General Medical Sciences/NIH/DHHS PAR-23-228

25-May-2025

Not Specified

Contact Name Mercedes Rubio

Contact Telephone

Contact Email rubiome@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025, 25-Sep-2025, 25-Jan-2026, 25-May-2026, 25-Sep-2026

The goal of the National Institute of General Medical Sciences (NIGMS) Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Basic Biomedical Sciences Research Training Program is to develop a diverse pool of well-trained scientists available to address the nation's biomedical research agenda. Specifically, this funding announcement provides support to eligible, domestic organizations to develop and implement effective, evidence-informed approaches to biomedical Synopsis graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the nation. This Notice of Funding Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

115738	Collaborative Program Grant for I Trial Optional)	Multidisciplinary Teams (RM1 - Clinical	National Institute of General Medical Sciences/NIH/DHHS	PAR-23- 077	28-May-2025	7,500,000 USD
	Contact Name					
	Contact Telephone	301-594-8494				
	Contact Email	RM1mailbox@nigms.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-May-2025 , 27-Jan-2026				
	Synopsis	This Funding Opportunity Announceme Program Directors/Principal Investigator the mission of NIGMS. Project goals sho program teams are expected to accomp are encouraged to consider far-reaching for applications that are mainly focused new technologies, or infrastructure development.	rs (PDs/PIs) to address ambitious a uld not be achievable with a collect lish goals that require considerable sobjectives that will produce majo on the creation, expansion, and/o	nd challengi tion of indiv e synergy an r advances in	ng research questions idual efforts or projec d managed team inte n their fields. This FOA	s that are within cts. Collaborative ractions. Teams A is not intended
128628	Research With Activities Related Optional)	to Diversity (ReWARD) (R01 Clinical Trial	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 117	07-May-2025	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.				
	Contact Telephone					
	Contact Email	laurie.stepanek@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Fe			•	•
	Synopsis	The NIH Research With Activities Related geographical location of research and refor the health-related research of scient Accessibility (DEIA) and who have no curboth the scientific research and the DEIA	search-related activities supported ists who are making a significant corrent NIH research project grant fu	by NIH. The ontribution t nding. The R	e ReWARD program p to Diversity, Equity, In ReWARD program pro	orovides support clusion, and vides funding for

to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

111423	Maximizing	Investigators'	Research Award	(R35 - Clinical T	rial Ontional)
TTT -CJ	WIGNITIE	mivestigators	MC3Carcii / Wara	(1133 Cillilical I	riai Optionai,

National Institute of General Medical Sciences/NIH/DHHS

PAR-22-180

16-May-2025

3,750,000 USD

Contact Name Zhongzhen Nie, Ph.D.

Contact Telephone

Contact Email MIRA2019RESEARCH@NIGMS.NIH.GOV

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-May-2025

The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented Synopsis and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows applications from eligible NIGMS-funded investigators and from New Investigators proposing research within the scientific mission of NIGMS. The FOA also allows renewal applications from all current MIRA grantees (established investigators and those previously funded as early-stage investigators). PD/PIs who are currently Early Stage Investigators (ESIs) should apply through the ESI MIRA FOA and should not apply through this FOA.

Biomedical Technology Optimization and Dissemination Center (BTOD)(RM1-Clinical Trial Not Allowed)

National Institute of General Medical Sciences/NIH/DHHS PAR-23-110

28-May-2025

4,250,000 USD

Contact Name

Contact Telephone

116619

Contact Email NIGMS BTODMailbox@nigms.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 28-May-2025, 27-Jan-2026

This Funding Opportunity Announcement (FOA) encourages applications for NIGMS Biomedical Technology Optimization and Dissemination (BTOD) Centers to support late-stage technology optimization and sustainable dissemination of the technology to the wider biomedical research community. A BTOD Center should be at the leading edge of its field with respect to both technology development and engagement with relevant research communities. BTOD projects should address biomedical research areas within the NIGMS mission. This FOA is an update of the funding opportunity for the Biomedical Technology Development and Dissemination (BTDD) Centers (PAR-20-104). Potential applicants are strongly encouraged to consult with NIGMS staff about adherence of their proposed research strategy to the goals and mission of the Institute, whether it addresses one or more high priority research areas, and its responsiveness to this FOA.

128746 of Concept (R21 - Clinical Trial Not Allowed)

Technology Development Research for Establishing Feasibility and Proof

National Institute of General Medical Sciences/NIH/DHHS PAR-25-202

07-May-2025

275,000 USD

Contact Name Alvin T. Yeh

Contact Telephone

Contact Email NIGMS techdev@nigms.nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-Deadline Dates (ALL) 2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028

This Funding Opportunity Announcement (FOA) supports exploratory research leading to the development of innovative technologies for biomedical research that is relevant to the NIGMS mission or that of other NIH Institutes or Centers (ICs) participating in this FOA. Projects should entail a high degree of risk and/or novelty, which will be offset by a high future potential impact in biomedical research. Outcomes or products of the proposed project, which should significantly advance the current state of the art, may include, but are not limited to: laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention to become research tools. This NOFO does not support technology development that is narrowly focused on addressing specific biological questions or that re-purposes existing technologies for new uses. Rather, applications should propose development of new tools that can potentially benefit a broad spectrum of biomedical research. Moreover, feasibility of the proposed technology must not have already been established in the literature or with preliminary data. Applications that are

Synopsis

focused on technology development to address specific biological questions and/or include unpublished or published data that provide proof of concept are not responsive to this NOFO and will be administratively withdrawn without review.

Maximizing Opportunities for Scientific and Academic Independent 127138 Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

National Institute of General Medical Sciences/NIH/DHHS

PAR-24-225

07-May-2025

Not Specified

Contact Name Kenneth D. Gibbs, Jr., Ph.D.

Contact Telephone

Contact Email kenneth.gibbs@nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-Deadline Dates (ALL) 2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027

The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral Synopsis researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Candidates seeking support through this NOFO are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Candidates proposing a clinical trial or an ancillary clinical trial as lead investigator, should

work with their institutions to apply to the companion NOFO PAR-24-226.

128748	Focused Technology Research an Allowed)	d Development (R01 Clinical Trial Not	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 203	07-May-2025	Not Specified
	Contact Name	Alvin T. Yeh				
	Contact Telephone					
	Contact Emai	NIGMS_techdev@nigms.nih.gov				
	Sponsor Website					
	Program URI	Link to program URL				
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-20 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-F			•	•
	Synopsis	This Funding Opportunity Announceme institutes or Centers (ICs) participating enable acquisition of biomedical knowle technical innovation for impacting future significantly advance the current state of biomedical research questions. These devices, algorithms and software, chemby human intervention to become resedemonstrated proof-of-concept that has such, applications should not propose questions are not responsive to this FO optimization, hardening, or obvious extends	in the FOA that focus solely on the edge. Projects should be justified in the biomedical research. Outcomes of the art and be sufficiently character outcomes may include, but are notical reagents and processes, biological reagents and will be administratively with	development in terms of te or products of cterized for a ot limited to gical molecul to support the challenges to ons. Applicati drawn witho	et of technologies with echnical innovation and of the proposed project pplication in addressing laboratory instrument es or systems that have development of tech of full implementation a ons proposing to test sut review. Applications	the potential to lutility of such t should g a broad range is and other e been modified nologies with nd broad utility. pecific biological with a focus on
128806	Advancing Research Careers (ARC Award to Promote Diversity (F99	C) Predoctoral to Postdoctoral Transition /K00 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-25- 084	07-May-2025	Not Specified
	Contact Name	Laurie Stepanek, Ph.D.				
	Contact Telephone					
	Contact Emai	laurie.stepanek@nih.gov				
	Sponsor Website					
	Program URI	Link to program URL				
	Deadline Dates (ALL)	07-May-2025 , 13-Jun-2025 , 07-Sep-20	25 , 10-Oct-2025 , 07-Jan-2026 , 13	3-Feb-2026 ,	07-May-2026 , 15-Jun-	2026 <i>,</i> 07-Sep-

2026 , 14-Oct-2026 , 07-Jan-2027 , 11-Feb-2027 , 07-May-2027 , 11-Jun-2027 , 07-Sep-2027 , 08-Oct-2027 , 07-Jan-2028 The purpose of the Advancing Research Careers (ARC) program is to support cohorts of promising, late-stage graduate students from diverse backgrounds pursuing research training in NIH mission areas. The program has two components: an individual predoctoral-to-postdoctoral transition award (F99/K00) and a research education cooperative agreement (UE5) awarded to organizations to provide F99/K00 fellows with additional mentoring, networking and professional development activities to support their transition to and success in mentored postdoctoral research positions. The ARC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The ARC Predoctoral to Postdoctoral Transition Award to Promote Diversity (F99/K00) is a two-phase award that will provide support for promising late-stage graduate students from diverse Synopsis backgrounds pursuing research related to the mission areas of participating NIH Institutes, Centers and Offices (ICOs), to complete their doctoral research training (F99 phase) and transition into and succeed in postdoctoral biomedical research and career development opportunities (K00 phase). The program also is designed to support predoctoral researchers who have, appropriate to their career stage, demonstrated contributions and propose meaningful plans to promote broad participation in the biomedical research workforce. It is anticipated that completion of this phased award program will position ARC scholars to advance in impactful careers in the biomedical research workforce that typically require postdoctoral training (for example, academic research and teaching at a range of organization types, industry, or government research). This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Advanced Laboratories for Accelerating the Reach and Impact of 119377 Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers (P50 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS

PAR-24-210

19-May-2025

7,500,000 USD

Contact Name Joel Sherrill, Ph.D.

Contact Telephone 301-443-2477

Contact Email jsherril@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 19-May-2025, 18-May-2026

This Notice of Funding Opportunity (NOFO) invites applications for centers to support transdisciplinary teams of clinical and mental health services researchers, behavioral scientists, social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) to engage in high-impact studies that will significantly advance clinical practice and generate

knowledge that will fuel transformation of mental health care in the United States. Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers will support the rapid development, testing, and refinement of novel and integrative approaches for (1) optimizing the effectiveness of therapeutic or preventive interventions for mental disorders within well-defined target populations; (2) organizing and delivering optimized mental health services within real world treatment settings; and (3) continuously improving the quality, impact, and durability of optimized interventions and service delivery within various care systems that provide mental health interventions and services. The ALACRITY Centers program is intended to support research that maximizes synergies across various components of the mental health research ecosystem, including new discoveries in clinical research, transformative health care technologies, advances in information science, and new federal and state mechanisms for organizing mental health care. The Centers are intended for transdisciplinary projects that could not be achieved using standard research project grant mechanisms. The ALACRITY Centers program is also expected to facilitate widespread sharing of relevant data, methods, and resources that will accelerate clinical research and practice and provide opportunities for graduate students, postdoctoral researchers, and early-career investigators to participate in transdisciplinary, T2 translational mental health research.

116555	NIMH Mentoring Networks for Mental Health Research Education (R25	National Institute of Mental	PAR-23-	25 May 2025	1,000,000
110555	Clinical Trial Not Allowed)	Health/NIH/DHHS	263	25-May-2025	USD

Contact Name Nick Gaiano, Ph.D.

Contact Telephone 301-827-3420

Contact Email nick.gaiano@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support innovative educational activities with a primary focus on: Mentoring Activities and in particular, Synopsis mentoring networks. Networks may be national or regional. All proposed networks should provide significant new opportunities, and should comprise efforts substantially beyond any ongoing mentoring, networking, or research education within academic programs, institutions, or pre-existing networks; or educational collaborations among institutions. Participants in proposed mentoring networks are limited to graduate/medical students, medical residents, postdoctoral scholars, and/or early-career investigators. Proposed networks are expected to enhance the participants' professional

development and to foster their career trajectory towards independent mental health research. Proposed programs are thus expected to contribute to the development of a skilled cadre of investigators in requisite scientific research areas to advance the objectives of the NIMH Strategic Plan.

116556 NIMH Short Courses for Mental H Independent Clinical Trial Not All		National Institute of Mental Health/NIH/DHHS	PAR-23- 265	25-May-2025	1,000,000 USD
Contact Name	Nick Gaiano, Ph.D.				
Contact Telephone	301-827-3420				
Contact Emai	nick.gaiano@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-May-2025				
Deadline Dates (ALL) 25-May-2025 The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. overarching goal of this R25 program is to support educational activities that complement and/or enhance the tra workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated overgoal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development short courses are expected to facilitate the development of a cadre of investigators with the requisite scientific reto advance the mission of the NIMH. Each short course is expected to include both didactics and hands-on research experiences. Participants are limited to graduate/medical students, medical residents, postdoctoral scholars, and/career investigators.				raining of a er-arching t Proposed research skills rch	
116560 NIMH Research Education Progra Independent Clinical Trial Not All	ams for Psychiatry Residents (R25- lowed)	National Institute of Mental Health/NIH/DHHS	PAR-23- 266	25-May-2025	1,000,000 USD

Contact Name Mark Chavez, Ph.D.

Contact Telephone 301-443-8942

Contact Email <u>mark.chavez@nih.gov</u>

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025

Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The

overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Research Experiences Specifically, this FOA will support research-oriented experiences and activities designed to develop, maintain, and expand the scientific abilities of psychiatry residents in areas relevant to the mission of NIMH.

1	1	1	6	U	7	

Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS

PAR-22-155

10-May-2025 [Optional][LOI/Pre-App] USD

10,000,000

Contact Name Susan Koester, Ph.D.

Contact Telephone 301-443-3563

Contact Email koesters@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 10-May-2025 [Optional][LOI/Pre-App], 09-Jun-2025

This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting Synopsis the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.

112626

RFA-MH-22-185 -- NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS

RFA-MH-22-185

21-May-2025 2,500,000 [Optional][LOI/Pre-App] USD

Contact Name Eric R. Murphy, Ph.D.

Contact Telephone 301-443-9230

Contact Email eric.murphy@nih.gov

	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-May-2025 [Optional][LOI/Pre-App], 2	0-Jun-2025			
	Synopsis	The NIMH Biobehavioral Research Awar and research career advancement of outheir careers and who plan to make a low award seeks to assist these individuals in that holds the potential to profoundly the NIMH BRAINS program will focus on	tstanding, exceptionally productive ng-term career commitment to resent In launching an innovative clinical, transform the understanding, diagno	scientists wearch in spec anslational, sis, treatme	tho are in the early, for cific mission areas of t basic, or services rese ent, or prevention of m	rmative stages of he NIMH. This earch program nental disorders.
124764	RFA-MH-25-110 BRAIN Initiative (R24 Clinical Trial Optional)	e: Data Archives for the BRAIN Initiative	National Institute of Mental Health/NIH/DHHS	RFA-MH- 25-110	25-May-2025 [Optional][LOI/Pre-A	Not app] Specified
	Contact Name	Ming Zhan, Ph.D.				
	Contact Telephone	301-827-3678				
	Contact Email	ming.zhan@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-May-2025 [Optional][LOI/Pre-App], 2	4-Jun-2025 , 25-May-2026 [Option	al][LOI/Pre- <i>l</i>	App], 24-Jun-2026	
	Synopsis	This Funding Opportunity Announcemer store, and curate data related to BRAIN to incorporate software tools that allow describe the data, but an application wit responsive to this NOFO. A goal of this pand summary information that is broad! NOFO requires a Plan for Enhancing Diverger review evaluation. Applications that Applicants are strongly encouraged to restore.	Initiative activities. The data archive users to analyze and visualize the case of the major focus on the creation of subrogram is to advance research by cay available and accessible to the reserve Perspectives (PEDP), which will the fail to include a PEDP will be cons	es teams will lata, and will ch software creating a da search comn be assessed idered incor	I work with the resear II use appropriate stand tools and data standata archive with appronunity for furthering relass part of the scientimplete and will be with	ch community adards to ards is not priate standards esearch. This fic and technical hdrawn.

National Institute of Mental

Health/NIH/DHHS

Contact Name Jennifer Humensky, Ph.D.

RFA-MH-25-136 -- Pilot Research Opportunities in Crisis Response

Services for Suicide Prevention (R34 Clinical Trial Optional)

126538

[Optional][LOI/Pre-App] USD

675,000

RFA-MH- 03-May-2025

25-136

Contact Telephone 301-480-1265

Contact Email jennifer.humensky@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 03-May-2025 [Optional][LOI/Pre-App], 02-Jun-2025

This NOFO seeks to promote pilot exploratory/developmental research examining the effectiveness and implementation of crisis response services, approaches to improve the quality and outcomes of services, and the impact of state and local policy on implementation and outcomes. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related characteristics (e.g., youth; adult; older adult), geographic context (rural/remote settings), racial/ethnic and cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems. Support for larger-scale or fullypowered studies is provided through a companion NOFO that utilizes the RO1 mechanism (RFA-MH-25-135; Research Opportunities in Crisis Response Services for Suicide Prevention (R01 Clinical Trial Optional).

RFA-MH-25-135 -- Research Opportunities in Crisis Response Services for National Institute of Mental 126537 Suicide Prevention (R01 Clinical Trial Optional)

Health/NIH/DHHS

RFA-MH- 03-May-2025 25-135

Not [Optional][LOI/Pre-App] Specified

Contact Name Jennifer Humensky, Ph.D.

Contact Telephone 301-480-1265

Contact Email jennifer.humensky@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 03-May-2025 [Optional][LOI/Pre-App], 02-Jun-2025

This Notice of Funding Opportunity (NOFO) encourages research examining the effectiveness and implementation of crisis response services, approaches to improve the quality and outcomes of services, and the impact of state and local policy on implementation and outcomes. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related characteristics (e.g., youth; adult; older adult), geographic context (rural/remote settings), racial/ethnic and cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems. Support for pilot studies is provided through a companion NOFO that utilizes the R34 mechanism (RFA-MH-25-136); Pilot Research Opportunities in Crisis Response Services for Suicide Prevention (R34 Clinical Trial Optional)).

126862 Standardizing Data and Metada Trial Not Allowed)	ta from Wearable Devices (R01 Clinical	National Institute of Mental Health/NIH/DHHS	PAR-24- 250	11-May-2025 [Optional][LOI/Pre-App]	Not Specified
Contact Nam	e Christina Liu, Ph.D.				
Contact Telephor	e 301-827-9193				
Contact Ema	il christina.liu@nih.gov				
Sponsor Websit	е				
Program UF	L Link to program URL				
Deadline Dates (AL	_) 11-May-2025 [Optional][LOI/Pre-App], :	10-Jun-2025 , 11-May-2026 [Option	al][LOI/Pre-،	App], 10-Jun-2026	
Synops	Wearable technology shows promise in providing information that can be used to create biomarkers of various diagnostic groups that have relevance to mental illness. However, there are barriers related to multiple and sometimes proprietary dat standards that make data aggregation difficult from existing devices. The purpose of this Notice of Funding Opportunity (NOFO) is to support the creation of standards for data as well as metadata and related coordination activities that will allow researchers to easily access data from personal tracking devices and integrate those data for subsequent data analysis. The recipients will be expected to partner with device manufacturers, the researcher community, and other interested parties such as ethics experts if the effort is going to be successful. It is expected that the recipient will create standards for person tracking device data that serve the same purpose as the Digital Imaging and Communications in Medicine (DICOM) or Neuroimaging Informatics Technology Initiative (NIfTI) formats and standards do for medical image files. Those medical image file standards have allowed secondary data analysis and have resulted in many software packages and workflows for secondary data analysis.				
	ve: Brain-Behavior Quantification and ion Sensor Technology Development (U01	National Institute of Mental Health/NIH/DHHS	RFA-MH- 26-140	14-May-2025 [Optional][LOI/Pre-App]	10,000,000 USD
Contact Nam	e Yvonne Bennett, Ph.D.				
Contact Telephor	e 301-222-7094				
Contact Ema	il yvonne.bennett@nih.gov				
Sponsor Websit	е				
Program UF	L Link to program URL				
Deadline Dates (AL	14-May-2025 [Optional][LOI/Pre-App], 1 [Optional][LOI/Pre-App], 15-Jun-2027	13-Jun-2025 , 16-May-2026 [Option	al][LOI/Pre-،	App], 15-Jun-2026 , 16-Ma	y-2027

This Notice of Funding Opportunity (NOFO) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the development of next generation sensor technologies and bioelectronic devices to further the goals of the Brain Behavior Quantification and Synchronization (BBQS) program of the NIH BRAIN Initiative. The BRAIN Initiative BBQS funding opportunities broadly support 1) development of tools for simultaneous, multimodal measurement of behavior within complex, dynamic physical and/or social environments and synchronize these data with simultaneously-recorded neural activity and 2) development of novel conceptual and computational models that capture dynamic behavior-environment relationships across multiple timescales and that can integrate correlated neural activity into the model. More information about the BRAIN Initiative including existing Notices of Funding Opportunities for the BBQS program can be found here. This NOFO focuses exclusively on the development of novel sensor technology and bioelectronic devices related to the BBQS program and follows a recent workshop BBQS Workshop May 2023. This NOFO will foster close interaction between engineers and behavioral scientists in a Research Consortium. Sensor developers in the Consortium will promote rigorous technology design, fabrication, testing, validation, and dissemination of information regarding sensors and bioelectronics toward improving our understanding of human and organismal behavior. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

Synopsis

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS

PAR-23-062

09-May-2025

Not Specified

Contact Name Gregory Greenwood, Ph.D.

Contact Telephone 240-669-5532

Contact Email gregory.greenwood@nih.gov

Sponsor Website

115128

Program URL Link to program URL

Deadline Dates (ALL) 09-May-2025, 09-Sep-2025, 09-Jan-2026

The NIMH invites applications for Research Project Grants (R01) that propose to advance innovative research to optimize HIV prevention, treatment, and care. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, large-scale intervention efficacy or effectiveness trials, implementation science studies, or data science approaches to optimize HIV prevention, treatment, and care. Applicants are Synopsis encouraged to read current Notice of Special Interest (NOSIs) from NIMH Division of AIDS Research (DAR) for further information about the Division's research priorities (NIMH DAR; https://www.nimh.nih.gov/about/organization/dar/aidsrelated-funding-opportunity-announcements-foas), and the NIH Strategic Plan for HIV and HIV-Related Research by NIH Office of AIDS Research (NIH OAR; https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan). This FOA, PAR-23-062, uses the R01 grant mechanism for applications with preliminary data or those including longitudinal analysis, advanced

modeling, large-scale clinical trials or implementation science studies. Applicants proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models or applications should consider the R21 mechanism (PAR-23-061). Applicants proposing the initial development and pilot testing of a clinical trial or formative implementation research should consider using the R34 mechanism (PAR-23-060).

1111)/	<u>Innovations to Optimize HIV Prevention and Care Continuum Outcomes</u>	National Institute of Mental	PAR-23-	00 May 2025	275,000
115127	(R21 Clinical Trial Optional)	Health/NIH/DHHS	061	09-May-2025	USD

Contact Name Gregory Greenwood, Ph.D.

Contact Telephone 240-669-5532

Contact Email gregory.greenwood@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 09-May-2025, 09-Sep-2025, 09-Jan-2026

The NIMH invites applications for Research Project Grants (R21) that advance innovative research to optimize HIV prevention and care. Applications may include novel basic or applied behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or preliminary research to identify and advance innovative intervention approaches. Applicants are encouraged to read current Notice of Special Interest (NOSIs) from NIMH Division of AIDS Research (DAR) for further information about the Division's research priorities NIMH

DAR; https://www.nimh.nih.gov/about/organization/dar/aids-related-funding-opportunity-announcements-foas), and the Synopsis NIH Strategic Plan for HIV and HIV-Related Research by NIH Office of AIDS Research (NIH OAR; https://www.oar.nih.gov/hivpolicy-and-research/strategic-plan. This FOA, R21 PAR-23-061 uses the R21 grant mechanism to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques or models. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials or implementation science approaches should consider using the R01 mechanism (R01 PAR-23-062), Applicants proposing the initial development and pilot testing of a clinical trial or formative implementation research should consider using the R34 mechanism (PAR-23-060).

Formative and Pilot Intervention Research to Optimize HIV Prevention National Institute of Mental PAR-23-450,000 115126 09-May-2025 and Care Continuum Outcomes (R34 Clinical Trial Optional) 060 USD Health/NIH/DHHS

Contact Name Gregory Greenwood, Ph.D.

Contact Telephone 240-669-5532

Contact Email gregory.greenwood@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 09-May-2025, 09-Sep-2025, 09-Jan-2026

The NIMH invites applications for Research Project Grants (R34) that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. For the purposes of this FOA, "intervention" is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that improve HIV prevention or treatment outcomes. Applications should be aligned with NIMH Division of AIDS Research (DAR) priorities. Applicants are encouraged to read current Notice of Special Interest (NOSIs) from NIMH Division of Synopsis AIDs Research (DAR) for further information about the Division's research priorities (NIMH

DAR; https://www.nimh.nih.gov/about/organization/dar/aids-related-funding-opportunity-announcements-foas), and the NIH Strategic Plan for HIV and HIV-Related Research by NIH Office of AIDS Research (NIH OAR; https://www.oar.nih.gov/hivpolicy-and-research/strategic-plan). This FOA, PAR-23-060, uses the R34 grant mechanism to provide support for the initial development and pilot testing of a clinical trial or formative implementation research. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials or implementation science approaches should consider using the companion R01 mechanism, PAR-23-062. Applicants proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models, or applications should consider the R21 mechanism (PAR-23-061).

125379

RFA-MH-25-130--Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

RFA-MH-14-May-2025 25-130 [Optional][LOI/Pre-App] USD

Contact Name Mary Rooney, Ph.D.

Contact Telephone 301-827-1325

Contact Email mary.rooney@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 14-May-2025 [Optional][LOI/Pre-App], 13-Jun-2025

Synopsis NIMH seeks applications for pilot research to adapt, optimize, and test empirically supported behavioral interventions that

450,000

address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. Pilot trials should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings, and to conduct a preliminary test of the intervention's impact on target mechanisms and sleep and mental health outcomes, and to obtain preliminary data needed as a prerequisite a larger-scale effectiveness trial. An emphasis is placed on studies that address the needs of youth from understudied and underserved populations.

128553

Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-206

06-May-2025 [Optional][LOI/Pre-App] USD

750,000

Contact Name Adam Haim, Ph.D.

Contact Telephone 301-435-3593

Contact Email haima@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025, 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Sep-2026 [Optional][LOI/Pre-App], 05-Jun-2026 [Optional][L App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027

NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) presumed to Synopsis underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This notice of funding opportunity (NOFO) supports pilot research to evaluate the feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of post-acute phase intervention approaches, to generate the preliminary data needed as a prerequisite to well powered effectiveness trials, and to inform the design of

definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase

128559 Effectiveness Trials for Post-Acute Interventions and Services to Optimize National Institute of Mental PAR-25-06-May-2025 Not

interventions is provided via the R01 NOFO, PAR-25-207.

Longer-term Outcomes (R01 Clini	cal Trial Required)	Health/NIH/DHHS	207	[Optional][LOI/Pre-	App] Specified
Contact Name	Adam Haim, Ph.D.				
Contact Telephone	301-435-3593				
Contact Email	haima@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-Ap [Optional][LOI/Pre-App], 05-Feb-202 App], 05-Oct-2026 , 06-Jan-2027 [Օր 05-Sep-2027 [Optional][LOI/Pre-App	26 , 06-May-2026 [Optional][LOI/Potional][LOI/Potional][LOI/Pre-App], 05-Feb-202	Pre-App], 05-Jun-	2026 , 05-Sep-2026 [C	Optional][LOI/Pre-
Synopsis	NIMH seeks applications for researce for the post-acute management of repportunity (NOFO) encourages clinaction, mediators, and predictors are matched to the stage of illness in temporary intensity/burden for promoting optipowered to provide a definitive answerfectiveness trials designed to evaluate the post-acute phase intervention approximately.	nental health conditions affecting ical trials to establish the effective of moderators of post-acute phase rms of both their focus (e.g., consorment, preventing relapse, promo mal longer-term outcomes. This Newer regarding the effectiveness of uate the initial feasibility, tolerabil	youth, adults, and youth, adults, and eness and test hy the therapeutic and olidating and mainting adherence as NOFO is intended the post-acute plity, acceptability	nd older adults. This nay potheses regarding modes services intervention intaining gains from irond appropriate servicate support trials that others intervention. Suppose intervention.	otice of funding nechanisms of as that are nitial treatment, e use) and are statistically pport for pilot
112309 Building in vivo Preclinical Assays Therapeutic Development (R01 C	of Circuit Engagement for Applicatio linical Trial Not Allowed)	n in National Institute of Mental Health/NIH/DHHS	PAR-22- 170	07-May-2025	Not Specified
Contact Name	Jamie Driscoll				
Contact Telephone	301-443-5288				
Contact Email	jdrisco1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep	-2025			
Synopsis	The goal of this Funding Opportunit	y Announcement (FOA) is to ident	ify, in animals, in	vivo neurophysiologi	cal and behavioral

measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.

Building in vivo Preclinical Assays of Circuit Engagement for Application in National Institute of Mental 115030 Therapeutic Development (R01 Clinical Trial Not Allowed)

Health/NIH/DHHS

PAR-25-035

07-May-2025

Not Specified

Contact Name Jamie Driscoll

Contact Telephone 301-443-5288

Contact Email idrisco1@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025

The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as

pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. The objectives of this FOA will be

accomplished by supporting basic neuroscience aimed at improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. The FOA may be considered a preguel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.

117750	Assay Development and Screenin Hits for Brain Disorders (R01 Clini	g for Discovery of Validated Chemical cal Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-25- 063	07-May-2025	Not Specified
	Contact Name	Enrique Michelotti, PhD				
	Contact Telephone	301-443-5415				

Contact Email michelottiel@mail.nih.gov Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026

The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a "hit" is defined as a compound Synopsis that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

	Development and Application of PET and SPECT Imaging Ligands as	N.L.
117550	Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS	Na
	Disorders (R01 Clinical Trial Optional)	Н

National Institute of Mental PAR-25-Not 07-May-2025 036 Specified lealth/NIH/DHHS

Contact Name Enrique Michelotti, Ph.D. Contact Telephone 301-443-5415

Contact Email michelottiel@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026

This Notice of Funding Opportunity (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in brain disorders as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this NOFO is to stimulate research in the identification and development of PET and SPECT probes for disorders of primary interest to the NIMH or NIA.

128944

Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R01 Clinical Trial Required)

National Institute of Mental PAR-25-Health/NIH/DHHS 289

06-May-2025 Not [Optional][LOI/Pre-App] Specified

Contact Name Mary Acri, Ph.D.

Contact Telephone 301-910-8230

Contact Email mary.acri@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025, 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Sep-2026 [Optional][LOI/Pre-App], 05-Jun-2026 [Optional][L App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027

The purpose of this notice of funding opportunity (NOFO) is to encourage

research applications that test the effectiveness, implementation, and optimization of patient navigation Emergency Department (ED) diversion models for non-urgent youth mental health problems. A non-urgent ED visit is that in which a delay of several hours would not increase the potential for an adverse outcome to occur. For the purposes of this NOFO, NIMH defines a patient navigation model as an evidence-based intervention that is delivered by a mental health provider, an allied provider such as a nurse, or a lay provider (e.g., peer, community health worker) whose role is to (a) utilize triage tools to identify mental health acuity, (b) provide emotional support and build mental health knowledge among caregivers, (c) facilitate linkages to mental health services and additional resources as needed to support the family, and (d) address barriers

to help-seeking. This NOFO is for projects for which there are preliminary data. Support for pilot studies is provided through a

companion NOFO that utilizes the R34 mechanism: PAR-25-288 Planning Grant (R34 Clinical Trial Required).

128915 Advance Neural Circuitry Underst Clinical Trial Optional)	Stimulating Opportunities in Humans to tanding of Mental Health Disorders (R01	National Institute of Mental Health/NIH/DHHS	PAR-25- 290	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
Contact Name	Jessica Tilghman, Ph.D.				
Contact Telephone	301-827-0439				
Contact Email	jessica.tilghman@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 0 [Optional][LOI/Pre-App], 05-Feb-2026 , 0 App], 05-Oct-2026 , 06-Jan-2027 [Option 05-Sep-2027 [Optional][LOI/Pre-App], 0	06-May-2026 [Optional][LOI/Pre-Ap nal][LOI/Pre-App], 05-Feb-2027 , 06	p], 05-Jun-2	026 , 05-Sep-2026 [Optio	nal][LOI/Pre-
Synopsis	The purpose of this Funding Opportunity recording studies focused on mental head into the human brain to explore the new functions, and behaviors with high spaticelectrodes, allows for direct causal tests knowledge of neural circuit function related invasive recording modalities that have this FOA, though development of novel uses the R01 grant mechanism, encouragement applications encouraging shorter,	alth-relevant questions. Invasive neural circuitry and neural dynamics unal and temporal resolution. Addition by modulating network dynamics. ated to mental health disorders. Resve high translational potential. Devetools/methods to enable relevant naging longer-term projects, whereas	ural recording to nally, the about this FOA ain searchers shelopment of nental health its companion	ngs provide an unparallele mplex moods, emotions, ility to stimulate, via the s ns to target a gap in the so ould target specific quest new therapies is outside h studies is encouraged. T ion R21 NOFO, PAR-25-29	ed window cognitive same cientific ions suited the scope of
Notice of Special Interest (NOSI): 128717 to Existing NIH Single Project Res Agreements	NIMH Funding for Competing Revisions earch Grants and Cooperative	National Institute of Mental Health/NIH/DHHS	NOT-MH- 25-010	01-May-2025	Not Specified
Contact Name	Nicholas Gaiano, Ph.D.				
Contact Telephone	301-827-3420				
Contact Email	nick.gaiano@nih.gov				
Sponsor Website					

Program URL Link to program URL

·	01-May-2025, 01-Sep-2025 The purpose of this Notice of Special Into existing projects and/or programs awar existing award must be a NIMH-funded	ded by the National Institute of M	ental Health	(NIMH). The parent activi	ty code of the
111480 Mental Health Research Disserta <u>Diversity (R36 Independent Clini</u>	ntion Grant to Enhance Workforce cal Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-22- 172	10-Apr-2025	Not Specified
Contact Name Contact Telephone	Ashley Smith, Ph.D.				
·	I ashley.smith2@nih.gov				
Sponsor Website	-				
•	L Link to program URL				
•) 10-Apr-2025 , 07-May-2025				
Synopsi	The purpose of this Funding Opportunit workforce by providing dissertation away diverse backgrounds, including those fresearch. This FOA provides support to readily available in NRSA predoctoral (Fallowance.	ards in all research areas within the om groups underrepresented in bicomplete a mental health-related	e strategic pr omedical, be doctoral rese	iorities of the NIMH to in havioral, clinical and soci arch project and include	dividuals from al sciences s funds not
128977 Full-Scale Hybrid Effectiveness-Interventions (R01 - Clinical Trial	nplementation Trials for Mental Health Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 177	18-May-2025 [Optional][LOI/Pre-App	Not] Specified
Contact Name	Joel Sherrill, Ph.D.				
Contact Telephone	301-443-2477				
Contact Ema	l jsherril@mail.nih.gov				
Sponsor Website	e				
Program UR	Link to program URL				
Deadline Dates (ALL	18-May-2025 [Optional][LOI/Pre-App], (Optional][LOI/Pre-App], 13-Feb-2026, App], 15-Oct-2026, 18-Jan-2027 [Optional]	16-May-2026 [Optional][LOI/Pre-A	.pp], 15-Jun-2	2026 , 15-Sep-2026 [Opti	onal][LOI/Pre-

15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

IMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO seeks to support well-powered clinical trials consistent with NIMH's priorities for: 1) optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use with broader target populations or for delivery routine care, school, community, or online settings, and 2) research on implementation strategies that support the delivery and sustainability of optimized interventions in accessible settings. Applications responsive to this NOFO are hybrid effectiveness implementation trials that examine the effectiveness and clinical impact of interventions to prevent or treat mental illness, implementation challenges and strategies within the intervention setting, and at least one mechanism of action associated with an intervention and/or implementation strategy. The research covered under this announcement addresses practice-relevant questions and must be conducted within accessible intervention settings where the typical consumer can be identified as in need of care and be readily connected to an intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

Synopsis

Notice of Special Interest (NOSI): NIMH Planning Grants for Natural History Studies of Rare Genetic Neurodevelopmental Disorders

National Institute of Mental Health/NIH/DHHS

NOT-MH-23-235

07-May-2025

Not Specified

Contact Name Margaret Grabb, Ph.D.

Contact Telephone 301-443-3563

118003

Contact Email mgrabb@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 2026

07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-

The National Institute of Mental Health (NIMH) is issuing this Notice to highlight its interest in supporting planning grants to conduct retrospective natural history studies that explore the prevalence of disabling psychiatric symptoms and disruptions in function in patients (birth to 25 years of age) with rare genetic neurodevelopmental disorders (NDD). The principal goal of these studies is to assess the time of onset and severity of these symptoms, identify appropriate outcome measures, and establish potential timepoints for intervention. Additionally, the planning grants should focus on identifying potential quantitative clinical functional measures or biomarkers that could be used as prognostics and/or measures of change in future clinical trials. These retrospective natural history studies are expected to enable future prospective longitudinal studies (see Food and Drug Administration's (FDA's) guidance on natural history studies for rare disorders).

118004	Notice of Special Interest (NOSI): for Rare Genetic Neurodevelopm	<u>Pre-Clinical Research on Gene Therapies</u> <u>ental Disorders</u>	National Institute of Mental Health/NIH/DHHS	NOT-MH- 23-236	07-May-2025	Not Specified
	Contact Name					
	Contact Telephone	301-443-3563				
	Contact Email	NIMHgenetherapies@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202 2026	25 , 05-Oct-2025 , 07-Jan-2026 , 05-	Feb-2026 , 0)7-May-2026 , 05-Jun-202	6 , 07-Sep-
	Synopsis	The National Institute of Mental Health clinical research aimed at developing no disorders with prominent cognitive, soci	vel approaches for somatic cell gen			
128677	Integrating Mental Health Care in Middle-Income Countries (R01 Cl	nto Health Care Systems in Low- and inical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25- 201	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
_	Contact Name	Vidya Vedham, Ph.D.				
	Contact Telephone					
	Contact Email	vidya.vedham@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 0 [Optional][LOI/Pre-App], 05-Feb-2026, (App], 05-Oct-2026, 06-Jan-2027 [Option 05-Sep-2027 [Optional][LOI/Pre-App], 0	06-May-2026 [Optional][LOI/Pre-Ap nal][LOI/Pre-App], 05-Feb-2027 , 06	p], 05-Jun-2	2026 , 05-Sep-2026 [Optio	nal][LOI/Pre-
	Synopsis	This notice of funding opportunity (NOF services with chronic health care (for bo non-healthcare settings (such as schools (LMICs). The objective is to develop, reficare with other services. This NOFO aim financial sustainability of integrated men	th communicable and non-communes, places of worship, and community ne, and evaluate innovative strateges to support research geared towar	nicable cond y centers) in gies to facilit ds impleme	litions) across various hea low and middle-income of ate the integration of men nting, scaling up, and enso	Ithcare and countries ntal health uring the

accessibility, utilization, and quality of mental health care services in both healthcare and non-healthcare settings. In
addition, this NOFO seeks to strengthen sustainable mental health research capacity in LMICs.

addition, this NOFO seeks to strengthen sustainable mental health research capacity in LMICs.					
128661 <u>Laboratories to Optimize Digital H</u>	lealth (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 136	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
Contact Name	Adam Haim, Ph.D.				
Contact Telephone	301-435-3593				
Contact Email	Haima@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 05-Feb-2026, App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 0	06-May-2026 [Optional][LOI/Pre- <i>A</i> nal][LOI/Pre-App], 05-Feb-2027 , 0	.pp], 05-Jun-2	2026 , 05-Sep-2026 [Optio	nal][LOI/Pre-
Synopsis	NIMH seeks applications for innovative and quality of digital mental health interserious mental illness. This Funding Opphealth test beds that leverage well-esta optimize existing evidence-based digital interventions that are statistically power particularly in populations who experies	erventions which may impact ment portunity Announcement (FOA) is in ablished digital mental health platfo all health interventions and to condu pered to provide a definitive answer	al health outontended to submission and infrance clinical responding the regarding the	comes, including suicide be upport the development o astructure to rapidly refine search testing digital ment e intervention's effectiven	ehaviors and f digital e and cal health
108834 Notice of Special Interest (NOSI): Complex Behaviors (R01 Clinical T	Neuro-Glia Mechanisms Governing Trial Optional)	National Institute of Mental Health/NIH/DHHS	NOT-MH- 22-090	07-May-2025	Not Specified
Contact Name	Michele Ferrante, Ph.D.				
Contact Telephone	301-435-6782				
Contact Email	michele.ferrante@nih.gov				
Sponsor Website					

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

102

Synopsis This Notice of Special Interest (NOSI) encourages projects to experimentally test mechanistic hypotheses on the ro			
123916 Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional) National Institute of Mental PAR-25- 17-May-2025 Health/NIH/DHHS 278 [Optional][LOI/Pre-App]	450,000 USD		
Contact Name Michael Freed, Ph.D.			
Contact Telephone 301-443-3747			
Contact Email michael.freed@nih.gov			
Sponsor Website			
Program URL Link to program URL			
Deadline Dates (ALL) 17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025			
This Notice of Funding Announcement (NOFO) solicits exploratory/developmental research applications within the learning health care framework to support adoption, implementation, sustainability, and continuous improvement of evidence-base practices in outpatient mental health and substance use treatment systems. These settings could include, but are not limit to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Servic Administration (SAMHSA) expansion grant program and CCBHCs participating in their states' Section 223 CCBHC Medicaid demonstration program, or as a part of independent state programs where the CCBHCs are meeting the federal CCBHC certification criteria. This NOFO requires active collaboration between behavioral health researchers and community Synopsis behavioral health partners across all phases of the research process. Studies that are co-designed between community clir staff/service users and health services researchers may focus on (1) identifying subgroups within the population of individual served by CCBHCs with unique needs, including health disparities experienced by people from racial and ethnic minority groups or underserved communities; (2) workforce development strategies, including new approaches to train providers we vary in terms of prior experience, expertise and skills; (3) developing and testing tools to promote measurement-based treatment; (4) hybrid effectiveness-implementation trials aimed at implementing and improving evidence-based preventic treatment, or services delivery approaches in real-world settings; and (5) research to establish and/or expand 988 crisis response services within CCBHC settings.			
128945 Navigator Emergency Department Diversion Models for Non-Urgent National Institute of Mental PAR-25- 17-May-2025 Mental Health Concerns (R34 Clinical Trial Required) Health/NIH/DHHS 288 [Optional][LOI/Pre-App]	675,000 USD		

Contact Name Mary Acri, Ph.D.

Contact Telephone 301-910-8230

Contact Email mary.acri@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

17-May-2025 [Optional][LOI/Pre-App], 16-Jun-2025, 16-Sep-2025 [Optional][LOI/Pre-App], 16-Oct-2025, 17-Jan-2026 [Optional][LOI/Pre-App], 16-Feb-2026, 17-May-2026 [Optional][LOI/Pre-App], 16-Jun-2026, 16-Sep-2026 [Optional][LOI/Pre-App], 16-Jun-2026 [Optional][LOI/Pre-App], App], 16-Oct-2026, 17-Jan-2027 [Optional][LOI/Pre-App], 16-Feb-2027, 17-May-2027 [Optional][LOI/Pre-App], 16-Jun-2027, 16-Sep-2027 [Optional][LOI/Pre-App], 16-Oct-2027

The purpose of this notice of funding opportunity (NOFO) is to encourage research applications that pilot test patient navigation Emergency Department (ED) diversion models for non-urgent mental health problems. A non-urgent ED visit is that for which a delay of several hours would not increase the potential for an adverse outcome to occur. For the purposes of this NOFO, NIMH defines a patient navigation model as an evidence-based intervention that is delivered by a mental health provider, an allied provider such as a nurse, or a lay provider (e.g., peer, community health worker) whose role is to (a) utilize Synopsis triage tools to identify mental health acuity, (b) provide emotional support and build mental health knowledge amongst caregivers, c) facilitate linkages to mental health services and additional resources as needed to support the family, and (d) address barriers to help-seeking. This NOFO is for 1) established navigator models that have limited evidence and need pilot testing to detect a signal, and (2) development and pilot testing of components of navigator models. Support for larger-scale or fully powered studies is provided through a companion NOFO that utilizes the R01 mechanism: PAR-25-289 (R01 Clinical

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based 128987 Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-184

18-May-2025 Not [Optional][LOI/Pre-App] Specified

Contact Name Margaret Grabb, Ph.D.

Contact Telephone 301-443-3563

Trial Required).

Contact Email mgrabb@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App] App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase) prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support evaluation of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult, and geriatric-focused interventions are appropriate for this NOFO. The R61/R33 NOFOs are intended to support biphasic high-risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion R33, PAR-25-183. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

Synopsis

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based 128986 Interventions for the Treatment of Mental Disorders (R33 - Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-183

18-May-2025 Not [Optional][LOI/Pre-App] Specified

Contact Name Margaret Grabb, Ph.D.

Contact Telephone 301-443-3563

Contact Email mgrabb@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025, 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025, 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App], 15-Jun-2026 [Optional][LOI/Pre-Ap App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to Synopsis effectiveness trials. The purpose of this NOFO is to support the early-stage testing of pharmacologic interventions with novel mechanisms of action or neuromodulatory device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness. Early intervention studies are also encouraged where symptoms of a disorder

have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this NOFO is intended to support early-stage testing of pharmacologic or neuromodulatory device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested to provide meaningful information where target modulation yields a well-controlled, dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult, and geriatric-focused interventions are appropriate for this NOFO. This R33 NOFO supports single-phased clinical trial awards. Applicants proposing high-risk projects are encouraged to apply to one of the companion NOFOs, PAR-25-184 or PAR-25-180.

128988

Effectiveness Trials to Test Mental Health System Interventions (R61/R33 National Institute of Mental Clinical Trial Required)

Health/NIH/DHHS

PAR-25-285

18-May-2025

Not [Optional][LOI/Pre-App] Specified

Contact Name Shahrzad Mavandadi, PhD

Contact Telephone 301-827-1167

Contact Email shahrzad.mavandadi@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025, 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025, 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. This NOFO complements NIMH's suite of clinical trial funding opportunities by supporting milestone-driven feasibility and infrastructure development (R61) research followed by well-powered clinical trials (R33) to test the effectiveness of system interventions or strategies that improve the organization, delivery, coordination, and outcomes of mental health care for priority populations. System interventions - which may span, for example, structural, Synopsis policy, and organizational domains - attend to issues about the access, equity, engagement/utilization, value (cost/financing), management, or quality and safety of mental health services, with the goal of improved care processes and clinical, functional, or population level outcomes. Accordingly, the focus of system interventions may include multiple factors/levels related to care delivered within or across a variety of care settings, such as health systems and organizations, mental health and community clinics, schools, and social welfare or justice systems. Projects may test the impact of policies and practices, interventions to facilitate care transitions and continuity across settings, and interventions to improve linkages/coordination

across systems. Researchers will have up to two years in the R61 phase to demonstrate feasibility and adequate

infrastructure to justify conducting the main trial (R33). Applicants pursuing other stages of intervention development and testing should refer to companion NOFOs listed at Support for Clinical Trials at NIMH.

First in Human and Early Stage Clinical Trials of Novel Investigational 128982 Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

National Institute of Mental PAR-25-18-May-2025 [Optional][LOI/Pre-App] Specified Health/NIH/DHHS 180

Contact Name Enrique Michelotti, Ph.D.

Contact Telephone 301-443-5415

Contact Email michelottiel@mail.nih.gov

consider one of the companion NOFOs listed above.

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025, 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025, 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App], 15-Jun-2026 [Optional][LOI/Pre-Ap App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action investigational drugs or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials, including First-in-human (FIH), Phase Ib, Phase II/PoC and early feasibility studies (EFS), in pediatric and adult populations. These studies are designed to objectively and dose dependently assess target engagement in the central nervous system (CNS), along with safety and tolerability. Phase II/PoC studies additionally must evaluate the drug's/device's impact on clinically Synopsis relevant physiological systems (functional measures) and clinical indicators of effect. The overall objective of this NOFO is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding (when appropriate) for further clinical development as Food and Drug Administration (FDA)-approved treatments. A key aspect of this NOFO is the formation of collaborative partnerships between the biomedical researchers and

biotechnology or industry researchers to facilitate psychiatric drug or device development. This NOFO is designed for applicants seeking funding for cooperative agreements supporting early stage clinical trials as outlined above. Applicants pursuing other stages of the clinical trial pipeline or funding for clinical research not involving cooperative agreements should

Not

Confirmatory Efficacy Clinical Trials of Non-Pharmacological and National Institute of Mental PAR-25-18-May-2025 Not 128979 Pharmacological Interventions for Mental Disorders (R01 Clinical Trial [Optional][LOI/Pre-App] Specified Health/NIH/DHHS 179 Required)

Contact Name Joel Sherrill, Ph.D.

Contact Telephone 301-443-2477

Contact Email isherril@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025, 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025, 14-Jan-2026 [Optional][LOI/Pre-App], 13-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App] App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notices of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to support confirmatory efficacy testing of non-pharmacological preventive and therapeutic interventions, and under certain conditions, selected pharmacological interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to, behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Pharmacological interventions to be studied under Synopsis this grant mechanism are expected to primarily focus on drugs approved for marketing by the FDA (for any indication). These will include medications off-patent which are undergoing development for a new mental health indication. Confirmatory efficacy trials studying monotherapy, combination treatments, and stepped approaches, including multiple treatment modalities, may be supported. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action (target), a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the target mechanism and change in functional or clinical effects. Ultimately, this NOFO is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit. Applicants

pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

128978 Pilot Hybrid Effectiveness-Implen Interventions (R01 – Clinical Trial	nentation Trials for Mental Health Required)	National Institute of Mental Health/NIH/DHHS	PAR-25- 178	18-May-2025 [Optional][LOI/Pre-App]	750,000 USD
	Joel Sherrill, Ph.D.				
Contact Telephone	301-443-2477				
Contact Email	jsherril@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 15-Sep-2025 [Optional][LOI/Pre-App], 15-Oct-2025 , 14-Jan-2026 [Optional][LOI/Pre-App], 15-Dct-2026 , 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026 , 15-Sep-2027 [Optional][LOI/Pre-App], 17-Feb-2027 , 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-202				
NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of interventions, confirmatory efficacy trials, thr effectiveness trials. This NOFO seeks pilot hybrid effectiveness implementation research consistent with NIMH's prior for: 1) refining and optimizing preventive and therapeutic interventions with previously demonstrated efficacy for use broader target populations or for delivery routine care, school, community, or online settings, and 2) research on Synopsis implementation strategies that support the delivery and sustainability of evidence supported interventions in accessit settings. This NOFO supports pilot research designed to generate the preliminary data needed as a prerequisite to a w powered clinical trial. This includes research designed to assess the feasibility, acceptability, safety, and fit of approach explore the impact of the approach on both the outcomes of interest and at least one hypothesized mechanism of action. Support for well powered hybrid effectiveness implementation studies is provided through separate NOFOs the described on the NIMH Support for Clinical Trials web page.					s, through to priorities or use with cessible o a well proach, and of
1 /4/145	e Access and Quality of Empirically- ental Health (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-25- 310	06-May-2025 [Optional][LOI/Pre-App]	Not Specified
Contact Name	Marcy Burstein, Ph.D.				

Contact Email <u>marcy.burstein@nih.gov</u>

Program URL Link to program URL

Sponsor Website

06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025 , 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025 , 06-Jan-2026 Deadline Dates (ALL) [Optional] [LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional] [LOI/Pre-App], 05-Jun-2026, 05-Sep-2026 [Optional] [LOI/Pre-App], 05-Sep-2026 [Optio Appl, 05-Oct-2026

Synopsis

This notice of funding opportunity (NOFO) is a call to action in response to the youth mental health crisis in the United States. NIMH seeks applications that will study methods to increase access to, and quality of, empirically-supported practices for youth mental health. Applications may address research related to: optimizing assessment, intervention and service strategies; overcoming challenges related to workforce shortages and waitlists for treatment; integration of treatment and preventive interventions into settings where youth are most likely to be identified as needing care (e.g., schools, pediatric medicine, community organizations, social services, and juvenile justice), and service interventions that address systemic barriers to access and quality of mental health care (e.g., structural, policy, organizational, value in terms of cost/financing, management).

128985

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-182

18-May-2025 Not [Optional][LOI/Pre-App] Specified

Contact Name Alexander Talkovsky, Ph.D.

Contact Telephone 301-827-7614

Contact Email alexander.talkovsky@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Sep-2025 [Optional][LOI/Pre-App], 17-Oct-2025 , 20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-inhuman, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental Synopsis therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective, and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious

interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of a novel intervention's impact on a target process or mechanism associated with mental disorder risk, causation, or maintenance (target engagement). Up to 3 years of additional support (R33 phase) will be provided for studies with findings that meet the "go/no-go" milestones embedded in the R61 phase. The R33 phase is intended to support the replication of target engagement and to test whether engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

128983

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS

PAR-25-18-May-2025 181

Not [Optional][LOI/Pre-App] Specified

Contact Name Alexander Talkovsky, Ph.D.

Contact Telephone 301-827-7614

Contact Email alexander.talkovsky@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025, 17-Sep-2025 [Optional][LOI/Pre-App], 17-Oct-2025, 20-Jan-2026 [Optional][LOI/Pre-App], 19-Feb-2026, 16-May-2026 [Optional][LOI/Pre-App], 15-Jun-2026, 15-Sep-2026 [Optional][LOI/Pre-App], 15-Oct-2026, 18-Jan-2027 [Optional][LOI/Pre-App], 17-Feb-2027, 16-May-2027 [Optional][LOI/Pre-App], 15-Jun-2027, 15-Sep-2027 [Optional][LOI/Pre-App], 15-Oct-2027

NIMH solicits clinical trial applications through a series of notice of funding opportunities (NOFOs) that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials. The purpose of this NOFO is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH's experimental therapeutics approach, this NOFO is intended to speed the translation of emergent research on mechanisms and processes Synopsis underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. Novel psychosocial interventions may be standalone interventions or novel augmentations to efficacious interventions for which there is an empirical rationale by which the augmentation (and corresponding target) is expected to substantially enhance outcomes. The R33 is intended to support the replication of target engagement and to test whether

engaging the intervention target/mechanism mediates changes in clinical outcomes. Ultimately, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development and/or testing of the intervention. Applicants pursuing other stages of the clinical trial pipeline should consider one of the companion NOFOs listed above.

<u>Trial Not Allowed)</u> Disorders and Stroke/NIH/DHHS 126 'Specified	124598	NINDS Advanced Institutional Research Training Program (T32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 126	25-May-2025	Not Specified
--	--------	---	--	----------------	-------------	------------------

Contact Name Stephen Korn, Ph.D.

Contact Telephone

Contact Email korns@ninds.nih.gov

Sponsor Website

Program URL Link to program URL

124344

Deadline Dates (ALL) 25-May-2025, 25-May-2026

The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research. Programs should be designed to enhance the breadth and depth of training in NINDS mission areas by incorporating didactic, research and career development components in the context of a defined scientific theme. Programs may support basic, clinical and/or translational research. Critical components of programs supported by this FOA include mechanisms to ensure a thorough understanding of experimental design, strong statistics and analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. Regardless of theme, programs should provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. NINDS institutional training programs are intended to be 1-2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this PAR). This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Synopsis

Institutional Translational Research Training Program (T32 - Clinical Trial Not Allowed)

National Institute of Neurological PAR-24-Disorders and Stroke/NIH/DHHS 108

25-May-2025

Not Specified

Contact Name Letitia Weigand, Ph.D. Contact Telephone 301-496-4188

Contact Email letitia.weigand@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025, 25-May-2026

The purpose of the Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support students postdocs, and/or fellowship-stage clinicians conducting basic, disease-relevant research in an environment that includes 1) basic scientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved Synopsis in translational research in the context of their individual projects. Programs supported by this Notice of Funding Opportunity (NOFO) must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies. This Notice of Funding

Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain

RFA-NS-25-023 -- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)

1,050,000 National Institute of Neurological RFA-NS-16-Apr-2025 [Optional][LOI/Pre-App] USD Disorders and Stroke/NIH/DHHS 25-023

Contact Name Julia L. Bachman, PhD

research experience in a clinical trial led by a mentor or co-mentor.

Contact Telephone

124926

Contact Email julia.bachman@nih.gov

Sponsor Website

Program URL Link to program URL

16-Apr-2025 [Optional][LOI/Pre-App], 16-May-2025, 18-Aug-2025 [Optional][LOI/Pre-App], 17-Sep-2025, 17-Dec-2025 Deadline Dates (ALL) [Optional] [LOI/Pre-App], 16-Jan-2026, 15-Apr-2026 [Optional] [LOI/Pre-App], 15-May-2026, 18-Aug-2026 [Optional] [LOI/Pre-App], 16-Jan-2026, 18-Aug-2026 [Optional] [LOI/Pre-App], 16-Jan-2026, 18-Aug-2026 [Optional] [LOI/Pre-App], 18-Aug-2026 [Optional] [Optional] [LOI/Pre-App], 18-Aug-2026 [Optional] [Op App], 17-Sep-2026, 16-Dec-2026 [Optional][LOI/Pre-App], 15-Jan-2027

Synopsis This notice of funding opportunity (NOFO) aims to encourage research grant applications for initial translational efforts that

will enable a drug discovery program for novel, non-opioid, and non-addictive treatments for pain. The program provides funding to develop and validate assays to support a distinct testing funnel and conduct screening efforts to identify and characterize potential therapeutic agents including small molecules, biologics, and natural products. Preliminary in vivo pharmacokinetic, pharmacodynamic, and efficacy studies may also be supported. The goal of this NOFO is to advance projects to the point where they meet the entry criteria for the Pain Therapeutics Development Program or other later-stage translational programs. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the discovery and preclinical development of safe and effective therapeutics to treat pain with little or no addiction liability.

	discovery and preclinical development of safe and effective therapeutics to treat pain with little or no addiction liability.					ability.
111360	Notice of Special Interest (NOSI): Pediatric Hydrocephalus	Disease Mechanisms of Prenatal and	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS- 23-004	07-May-2025	Not Specified
	Contact Name	Jill Morris, Ph.D.				
	Contact Telephone	301-496-5754				
	Contact Email	jill.morris@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202	25 , 05-Oct-2025			
	The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in hypothesis research projects that focus on deciphering the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus and to examine new approaches for treatment.					
128304	Towards a Better Understanding Associated Chronic Illnesses (R01	of the Neurological Effects of Infection- - Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25- 116	06-May-2025 [Optional][LOI/Pre-App]	2,499,995 USD
	Contact Name	William Daley, Ph.D.				
	Contact Telephone	301-496-1431				
	Contact Email	william.daley@nih.gov				

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025

Synopsis The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19

(Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.

must propose such studies in the context of a post-infectious etiology.						
129400 Ultra-Rare Gene-based Therapy Clinical Trial Not Allowed)	(URGenT) Network Resource Access (X01,	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25- 326	31-May-2025	Not Specified	
Contact Nam	e Chris Boshoff, Ph.D.					
Contact Telephor	ne 301-496-1779					
Contact Ema	il chris.boshoff@nih.gov					
Sponsor Websi	te					
Program Uf	RL Link to program URL					
Deadline Dates (ALL) 31-May-2025, 30-Sep-2025, 31-Jan-2026, 31-May-2026, 30-Sep-2026, 31-Jan-2027, 31-May-2027, 30-Sep-2027, 31-Jan-2028					27 , 31-Jan-	
Synops	The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.					
126685 NINDS Faculty Development Av Research (K01 Independent Clir	vard to Promote Diversity in Neuroscience nical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 228	07-May-2025	Not Specified	
Contact Nam	ne Michelle Jones-London, Ph.D.					
Contact Telephor	ne 301-451-7966					

Contact Email NINDSDiversityTraining@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-

2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027

The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (KO1) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion NOFO (PAR-24-229).

126690

NINDS Faculty Development Award to Promote Diversity in Neuroscience National Institute of Neurological Disorders and Stroke/NIH/DHHS

PAR-24-229

07-May-2025

Not Specified

Research (KO1 Independent Clinical Trial Required)

Contact Name Michelle Jones-London

Contact Telephone 301-451-7966

Contact Email NINDSDiversityTraining@mail.nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-Deadline Dates (ALL) 2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027, 12-Jun-2027, 07-Sep-2027

The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (KO1) is to enhance participation in the independent neuroscience research workforce by providing junior faculty from diverse backgrounds, including those from groups underrepresented in biomedical research, with research cost support, protected research time, and career stage-appropriate mentorship and professional development in neuroscience research. Individuals are eligible for Synopsis support under this award if they are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-228).

115920 NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)

National Institute of Neurological PAR-25-

07-May-2025

Not

		Disorders and Stroke/NIH/DHHS	049	[Optional][LOI/Pre-Ap	pp] Specified	
Contact Name	Jeremy Brown, MD					
Contact Telephone	301-594-4481					
Contact Emai	jeremy.brown@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 [Optional][LOI/Pre-App], 06-Jun-2025 , 07-Sep-2025 [Optional][LOI/Pre-App], 07-Oct-2025 , 07-Jan-2026 [Optional][LOI/Pre-App], 06-Feb-2026					
Synopsis	This Notice of Funding Opportunity (NOFO) encourages applications for multi-center clinical trials focused on neurologic emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently a SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and the affiliated clinical sites will provide on-site implementation of the clinical protocols. Applicants do not need to be part of existing SIREN infrastructure to apply under this NOFO. The NIH SIREN Network will also be uniquely poised to collaborate with other U.S. and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS conducted in the NIH StrokeNet, and not within SIREN.					
128662 NINDS Ruth L. Kirschstein Nation Training of Postdoctoral Fellows	al Research Service Award (NRSA) for (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25- 234	07-May-2025	Not Specified	
Contact Name	Tish Weigand, Ph.D.					
Contact Telephone	301-496-4188					
Contact Emai	letitia.weigand@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 09-Jun-2025 , 07-Sep-202 2026 , 09-Oct-2026 , 07-Jan-2027 , 09-Fe					
Synopsis	The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months (or 18 months fo resubmissions) after starting in the proposed					

postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Notice of Funding Opportunity (NOFO) does not allow candidates to propose to lead an independent clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or cosponsor.

124266 T	ranslational	Neural Devices	(R61/R33 -	Clinical	Trial Optional)
----------	--------------	----------------	------------	----------	-----------------

National Institute of Neurological PAR-24-Disorders and Stroke/NIH/DHHS

151

28-May-2025

Not Specified

Contact Name Nick Langhals, PhD

Contact Telephone 301-496-1779

Contact Email NINDS-Devices@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 28-May-2025, 29-Sep-2025, 28-Jan-2026, 28-May-2026, 28-Sep-2026, 28-Jan-2027

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study (R61 phase), as well as a subsequent small clinical study (R33 phase). The clinical study is expected to provide information about the device function or final design that cannot be practically obtained Synopsis through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO utilizes an Exploratory/Developmental Phased Award and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Transition from the R61 to the R33 phase is contingent upon the successful completion of proposed milestones. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

128305	Associated Chronic Illnesses (R21		Disorders and Stroke/NIH/DHHS	115	[Optional][LOI/Pre-App]	USD	
	Contact Name	William Daley, Ph.D.					
	Contact Telephone	301-496-1431					
	Contact Email	william.daley@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	17-May-2025 [Optional][LOI/Pre-App], 1	.6-Jun-2025 , 16-Sep-2025 [Optional][LOI/Pre-A	pp], 16-Oct-2025		
	Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.					
		must propose such studies in the contex				Spinoution 5	
127141		entific and Academic Independent areer Transition Award to Promote	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 227	07-May-2025	Not Specified	
127141	Careers (MOSAIC) Postdoctoral C Diversity (K99/R00 - Independent Humans Required (BESH))	entific and Academic Independent areer Transition Award to Promote	National Institute of Neurological		07-May-2025	Not	
127141	Careers (MOSAIC) Postdoctoral C Diversity (K99/R00 - Independent Humans Required (BESH))	entific and Academic Independent areer Transition Award to Promote Basic Experimental Studies with Lanay M. Mudd, Ph.D., FACSM	National Institute of Neurological		07-May-2025	Not	
127141	Careers (MOSAIC) Postdoctoral C Diversity (K99/R00 - Independent Humans Required (BESH)) Contact Name Contact Telephone	entific and Academic Independent areer Transition Award to Promote Basic Experimental Studies with Lanay M. Mudd, Ph.D., FACSM	National Institute of Neurological		07-May-2025	Not	
127141	Careers (MOSAIC) Postdoctoral C Diversity (K99/R00 - Independent Humans Required (BESH)) Contact Name Contact Telephone	Lanay M. Mudd, Ph.D., FACSM 301-594-9346 lanay.mudd@nih.gov	National Institute of Neurological		07-May-2025	Not	
127141	Careers (MOSAIC) Postdoctoral C Diversity (K99/R00 - Independent Humans Required (BESH)) Contact Name Contact Telephone Contact Email Sponsor Website Program URL	Lanay M. Mudd, Ph.D., FACSM 301-594-9346 lanay.mudd@nih.gov	National Institute of Neurological Disorders and Stroke/NIH/DHHS	227	·	Not Specified	

National Institute of Neurological

17-May-2025

PAR-25-

400,000

Towards a Better Understanding of the Neurological Effects of Infection-

128305

2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027 , 12-Jun-2027 , 07-Sep-2027

the participating NIH Institutes and Centers (ICs) based on their scientific missions.

The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical

Synopsis

Notice of Special Interest (NOSI): Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus

111323

National Institute of Neurological NOT-NS-Disorders and Stroke/NIH/DHHS 23-003

Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of

07-May-2025

Not Specified

Contact Name Jill Morris, Ph.D.

Contact Telephone 301-496-5754

Contact Email jill.morris@nih.gov

Sponsor Website

Deadline Dates (ALL) Synopsis	Link to program URL 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025 The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.				
128451 Development of Biomarkers or Bi Neuromuscular Disorders (R61/R)	<u>Omarker Signatures for Neurological and Disorders and Stroke/NIH/DHHS 024 07-May-2025 Not Specified </u>				
Contact Name	Carol Taylor-Burds Ph.D				
Contact Telephone	301-496-1779				
Contact Email	carol.taylor-burds@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025, 21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025, 07-Sep-2025, 20-Sep-2025 [Optional][LOI/Pre-App], 20-Oct-2025, 07-Jan-2026, 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026, 07-May-2026, 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026, 07-Sep-2026, 20-Sep-2026 [Optional][LOI/Pre-App], 20-Oct-2026, 07-Jan-2027, 23-Jan-2027 [Optional][LOI/Pre-App], 22-Feb-2027, 07-May-2027, 22-May-2027 [Optional][LOI/Pre-App], 21-Jun-2027, 07-Sep-2027, 20-Sep-2027 [Optional][LOI/Pre-App], 20-Oct-2027, 07-Jan-2028				
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of fit-for-purpose candidate biomarkers and composite biomarker that enable more efficient clinical trials advance therapeutic development or clinical practice help guide clinical care decisions. Specifically, the goal of this phased funding mechanism is to first identify or confirm candidate biomarker(s) or biomarker signatures using human samples and/or data, followed by an independent retrospective or prospective clinical study to conduct initial clinical validation of the biomarker/signature's clinical utility for one or two defined Context(s) of Use. In the first phase, applicants are expected to demonstrate that the biomarker acceptably identifies or predicts the concept of interest and may include optimization of the detection method using careful standardized human samples or datasets. The overarching purpose of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies. This Notice of Funding Opportunit (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).				

128722 <u>Digital Health Technology Derived Biomarkers and Outcome Assessments</u> National Institute of Neurological PAR-25-

Not

21-May-2025

for Remote Monitoring and Endp	oint Development (UG3/UH3 - Clinical Disorders and Stroke/NIH/DHHS 170 [Optional][LOI/Pre-App] Specified
	Scott Janis, Ph.D.
Contact Name	
•	moyc@ninds.nih.gov
Sponsor Website	
Program Okt	Link to program URL
Deadline Dates (ALL)	21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025 , 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026 , 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026
Synopsis	The purpose of this notice of funding opportunity (NOFO) is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. To increase standardization and improve clinical adoption, applicants must propose to develop and evaluate the DHT enabled biomarkers or COAs in three or more diseases or conditions. Applicants must also propose to conduct development studies that are informed by people with lived experience (PWLE) and patient advocacy organizations. The first phase of this funding mechanism is to evaluate the technical performance of the proposed DHTs with PWLE input; the second phase is to support a prospective longitudinal clinical study in representative populations to validate the DHT. Research outcomes should include demonstrating how a meaningful change in the biomarkers or COAs derived from the DHT(s) can be statistically measured and quantified at the individual participant level.
179691	euroscience Research Grant (R21 Clinical National Institute of Neurological PA-25-150 07-May-2025
Trial Optional)	Disorders and Stroke/NIH/DHHS TA 25 150 07 May 2025 USD
Contact Name	Karrah Benson
Contact Telephone	301-496-0838
Contact Emai	Karrah.benson@nih.gov
Sponsor Website	
Program URI	Link to program URL
Deadline Dates (ALL)	07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026, 16-Oct-2026, 07-Jan-2027, 16-Feb-2027, 07-May-2027, 16-Jun-2027, 07-Sep-2027, 16-Oct-2027, 07-Jan-2028
Synopsis	The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual

stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing "mechanistic clinical trials or studies" (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.

126542	Summer Research Education Experimental Allowed)	erience Program (R25 Clinical Trial Not	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-24- 204	18-Mar-2025	625,000 USD
	Contact Name	Marguerite Matthews, Ph.D.				
	Contact Telephone	301-496-3272				
	Contact Email	laura.kwako@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Mar-2025, 07-May-2025, 18-Feb-2026 [Optional][LOI/Pre-App], 17-Mar-2026, 07-May-2026, 18-Feb-2027 [Optional][LOI/Pre-App], 17-Mar-2027, 07-May-2027				
	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences for high school students, undergraduate students, and/or science teachers during the summer academic break.					aining of a r-arching
109940	Prospective Observational Compa	arative Effectiveness Research in Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-25- 048	07-May-2025	Not Specified
	0	A de la della dell				

Contact Name Adam L. Hartman, MD
Contact Telephone 301-496-9135
Contact Email adam.hartman@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 18-Jun-2025, 07-Sep-2025

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). The study must address questions within Synopsis the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.

123610

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

National Institute of Neurological PAR-25-Disorders and Stroke/NIH/DHHS 050

20-May-2025 Not [Optional][LOI/Pre-App] Specified

Contact Name Carol Taylor-Burds, PhD

Contact Telephone 301-496-1779

Contact Email carol.taylor-burds@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

20-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025, 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026, 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026

The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFOinstructions carefully and view the available PEDP guidance material. The NIH recognizes that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogeneous teams. There are many benefits that flow from a diverse scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. To support the best science, the NIH encourages inclusivity in research. Examples of structures that promote diverse

Synopsis

perspectives include but are not limited to: Transdisciplinary research projects and collaborations among neuroscientists and researchers from fields such as computational biology, physics, engineering, mathematics, computer and data sciences, as well as bioethics. Engagement from different types of institutions and organizations (e.g., research-intensive, undergraduatefocused, minority-serving, community-based). Individual applications and partnerships that enhance geographic and regional heterogeneity. Investigators and teams composed of researchers at different career stages. Participation of individuals from diverse backgrounds, including groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce (see NOT-OD-20-031), such as underrepresented racial and ethnic groups, those with disabilities, those from disadvantaged backgrounds, and women. Opportunities to enhance the research environment to benefit early- and midcareer investigators.

122612	Clinical Validation of a Candidate Biomarker for Neurological or
123613	Neuromuscular Disorders (U01 Clinical Trial Optional)

National Institute of Neurological PAR-25-21-May-2025 Disorders and Stroke/NIH/DHHS 055 [Optional][LOI/Pre-App] Specified

Contact Name Carol Taylor-Burds, PhD

Contact Telephone 301-496-1779

Contact Email carol.taylor-burds@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

21-May-2025 [Optional][LOI/Pre-App], 20-Jun-2025, 21-Jan-2026 [Optional][LOI/Pre-App], 20-Feb-2026, 23-May-2026 [Optional][LOI/Pre-App], 22-Jun-2026

The purpose of this notice of funding opportunity (NOFO) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and Synopsis specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)

National Institute of Nursing Research/NIH/DHHS

PAR-22-230

05-Mar-2025

Not Specified

Not

113257

Contact Name David L. Tilley, MPH, MS, CPH

Contact Telephone 301-827-6014

Contact Email david.tilley@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Mar-2025 , 07-May-2025

This funding announcement solicits R01 grant applications that propose independent research projects that are consistent with the scientific framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.

SPIN ID	Program Title	I Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
113258	NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-22- 231	16-Mar-2025	200,000 USD

Contact Name David L. Tilley, MPH, MS, CPH

Contact Telephone 301-827-6014

Contact Email david.tilley@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-Mar-2025, 07-May-2025

This funding announcement solicits R21 grant applications that propose exploratory/developmental research projects that are consistent with the research framework detailed in the 2022-2026 National Institute of Nursing Research (NINR) Strategic Synopsis Plan. This research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the nation's most pressing and persistent health challenges with a solutions orientation, and employ innovative and rigorous study designs to inform practice and policy.

NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 - Independent Clinical Trial Not Allowed)

National Institute on Aging/NIH/DHHS

PAR-24- [Optional][LOI/Pre-App]

1,875,000 USD

Contact Name NIA Training Office Contact Telephone Contact Email NIAtraining@nih.gov **Sponsor Website** Program URL Link to program URL Deadline Dates (ALL) 25-Apr-2025 [Optional] [LOI/Pre-App], 25-May-2025, 25-Apr-2026 [Optional] [LOI/Pre-App], 25-May-2026 The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse Synopsis backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences Complex Integrated Multi-Component Projects in Aging Research (U19 National Institute on PAR-22-Not 25-May-2025 112312 Aging/NIH/DHHS Clinical Trial Optional) 213 Specified Contact Name Sanoj Suneja, PhD Contact Telephone 301-402-7710 Contact Email sunejas@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 25-May-2025, 25-Sep-2025 This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated Synopsis components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. National Institute on PAR-22-Not 07-May-2025 109722 NIA Program Project Applications (P01 Clinical Trial Optional) Aging/NIH/DHHS 130 Specified Contact Name Robin A. Barr, D.Phil Contact Telephone 301-496-9322 Contact Email BarrR@mail.nih.gov Sponsor Website

Program URL Link to program URL Deadline Dates (ALL) 07-May-2025, 25-May-2025, 07-Sep-2025 The National Institute on Aging (NIA) invites the submission of investigator-initiated research program project (P01) applications addressing scientific areas relevant to NIA's mission. Each application submitted to this Funding Opportunity Announcement (FOA) must include at least three related research projects that share a common central theme, focus, and Synopsis overall objective, in addition to an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within the context and theme of the parent PO1 award. Revision applications may not request support beyond the end date of the parent PO1 award, but may propose to expand existing cores, or propose new cores, to support the expansion or creation of new projects. Notice of Special Interest (NOSI): Development of Radiotracers for National Institute on NOT-AG-Not 113465 Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related 05-Apr-2025 Aging/NIH/DHHS 22-032 Specified Dementias (ADRD) Contact Name Lorenzo M. Refolo, Ph.D. Contact Telephone 301-594-7576 Contact Email refolol@nia.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Apr-2025, 07-May-2025, 05-Jun-2025, 05-Sep-2025 This Notice of Special Interest (NOSI) invites applications for research grants that propose to develop radiotracers for Positron Emission Tomography (PET) for use in Alzheimer's disease (AD) and AD-related dementias (ADRD) research targeting new and/or emerging biological process or molecular pathways that have been shown to be relevant in the etiology and pathophysiology of neurodegeneration. 06-May-2025 Not National Institute on PAR-25-[Optional][LOI/Pre-126708 Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) Aging/NIH/DHHS 297 Specified App] Contact Name Lorenzo M. Refolo, Ph.D. Contact Telephone 301-594-7576

Contact Email refolo@nia.nih.gov
Sponsor Website Link to sponsor website

Program URI	Link to program URL						
Deadline Dates (ALL)	06-May-2025 [Optional][LOI/Pre-App], 05-Jun-2025, 05-Sep-2025 [Optional][LOI/Pre-App], 05-Oct-2025, 06-Jan-2026 [Optional][LOI/Pre-App], 05-Feb-2026, 06-May-2026 [Optional][LOI/Pre-App], 05-Jun-2026 [Optional][LOI/Pre-App], 05-Jun-2026, 05-Jul-2026, 05-Sep-2026 [Optional][LOI/Pre-App], 05-Oct-2026, 06-Oct-2026 [Optional][LOI/Pre-App], 05-Nov-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027, 06-Oct-2027 [Optional][LOI/Pre-App], 05-Nov-2027						
Synopsis	This Notice of Funding Opportunity (NOFO) invites applications proposing pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Grant recipients will receive funding for therapy development activities, such as the following: Medicinal chemistry; Pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); Efficacy in animal models; Development of biomarkers for target engagement; Formulation development chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; Initial Phase I clinical testing.						
114120 Engineering Next-Generation Hun Systems (R01 Clinical Trials Not A	man Nervous System Microphysiological llowed)	National Institute on Aging/NIH/DHHS	PAR-25- 198	07-May-2025	Not Specified		
Contact Name	Amanda DiBattista, Ph.D.						
Contact Telephone	301-496-9350						
Contact Emai	amanda.dibattista@nih.gov						
Sponsor Website							
Program URI	Link to program URL						
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202	5 , 05-Oct-2025 , 07-Jan-2026					
Synopsis	This Notice of Funding Opportunity (NOF generation human cell-derived microphy architectures and physiology with improve future studies of complex nervous system intended to encourage the further developroposing exploratory research at the eacompanion R21 NOFO, which is identified	siological systems (MPS) and related yed fidelity over current capabilities. In development, function, and aging it opment of projects with feasibility surry and conceptual stages of project.	assays that Supported n healthy a pport for th developme	replicate complex nerve projects will be expected and disease states. This Note the ne line of investigation. And the may instead wish to a	ous system d to enable IOFO is Applicants		
1 ///h3x	Advance Translational Research on Related Dementias (T32 Clinical Trial Not	National Institute on Aging/NIH/DHHS	PAR-25- 247	26-Apr-2025 [Optional][LOI/Pre-	Not Specified		

Allowed) App] Contact Name Yuan Luo, Ph.D. Contact Telephone 301-496-9350 Contact Email vuan.luo@nih.gov Sponsor Website Link to sponsor website Program URL Link to program URL 26-Apr-2025 [Optional][LOI/Pre-App], 25-May-2025, 26-Aug-2025 [Optional][LOI/Pre-App], 25-Sep-2025, 26-Apr-2026 Deadline Dates (ALL) [Optional][LOI/Pre-App], 25-May-2026, 26-Aug-2026 [Optional][LOI/Pre-App], 25-Sep-2026 This Notice of Funding Opportunity (NOFO) seeks to enable the development of a diverse, translational research workforce capable of participating and/or leading cross-disciplinary team science programs focused on advancing translational research for Alzheimer's disease (AD) and AD-related dementias (ADRD). This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers from various educational backgrounds (i.e., basic biology, translational and Synopsis clinical research, data science, and behavioral research). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills necessary to conduct rigorous and cutting-edge basic, translational, behavioral, population-based, and clinical research for AD/ADRD. This Notice of Funding Opportunity (NOFO) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. National Institute on Alcohol Abuse PAR-24-Not 122739 Alcohol Research-Related Resource Award (R24 Clinical Trial Not Allowed) 25-May-2025 and Alcoholism/NIH/DHHS 071 Specified Contact Name Gary J Murray, Ph.D. Contact Telephone 301-443-9940 Contact Email gary.murray@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 25-May-2025, 25-Sep-2025, 25-Jan-2026, 25-May-2026, 25-Sep-2026 The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to Synopsis provide materials and services to support and advance biomedical, behavioral, and social sciences research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that

are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications

should not be submitted in response to this program announcement but to another mechanism that encourages this type of
research. Resources should be designed to provide services to the broad alcohol research community and should not be
limited by any specific regional focus. The resource should be available to any qualified investigator, and should be highly
quality controlled, and not duplicate resources available commercially or through other sources.

quality controlled, and not duplicate resources available commercially or through other sources.						
Notice of Special Interest (NOSI): 107782 Misuse in Understudied Young Ac Community College	Epidemiology and Prevention of Alcohol lult Populations; Military, Workforce, and	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 22-001	05-Apr-2025	Not Specified	
Contact Name	Bradley Kerridge, Ph.D.					
Contact Telephone	301-827-7493					
Contact Email	bradley.kerridge@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025 , 05-Jun-2025	5 , 16-Jun-2025 , 05-Sep-2025 , 07-Se	p-2025			
Synopsis	The purpose of this future grant application solicitation is to balance the NIAAA research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged.					
116584 Notice of Special Interest (NOSI): Understanding and Preventing Ale	Advancing mHealth Interventions for cohol-Related Domestic Violence	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA- 23-003	07-May-2025	Not Specified	
Contact Name	Robert Freeman, Ph.D.					
Contact Telephone	301-443-8820					

Contact Email rfreeman@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 12-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 12-Oct-2025, 16-Oct-2025, 07-Jan-2026, 05-Feb-2026, 12-Feb-2026, 16-Feb-2026, 07-May-2026, 05-Jun-2026, 16-Jun-2026, 07-Sep-2026

Synopsis In light of the documented increases in both alcohol misuse (among some individuals) and domestic violence (DV) as a result

of the global COVID-19 pandemic and array of mandated restrictions enacted to mitigate COVID spread, the purpose of this grant application solicitation is to announce NIAAA's interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. In particular, this solicitation seeks to advance the development, feasibility, acceptability, pilot testing, potential efficacy, and implementation of scalable, low resource, and remotely delivered interventions via mobile devices (mHealth) that rely on communication technologies for reducing and preventing alcohol consumption and DV. For this FOA, the term "domestic violence" will extend to child maltreatment (abuse and neglect) and elder abuse, in addition to intimate partner violence (IPV).

	partiter violetice (ii v).					
116064 Advancing HIV/AIDS Research with Clinical Trial Optional)	thin the Mission of the NIDCD (R21	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-25- 318	07-May-2025	275,000 USD	
Contact Name	Trinh T. Ly, MD					
Contact Telephone	301-435-4085					
Contact Email	trinh.ly@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-2020 2028	07-May-2025, 07-Sep-2025, 07-Jan-2026, 07-May-2026, 07-Sep-2026, 07-Jan-2027, 07-May-2027, 07-Sep-2027, 07-Jan- 2028				
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities) in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications proposing a clinical trial, only low risk clinical trials will be supported.					
117688 Notice of Special Interest (NOSI):	NIDCD National Research Service Award	National Institute on Deafness and Other Communication	NOT-DC-	07-May-2025	Not	

Disorders/NIH/DHHS

Contact Name Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone 301-496-1804

(NRSA) T32 and T35 Diversity Administrative Supplement

23-010

Specified

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 25-Sep-2025, 07-Jan-2026, 25-Jan-2026, 07-May-2026

This program offers institutions an opportunity to apply for additional trainee research slots to support eligible candidates under an existing T32 or T35 award when all regularly-awarded positions have been filled. The NIDCD administratively funds a supplemental slot designated specifically for a selected trainee - either predoctoral or postdoctoral - to an existing T32 or T35 award. That position remains a part of the T32 or T35 for as long as the named individual is a member of the training program. When the individual no longer receives support from the T32 or T35, the funds for the position are removed from the grant. To ensure an appropriate training experience, only predoctoral slots are considered for programs that exclusively support predoctoral training; the same applies to postdoctoral slots. Programs supporting both predoctoral and postdoctoral training may apply for either. NIDCD encourages institutions to recruit prospective predoctoral and postdoctoral students from diverse backgrounds to consider participating in this program, including but not limited to individuals from underrepresented groups, such as those from underrepresented racial and ethnic groups, individuals with disabilities and individuals from disadvantaged backgrounds. For more information, see NOT-OD-20-031 "Notice of NIH's Interest in Diversity".

NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)

National Institute on Deafness and Other Communication Disorders/NIH/DHHS

PAR-24-051

07-May-2025

2,499,995 USD

Contact Name Trinh T. Ly, M.D.

Contact Telephone 301-435-4085

Contact Email trinh.ly@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026 , 05-Oct-2026 , 07-Jan-2027

The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This notice of funding opportunity announcement (NOFO) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH

defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred to companion U01 NOFO, PAR-24-050, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

	Agreement for Clinical Trials in Commun	ication Disorders.			
116060 Advancing HIV/AIDS Research with Clinical Trial Optional)	hin the Mission of the NIDCD (R01	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-25- 319	07-May-2025	2,499,995 USD
Contact Name	Trinh T. Ly, MD				
Contact Telephone	301-435-4085				
Contact Email	trinh.ly@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-202 2028	26 , 07-May-2026 , 07-Sep-2026 , 07-Ja	an-2027 , 0	7-May-2027 , 07-Sep-20	27 , 07-Jan-
Synopsis	The purpose of this Funding Opportunity areas of the National Institute on Deafne priority HIV/AIDS research outlined by the research/research-priorities] in the area proposing a clinical trial, only low risk cli	ess and Other Communications Disorc ne NIH Office of AIDS Research (OAR) s of hearing, balance, taste, smell, voi	lers (NIDCD [https://ww)). Applications should a ww.oar.nih.gov/hiv-polic	ddress high cy-and-
122637 NIDCD Research Dissertation Fello	owship for Au.D. Audiologists (F32)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 069	08-Apr-2025	Not Specified
Contact Name	Jaclyn Schurman, Au.D., Ph.D.				
Contact Telephone	301-402-4888				
Contact Email	riverara@nidcd.nih.gov				
Sponsor Website					

Program URL Link to program URL

08-Apr-2025, 07-May-2025, 08-Aug-2025, 07-Sep-2025, 08-Dec-2025, 07-Jan-2026, 08-Apr-2026, 07-May-2026, 08-Aug-Deadline Dates (ALL) 2026, 07-Sep-2026, 08-Dec-2026, 07-Jan-2027

The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) Synopsis in the biomedical, behavioral, or clinical sciences. This Notice of Funding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

National Institute on Deafness and Other Communication Disorders/NIH/DHHS

PAR-24-142

Not 07-May-2025 Specified

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 09-Jun-2025, 07-Sep-2025, 08-Oct-2025, 07-Jan-2026, 09-Feb-2026, 07-May-2026, 08-Jun-2026, 07-Sep-2026, 08-Oct-2026, 07-Jan-2027, 08-Feb-2027, 07-May-2027

The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a

	companion NOFOs PAR-24-140 and PAR-	24-143						
arch Career Enhancement Award for Established Investigators ndent Clinical Trial Not Allowed)		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	ommunication PAR-24-		Not Specified			
Contact Name	Alberto L. Rivera-Rentas, Ph.D.							
Contact Telephone	301-496-1804							
Contact Email	riverara@nidcd.nih.gov							
Sponsor Website								
Program URL	Link to program URL							
Deadline Dates (ALL)	07-May-2025 , 09-Jun-2025 , 07-Sep-202 2026 , 08-Oct-2026 , 07-Jan-2027 , 08-Fel	7-May-2025 , 09-Jun-2025 , 07-Sep-2025 , 08-Oct-2025 , 07-Jan-2026 , 09-Feb-2026 , 07-May-2026 , 08-Jun-2026 , 07-Sep- 026 , 08-Oct-2026 , 07-Jan-2027 , 08-Feb-2027 , 07-May-2027						
	ne purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable							

Synopsis Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an

separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to

established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Notice of

independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an

ancillary clinical trial as lead investigator, should apply to the companion NOFO (NOFO# PAR-24-140 and PAR-24-142).

.23922 NIDCD Research Career Enhancement Award for Established Investigators
(K18 Clinical Trial Required)

National Institute on Deafness and Other Communication

Disorders/NIH/DHHS

PAR-24140

07-May-2025

Specified

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 09-Jun-2025, 07-Sep-2025, 08-Oct-2025, 07-Jan-2026, 09-Feb-2026, 07-May-2026, 08-Jun-2026, 07-Sep-

	2026, 08-Oct-2026, 07-Jan-2027, 08-Feb-2027, 07-May-2027					
Synopsis	the purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable stablished, proven investigators to augment or redirect their research programs through the acquisition of new research stills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding apportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an adependent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their esearch and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFOs PAR-24-142 and PAR-24-143.					
NIDCD Mentored Career Develop		National Institute on Deafness and	PAR-24-		315,000	
124298 Au.D./Ph.D. Audiologists (K01 Indo	ependent Basic Experimental Studies	Other Communication	150	07-May-2025	USD	
with Humans Required)		Disorders/NIH/DHHS				
	Alberto L. Rivera-Rentas, Ph.D.					
Contact Telephone						
Contact Email	riverara@nidcd.nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 13-Jun-2025 , 07-Sep-2025 2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Fel	5 , 15-Oct-2025 , 07-Jan-2026 , 13-Fe b-2027 , 07-May-2027	b-2026 , 07	-May-2026 , 15-Jun-2020	5 , 07-Sep-	
Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-24-159).					
124297 NIDCD Mentored Career Development Au.D./Ph.D. Audiologists (K01 Clin		National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-24- 149	07-May-2025	315,000 USD	

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 13-Jun-2025, 07-Sep-2025, 15-Oct-2025, 07-Jan-2026, 13-Feb-2026, 07-May-2026, 15-Jun-2026, 07-Sep-2026, 14-Oct-2026, 07-Jan-2027, 17-Feb-2027, 07-May-2027

The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Synopsis Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial

NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Clinical Trial Not Allowed) National Institute on Deafness and Other Communication Disorders/NIH/DHHS

Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..

PAR-24-159

07-May-2025

315.000 USD

124299

Contact Name Alberto L. Rivera-Rentas, Ph.D.

Contact Telephone 301-496-1804

Contact Email riverara@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 13-Jun-2025, 07-Sep-2025, 15-Oct-2025, 07-Jan-2026, 13-Feb-2026, 07-May-2026, 15-Jun-2026, 07-Sep-2026 , 14-Oct-2026 , 07-Jan-2027 , 17-Feb-2027 , 07-May-2027

The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to

support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, Synopsis behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent

clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to
propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary
clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).

clinical trial as lead investigator, should apply to the companion NOFOs (PAR-24-149 and PAR-24-150).							
117259 Notice of Special Interest (NOSI): within the NIDCD Mission Areas	Encouraging Women's Health Research	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 23-006	25-Feb-2025	Not Specified		
Contact Name	e Christopher Myers						
Contact Telephone	e 301-435-0713						
Contact Emai	il myersc@nidcd.nih.gov						
Sponsor Website	е						
Program UR	L <u>Link to program URL</u>						
Deadline Dates (ALL	M · · · · · · · · · · · · · · · · · · ·	25-Feb-2025, 07-May-2025, 05-Jun-2025, 16-Jun-2025, 25-Jun-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 25-Oct- 2025, 07-Jan-2026, 05-Feb-2026, 16-Feb-2026, 25-Feb-2026, 07-May-2026					
Synopsi	(NOSI) to stimulate research in areas reg to conduct and support research and res smell, voice, speech, and language. As no Strategic Plan NIDCD), research project the NIDCD mission areas. These projects	The National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to stimulate research in areas regarding the health of women within the scope of NIDCD's mission. NIDCD's mission is to conduct and support research and research training in the normal and disordered processes of hearing, balance, taste, smell, voice, speech, and language. As noted in the recently issued 2023–2027 NIDCD Strategic Plan (2023-2027 NIDCD Strategic Plan NIDCD), research projects to improve the health of women covering the lifespan are encouraged across all the NIDCD mission areas. These projects may include biological studies which may incorporate anatomical, structural, hormonal, or genetic aspects, behavioral traits, societal aspects, or healthcare related activities that may benefit a women's quality of life.					
114999 Notice of Special Interest (NOSI): Neural Circuits Underlying Senso	Fundamental Science Research on the ry Processing	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 23-001	07-May-2025	Not Specified		
Contact Name	e Merav Sabri, Ph.D.						
Contact Telephone	e 301-827-0908						
Contact Ema	il <u>merav.sabri@nih.gov</u>						
Sponsor Website	e						

Program URL Link to program URL

Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025	5 , 07-Sep-2025 , 05-Oct-2025 , 16-Oc	t-2025 , 07	-Jan-2026	
Synopsis	The National Institute on Deafness and Offrom its new strategic plan, in basic and modulate, taste and smell. NIDCD encourage mechanistic understanding of the behavior cutting-edge technologies and approache imaging, optogenetics, chemogenetics, so expected to integrate appropriate domain sciences, engineering, computational modulated and comparative, cross-species projects and comparative.	nechanistic research on neural circuinges multidisciplinary and innovative por of neural circuits at cellular and substitutes for recording and modulation of ceonogenetics, magnetogenetics, pharmans of expertise, including but not limudeling, statistical analysis, and bioethers.	ts underlying to indicate the condition of the condition	ng sensory processing in diverse teams, to accemporal resolution by uits (e.g., electrophysication). Application processing it is a second processing the processing and processing the processing it is a second processing the processing the processing it is a second processing the processing it is a second processing the processing it is a second processi	n hearing, dvance a integrating ology, optical ons are nysical
117406 Notice of Special Interest (NOSI): in Minimally Verbal/Non-Speaking	Promoting Language and Communication g Individuals with Autism	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC- 23-009	05-Apr-2025	Not Specified
Contact Name	Holly L. Storkel, Ph.D.				
Contact Telephone	301-496-5061				
Contact Email	holly.storkel@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025 , 05-Jun-2025 2026 , 07-Jan-2026 , 05-Feb-2026 , 16-Feb				25 , 05-Jan-
Synopsis	The purpose of this Notice of Special Inte communication in autistic individuals who tailor existing interventions, develop now intervention efforts, and identify meaning	o are minimally verbal/non-speaking el interventions, develop and apply r	. Further re	search is needed to ev	aluate and
Development & Testing of Novel 129708 Treatment, and Program Impleme (R34 Clinical Trial Required)	Interventions to Improve HIV Prevention, entation for People Who Use Substances	National Institute on Drug Abuse/NIH/DHHS	PAR-24- 329	07-May-2025	450,000 USD
Contact Name	Richard A. Jenkins, PhD				

Contact Telephone 301-443-1923

Contact Email jenkinsri@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025, 07-Sep-2025, 07-Jan-2026, 07-May-2026, 07-Sep-2026, 07-Jan-2027, 07-May-2027 This notice of funding opportunity (NOFO) encourages formative research, intervention development, and pilot-testing of interventions for people who use drugs. Primary outcomes of interest include the feasibility, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. Interventions here may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition or transmission of HIV infection, or improve clinical outcomes for persons living with HIV. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP). PAR-23-Not National Institute on Drug 115093 NIDA Program Project Grant Applications (P01 Clinical Trial Optional) 07-May-2025 Abuse/NIH/DHHS 064 Specified Contact Name Tamara Haegerich, Ph.D. Contact Telephone 301-443-1185 Contact Email Tamara. Haegerich@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025, 25-May-2025, 07-Sep-2025, 25-Sep-2025, 07-Jan-2026 The National Institute on Drug Abuse (NIDA) seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, medications development, health Synopsis services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in people who use or misuse substances or have a substance use disorder, or other research areas relevant to substance use, misuse, or use disorders. National Institute on Drug PAR-22-Not 07-May-2025 112163 NIDA Program Project Grant Applications (P01 Clinical Trial Optional) Abuse/NIH/DHHS 201 Specified Contact Name Tamara Haegerich, Ph.D.

Contact Telephone 301-443-1185

Contact Email Tamara.Haegerich@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 25-May-2025, 07-Sep-2025

The National Institute on Drug Abuse (NIDA) seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS and cooccurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in substance abusing populations, medication development, or other research areas relevant to drug abuse.

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

National Institute on Drug Abuse/NIH/DHHS

PAR-24-298

05-Apr-2025 [Optional][LOI/Pre-App]

275,000 USD

Contact Name Marsha F. Lopez, PhD, MHS

Contact Telephone 301-443-6504

Contact Email lopezmar@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

05-Apr-2025 [Optional][LOI/Pre-App], 05-May-2025, 10-Aug-2025 [Optional][LOI/Pre-App], 09-Sep-2025, 13-Dec-2025 [Optional][LOI/Pre-App], 12-Jan-2026, 04-Apr-2026 [Optional][LOI/Pre-App], 04-May-2026, 10-Aug-2026 [Optional][LOI/Pre-App] App], 09-Sep-2026, 12-Dec-2026 [Optional][LOI/Pre-App], 11-Jan-2027, 03-Apr-2027 [Optional][LOI/Pre-App], 03-May-2027, 10-Aug-2027 [Optional][LOI/Pre-App], 09-Sep-2027

This notice of funding opportunity (NOFO) will support pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services, including: 1) Research in response to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) Research in response to emerging trends and topics related to a change in federal, state, or local drug policy. The work proposed must be related to imminent policy change; 3) Research in response to unexpected and time-sensitive Synopsis medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 4) Responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes)

that relate to drug misuse and access and provision of health care service; 5) Research that examines the early implementation of new or newly changed federal, state, or local programs, policy, financing, or payment approaches related to substance use, substance use epidemiology, prevention, treatment, or recovery. Activities may include infrastructurebuilding partnerships among researchers and state or local organizations to address later implementation phases; 6)

Research in response to natural disasters or newly emergent public health emergencies, to understand their impacts on drug markets, substance use epidemiology, prevention, treatment or recovery outcomes. For the purposes of this NOFO, "timesensitive" is defined as in need of expedited review and funding in order to answer the scientific research question(s) posed (e.g. an imminent policy change will not allow for standard review and funding timeline). Applications whose aims can be accomplished with standard NIH submission, review, and award cycles will not be considered time-sensitive.

1	2	7	q	Ջ	U	

Behavioral & Integrative Treatment Development Program (R01 Clinical **Trial Optional)**

National Institute on Drug Abuse/NIH/DHHS

PAR-24-299

07-May-2025

Not Specified

Contact Name Will M. Aklin, Ph.D.

Contact Telephone 301-827-5909

Contact Email aklinwm@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus

on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies

	that optimize combined, sequential, or in	ntegrated behavioral/pharmacologica	al treatment	S.		
114003 Notice of Special Interest (NOSI): Treating Addiction and Substance	Targeting Epigenetic Regulators for Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-004	08-Apr-2025	Not Specified	
Contact Name	Sam Ananthan, Ph.D.					
Contact Telephone	301-435-2199					
Contact Email	sam.ananthan@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025 , 05-Jun-2025 , 12-Jun-2025 , 16-Jun-2025 , 08-Aug-2025 , 07-Sep-2025 , 05-Oct-2025 , 12-Oct- 2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Jan-2026					
Synopsis	The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform applicants about NIDA's special interest in innovative research that uses chemical and pharmacological approaches to identify and target epigenetic regulators and mechanisms for the treatment of addiction and substance use disorders.					
Notice of Special Interest (NOSI): on the Treatment of Drug, Alcoho R03)	Health Services and Economic Research ol, and Tobacco Use Disorders (R01, R21,	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 23-012	07-May-2025	Not Specified	
Contact Name	Tisha Wiley, Ph.D.					
Contact Telephone	301-594-4381					
Contact Email	tisha.wiley@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-202	5 , 07-Sep-2025 , 05-Oct-2025 , 16-O	ct-2025,07	-Jan-2026		
Synopsis	The purpose of this Notice is to inform potential applications to the National Institute on Drug Abuse (NIDA) of special interest in grant applications to conduct rigorous health services and economic research to maximize the availability and delivery of efficient, effective drug, alcohol, and tobacco treatment and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation science; (4) availability, demand, access, and financing; (5) effectiveness; and (6) development or improvement of research methodology, analytic approaches, and measurement instrumentation.					

114150 Notice of Special Interest (NOSI): Medical/Psychosocial Consequence		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-002	07-May-2025	Not Specified
Contact Name	Raul Mandler, MD				
Contact Telephone	240-281-0569				
Contact Email	mandlerr@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-202	5 , 07-Sep-2025 , 05-Oct-2025 , 16-Oc	ct-2025, 07	-Jan-2026	
Synopsis	The purpose of this notice is to support r therapeutic measures for chemsex in peo- lesbian, gay, bisexual.				
114048 Notice of Special Interest (NOSI): Discovery of Targets and Therape	Chemoproteomic Approaches for utics to Treat Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-005	08-Apr-2025	Not Specified
Contact Name	Sam Ananthan, Ph.D.				
Contact Telephone	301-435-2199				
Contact Email	sam.ananthan@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025 , 05-Jun-202 2025 , 16-Oct-2025 , 08-Dec-2025 , 07-Ja		ıg-2025 , 07	-Sep-2025 , 05-Oct-2025	, 12-Oct-
Synopsis	The purpose of this Notice is to inform pointerest in supporting basic research on t development of drugs to treat addiction	he application of chemoproteomic a		. ,	•
114151 Notice of Special Interest (NOSI): Medical/Psychosocial Consequence		National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-002	07-May-2025	Not Specified
Contact Name	Raul Mandler, MD				

Contact Telephone 240-281-0569

Contact Email mandlerr@nih.gov

Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-May-2025 , 05-Jun-202 2025 , 07-Jan-2026	25 , 12-Jun-2025 , 16-Jun-2025 , 07-S	ep-2025 , 05	5-Oct-2025 , 12-Oct-2	025 , 16-Oct-
Synopsis	The purpose of this notice is to support r therapeutic measures for chemsex in peo- lesbian, gay, bisexual.	· · · · · · · · · · · · · · · · · · ·			
Notice of Special Interest (NOSI):	Pharmacogenomic Approaches to	National Institute on Drug	NOT-DA-		Not
115450 Enhancing HIV and Substance Use	e Disorder (SUD) Treatment Strategies, A	Abuse/NIH/DHHS	24-001	07-May-2025	Specified
Jump Into Precision Medicine.					
Contact Name	Guifang Lao, Ph.D.				
Contact Telephone	301-827-5931				
Contact Email	laog@nih.gov				
Sponsor Website					
Sponsor Website Program URL					
Program URL		5 , 07-Sep-2025 , 05-Oct-2025 , 16-O	ct-2025 , 07-	-Jan-2026 , 05-Feb-20	026 , 16-Feb-
Program URL	07-May-2025, 05-Jun-2025, 16-Jun-2025 2026, 07-May-2026	proposals focusing on studying pharn	nacogenomi	cs in PLWH with SUD	
Program URL Deadline Dates (ALL) Synopsis	07-May-2025, 05-Jun-2025, 16-Jun-2025, 2026, 07-May-2026 NIDA is interested in receiving research pattern in the science of Precision Medicine	proposals focusing on studying pharn , in the path of personalized care for	nacogenomi	cs in PLWH with SUD ig abuse	
Program URL Deadline Dates (ALL)	07-May-2025, 05-Jun-2025, 16-Jun-2020 2026, 07-May-2026 NIDA is interested in receiving research p step in the science of Precision Medicine Leveraging Data Science to Bring	proposals focusing on studying pharn	nacogenomic HIV and dru	cs in PLWH with SUD	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI): Actionable Insights for Substance	07-May-2025, 05-Jun-2025, 16-Jun-2020 2026, 07-May-2026 NIDA is interested in receiving research p step in the science of Precision Medicine Leveraging Data Science to Bring	proposals focusing on studying pharn , in the path of personalized care for National Institute on Drug	nacogenomio HIV and dru NOT-DA-	cs in PLWH with SUD ig abuse	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI): Actionable Insights for Substance Contact Name	07-May-2025, 05-Jun-2025, 16-Jun-2022, 2026, 07-May-2026 NIDA is interested in receiving research particles in the science of Precision Medicine Leveraging Data Science to Bring use Prevention and Treatment Janet Kuramoto-Crawford, PhD	proposals focusing on studying pharn , in the path of personalized care for National Institute on Drug	nacogenomio HIV and dru NOT-DA-	cs in PLWH with SUD ig abuse	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI): Actionable Insights for Substance Contact Name Contact Telephone	07-May-2025, 05-Jun-2025, 16-Jun-2020, 2026, 07-May-2026 NIDA is interested in receiving research particles in the science of Precision Medicine Leveraging Data Science to Bring use Prevention and Treatment Janet Kuramoto-Crawford, PhD 301-443-8856	proposals focusing on studying pharn , in the path of personalized care for National Institute on Drug	nacogenomio HIV and dru NOT-DA-	cs in PLWH with SUD ig abuse	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI): Actionable Insights for Substance Contact Name Contact Telephone Contact Email	07-May-2025, 05-Jun-2025, 16-Jun-2022, 2026, 07-May-2026 NIDA is interested in receiving research pastep in the science of Precision Medicine Leveraging Data Science to Bring use Prevention and Treatment Janet Kuramoto-Crawford, PhD 301-443-8856 janet.kuramoto-crawford@nih.gov	proposals focusing on studying pharn , in the path of personalized care for National Institute on Drug	nacogenomio HIV and dru NOT-DA-	cs in PLWH with SUD ig abuse	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI): Actionable Insights for Substance Contact Name Contact Telephone Contact Email Sponsor Website	07-May-2025, 05-Jun-2025, 16-Jun-2020, 2026, 07-May-2026 NIDA is interested in receiving research particles in the science of Precision Medicine Leveraging Data Science to Bring use Prevention and Treatment Janet Kuramoto-Crawford, PhD 301-443-8856 janet.kuramoto-crawford@nih.gov	proposals focusing on studying pharn , in the path of personalized care for National Institute on Drug	nacogenomio HIV and dru NOT-DA-	cs in PLWH with SUD ig abuse	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI): Actionable Insights for Substance Contact Name Contact Telephone Contact Email Sponsor Website Program URL	07-May-2025, 05-Jun-2025, 16-Jun-2022 2026, 07-May-2026 NIDA is interested in receiving research particles in the science of Precision Medicine Leveraging Data Science to Bring use Prevention and Treatment Janet Kuramoto-Crawford, PhD 301-443-8856 janet.kuramoto-crawford@nih.gov Link to program URL	proposals focusing on studying pharm , in the path of personalized care for National Institute on Drug Abuse/NIH/DHHS	nacogenomio HIV and dru NOT-DA-	cs in PLWH with SUD ig abuse	as a crucial
Program URL Deadline Dates (ALL) Synopsis 109484 Notice of Special Interest (NOSI):	07-May-2025, 05-Jun-2025, 16-Jun-2020, 2026, 07-May-2026 NIDA is interested in receiving research particles in the science of Precision Medicine Leveraging Data Science to Bring use Prevention and Treatment Janet Kuramoto-Crawford, PhD 301-443-8856 janet.kuramoto-crawford@nih.gov	oroposals focusing on studying pharm, in the path of personalized care for National Institute on Drug Abuse/NIH/DHHS	nacogenomic HIV and dru NOT-DA- 23-006	cs in PLWH with SUD ig abuse 07-May-2025	as a crucial Not Specified

prevention and treatment 2) shorten the time between data capture and data availability so that data are available real-time or near real-time, and 3) explore methods and tools that may allow for faster or better localized responses for substance use treatment and prevention. Priority will be given to projects that emphasize the use of existing data streams (e.g., electronic health records, syndromic surveillance, claims data, registry data, pharmacy dispensing, social media, and mortality records).

109268 Notice of Special Interest (NOSI): Epidemiology of Drug Abuse

National Institute on Drug Abuse/NIH/DHHS

NOT-DA-22-004

07-May-2025

Not Specified

Contact Name Marsha Lopez, PhD, MHS

Contact Telephone 301-443-6504

Contact Email Marsha.Lopez@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025

The purpose of this Notice is to encourage the submission of research project applications that enhance our understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse, and addiction across individuals, families, communities, and diverse population groups. Of interest are applications that address multiple levels of risk, resilience, and causation across scientific disciplines, and that apply novel methods to advance knowledge of the interplay among genetic, environmental, neurobiological, and developmental factors and associated health and disease Synopsis outcomes. Priority will be given to research with a well described path towards translation and/or public health impact. In addition to novel data collection, approaches are encouraged that build on the research investments of NIH and sister HHS agencies to harness existing data on the epidemiology and etiology of drug misuse to improve public health prevention and treatment programs. The research areas noted below should be considered in the context of topics such as health disparities or inequities, familial/genetic liability, and physical, psychiatric, and polysubstance comorbidities and interactions.

Notice of Special Interest (NOSI): High Priority Areas in Integrative 111673 Neuroscience Branch in the Division of Neuroscience and Behavior

National Institute on Drug Abuse/NIH/DHHS

NOT-DA-22-058

07-May-2025

Not Specified

Contact Name Olivier Berton, Ph.D.

Contact Telephone 301-827-7771

Contact Email Olivier.berton@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 07-May-2025, 05-Jun-2025, 12-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 12-Oct-2025, 16-Oct-2025, 07-Jan-2026

The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Branch covers: 1) Synopsis the regulation and plasticity of neurotransmitter and neuromoduatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD, and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substanceinduced neuroinflammation.

119295

Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)

National Institute on Drug Abuse/NIH/DHHS

PAR-25-347

07-May-2025

100,000 USD

Contact Name Marsha F. Lopez, Ph.D., M.H.S.

Contact Telephone 301-443-6504

Contact Email marsha.lopez@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 16-Jun-2025, 07-Sep-2025, 16-Oct-2025, 07-Jan-2026, 16-Feb-2026, 07-May-2026, 16-Jun-2026, 07-Sep-2026

The goal of this Notice of Funding Opportunity (NOFO) is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan (2022-2026 NIDA Strategic Plan Director's Message | National Institute on Drug Abuse (NIDA) (nih.gov). This award will facilitate the entry of promising new investigators into the field of substance use/substance use Synopsis disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from individuals from diverse backgrounds, including those from underrepresented groups as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031). This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

117405 Notice of Special Interest (NOSI):	Liveraging Glial Cells to Treat Addiction	National Institute on Drug Abuse/NIH/DHHS	NOT-DA- 24-006	07-May-2025	Not Specified
Contact Name	Shang-Yi Anne Tsai, Ph.D.				
Contact Telephone	301-827-5842				
Contact Email	stsai@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 12-Jun-202 2026 , 05-Feb-2026 , 12-Feb-2026 [LOI/F Sep-2026	•	•	•	•
Synopsis	This Notice of Special Interest (NOSI) en develop strategies to mitigate Central N substances or therapeutic avenues for a	ervous System (CNS) damage due		•	
.27982 Behavioral & Integrative Treatme Trial Optional)	nt Development Program (R34 Clinical	National Institute on Drug Abuse/NIH/DHHS	PAR-24- 300	07-May-2025	450,000 USD
Contact Name	Will M. Aklin, Ph.D.				
Contact Telephone	301-827-5909				

Contact Email aklinwm@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for substance use and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as

well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

	1				
127894 Imaging - Science Track Award for Clinical Trial Optional)	or Research Transition (I/START) (R03-	National Institute on Drug Abuse/NIH/DHHS	PAR-24- 297	07-May-2025	150,000 USD
Contact Name	Hoang Le, Ph.D.				
Contact Telephone	301-451-8849				
Contact Email	l <u>hoang.le@nih.gov</u>				
Sponsor Website	e				
Program UR	L Link to program URL				
Deadline Dates (ALL	07-May-2025 , 16-Jun-2025 , 07-Sep-202 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Fe	25 , 16-Oct-2025 , 07-Jan-2026 , 16-Fo 2b-2027 , 07-May-2027 , 16-Jun-2027	eb-2026 , 07 , 07-Sep-20	7-May-2026 , 16-Jun-2026 027 , 16-Oct-2027 , 07-Jar	ว <i>์ ,</i> 07-Sep- า-2028
Synopsi	This Funding Opportunity Announcemer investigators to the area of neuroimagins investigators seeking to adopt neuroima of concept" studies. The RO3 is intended limited resources.	g, including both newly independent ging methodologies in their research	investigato programs,	rs and established to enable the conduct of	small "proof
129345 D-START: Data Science Track Awa	ard for Research Transition (D/START)	National Institute on Drug	PAS-25-	07-May-2025	200,000

Abuse/NIH/DHHS

236

Contact Name Susan N. Wright, Ph.D.

Contact Telephone 301-402-6683

(R03-Clinical Trial Optional)

USD

Contact Email	susan.wright@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-202 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Fe				026 , 07-Sep-
Synopsis	This notice of funding opportunity (NOFO techniques to address timely and challen (SUD) in all areas of research supported to Grant (R03) applications to support research support resources.	ging research questions related to so by the National Institute on Drug Abo	ubstance us use (NIDA). [·]	e and/or substance us This NOFO requests Sn	e disorder nall Research
129186 Pilot Health Services and Econom Alcohol, and Tobacco Use Disorder	ic Research on the Treatment of Drug, ers (R34 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-25- 100	07-May-2025	450,000 USD
Contact Name	Carrie Mulford				
Contact Telephone	301-827-6473				
Contact Email	Carrie.Mulford@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-202 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Fe		eb-2026 , 07	-May-2026 , 16-Jun-20	026 , 07-Sep-
Synopsis	This Funding Opportunity Announcemen services research effectiveness trials. Rel and policies designed to optimize access alcohol use disorder treatments and rela conditions. Relevant approaches may inclack an evidence base. This FOA provides in addition to usual trial preparation activities Diverse Perspectives (PEDP).	evant trials may test a wide range of to, and the quality, effectiveness, af ted services, as well as services for c lude both those that are novel, and resources for assessing the feasibili	approache fordability a omorbid me those that a ty, acceptab	s, including intervention of drug, and utilization of drug, edical and mental disorate commonly used in patility, and utility of thes	ons, practices, tobacco, or rder practice but se approaches,
171868	Disparities in Non-Communicable and : Setting the Stage for Better Health	National Institute on Minority Health and Health	PAR-25- 377	07-May-2025	Not Specified

Outcomes Across the Hemisphere	e (R01 - Clinical Trials Not Allowed)	Disparities/NIH/DHHS			
Contact Name	Larissa Avilés-Santa, MD, MPH, Director				
Contact Telephone	301-827-6924				
Contact Email	avilessantal@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202 2026 , 05-Oct-2026 , 07-Jan-2027	5 , 05-Oct-2025 , 07-Jan-2026 , 05-Fε	eb-2026 , 07	-May-2026 , 05-Jun-202	26 , 07-Sep-
Synopsis	This Notice of Funding Opportunity (NOF application due dates after January 25, 2 collaborative, and interdisciplinary resea and validation of measurements that addiseases (NCDs) with the highest disease	025. This Notice of Funding Opporturch focused on clinical epidemiology dress health and healthcare disparition	nity (NOFO) , evaluation es related to	will support innovative of public and/or health non-communicable ar	e, n care policies, nd chronic
125421 Interventions to Reduce Sleep He Optional)	alth Disparities (R01 - Clinical Trials	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24- 330	07-May-2025	Not Specified
Contact Name	Arielle S. Gillman, PhD, MPH				
Contact Telephone	301-435-0060				
Contact Email	arielle.gillman@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Fe				26 , 07-Sep-
Synopsis	The purpose of this initiative is to supporting disparities, and examine sleep as a modi experience health disparities.	•	•		•
127614 Advancing Healthcare for Older A Health Disparities (R01 - Clinical T	dults from Populations that Experience rial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-24- 273	07-May-2025	Not Specified

Contact Name	Yewande Oladeinde, PhD				
Contact Telephone					
·	yewande.oladeinde@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb			•	•
Synopsis	The purpose of this initiative is to advance older adults from populations that experi better understanding of appropriate scre shared decision-making that is needed to the older adult and their caregiver(s), and	ence health disparities. The initiative ening, diagnostic, and clinical care go enhance care planning and patient	e will suppo uidelines in agency betv	rt research designed to a primary care setting, (veen clinicians and care	(1) gain a 2) explore
128943 The Role of Work in Health Disparation Optional)	rities in the U.S. (R01 Clinical Trials	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-25- 292	07-May-2025	Not Specified
Contact Name	Rada K. Dagher, PhD, MPH				
Contact Telephone	301-451-2187				
Contact Email	rada.dagher@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb				
Synopsis	The purpose of this Funding Opportunity contribute to identifying and characterizing outcomes and health status among populaterminant of health.	ng pathways and mechanisms throu	gh which wo	ork or occupation influe	nces health
115679 NIMHD Exploratory/Development Trial Optional)	tal Research Grant Program (R21 - Clinical	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-23- 111	07-May-2025	275,000 USD

Contact Name					
Contact Telephone	301-402-1366				
Contact Emai	GrantsInfo@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	07-May-2025 , 16-Jun-2025 , 07-Sep-202	5 , 16-Oct-2025 , 07-Jan-2026 , 16-Fel	b-2026 , 07	-May-2026	
Synopsis	NIMHD invites applications to support sh break new ground in the fields of minorit directions or applications that can directl U.S.	y health and/or health disparities or	extend prev	vious discoveries toward	l new
121524 RFA-DA-24-067 HEAL Initiative: Substance Use Preventive Service	Research to Increase Implementation of es (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA- 24-067	18-May-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Amy B. Goldstein, PhD				
Contact Telephone	301-827-4124				
Contact Emai	amy.goldstein@nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL	18-May-2025 [Optional][LOI/Pre-App], 17	7-Jun-2025 , 17-Dec-2025 [Optional][I	LOI/Pre-Ap _l	o], 16-Jan-2026	
Synopsis	Despite an evidence base of effective processes of the practice gap exists. The goal of public health and responding to the opiois. This notice of funding opportunity (NOFC researched, could create the foundation of interventions to prevent opioid and ot preliminary or feasibility data is available pilot data is unavailable.	of this initiative is to support projects id crisis by increasing knowledge pert of solicits applications to address und needed to inform a prevention infrascher substance misuse and use disord	that fill thi aining to the erstudied a tructure fo ers. This NC	s research to practice ga ne delivery of preventior reas of opportunity that r ongoing delivery and s DFO invites projects for v	ip, improving in services.
1/15/5	Research to Increase Implementation of es (R61/R33 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-DA- 24-066	18-May-2025 [Optional][LOI/Pre-	Not Specified

				App]	
Contact Name	Amy B. Goldstein, PhD				
Contact Telephone	301-827-4124				
Contact Email	amy.goldstein@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025 , 17-Dec-	2025 [Optional][LOI/Pre-Ap	p], 16-Jan-2026	
Synopsis	Despite an evidence base of effective programs to prevent the research to practice gap exists. The goal of this initiative is to public health and responding to the opioid crisis by increasing services. This notice of funding opportunity (NOFO) solicits agresearched, could create the foundation needed to inform a of interventions to prevent opioid and other substance misus preliminary or feasibility data is not available. This NOFO is a which pilot data is available.	support projects g knowledge pert oplications to add prevention infras se and use disord	that fill thi aining to th Iress under tructure fo ers. This NO	s research to practice ne delivery of preventi studied areas of oppo r ongoing delivery and DFO invites projects fo	gap, improving ion rtunity that, if I sustainment or which
117590 Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed) National Institutes	of Health/DHHS	PAR-23- 171	15-May-2025	Not Specified
Contact Name	Argenia Doss				
Contact Telephone	301-827-1373				
Contact Email	argenia.doss@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-May-2025				
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is the Data Management Coordinating Center for Diagnostic Ce the Undiagnosed Diseases Network. Resources include infras new Network of clinical sites that provide diagnostic services	nters of Excellend tructure, data ma	ce (RFA-NS- anagement,	-22-051), as part of the , and clinical research	e next phase o
116623 Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed) National Institutes	of Health/DHHS	PAR-23- 120	15-May-2025	Not Specified

	tein National Research Service Award National Institutes of Health/DHHS PAR-22- 25-May-2025	Not Specified
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devicuse as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD), program is to demonstrate treatment using credible neural targets for device-based interventions and/or or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spi pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary studies. The scope of the program includes technology development and optimization, and studies to prepare for human use.	The goal of the diagnostics for pain nal, and peripheral e stage of proof-of-concept
Deadline Dates (ALL)	18-May-2025 [Optional][LOI/Pre-App], 17-Jun-2025	
Program URL	Link to program URL	
Sponsor Website		
Contact Email	moria.bittmann@nih.gov	
Contact Telephone	301-496-7699	
Contact Name	Moria F. Bittmann	
113055 RFA-EB-22-002 HEAL Initiative: 3 and Therapeutic Devices (R18 Clin	<u>Translational Development of Diagnostic</u> <u>nical Trial Not Allowed)</u> National Institutes of Health/DHHS RFA-EB- 22-002 [Optional][LOI/F	2,250,000 USD
Synopsis	The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to rest the Data Management Coordinating Center for Diagnostic Centers of Excellence (RFA-NS-22-051), as part of the Undiagnosed Diseases Network. Resources include infrastructure, data management, and clinical research new Network of clinical sites that provide diagnostic services for patients with undiagnosed diseases.	of the next phase of
Deadline Dates (ALL)	15-May-2025	
Program URL	Link to program URL	
Sponsor Website		
Contact Email	argenia.doss@mail.nih.gov	
Contact Telephone	301-827-1373	
Contact Name	Argenia Doss	

Clinical	Trial	Not Al	lowed)
Cilitical	HIII	INULA	ioweu,

Contact Name Dr. Ashlee Van't Veer

Contact Telephone

Contact Email ashlee.vantveer@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025

The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be well-trained scientists equipped to pursue careers in neuroscience. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

119079 ClinGen Genomic Curation Expert Panels (U24 Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PAR-23-199

25-May-2025

660,000 USD

Contact Name Mollie Minear, PhD

Contact Telephone

Contact Email mollie.minear@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025

NIH established a clinical genomics infrastructure to develop an openly accessible knowledgebase that promotes data sharing and provides standardized infrastructure and tools for determining the clinical relevance of genetic variants through two initiatives: the Clinical Genomics Resource (ClinGen) and the Clinical Variant Database (ClinVar) of clinical variation. ClinGen defines the clinical relevance of genes and variants for use in precision medicine and research by standardizing clinical annotation and interpretation of variants and implementing evidence-based expert consensus assertions. The purpose of this Notice of Funding Opportunity (NOFO) is to establish Expert Panels that will select genes and genomic variants associated

with diseases or conditions of high priority to participating NIH Institutes and Centers (ICs) and systematically determine their
clinical significance for diagnosis and treatment of these diseases or conditions. The Genomic Curation Expert Panels funded
through this NOFO are required to utilize the NHGRI Clinical Genomics Resource (ClinGen) and the NCBI ClinVar procedures,
interfaces, tools, and informatics infrastructure.

	interfaces, tools, and informatics infrasti	ucture.			
117962 <u>RFA-NS-23-028 HEAL Initiative:</u> Uncover the Mechanisms of Pain <u>Trial Optional)</u>		National Institutes of Health/DHHS	RFA-NS- 23-028	10-May-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Eric Hudak, Ph.D.				
Contact Telephone	301-496-1779				
Contact Email	NINDS-Devices@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-May-2025 [Optional][LOI/Pre-App], 0	9-Jun-2025			
This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the understanding of pain relief by medical devices.					
117659 Centers of Excellence in Genomic	Science (RM1 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-23- 098	09-May-2025 [Optional][LOI/Pre- App]	7,500,000 USD
Contact Name	Stephanie A. Morris, Ph.D.				
Contact Telephone	301-435-5738				

Contact Email morriss2@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 09-May-2025 [Optional][LOI/Pre-App], 24-Jun-2025

Synopsis The Centers of Excellence in Genomic Science (CEGS) program establishes academic Centers for advanced genome research.

Each CEGS award supports a multi-investigator, interdisciplinary team to develop integrated, transformative genomic approaches to address a biomedical problem. A CEGS project will address a critical issue in genomic science, genomic medicine, or computational genomics, proposing a highly innovative solution that would be a major advance. The research will entail substantial risk, balanced by outstanding scientific and management plans and very high potential payoff. A CEGS will focus on the development of novel technological or computational methods for the production or analysis of comprehensive data sets, on a genome-scale biomedical problem, or on other ways to develop and use genomic approaches for understanding biological systems or furthering the application of genomic knowledge, data, and methods towards clinical applications. Each CEGS will nurture genomics by facilitating the interaction of investigators from several disciplines. Along with its scientific goals, CEGS will also expand the pool of genomic scientists and engineers that can use and apply the novel methods, concepts, and knowledge developed by the CEGS by providing education and outreach experiences to scientists at all career levels.

CCRP Initiative: NIH Countermeasures Against Chemical Threats 117067 (CounterACT) Translational Exploratory/Developmental Research Projects National Institutes of Health/DHHS

PAR-23-

30-May-2025

275,000 USD

(R21 Clinical Trial Not Allowed)

Contact Name Shardell Spriggs, Ph.D.

Contact Telephone 301-443-8189

Contact Email shardell.spriggs@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-May-2025

This Notice of Funding Opportunity (NOFO) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. This NOFO supports Synopsis translational research that includes, but is not limited to, preliminary efficacy and/or early preclinical development studies towards discovery and validation of novel molecular entities or biologics as candidate MCMs. In addition to novel agents, new treatment strategies may involve repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects supported by this NOFO are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement program or other related initiatives.

118479 HIV Prevention and Alcohol (R34 (Clinical Trials Optional)	National Institutes of Health/DHHS	PAS-25- 161	07-May-2025	450,000 USD
Contact Name	Kendall Bryant, Ph.D.				
Contact Telephone	301-402-0332				
Contact Email	kbryant@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-20	026 , 07-May-2026			
Synopsis	episodic and long-term use and associate effective prevention and treatment intincidence of new infections by facilitat supports studies that are both necessary companion announcement PA-25-187 applications to this NOFO will describe research is scientifically necessary to deprojects that are designed to provide a planned Phase II, III, or IV trial must be implementation of intervention(s) in the mechanism is intended to provide new	DS prevention toolkit among alcohol im ated behavioral and biological risks for lated behavioral and biological risks for later terventions with an understanding of the ing cross-cutting informative research. The planning and sufficient to inform the planning the Prevention and Alcohol (R01 Clinical the planned clinical trial and in so doin the planned clinical trial and in so doin the subsequent trial. Further that will be sufficient to inform the primarily intended to test the efficacy, the prevention of HIV. In this NIAAA function that answers a scientific of the promotion that answers a scientific of the primarily intended to the prevention of the prevention of a clinical trial development of a clinical trial development of a clinical trial development of a clinical trial	HIV acquising overarch This R34 Not a clinical Trials Opting demonst thermore, the future to safety, cling opportor operation	tion. This includes integring framework for reduce otice of Funding Opportual trial within the scope of the control of the NIAAA expectate that the proposed (I his NOFO will support retail without further studinical management, or tunity for pilot clinical trinal question(s) which ma	ation of cing the unity (NOFO) of the ts that R34) search des. The als the R34 by be
118478 HIV Prevention and Alcohol (R01 0	Clinical Trials Optional)	National Institutes of Health/DHHS	PAS-25- 208	07-May-2025	Not Specified
Contact Name	Kendall Bryant, Ph.D.				
Contact Telephone	301-402-0332				
Contact Email	kbryant@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				

Deadline Dates (ALL) 07-May-2025 , 07-Sep-2025 , 07-Jan-2026 , 07-May-2026

Synopsis	The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol imepisodic and long-term use and associated behavioral and biological risks for effective prevention and treatment interventions with an understanding of the incidence of new infections by facilitating cross-cutting informative research, and testing of new interventions and expansion of existing effective intervent integrative preventive activities in diverse settings and populations. Six areas alcohol use and related mental health and substance use comorbidities. These Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Inteross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and	HIV acquisine overarch This resear ions as well of research e include be	tion. This includes int ing framework for re ch activity includes th I as the implementat are of primary inter out are not limited to Strategies, 4) Prevent	egration of ducing the ne development ion of these est related to 1) PrEP
Providing Research Education Exp 122726 <u>Diverse Substance Use and Addic</u> <u>Trials Not Allowed)</u>	tion Scientific Workforce (R25 Clinical National Institutes of Health/DHHS	PAR-24- 048	14-May-2025	1,250,000 USD
Contact Name	Angela Holmes, PhD			
Contact Telephone	301-827-2487			
Contact Email	angela.holmes2@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	14-May-2025 , 13-Aug-2025 , 13-Nov-2025 , 14-May-2026 , 13-Aug-2026 , 13-	Nov-2026		
Synopsis	The NIH Research Education Program (R25) supports research education active overarching goal of this R25 program is to support educational activities that backgrounds, including those from groups underrepresented in the biomedical studies or careers in research. To accomplish the stated over-arching goal, this primary focus on: Courses for Skills Development Research Experiences	encourage al and beha	individuals from dive	rse Irsue further
	Opportunity Announcement (ROA): NIH ations, and Enrollment Partnerships National Institutes of Health/DHHS	OTA-22- 006	28-Feb-2025	Not Specified
Contact Name	All of Us ROA Inquiries			

Contact Telephone

Sponsor Website

Contact Email AOU-ROA@nih.gov

Program URL Link to program URL

Deadline Dates (ALL) 28-Feb-2025, 23-May-2025

Research Opportunity Announcement (ROA) Title: All of Us Engagement, Communications, and Enrollment Partnerships ROA Number: OTA-22-006 ROA Open Period: May 26, 2022 to May 23, 2025 (Note: open period includes multiple white paper deadlines) Overview: The All of Us Research Program, within the Office of the Director (OD) at the National Institutes of Health (NIH), has issued a research opportunity announcement to solicit white papers supporting various Areas of Interest (AOIs). A ROA is a method of solicitation that announces the anticipated availability of Other Transactions (OT) awards, a special type of legal instrument other than contracts, grants, or cooperative agreements. Purpose: The All of Us Research Program is a historic effort to gather data from at least 1 million people, with the goal of accelerating health research and medical breakthroughs, and enabling individualized prevention, treatment, and care. The program is creating a national research resource to inform thousands of studies, covering a wide variety of health conditions. Researchers will use data from the program to learn more about how individual differences in lifestyle, environment, and biological makeup can influence health and disease. The purpose of this announcement is to fund organizations who can help All of Us build its cohort of volunteers who reflect the rich diversity of the United States and are actively engaged as partners. These funded Synopsis organizations will help design and implement strategies to raise awareness of the program through community and health care provider organizations, drive increased enrollment of participants, foster regular communication with participants, and engage the research community to use the data being gathered. Award Project Duration: Award periods are anticipated to be up to five (5) years but may be shortened or extended as needed. Pre-Submission Webinar: A webinar will be conducted on June 27, 2022 at [Time TBD]. Registration information will be posted here once it is available. White Paper Deadlines: This ROA will remain open for three (3) years from its issue date, unless otherwise updated via an amendment, and includes multiple white paper (WP) submission deadlines. All WP deadline times are 3:00 PM Eastern Time: Calendar Year 2022 WP Deadlines August 31, 2022 November 30, 2022 Calendar Year 2023 WP Deadlines February 28, 2023 May 31, 2023 August 31, 2023 November 30, 2023 Calendar Year 2024 WP Deadlines February 29, 2024 May 31, 2024 August 30, 2024 November 29, 2024 Calendar Year 2025 WP Deadlines February 28, 2025 May 23, 2025 Documents and Related Links: The full ROA package is attached in the 'Attachments/Links' section. Potential offerors are encouraged to carefully review the announcement before submitting questions and/or preparing a white paper submission. A link to the All of Us Research Program webpage has been provided for additional information about our program.

RFA-MD-2D-24-007 -- Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)

124567

National Institutes of Health/DHHS

11-May-2025 RFA-MD-[Optional][LOI/Pre-24-007 [qqA

Not Specified

Contact Name LCDR Michael Banyas, USPHS, MPA Contact Telephone 240-619-9483

Contact Email	nimhdsbirsttr@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-May-2025 [Optional][LOI/Pre-App], 10-Jun-2025 , 07-Jul-2025 , 10-Nov-2025 [Optional][LOI/Pre-App], 09-Dec-2025 , 11- May-2026 [Optional][LOI/Pre-App], 10-Jun-2026 , 06-Jul-2026 , 10-Nov-2026 [Optional][LOI/Pre-App], 09-Dec-2026
Synopsis	This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations that expeience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.
124669 Support for Research Excellence – Award (R16 - Clinical Trial Not Allo	- <u>First Independent Research (SuRE-First)</u> National Institutes of Health/DHHS PAR-24- 28-May-2025 USD
Contact Name	Pauline Cupit, Ph.D.
Contact Telephone	
Contact Email	pauline.cupit@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	28-May-2025 , 07-Sep-2025 , 29-Sep-2025 , 07-Jan-2026 , 27-May-2026 , 07-Sep-2026 , 28-Sep-2026 , 07-Jan-2027
Synopsis	The SuRE program supports research capacity building at eligible higher education institutions through funding investigator-initiated biomedical research in basic, social, clinical, behavioral, or translational science that falls in the mission areas of the NIH. The purpose of SuRE-First awards is to provide research grant support for faculty investigators who have not had prior independent external research grants, to furnish students with high-quality undergraduate and/or graduate research experiences and to enhance the institutional scientific research culture. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
124520 NIH Support for Conferences and Trial Not Allowed)	Scientific Meetings (Parent R13 Clinical National Institutes of Health/DHHS PA-25- 080 12-Apr-2025 Not Specified
Contact Name	

Contact Telephone Contact Email grantsinfo@nih.gov Sponsor Website Program URL Link to program URL

12-Apr-2025, 07-May-2025, 12-Aug-2025, 07-Sep-2025, 12-Dec-2025, 07-Jan-2026, 12-Apr-2026, 07-May-2026, 12-Aug-Deadline Dates (ALL) 2026, 07-Sep-2026, 12-Dec-2026, 07-Jan-2027, 12-Apr-2027, 07-May-2027, 12-Aug-2027, 07-Sep-2027

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

PAR-23-Not 13-May-2025 115173 Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) National Institutes of Health/DHHS 084 Specified

Contact Name Greg Deye, M.D.

Contact Telephone 240-627-3371

Contact Email gregory.deye@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-May-2025, 15-Sep-2025, 13-Jan-2026

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to Synopsis the research mission of the participating IC. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.

Research Enhancement Award Program (REAP) for Health Professional 129182 Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

375,000 PAR-25-National Institutes of Health/DHHS 25-Feb-2025 298 **USD**

Contact Name Lynn Mertens King, Ph.D.

Contact Telephone 301-757-5538

Contact Email lynn.king@nih.gov

Sponsor Website

Program URL Link to program URL

25-Feb-2025, 07-May-2025, 25-Jun-2025, 07-Sep-2025, 25-Oct-2025, 07-Jan-2026, 25-Feb-2026, 07-May-2026, 25-Jun-Deadline Dates (ALL) 2026, 07-Sep-2026, 25-Oct-2026, 07-Jan-2027, 25-Feb-2027, 07-May-2027, 25-Jun-2027, 07-Sep-2027, 25-Oct-2027, 07-Jan-2028

Synopsis

The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate or advanced science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htm.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual 120839 Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

National Institutes of Health/DHHS

PA-23-260

08-Apr-2025

Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Apr-2025, 07-May-2025, 08-Aug-2025, 07-Sep-2025

This Notice of Funding Opportunity (NOFO) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a Synopsis dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Notice of Funding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does

	allow applicants to propose research ex	perience in a clinical trial led by a spor	nsor or co-	sponsor.	
120841 Ruth L. Kirschstein National Research	arch Service Award (NRSA) Individual 31)	National Institutes of Health/DHHS	PA-23- 272	08-Apr-2025	Not Specified
Contact Name					
Contact Telephone					
Contact Email	GrantsInfo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025 , 08-Aug-20	25 , 07-Sep-2025			
Synopsis	The purpose of the Ruth L. Kirschstein Naward is to enable promising predoctor faculty sponsors while conducting disse participating NIH Institutes and Centers research project and is expected to clear research scientist. This Notice of Fundir clinical trial, but does allow applicants to	al students to obtain individualized, m rtation research in scientific health-rel . The proposed mentored research tra rly enhance the individual's potential ng Opportunity (NOFO) does not allow	entored re lated fields lining must to develop applicants	esearch training from of relevant to the mission reflect the candidate into a productive, ind s to propose to lead ar	outstanding ons of the 's dissertation ependent n independent
107815 RFA-EB-21-001 Technology Dev (R01 Clinical Trial Optional)	relopment to Reduce Health Disparities	National Institutes of Health/DHHS	RFA-EB- 21-001	02-May-2025	2,000,000 USD
Contact Name	Zeynep Erim, Ph.D.				
Contact Telephone	301-451-4797				
Contact Email	Zeynep.Erim@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	02-May-2025				
Synopsis	This Funding Opportunity Announceme aimed at reducing disparities in healthcateffective, affordable, culturally acceptal	are access and health outcomes. Appr	opriate me	-	_
115336 Ruth L. Kirschstein National Resea	arch Service Award (NRSA) Short-Term	National Institutes of Health/DHHS	PA-23-	07-May-2025	Not

Institutional Research Training Gr	ant (Parent T35)		080	Specified
Contact Name				
Contact Telephone				
Contact Email	GrantsInfo@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 07-Sep-2	025 , 25-Sep-2025 , 07-Jan-2026 , 25-Ja	an-2026 <i>,</i> 07-May	<i>y</i> -2026
Synopsis	The National Institutes of Health (NIH) Institutional Research Training Grants (opportunities for predoctoral students Institutes and Centers (ICs) use this NRS for health professional students (medic programs) during the summer. This programs that the sciences to pursue researched training should be of sufficient depexposure to the principles underlying the does not allow appointed Trainees to lead clinical trial led by a mentor or co-me	T35) to eligible, domestic institutions to interested in careers in biomedical, below a program exclusively to support interestal students, veterinary students, and/orgram is also intended to encourage train had careers by short-term exposure to, a th to enable the trainees, upon complete conduct of biomedical research. This ead an independent clinical trial, but do	o develop and/or havioral, or clinic nsive, short-term or students in oth ining of graduate nd involvement i etion of the programment of the programment of the programment in the progr	r enhance research training cal research. Many NIH research training experiences her health-professional estudents in the physical or in, the health-related sciences. ram, to have a thorough tunity Announcement (FOA)
116527 Genomic Community Resources (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-23- 124 25-N	May-2025 Not Specified
Contact Name	Christopher Wellington			
Contact Telephone	301-480-3496			
Contact Email	wellingtonc@mail.nih.gov			
Sponsor Website				
Program URL	Link to program URL			

To facilitate genomic research and the dissemination of its products, NHGRI supports both new and existing genomic Synopsis resources of demonstrated broad value to the research community. Awards under this FOA will support the development

and distribution of high-value genomic resources valuable for both basic and clinical genomics research.

Deadline Dates (ALL) 25-May-2025, 25-Sep-2025, 25-Jan-2026

122321 <u>Development [Small Molecules ar</u> Clinical Trial Optional)	Non-addictive Analgesic Therapeutics and Biologics] to Treat Pain (UG3/UH3	National Institutes of Health/DHHS	RFA-NS- 24-019	07-May-2025	Not Specified
	Mary Ann Pelleymounter, Ph.D.				
Contact Telephone	301-496-1779				
Contact Email	20mary.pelleymounter@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 23-May-2025 , 07-Sep-20 2026 , 07-Oct-2026 , 07-Jan-2027	25 , 24-Sep-2025 , 23-Jan-2026 , 07-N	1ay-2026 ,	22-May-2026 , 07-Sep	-2026 , 24-Sep-
Synopsis	The purpose of this notice of funding opperfective, and non-addictive small molecthe optimization and development of propain Investigation Clinical Network (EPPI small molecule starting point for optimiz optimization of the agent. The scope of total studies, development of a pharmacodyn Drug (IND) application and Phase I clinical involving participation of NIH program st	ule and biologic therapeutics to treat omising early therapeutic molecules a C-Net) or other Phase II clinical studie ation, robust biological rationale for this program includes optimization anamic/target engagement biomarker, all testing. This is a milestone-driven plant.	pain. The gand to facilities. Applicar the intended dearly devassembly a hased coop	goal of the program is itate readiness for the nts must have a promised approach, and identications of an Investiguerative agreement pr	to accelerate Early Phase sing biologic or tified assays for ND-enabling ational New ogram
121523 Specialized Programs of Research for Years 2024, 2025, and 2026 (P	Excellence (SPOREs) in Human Cancers 50 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-23- 284	25-May-2025	7,000,000 USD
Contact Name	Toby T. Hecht, Ph.D, Associate Director				
Contact Telephone	240-276-5683				
Contact Email	hechtt@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-May-2025 , 25-Sep-2025 , 25-Jan-202	6 , 25-May-2026 , 25-Sep-2026			
Synopsis	Through this Notice of Funding Opportur Center Grants for Specialized Programs of	nity (NOFO), the National Cancer Insti of Research Excellence (SPORE). Based	tute (NCI) i d on the re	invites applications for esearch proposed, app	P50 Research lications may

RFA-NS-24-019 -- HEAL Initiative: Non-addictive Analgesic Therapeutics

be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this NOFO, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

120406 Alcohol and Other Substance Use Professionals (R25 Clinical Trial No.	Research Education Programs for Health ot Allowed)	National Institutes of Health/DHHS	PAR-23- 240	25-May-2025	1,000,000 USD
Contact Name	Laura E. Kwako, Ph.D.				
Contact Telephone	301-451-8507				
Contact Email	laura.kwako@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-May-2025 , 25-Sep-2025 , 25-Jan-2026	6 , 25-May-2026			
Synopsis	The NIH Research Education Program (R2 overarching goal of this R25 program is to behavioral and clinical research and its in educational activities with a primary focu	o support educational activities that f nplications. To accomplish the stated	oster a bet	ter understanding of bior	nedical,
113706 Development of Animal Models a Syndrome Research (R24 Clinical	nd Related Biological Materials for Down Trials Not-Allowed)	National Institutes of Health/DHHS	PAR-22- 247	25-May-2025	Not Specified

Contact Name Sige Zou, Ph.D.

Contact Email zous@mail.nih.gov

Contact Telephone 301-435-0749

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025

The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE)

Project encourages grant applications aimed at developing, characterizing, or improving animal models and related biological materials for Down syndrome (DS) related research and improving access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic Synopsis science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS

Leveraging Health Information Technology (Health IT) to Address and 110112 Reduce Health Care Disparities (R01 Clinical Trial Optional)

National Institutes of Health/DHHS

PAR-22-07-May-2025 145

Not Specified

Not

Specified

Contact Name Yewande A. Oladeinde, Ph.D.

research.

Contact Telephone 301-402-4307

Contact Email beda.jean-francois@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health Synopsis information technology (health IT) to reduce disparities in access to and utilization of health care services, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.

Notice of Special Interest (NOSI): Sustained Release of Antivirals for 110794 Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

NOT-AI-National Institutes of Health/DHHS 07-May-2025 22-042

Contact Name Marina Protopopova, Ph.D.

Contact Telephone 301-761-7653

Contact Email marina.protopopova@niaid.nih.gov

Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025 The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention. Notice of Special Interest (NOSI): High Priority Areas in Genetics, Not National Institutes of Health/DHHS 110513 Epigenetics, and Developmental Neuroscience Branch in the Division of 07-May-2025 Specified Neuroscience and Behavior Contact Name Jonathan D. Pollock, Ph.D. Contact Telephone 301-435-1309 Contact Email jpollock@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025 The mission of the Division of Neuroscience and Behavior (DNB) is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to **Synopsis** guide treatment strategies. The Genetics, Epigenetics, and Development (GED) Branch within DNB supports research on the genetics, epigenetics, and developmental mechanisms that underlie addiction and substance use disorders (SUD). Notice of Special Interest (NOSI): Understanding Sudden Death in the NOT-HL-Not 115307 National Institutes of Health/DHHS 07-May-2025 Young Through Research 22-040 Specified Contact Name Kristin M. Burns, MD Contact Telephone 301-594-6859 Contact Email kristin.burns@nih.gov **Sponsor Website** Program URL Link to program URL Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-

Synopsis	2026, 05-Oct-2026, 07-Jan-2027, 05-Feb-2027, 07-May-2027, 05-Jun-2027, 07-Sep-2027, 05-Oct-2027, 07-Jan-2028 This Notice of Special Interest (NOSI) highlights interest in receiving grant applications focused on mechanistic, genetic, an other studies to evaluate causes and consequences of, and risk factors for sudden death in the young (SDY). Studies are required to use phenotypic data and/or DNA samples and/or associated sequence data from the NIH/CDC Sudden Death is the Young (SDY) Case Registry as foundations for their research. Studies may use SDY Case Registry phenotypic data and/or samples and/or sequence data alone or in combination with other cohorts. Results of such studies are required to adhere the NIH Data Sharing Policy so that the data is disseminated widely and provides an evidence base to advance discussions about screening and prevention of SDY.	in or to
· · · · · · · · · · · · · · · · · · ·	Ithcare Disparities on Non-Communicable Nerica: Improving Health Outcomes Across	ed
Contact Name	Larissa Avilés-Santa, MD, MPH, Director	
Contact Telephone	e 301-827-6924	
Contact Email	il avilessantal@nih.gov	
Sponsor Website	e e	
Program URL	L Link to program URL	
Deadline Dates (ALL)	07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Oct-2026, 07-Jan-2027, 07-May-2027)-
Synopsis	The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos.	
121337 NIAID and NIDDK Research Oppor	ortunities for New and "At-Risk" Orce Diversity (R01 Clinical Trial Optional) National Institutes of Health/DHHS PA-25- 249 07-May-2025 Specific	ed
Contact Name	e Carmen Moten, Ph.D., MPH	
Contact Telephone	e 240-669-2924	
Contact Email	il Altraininghelpdesk@niaid.nih.gov	

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) Synopsis	07-May-2025, 05-Jun-2025, 07-Sep-2025 The purpose of this notice of funding opportunity (NOFO) is to encourage reswith their institutions to submit applications for research projects within the research support either (a) a New Investigator (NI), who has not previously confidenedent funding from NIH, or (b) an 'At-Risk' investigator, who had prior research award and unless successful in securing a substantial research grant substantial research grant funding in the following fiscal year.	mission of e mpeted suc support as	either NIAID or NIDDK. T ccessfully for substantial a PD/PI on a substantial	his NOFO , independent
116616 Notice of Special Interest (NOSI): Disease (CAROL Act)	Research Project Grants in Valvular Heart National Institutes of Health/DHHS	NOT-HL- 23-079	07-May-2025	Not Specified
Contact Name	Frank Evans, PhD			
Contact Telephone	301-435-0510			
Contact Email	evansf@nhlbi.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Fe	b-2026 , 07	'-May-2026	
Synopsis	As part of the National Heart, Lung, and Blood Institute's implementation of t Opportunities Legacy (CAROL) Act, this Notice of Special Interest is seeking RO heart disease.			
128630 Natural History of Disorders Screen	enable in the Newborn Period (R01 National Institutes of Health/DHHS	PAR-25- 227	06-May-2025 [Optional][LOI/Pre- App]	Not Specified
Clinical Trial Optional)	nable in the Newborn Period (R01 National Institutes of Health/DHHS Melissa Parisi, MD, PhD		[Optional][LOI/Pre-	
Clinical Trial Optional)	Melissa Parisi, MD, PhD		[Optional][LOI/Pre-	
Clinical Trial Optional) Contact Name Contact Telephone	Melissa Parisi, MD, PhD		[Optional][LOI/Pre-	
Clinical Trial Optional) Contact Name Contact Telephone	Melissa Parisi, MD, PhD 301-435-6880 parisima@mail.nih.gov		[Optional][LOI/Pre-	
Clinical Trial Optional) Contact Name Contact Telephone Contact Email	Melissa Parisi, MD, PhD 301-435-6880 parisima@mail.nih.gov		[Optional][LOI/Pre-	

App], 05-Oct-2026, 06-Jan-2027 [Optional][LOI/Pre-App], 05-Feb-2027, 06-May-2027 [Optional][LOI/Pre-App], 05-Jun-2027, 06-Sep-2027 [Optional][LOI/Pre-App], 05-Oct-2027

This Notice of Funding Opportunity (NOFO) encourages applications that will expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs. A comprehensive understanding of the natural history of a condition is necessary to facilitate appropriate interventions for infants identified by newborn screening. Characterization of the sequence and timing of symptom development provides information crucial for developing targeted, age-appropriate treatments and for establishing a baseline against which to assess novel interventions. In addition, for some conditions, establishment of genotype-phenotype correlations may facilitate prediction of the clinical Synopsis course; for others, identification of modifying genetic, epigenetic, or environmental factors may enhance understanding of clinical outcomes. Comprehensive data on the natural history of a condition will facilitate the field's ability to: 1) identify the underlying biological mechanisms; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the condition; 3) improve diagnostic accuracy; 4) facilitate clinical trials by providing comprehensive natural history data; 5) prevent, manage, and treat symptoms and complications of the condition; 6) furnish physicians and families with needed support and predictive information about the condition; and 7) establish data collection systems or patient registries to collect longitudinal data (e.g., child/family outcomes following newborn screening).

Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)

National Institutes of Health/DHHS

PAR-24-

07-May-2025

2,500,000 USD

Contact Name Rada K. Dagher, Ph.D., M.P.H.

Contact Telephone 301-451-2187

122756

Contact Email ada.dagher@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026 . 05-Oct-2026 . 07-Jan-2027

The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative observational and intervention-based

research to identify and characterize the pathways and mechanisms through which health and health care disparities occur among sexual and gender minority populations of minoritized racial/ethnic and socio-economic statuses. Per Notice Synopsis Number: NOT-MH-24-170: Research Priorities The National Institute of Mental Health (NIMH) will only accept nonclinical trials applications that reflect the mission and scientific priorities as identified in the strategic plan NIMH » The National Institute of Mental Health Strategic Plan (nih.gov) and also NIMH's Approach to Mental Health Disparities Research. Clinical trial applications will not be accepted under this notice. Per NOT-MH-20-067, NIMH expects that grant applications involving

human research participants will collect a minimum set of Common Data Elements.						
122108 RFA-AI-23-061 Long-Acting in Children Living with HIV-1 I Allowed)	Drug Delivery Systems for ART Optimization (LADDS II) (R61/R33 Clinical Trial Not	National Institutes of Health/DHHS	RFA-AI- 23-061	07-May-2025	5,450,000 USD	
Contact Na	ame Tania B. Lombo Rodriguez, Ph.D.					
Contact Teleph	one 301-761-7612					
Contact E	mail tania.lombo@mail.nih.gov					
Sponsor Web	site					
Program	URL Link to program URL					
Deadline Dates (ALL) 07-May-2025					
Syno	The purpose of this Notice of Funding Operating delivery systems for improved, simples development of existing long-acting plat that enable product optimization and activity with industry are required.	plified treatment of HIV-1 in children. forms at early stages of development	This NOFO stages to p	invites applicants engag perform specific preclinic	ged in the cal activities	
124219 Long-Term Effects of Disaster Health Disparities (R01- Clinic	s on Healthcare Systems in Populations with al Trial Optional)	National Institutes of Health/DHHS	PAR-24- 109	06-May-2025 [Optional][LOI/Pre- App]	Not Specified	
Contact Na	ame Carolina Solis-Sanabria, MD, MPH, FACS					
Contact Teleph	one 301-827-3460					
Contact E	mail carolina.solissanabria@nih.gov					
Sponsor Web	site					
Program	URL Link to program URL					
Deadline Dates (07-Jan-2027 , 05-Feb-2027 , 07-May-202	re-App], 07-Jan-2026 , 05-Feb-2026 , onal][LOI/Pre-App], 07-Sep-2026 , 05-0 27	06-May-20 Oct-2026 , (26 [Optional][LOI/Pre-Ap 06-Jan-2027 [Optional][L	op], 07-May- OI/Pre-App],	
Syno	psis The purpose of this Notice of Funding O	pportunity (NOFO) is to support collab	orative res	search focused on under	standing the	

	long-term effects of natural and/or humadisparities living in the U.S. and its territor	•	ems serving	g populations that experi	ence health
108065 Notice of Special Interest (NOSI): Co-infection	Pediatric COVID-19 and Respiratory Viral	National Institutes of Health/DHHS	NOT-HL- 22-004	07-May-2025	Not Specified
Contact Name					
Contact Telephone					
Contact Email					
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202	5			
Synopsis	This NOSI is intended to support projects screen for co-infection, phenotype and convestigator-initiated applications for bases.	ollect biospecimens to answer some of	of these qu	estions and to encourage	е
Interventions to Expand Cancer Solutions 117793 ADVANCE Health in Populations to Clinical Trial Required)	creening and Preventive Services to hat Experience Health Disparities (R01,	National Institutes of Health/DHHS	PAR-25- 098	07-May-2025	Not Specified
Contact Name	JoyAnn Courtney, Ph.D.				
Contact Telephone	301-402-3911				
Contact Email	joyann.courtney@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202 2026 , 05-Oct-2026 , 07-Jan-2027	5 , 05-Oct-2025 , 07-Jan-2026 , 05-Fel	o-2026 <i>,</i> 07	-May-2026 , 05-Jun-2026	, 07-Sep-
Synopsis	The Office of Disease Prevention (ODP) a (ICs) are issuing this R01 to solicit applica screening and preventive services in pop preventive services, or other healthcare care. Projects are encouraged to leverage	tions to address barriers and facilitate ulations that experience health dispa processes, including timely follow-up	ors that im rities. Inte of abnorm	pede use or uptake of ca rventions should include al findings, and referral t	ncer screening, o accessible

should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. Projects are encouraged to leverage collaborations with community partners and service providers to promote or enhance existing interventions and/or adapt new combinations of evidence-based strategies. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.

Synopsis The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices

more of the following levelst patient, similarly neutrinous e secting, and neighborhood, sommunity.						
106975	Promoting Research To Understand ve Impairment and Dementia (VCID)	National Institutes of Health/DHHS	NOT-HL- 23-002	07-May-2025	Not Specified	
Contact Name	Jue Chen, Ph.D.					
Contact Telephone	301-435-0550					
Contact Email	jue.chen@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025					
Synopsis	The purpose of this Notice is to inform presearch to understand mechanisms of vonew approaches for the treatment of VC	vascular contributions to cognitive imp	•	•		
(SBIRT/P) for Alcohol, Tobacco, a	Referral to Treatment or Prevention nd Other Drugs (ATOD) Use and Misuse in e Health Disparities (R01, Clinical Trial	National Institutes of Health/DHHS	PAR-26- 001	07-May-2025	Not Specified	
Contact Name	Denise Stredrick, Ph.D.					
Contact Telephone	301-402-9749					
Contact Email	denise.stredrick@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-202 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Fe	25 , 05-Oct-2025 , 07-Jan-2026 , 05-Fe b-2027 , 07-May-2027	b-2026 , 07	-May-2026 , 05-Jun-20	26 , 07-Sep-	

(ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners Specific research interests of participating NIH ICOs are detailed within.

RFA-HD-24-007 Understanding 120821 Experienced by People with Disab Trial Optional)	and Mitigating Health Disparities ilities Caused by Ableism (R01 Clinical	National Institutes of Health/DHHS	RFA-HD- 24-007	07-May-2025	2,499,995 USD
Contact Name	Toyin Ajisafe, PhD				
Contact Telephone	301-827-9242				
Contact Email	toyin.ajisafe@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025				
Synopsis	The goal of this NOFO is to encourage resunderlying mechanisms by which ableisn developing and/or testing interventions are high priority.	n adversely influences the health of pe	ersons with	disabilities (PWD), as we	ell as
Ruth L. Kirschstein National Research 121312 Predoctoral Fellowship to Promot (Parent F31-Diversity)	rch Service Award (NRSA) Individual e Diversity in Health-Related Research	National Institutes of Health/DHHS	PA-23- 271	08-Apr-2025	Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Apr-2025, 07-May-2025, 08-Aug-2025, 07-Sep-2025

Synopsis	the research training of predoctoral students from diverse backgrounds, including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Notice of Funding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.					
3 Opportunities for HIV Cure Strate Clinical Trial Not Allowed)	gies at the Time of ART Initiation (R21	National Institutes of Health/DHHS	PAR-23- 296	07-May-2025	275,000 USD	
Contact Name	Brigitte Sanders, DVM, Ph.D.					
Contact Telephone	240-627-3209					
Contact Email	sandersbe@niaid.nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-202	6 , 07-May-2026 , 07-Sep-2026				
The purpose of this Notice of Funding Opportunity (NOFO) is to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission.						
5 Opportunities for HIV Cure Strate Clinical Trial Not Allowed)	gies at the Time of ART Initiation (R01	National Institutes of Health/DHHS	PAR-23- 297	07-May-2025	Not Specified	

121483

121485

Contact Name Brigitte Sanders, DVM, Ph.D.

Contact Email sandersbe@niaid.nih.gov

Deadline Dates (ALL) 07-May-2025, 07-Sep-2025, 07-Jan-2026, 07-May-2026, 07-Sep-2026

Program URL Link to program URL

Contact Telephone 240-627-3209

Sponsor Website

The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting

	Synopsis	The purpose of this Notice of Funding Op of combination antiretroviral therapy (characteristics) ultimate goal of achieving sustained treaters.	ART) and/or at cART restart after an a	_			
124671	Support for Research Excellence (Allowed)	SuRE) Award (R16 Clinical Trial Not	National Institutes of Health/DHHS	PAR-24- 144	28-May-2025	400,000 USD	
	Contact Name	Irina N. Krasnova, Ph.D.					
	Contact Telephone						
	Contact Email	irina.krasnova@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	28-May-2025 , 07-Sep-2025 , 29-Sep-202	25 , 07-Jan-2026 , 27-May-2026 , 07-S	ep-2026 , 2	8-Sep-2026 , 07-Jan-20	027	
	Synopsis	The SuRE program supports research capacity building at eligible higher education institutions by funding investigator-initiated biomedical research in basic, social, clinical, behavioral, or translational science that falls in the mission areas of the NIH. The purpose of SuRE awards is to provide research grant support for faculty investigators at resource-limited institutions who are not currently funded by any NIH Research Project Grants (RPGs) with the exception of SuRE or SuRE-First awards, to furnish students with high-quality undergraduate and/or graduate research experiences and to enhance the institutional scientific research culture. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.					
120775	NIH Brain Development Cohorts (Trial Not Allowed)	NBDC) Biospecimen Access (X01 Clinical	National Institutes of Health/DHHS	PAR-23- 229	05-May-2025	Not Specified	
	Contact Name	Kimberly LeBlanc, Ph.D					
	Contact Telephone	301-827-4102					

Contact Email <u>kimberly.leblanc@nih.gov</u>

Deadline Dates (ALL) 05-May-2025 , 07-Oct-2025 , 06-Feb-2026 , 05-May-2026

Program URL Link to program URL

Sponsor Website

The Adolescent Brain Cognitive DevelopmentSM (ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays. This initiative allows Synopsis investigators to apply for access to biological samples from the ABCD Study. More information about the ABCD Study can be found on the NIDA ABCD Study web page. Additional information about this resource is available on the NIDA funding opportunities page, under Supplemental Information for NOFOs. ABCD Study biospecimens are managed through the NIH Brain Development Cohorts (NBDC) Biorepository and Analysis Center, which offers a web portal with services related to biospecimen access. Visit the NBDC portal to query available samples using the Biospecimen Explorer, submit a Biospecimen Availability Inquiry to determine the resource availability and impact on existing samples, and learn more about this resource.

Mentored Quantitative Research Development Award (Parent K25 125485 Independent Basic Experimental Studies with Humans Required)

National Institutes of Health/DHHS

PA-24-192

07-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant Synopsis research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent

clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125482	Mentored Quantitative Research Independent Clinical Trial Require		National Institutes of Health/DHHS	PA-24-190	07-May-2025	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	GrantsInfo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	eb-2026 <i>,</i> 07	7-May-2026 , 12-Jun-2026	, 07-Sep-		
The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevations of health and disease. The K25 award will provide support and "protected time" for a period of supervand research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with research. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve a investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an exi part of their research and career development. Candidates not planning an independent clinical trial, or proposi research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-191).					on ed study ience, H-relevant the lead ing trial, as	
125483	Mentored Quantitative Research Independent Clinical Trial Not Allo		National Institutes of Health/DHHS	PA-24-191	07-May-2025	Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, Synopsis imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-192).

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)

National Institutes of Health/DHHS

PA-24-186 07-May-2025

Not Specified

Contact Name

Contact Telephone

125230

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-Deadline Dates (ALL) 2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Announcement is for basic science experimental studies involving humans, referred Synopsis to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the

fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

125516

Mentored Clinical Scientist Research Career Development Award (Parent KO8 Independent Basic Experimental Studies with Humans Required)

National Institutes of Health/DHHS

PA-24-183 07-May-2025

Not Specified

Contact Name

Contact Telephone 301-496-8580

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (KO8) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards

Synopsis Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

125228 Mentored Patient-Oriented Research Career Development Award (Parent

National Institutes of

PA-24-185 07-May-2025

Not

K23 – Independent Clinical Trial N	lot Allowed)	Health/DHHS		Specified		
Contact Name						
Contact Telephone						
Contact Email	grantinfo@nih.gov					
Sponsor Website						
Program URL	<u>Link to program URL</u>					
Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2027 , 12-Feb-2027 , 07-May-2027						
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endead on patient-oriented research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or comentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion Not (PA-24-184).					
125512 Mentored Clinical Scientist Resea K08 - Independent Clinical Trial Re	rch Career Development Award (Parent equired)	National Institutes of Health/DHHS	PA-24-181 07-May-2025	Not Specified		
Contact Name						
Contact Telephone	301-496-8580					
Contact Email	grantinfo@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	Deadline Dates (ALL) 07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2027					
The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. Synopsis This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields biomedical and behavioral research, including translational research. This Parent Announcement is for basic science						

experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-182).

Mentored Clinical Scientist Research Career Development Award (Parent 125513 K08 – Independent Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PA-24-182 07-May-2025

Not Specified

Contact Name

Contact Telephone 301-496-8580

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of Synopsis biomedical and behavioral research, including translational research. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-181).

125524 Mentored Research Scientist Dev Independent Clinical Trial Require		National Institutes of Health/DHHS	PA-24-175 07-May-2025	Not Specified				
Contact Name								
Contact Telephone								
Contact Emai	grantsinfo@nih.gov							
Sponsor Website								
Program URL	Link to program URL							
Deadline Dates (ALL)		7-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep- 026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027						
Synopsis	The purpose of the NIH Mentored Researd (three to five years) for an intensive, super sciences leading to research independent mechanism to support career developmed individuals who propose to train in a new illness or pressing family circumstances. The proposing to serve as the lead investigated ancillary study to an existing trial, as particular clinical trial, or proposing to gain research NOFO (PA-24-176).	ervised career development exe. Although all of the particip of experiences that lead to refield or for individuals who have been solved in the participal transfer of an independent clinical transfer of their research and career of	sperience in the biomedical, behaviora ating NIH Institutes and Centers (ICs) is search independence, some ICs use the ave had a hiatus in their research care unity (NOFO) is designed specifically for itial, a clinical trial feasibility study, or a levelopment. Applicants not planning	al, or clinical use this support ne K01 award for er because of or applicants a separate an independent				
125559 Midcareer Investigator Award in Independent Basic Experimental	Patient-Oriented Research (Parent K24 - Studies with Humans Required)	National Institutes of Health/DHHS	PA-24-189 07-May-2025	Not Specified				
Contact Name								
Contact Telephone								
Contact Emai	grantinfo@nih.gov							
Sponsor Website								
_	Link to program URL							
Deadline Dates (ALL)	Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2027 , 07-May-2027							
Synopsis	The purpose of the NIH Midcareer Invest	igator Award in Patient-Orien	ted Research (K24) is to provide suppo	ort to mid-career				

health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Independent Scientist Award (Parent KO2 Independent Basic Experimental Studies with Humans Required)

National Institutes of Health/DHHS

PA-24-180 07-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the NIH Independent Scientist Award (KO2) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The KO2 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards

Synopsis

processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

	scientific missions.				
129398 NIH Research Project Grant (Pare	nt R01 Clinical Trial Required)	National Institutes of Health/DHHS	PA-25-30.	5 07-May-2025	Not Specified
Contact Name					
Contact Telephone					
Contact Email	grantsinfo@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb				
Synopsis	The NIH Research Project Grant supports interests and competencies of the investig trial be proposed. The proposed project m NIH Institutes and Centers (ICs) based on tapplications proposing mechanistic studies announcement.	rator(s). This Parent Notice of Fu lust be related to the programm heir scientific missions. Applica	unding Oppor natic interests nts should no	tunity requires that at least of one or more of the part te that some ICs only accep	t 1 clinical cicipating ot
129320 Risk and Protective Factors of Fan (R01 - Clinical Trial Optional)	nily Health and Family Level Interventions	National Institutes of Health/DHHS	PAR-25- 317	07-May-2025	Not Specified
Contact Name	Arundhati Gogineni, PhD				
Contact Telephone	301-827-9545				
Contact Email	Arundhati.Gogineni@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Feb	, 05-Oct-2025 , 07-Jan-2026 , 05 -2027 , 07-May-2027	5-Feb-2026 <i>,</i> (97-May-2026 , 05-Jun-2026	5 , 07-Sep-

Synopsis	The purpose of this initiative is to advance family health and well-being and resilience family resilience as critically important ar	ce. The NIMHD Research Fram	ework recognizes family health, family			
129396 NIH Research Project Grant (Pare Humans Required)	nt R01 Basic Experimental Studies with	National Institutes of Health/DHHS	PA-25-303 07-May-2025	Not Specified		
Contact Name						
Contact Telephone						
Contact Email	grantsinfo@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026, 05-Feb-2026, 07-May-2026, 05-Jun-2026, 07-Sep-2026, 05-Jun-2026, 07-Jan-2028, 05-Oct-2026, 07-Jan-2027, 07-Jan-2028, 05-Oct-2027, 07-Jan-2028					
Synopsis	This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e. experimentally manipulate independent variables)					
129395 NIH Research Project Grant (Pare	nt R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-25-301 07-May-2025	Not Specified		
Contact Name						
Contact Telephone						
Contact Email	grantsinfo@nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025 2026 , 05-Oct-2026 , 07-Jan-2027 , 05-Fel	5 , 05-Oct-2025 , 07-Jan-2026 o-2027 , 07-May-2027 , 05-Jun	, 05-Feb-2026 , 07-May-2026 , 05-Jun- -2027 , 07-Sep-2027 , 05-Oct-2027 , 0	2026 , 07-Sep- 7-Jan-2028		

Synopsis	The NIH Research Project Grant supports a interests and competencies of the investigor more of the participating NIH Institutes Announcement does not accept application	rator(s). The proposed project mu and Centers (ICs) based on their	ust be related	d to the programmatic i	nterests of one
Mentored Career Development P 115095 Nonhuman Primate Research Mo Allowed)	Program for Early Stage Investigators Using odels (K01 Independent Clinical Trial Not	National Institutes of Health/DHHS	PAR-23- 073	07-May-2025	Not Specified
Contact Name					
Contact Telephone					
Contact Emai	AlTraininghelpdesk@niaid.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025	, 12-Oct-2025 , 07-Jan-2026			
The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support ar "protected time" (up to five years) for intensive, research-focused career development program activities under the good an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models to address complex translational biomedical research designed to foster translational biomedical research designed to foster translational period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant RO1) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.					er the guidance HP) models and e number of ster translation ent and grant (e.g., research that linical trial.
125538 NIH Pathway to Independence Av Experimental Studies with Human	ward (Parent K99/R00 Independent Basic ns Required)	National Institutes of Health/DHHS	PA-24-195	5 07-May-2025	Not Specified
Contact Name Contact Telephone					

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-Deadline Dates (ALL) 2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical National Institutes of Not PA-24-193 07-May-2025 Trial Required) Health/DHHS Specified

Contact Name

Contact Telephone

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

Centers (ICs) based on their scientific missions.

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding

Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-194).

clinical trial led by another investigator, must apply to companion NOFO (PA-24-194).								
125537 NIH Pathway to Independence Aw Trial Not Allowed)	vard (Parent K99/R00 Independent Clinical	National Institutes of Health/DHHS	PA-24-194 07-May-2025	Not Specified				
Contact Name								
Contact Telephone								
Contact Email	grantinfo@nih.gov							
Sponsor Website								
Program URL	<u>Link to program URL</u>							
Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Se 2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027							
Synopsis	The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-193).							
125557 Midcareer Investigator Award in F Independent Clinical Trial Require	Patient-Oriented Research (Parent K24 ed)	National Institutes of Health/DHHS	PA-24-187 07-May-2025	Not Specified				
Contact Name								
Contact Telephone								
Contact Email	grantinfo@nih.gov							

Deadline Dates (ALL) 07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-

Sponsor Website

Program URL Link to program URL

2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-188).

Mentored Research Scientist Development Award (Parent K01 Independent National Institutes of Basic Experimental Studies with Humans Required)

Health/DHHS

PA-24-177 07-May-2025

Not Specified

Contact Name

Contact Telephone

125527

Contact Email grantsinfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical Synopsis sciences leading to research independence. Although all participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of

illness or pressing family circumstances. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

125530 Independent Scientist Award (Parent KO2 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	PA-24-178 07-May-2025	Not Specified
---	---------------------------------------	-----------------------	------------------

Contact Name

Contact Telephone

Contact Email grantinfo@nih.gov

Sponsor Website

Program URL Link to program URL

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-Deadline Dates (ALL) 2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb-2027 , 07-May-2027

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The KO2 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another

investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).

125558 Midcareer Investigator Award Independent Clinical Trial Not	in Patient-Oriented Research (Parent K24 Allowed)	National Institutes of Health/DHHS	PA-24-188 07-May-2025	Not Specified					
Contact Na Contact Telepho				· · · · · · · · · · · · · · · · · · ·					
Contact En	nail grantinfo@nih.gov								
Sponsor Web	site								
Program U	JRL Link to program URL	nk to program URL							
Deadline Dates (A		07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep- 2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027							
Syno	The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-187).								
125532 Independent Scientist Award (Allowed)	Parent K02 - Independent Clinical Trial Not	National Institutes of Health/DHHS	PA-24-179 07-May-2025	Not Specified					
Contact Na	me		•						
Contact Telepho	one								
Contact En	nail grantinfo@nih.gov								

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025 , 12-Jun-2025 , 07-Sep-2025 , 12-Oct-2025 , 07-Jan-2026 , 12-Feb-2026 , 07-May-2026 , 12-Jun-2026 , 07-Sep-2027 , 07-May-2027

The purpose of the NIH Independent Scientist Award (KO2) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The KO2 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by another investigator. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-178). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PA-24-179).

Mentored Research Scientist Development Award (Parent K01 -Independent Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PA-24-176 07-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email grantsinfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 12-Jun-2025, 07-Sep-2025, 12-Oct-2025, 07-Jan-2026, 12-Feb-2026, 07-May-2026, 12-Jun-2026, 07-Sep-2026, 12-Oct-2026, 07-Jan-2027, 12-Feb-2027, 07-May-2027

The purpose of the NIH Mentored Research Scientist Development Award (KO1) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs use the K01 to support career development in specific fields. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO (PA-24-175).

		_	_	_	_
1	1	9	6	n	7

HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)

National Institutes of Health/DHHS

PAR-23-225

07-May-2025

Not Specified

Contact Name Biao Tian, PhD

Contact Telephone 301-594-5367

Contact Email biao.tian@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 07-Sep-2025

The purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as preclinical models. These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans. The expectation is that this sustained experience will launch independent research careers and enable awardees to become competitive for new research project grant (e.g., R01) funding. This funding initiative addresses research priorities of the fiscal year (FY) 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan): reduce the incidence of HIV; develop next-generation HIV therapies; research toward HIV cure; and address HIV-associated comorbidities, coinfections, and complications. This Notice of Opportunity Announcement (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor and/or comentor.

Ruth L. Kirschstein National Research Service Award (NRSA) Individual 121244 Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

National Institutes of Health/DHHS

PA-23-261 08-Apr-2025

Not Specified

Contact Name

Contact Telephone

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Apr-2025, 07-May-2025, 08-Aug-2025, 07-Sep-2025

This Notice of Funding Opportunity (NOFO) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This NOFO is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Notice of Funding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

National Institutes of Health/DHHS

to propose research experience in a clinical trial led by a sponsor or co-sponsor.

PA-23-262 08-Apr-2025

Not Specified

Contact Name

Contact Telephone

121245

Contact Email GrantsInfo@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Apr-2025, 07-May-2025, 08-Aug-2025, 07-Sep-2025

The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become Synopsis productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent

clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Notice of Funding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

	enmedicinal led by a sponsor of co sponsor	•					
120948 Ruth L. Kirschstein National Research Senior Fellowship (Parent F33)	arch Service Award (NRSA) Individual	National Institutes of Health/DHHS	PA-23-26	3 08-Apr-2025	Not Specified		
Contact Name							
Contact Telephone							
Contact Email	GrantsInfo@nih.gov						
Sponsor Website							
Program URL	Link to program URL	nk to program URL					
Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025 , 08-Aug-2025	, 07-Sep-2025					
Synopsis	The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Notice of Eunding Opportunity (NOFO) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.						
122946 Multidisciplinary Studies of HIV/A	AIDS and Aging (R21 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25- 355	07-May-2025	275,000 USD		
Contact Name	Ann Namkung, MPH						
Contact Tolonhono	201 406 6020						

Contact Telephone 301-496-6838

Contact Email ann.namkung@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 07-Sep-2025, 07-Jan-2026, 07-May-2026, 07-Sep-2026, 07-Jan-2027

Synopsis	This NOFO invites applications at the intersobjectives: 1) Improve the understanding of infection and its treatment; and 2) Improve related comorbidities, co-infections, and coaging science approaches. Proposed resear Office of AIDS Research (OAR) as described	of biological, clinical, and socio-be e approaches for testing, prevent omplications in different populati rch must be consistent with the H	ehavioral asp ing, and treations and cult	pects of aging through the ating HIV infection, and n tural settings by applying	e lens of HIV nanaging HIV- current
122945 Multidisciplinary Studies of HIV/A	IDS and Aging (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-25- 354	07-May-2025	Not Specified
Contact Name	Ann Namkung, MPH				
Contact Telephone	301-496-6838				
Contact Email	ann.namkung@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 07-Sep-2025 , 07-Jan-2026	, 07-May-2026 , 07-Sep-2026 , 07	-Jan-2027		
This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the follow objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and manag related comorbidities, co-infections, and complications in different populations and cultural settings by applying curre aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NI Office of AIDS Research (OAR), as described in NOT-OD-20-018.					e lens of HIV nanaging HIV- current
123146 Stephen I. Katz Early Stage Investi Experimental Studies with Human	gator Research Project Grant (R01 Basic	National Institutes of Health/DHHS	PAR-24- 076	26-Apr-2025	Not Specified
	`	Treattif Diffis			эрестеч
	Lindsey Nicole Friend				
Contact Telephone					
	lindsey.friend@nih.gov				
Sponsor Website					
Program URL	Link to program URL 26-Apr-2025 , 28-May-2025 , 26-Aug-2025 2026 , 28-Sep-2026 , 28-Dec-2026	26 Can 2025 20 Dag 2025 27	/ lan 2026 - 1	26 Apr 2026 27 May 20	26 26 Aug
Deadline Dates (ALL)	1 / 10 - / 1 1 / 1 / 1 / 2 / 3 / 3 / 4 / 4 / 4 / 4 / 4 / 4 / 4 / 4	/n->un-//// /X-//////////////////////////////			/n /n-4110-

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NIH Grants Policy Statement Synopsis Section 4.1.3.1 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional NOFO.

123145	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical	National Institutes of	PAR-24-	2C Amm 2025	Not
123145	Trial Not Allowed)	Health/DHHS	075	26-Apr-2025	Specified

Contact Name Lindsey Nicole Friend

Contact Telephone

Contact Email lindsey.friend@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

26-Apr-2025, 28-May-2025, 26-Aug-2025, 26-Sep-2025, 28-Dec-2025, 27-Jan-2026, 26-Apr-2026, 27-May-2026, 26-Aug-2026 , 28-Sep-2026 , 28-Dec-2026

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this notice of funding opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This notice of funding opportunity does not accept applications proposing clinical trials.

Notice of Special Interest (NOSI): Research Using Implementation Science To National Institutes of NOT-MH-Not 110034 07-May-2025 Support the Delivery of Evidence-Based Practices in Community-Based Health/DHHS 22-170 Specified

Mental or General Medical Health	ncare Settings				
Contact Name					
Contact Telephone					
Contact Email					
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025				
	This Notice of Special Interest (NOSI) highli support the adoption and sustainability of people with mental illness. These settings (CCBHCs) funded through the Substance A Behavioral Health Clinic-Expansion (CCBHC	evidence-based practices (EBPs) could include, but are not limited buse and Mental Health Services	in communit to, Certified	cy-based settings that de I Community Behavioral	eliver care to Health Clinics
110813 Notice of Special Interest (NOSI): HIV/HBV Co-Infection	Towards Developing a Cure for HBV in	National Institutes of Health/DHHS	NOT-AI- 22-043	05-Apr-2025	Not Specified
Contact Name	Chris Lambros, PhD				
Contact Telephone	240-627-3093				
Contact Email	clambros@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025				
	The purpose of this NOSI is to encourage a identify and address the unique challenges relating to the following areas will be enco	s to achieving HBV cure in the pre	sence of HIV	/. Research on HIV/HBV	
-	Research on the Impact of Policy Changes Health Crises on NICHD Populations of	National Institutes of Health/DHHS	NOT-HD- 22-038	07-May-2025	Not Specified
Contact Name Contact Telephone	Elyse R. Grossman 240-551-3628				

Contact Email elyse.grossman@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 07-Jan-2026

This notice informs applicants of an expansion to the NOT-HD-22-038 "Notice of Special Interest (NOSI): Research on the Impact of Policy Changes and Emerging and Evolving Public Health Crises on NICHD Populations of Interest" to include research priority areas for the National Institute on Drug Abuse (NIDA). The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to announce that research on the effects of: emerging and evolving public health crises; and/or policy changes on the health, development, and well-being of populations of interest to the NIDA is of high program priority. The NIDA populations of interest include neonates, infants, children, adolescents, young adults, adults, and older adults, people using or misusing substances, people with substance use disorders, as well as the families of these individuals. The NIDA supports research on the impact of policy in understanding and addressing substance use risk and behavior across the life span. For information on the NIDA Strategic Goals and Mission, see https://nida.nih.gov/about-nida/strategicplan/nidas-mission.

Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

National Institutes of Health/DHHS

PA-25-169 16-Mar-2025

400,000 USD

Contact Name Randy King, Ph.D.

Contact Telephone 301-451-0707

114250

Contact Email Randy.King@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-Mar-2025, 07-May-2025, 16-Jun-2025, 16-Jul-2025, 07-Sep-2025, 16-Oct-2025, 16-Nov-2025, 07-Jan-2026

This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators

(https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discoverydriven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and

	limited to one-half page, which may includ one figure will be considered noncomplian		-		nore than
11/1061	Explainable Artificial Intelligence for Circuit Activity Linked to Behavior	National Institutes of Health/DHHS	NOT-MH- 23-110	07-May-2025	Not Specified
Contact Name Contact Telephone	Mauricio Rangel-Gomez, Ph.D.				
·	mauricio.rangel-gomez@nih.gov				
Sponsor Website					
·	Link to program URL				
· · ·	07-May-2025 , 05-Jun-2025 , 16-Jun-2025	, 07-Sep-2025 , 05-Oct-2025 , 16-	Oct-2025 , 07	7-Jan-2026 , 05-Feb-2026	õ
Synopsis	This Notice of Special Interest (NOSI) solici decoding, and modulation of neural circuit computationally and experimentally focuses that are able to mechanistically explain ho humans or animals. Proof-of-concept appliprovide unbiased, hierarchical explanation appropriate.	s linked to behavior. This NOSI ered investigators. This NOSI seeks we experimental manipulations after the cations aimed at improving the c	ncourages co the developr fect cognitive urrent state	llaborations between ment of machine learning e, affective, or social proof the technology that us	g algorithms cessing in ses XAI to
114367 Notice of Special Interest (NOSI): Care Hepatitis C Virus Diagnostics	Advancing Development of Rapid Point-of-	National Institutes of Health/DHHS	NOT-AI- 23-001	05-Apr-2025	Not Specified
Contact Name	Julie Dyall, PhD				
Contact Telephone	301-631-7296				
Contact Emai	dyallj@niaid.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	05-Apr-2025 , 07-May-2025 , 05-Jun-2025 2026 , 07-Jan-2026	, 16-Jun-2025 , 05-Sep-2025 , 07-	Sep-2025 , 0	5-Oct-2025 , 16-Oct-2025	5 , 05-Jan-
Synopsis	The purpose of this Notice of Special Interest (NIAID) and National Institute of Biomedical	est is to announce that the Natior al Imaging and Bioengineering (N	nal Institute of BIB) and the	of Allergy and Infectious National Cancer Institut	Diseases :e (NCI) are

	encouraging applications in the area of tra diagnose active viremic HCV infections.	nslational research and developm	nent of rapid	Point-of-Care diagnost	ics that will
115289 Notice of Special Interest (NOSI): Response Services	Priority Research Opportunities in Crisis	National Institutes of Health/DHHS	NOT-MH- 23-140	07-May-2025	Not Specified
Contact Name	Stephen O'Connor, Ph.D.				
Contact Telephone	301-480-8366				
Contact Email	stephen.o'connor2@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025				
Synopsis	The National Institute of Mental Health (N Health (ORWH) are issuing this Notice of S Research is sought that is conducted in reage-related (e.g., youth; adult; older adult influence the types of care that are provid well as applications that address crisis serv	pecial Interest (NOSI) to outline pal-world settings, where a wide ra), geographic (rural/remote settin ed. Studies are encouraged that a	riorities for r nge of clinica gs), cultural address the c	research in crisis respor al presentations, psycho considerations, and he continuum of crisis servi	nse services. osocial factors, alth disparities
	argeting the Endocannabinoid System for	National Institutes of	NOT-DA-	07-May-2025	Not
Brain Health and Acute and Chron	nic Diseases	Health/DHHS	22-048	07-1VIAy-2023	Specified
Contact Name	Yu (Woody) Lin, PhD				
Contact Telephone	301-435-1318				
Contact Email	ylin1@mail.nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 25-May-2025 , 05-Jun-2025 2025 , 16-Oct-2025 , 07-Jan-2026	5 , 12-Jun-2025 , 16-Jun-2025 , 07-	Sep-2025 , 2	25-Sep-2025 , 05-Oct-20)25 , 12-Oct-
Synopsis	This Notice of Special Interest (NOSI) enco and acute and chronic disease, substance mechanistic understanding of how cannab	use, and substance use disorder (SUD). The de	esired outcomes of rese	arch will be a

	effects as well as the role of cannabinoids	and ECS in symptom managemen	nt.		
125227 Mentored Patient-Oriented Research K23 – Independent Clinical Trial R	arch Career Development Award (Parent equired)	National Institutes of Health/DHHS	PA-24-18	4 07-May-2025	Not Specified
Contact Name Contact Telephone					
Contact Email Sponsor Website	grantinfo@nih.gov				
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb		-Feb-2026 , (07-May-2026 , 12-Jun-2026	6 , 07-Sep-
Synopsis	The purpose of the NIH Mentored Patient development of individuals with a clinical on patient-oriented research. This Notice serve as the lead investigator of an independent of their research and proposing to gain research experience in a 185).	doctoral degree who have made of Funding Opportunity (NOFO) is endent clinical trial, a clinical trial career development. Applicants	a commitme s designed s feasibility st not planning	ent to focus their research pecifically for applicants pr cudy, or a separate ancillar g an independent clinical to	endeavors roposing to y study to an rial, or
	entific and Academic Independent Careers ansition Award to Promote Diversity rial Required)	National Institutes of Health/DHHS	PAR-24- 226	07-May-2025	Not Specified
Contact Telephone Contact Email Sponsor Website	lanay.mudd@nih.gov				
Deadline Dates (ALL)	07-May-2025 , 12-Jun-2025 , 07-Sep-2025 2026 , 12-Oct-2026 , 07-Jan-2027 , 12-Feb				6 , 07-Sep-

Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) program is to

support a cohort of early career, independent investigators from diverse backgrounds (for example, individuals from underrepresented groups) conducting research in NIH mission areas. The program has two components: an individual career transition award for postdoctoral scholars (K99/R00) and a research education cooperative agreement (UE5) awarded to organizations to provide these scholars with additional mentoring, networking and professional development activities to support their transition to and success in independent, tenure-track or equivalent research-intensive faculty careers. The MOSAIC program supports NIH's efforts to develop a biomedical research workforce that will benefit from the full range of perspectives, experiences and backgrounds needed to advance discovery. The goal of the MOSAIC Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds from their mentored postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The program is designed to support postdoctoral researchers who have demonstrated meaningful contributions and proposed compelling future plans to promote broad participation in the biomedical research workforce, such as activities that promote inclusive, supportive, and accessible biomedical research environments that support the success of trainees and scientists from all backgrounds, including individuals from underrepresented groups. This Notice of Funding Opportunity (NOFO) is designed specifically to support candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Candidates not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must work with their institutions to apply to companion NOFO PAR-24-225.

1	26880	

Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis **Response Services**

National Institutes of Health/DHHS

NOT-MH-22-110

07-May-2025

Not Specified

Contact Name Stephen O'Connor, Ph.D.

Contact Telephone 301-480-8366

Contact Email stephen.o'connor2@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

The National Institutes of Health seeks research conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural Synopsis considerations, and health disparities influence the types of care that are provided. Examples of NIMH and NIDA studies that are encouraged through this Notice address the continuum of crisis service systems. Applications that include crisis services for children and under-resourced populations are encouraged. Topics of research interest span the crisis care continuum,

		including the effectiveness of these comp mobile crisis outreach and support, and c	•			are, deployed	
11 Juni	exual+ People	Research on the Health of Bisexual and	National Institutes of Health/DHHS	NOT-OD- 22-166	07-May-2025	Not Specified	
	Contact Name	Christopher Barnhart, PhD					
	Contact Telephone	301-594-8983					
	Contact Email	christopher.barnhart@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2025					
	Synopsis	This Notice of Special Interest (NOSI) solic well-being of people who identify as bised potential to be attracted, romantically an time, not necessarily in the same way, and umbrella term that is intended to encomposexually fluid, and queer.	kual or bisexual+. "Bisexual" or "k d/or sexually, to people of more d not necessarily to the same de	oi" in this NOS than one sex gree. "Bisexua	I may describe those or gender, not necess al+" or "bi+" in this NO	with the arily at the same OSI is an	
11/2/16	ntice of Special Interest (NOSI):	Research on the Health of Sexual and	National Institutes of Health/DHHS	NOT-MD- 22-012	07-May-2025	Not Specified	
	Contact Name	Crystal L. Barksdale, PhD MPH					
	Contact Telephone	301-827-4228					
	Contact Email	crystal.barksdale@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 12-Jun-2025	, 16-Jun-2025				
	Synopsis	This Notice calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex					

	orientation, gender identity or expression orientation, gender, and/or sex.	, or reproductive development	is characterize	d by non-binary cons	tructs of sexual
112420 Notice of Special Interest (NOSI): Screening in Diverse Populations	Increasing Uptake of Evidence-Based Across the Lifespan	National Institutes of Health/DHHS	NOT-OD- 22-178	07-May-2025	Not Specified
Contact Name	Melissa C. Green Parker, PhD				
Contact Telephone	301-480-1161				
Contact Email	melissa.greenparker@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025				
Synopsis	The Office of Disease Prevention (ODP) are (ICs) are issuing this Notice of Special Interventions to improve the uptake of experiencing her effectiveness, dissemination and implementation are encouraged.	rest (NOSI) to encourage applic ridence-based screening service alth disparities and those that a	ations proposires across the life re underserved	ng to test multilevel s espan and in populat I. Studies addressing	strategies and ions including, efficacy,
112421 Notice of Special Interest (NOSI):	Addressing Evidence Gaps in Screening	National Institutes of Health/DHHS	NOT-OD- 22-179	07-May-2025	Not Specified
Contact Name	Melissa C. Green Parker, PhD				
Contact Telephone	301-480-1161				
Contact Email	melissa.greenparker@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025				
Synopsis	The Office of Disease Prevention (ODP) and (ICs) are issuing this Notice of Special Interpreventive screening services where the cannot be determined. This NOSI encourage	rest (NOSI) to solicit application evidence is lacking, of poor qual	ns proposing to ity, conflicting,	strengthen the evide or the balance of be	ence base for nefits and harms

	to close high priority evidence gaps to ele- recommendation.	vate screening services to a level	suitable for a	a definitive grade or	
112325 Notice of Special Interest (NOSI): Improve Health Outcomes	Research on Addressing Violence to	National Institutes of Health/DHHS	NOT-OD- 22-167	07-May-2025	Not Specified
Contact Name	Dara R. Blachman, Ph.D.				
Contact Telephone	301-496-8522				
Contact Email	Dara.blachman-demner@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025	, 07-Sep-2025 , 05-Oct-2025			
Synopsis	The purpose of this Notice is to highlight in violence-related screening and intervention of the purpose of the violence of th	ons into health care settings. This ce - including but not limited to cl	Notice is to hild maltreat	encourage intervention rement, intimate partner vi	esearch olence/teen
11 // /1	Single-Cell Level Spatiotemporal Mapping	National Institutes of	NOT-DE-	07-May-2025	Not
of Dental and Craniofacial Embry		Health/DHHS	22-003	·	Specified
	Kathryn Stein, PhD				
Contact Telephone					
	kathryn.stein@nih.gov				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025	•			
Synopsis	The National Institute of Dental and Cranisencourage research that applies cutting edunderstand the complex spatiotemporal c	dge imaging and high-throughput	'omics appr	oaches at the single-cell l	evel to
112267 Notice of Special Interest (NOSI): Loss	Advancing Research on Early Pregnancy	National Institutes of Health/DHHS	NOT-HD- 22-026	07-May-2025	Not Specified

Contact Name Clara Cheng, PhD

Contact Telephone 301-435-6992

Contact Email clara.cheng@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025

Early Pregnancy loss (EPL), defined as a pregnancy loss occurring up to 20 weeks gestation, is a very common pregnancy complication, occurring in 12-15% of clinically recognized pregnancies, with increased prevalence associated with increasing maternal age. The use of highly sensitive hCG assays allows the detection of pregnancy earlier in gestation than the time of clinical recognition, and gives an even higher estimated loss of 50-70% of conceptions prior to the second trimester. To achieve a successful pregnancy, a series of strict embryonic and maternal conditions must be met, that include high quality embryos, favorable conditions for embryo implantation, receptive maternal endometrium and optimal uterine environment to sustain the conceptus to term. In addition, maternal immune tolerance and hormonal factors play a critical role. While approximately half of all cases of EPL appear to be due to embryonic aneuploidy, very little is known about the physiologic and pathophysiologic processes that underlie non-aneuploid EPL. As a result, there is also a lack of understanding for the underlying causes of recurrent pregnancy loss (RPL). This NOSI seeks to address these critical knowledge gaps by encouraging basic, translational and clinical studies on biological processes that may uncover potential etiologies of EPL and RPL. This includes research to understand implantation mechanistically and identify a range of key factors, involved in implantation and placentation that are important for early pregnancy establishment, including abnormalities that contribute to sporadic

Synopsis

Notice of Special Interest (NOSI): Expanding the Otitis Media Research 107545 Workforce: Focus on Early Stage Investigators

National Institutes of Health/DHHS

NOT-DC-22-001

07-May-2025

Not Specified

Contact Name Bracie Watson, Jr., Ph.D.

EPL and recurrent pregnancy loss.

Contact Telephone 301-402-3458

Contact Email watsonb@nidcd.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025

Synopsis The National Institute on Deafness and Other Communication Disorderse (NIDCD) is interested in expanding the cadre of

	NIH https://grants.nih.gov/grants/new_in OM—commonly known as ear infections. approaches that accelerate the developm	ivestigators/index.htm#earlyst There is a critical need for foc	used, novel, cre	ative and innovative r	
107484 Notice of Special Interest (NOSI):	The Functional Oral Microbiome	National Institutes of Health/DHHS	NOT-DE- 21-015	07-May-2025	Not Specified
Contact Name	Tamara McNealy, PhD.				
Contact Telephone	202-430-1474				
Contact Email	tamara.mcnealy@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 16-Jun-2025	, 07-Sep-2025			
Synopsis	The National Institute of Dental and Crani encourage research studies that focus bey		-	•	•
Notice of Special Interest (NOSI): 111858 Cardiometabolic Risk Factors in Polisparities	Preventive Interventions to Address opulations that Experience Health	National Institutes of Health/DHHS	NOT-OD- 22-154	07-May-2025	Not Specified
Contact Name	Jennifer Alvidrez, PhD				
Contact Telephone	301-827-0071				
Contact Email	Jennifer.alvidrez@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025				
Synopsis	The purpose of this NOSI is to solicit proje populations that experience health dispar		ns that address o	cardiometabolic risk fa	actors in
114765 Notice of Special Interest (NOSI): Research	Firearm Injury and Mortality Prevention	National Institutes of Health/DHHS	NOT-OD- 23-039	07-May-2025	Not Specified

Health/DHHS

23-039

is to invite Early Stage Investigators (ESIs), as defined by the

Research

basic and clinical scientists who conduct research on otitis media (OM). The purpose of this Notice of Special Interest (NOSI)

Specified

Contact Name Dara R. Blachman, Ph.D.

Contact Telephone

Contact Email Dara.blachman-demner@nih.gov

Sponsor Website

Program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 16-Jun-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 07-Jan-2026, 05-Feb-2026

The purpose of this Notice is to highlight interest in research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including self- and other-directed, victims and perpetrators, accidental Synopsis injury), the development, piloting, and testing of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.

114377

(TBDs)

Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases National Institutes of

Health/DHHS

NOT-AI-23-013

05-Apr-2025

Not Specified

Contact Name Samuel Perdue, Ph.D.

Contact Telephone 240-627-3341

Contact Email sperdue@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

05-Apr-2025, 07-May-2025, 05-Jun-2025, 16-Jun-2025, 05-Sep-2025, 07-Sep-2025, 05-Oct-2025, 16-Oct-2025, 05-Jan-2026 . 07-Jan-2026

The purpose of this Notice of Special Interest (NOSI) is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS), encourage applications to advance research activities relevant to the five strategic priorities identified in the recently released NIH Strategic Plan for Synopsis Tickborne Disease Research: Improve fundamental knowledge of Tickborne Diseases (TBDs) to understand the host, vector, and pathogen factors that drive TBD pathogenesis and transmission. Elucidate the host immune mechanisms in response to and exploited by TBD pathogens. Advance research to improve the diagnosis of TBDs using both host- and pathogen-targeted approaches, including research for rapid diagnostics and multiplex platform approaches that detect multiple tickborne pathogens. Accelerate research to improve TBD prevention by supporting science to design, develop, and evaluate vaccines,

vector control strategies, and other prevention approaches. Promote research to improve treatment for all forms of TBDs, including studies to develop effective therapies to treat symptoms that persist after TBD treatment, therapies for non-infectious TBDs, and new antimicrobials. Support tools and resources to advance research in understanding, preventing, diagnosing, and treating TBDs, including repositories, genomic resources, animal models, and preclinical services to aid the development and assessment of diagnostic, vaccine, and therapeutic candidates.

	Research to Address 'Ending the HIV t to Substance Using Populations At-Risk	National Institutes of Health/DHHS	NOT-DA- 23-013	21-Mar-2025	Not Specified
Contact Name	Vasundhara Varthakavi, PhD				
Contact Telephone	301-443-2146				
Contact Email	vasundhara.varthakavi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Mar-2025 , 07-May-2025 , 05-Jun-2025 2026 , 16-Feb-2026 , 07-May-2026 , 05-Jur	, 16-Jun-2025 , 07-Sep-2025 , 05- n-2026 , 16-Jun-2026 , 07-Sep-202	Oct-2025 , 1 6 , 05-Oct-2	.6-Oct-2025 , 07-Jan-2026 026 , 16-Oct-2026 , 07-Oc	, 05-Feb- t-2027
Syriopsis	The purpose of this NOSI is to support a b the four pillars, including Diagnose, Treat, Projects proposed in response to this NOS high risk for contracting HIV or living with	Prevent, and Respond of the 'End I are required to meet the needs of	ing the HIV I	Epidemic in the U.S. (EHE) ance using populations wh	' initiative.
114675 Notice of Special Interest (NOSI): <u>Utilization for the Sequence Read</u>		National Institutes of Health/DHHS	NOT-GM- 23-015	25-Feb-2025	Not Specified
Contact Name					

Contact Telephone

Contact Email

Sponsor Website

Program URL Link to program URL

25-Feb-2025, 05-Apr-2025, 12-Apr-2025, 07-May-2025, 16-May-2025, 05-Jun-2025, 12-Jun-2025, 16-Jun-2025, 25-Jun-Deadline Dates (ALL) 2025, 08-Aug-2025, 05-Sep-2025, 05-Sep-2025, 07-Sep-2025, 05-Oct-2025, 12-Oct-2025, 16-Oct-2025, 25-Oct-2025, 08-Dec-2025

Synopsis	The purpose of this Notice of Special Into ODSS in supporting efficiency optimizati	erest (NOSI) is to inform the sc on and cost reduction for Sequ	ientific community of the interest of N ence Read Archive (SRA) data storage	IIGMS, NLM, and and utilization.
129392 NIH Exploratory/Developmental In Clinical Trial Not Allowed)	Research Grant Program (Parent R21	National Institutes of Health/DHHS	PA-25-304 07-May-2025	275,000 USD
Contact Name				
Contact Telephone	301-480-7075			
Contact Email	grantsinfo@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-202 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Fe		·	•
Synopsis	The NIH Exploratory/Developmental Gra for the early and conceptual stages of the breakthrough in a particular area, or to the that could have a major impact on a field does not accept applications proposing of	ese projects. These studies ma the development of novel technod d of biomedical, behavioral, or	y involve considerable risk but may le niques, agents, methodologies, mode	ad to a ls, or applications
129393 NIH Exploratory/Developmental I Clinical Trial Required)	Research Grant Program (Parent R21	National Institutes of Health/DHHS	PA-25-306 07-May-2025	275,000 USD
Contact Name				
Contact Telephone				
Contact Email	grantsinfo@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-202 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Fe		·	•
Synopsis	The NIH Exploratory/Developmental Gra for the early and conceptual stages of the breakthrough in a particular area, or to t	ese projects. These studies ma	y involve considerable risk but may le	ad to a

that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (seeRelated Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

Synopsis This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-

	definition of a clinical trial through this fu	,	ment.	
129391 NIH Small Research Grant Progra	m (Parent R03 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-25-302 07-May-2025	100,000 USD
Contact Name				
Contact Telephone	301-480-7075			
Contact Emai	grantsinfo@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb			
Synopsis	The NIH Small Research Grant Program sultimited resources. This program supports of existing data; small, self-contained research technology. This Funding Oppor	different types of projects incearch projects; development	cluding pilot and feasibility studies; sed of research methodology; and develor	condary analysis ment of new
129394 NIH Exploratory/Developmental R21 Basic Experimental Studies w	Research Project Grant Program (Parent vith Humans Required)	National Institutes of Health/DHHS	PA-25-307 07-May-2025	275,000 USD
Contact Name				
Contact Telephone	301-496-4000			
Contact Emai	grantsinfo@od.nih.gov			
Sponsor Website				
Program URI	Link to program URL			
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb	5 , 16-Oct-2025 , 07-Jan-2026	, 16-Feb-2026 , 07-May-2026 , 16-Jun-	2026 , 07-Sep-

18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' NOFO.

111641 Notice of Special Interest (NOSI):	Climate Change and Health	National Institutes of Health/DHHS	NOT-ES- 22-006	08-Apr-2025	Not Specified
Contact Name	Claudia L. Thompson				
Contact Telephone	984-287-3330				
Contact Email	thompso1@niehs.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Apr-2025 , 07-May-2025				
Synopsis	The National Institute of Environmental He National Institute of Minority Health and Health and Human Development (NICHD), (NINR), National Heart Blood and Lung Insleading an NIH-wide Climate Change and Eclimate change across the lifespan; improclimate change impacts; and building heal increasing health equity. As a part of this conhealth and well-being over the life could globally.	Health Disparities (NIMHD), Eunice National Institute of Mental Heal titute (NHBLI) and National Institute dealth Initiative (CCHI) with the going the health of people who are th resilience among individuals, concept, this NOSI encourages applications.	e Kennedy SI th (NIMH), Nate of Allergy pals of: reduce at increased ommunities, ations that a	hriver National Institute of National Institute of Nursi y and Infectious Disease (I cing the health threats po d risk from or disparately of nations around the world address the impact of clim	of Child ing Research NIAID) is osed by affected by d, thereby nate change
115310 Notice of Special Interest (NOSI): Enhance Discovery from Health D	Computational and Statistical Methods to ata	National Library of Medicine/NIH/DHHS	NOT-LM- 23-001	07-May-2025	Not Specified

Contact Name Meryl Sufian, PhD

Contact Telephone 301-496-4671

Contact Email	sufianm@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 07-Sep-2025	5 , 05-Oct-2025 , 07-Jan-2026			
Synopsis	The National Library of Medicine is issuing research that aims to reduce or mitigate a	g this Notice to highlight its inter gaps and errors in health data se	est in receivinets.	g grant applications focuse	ed on
128484 Computational Approaches to Cu	ration at Scale for Biomedical Research	National Library of	PAR-25-	15-Apr-2025	1,000,000
Assets (R01 Clinical Trial Not Allov	<u>wed)</u>	Medicine/NIH/DHHS	131	[Optional][LOI/Pre-App]	USD
Contact Name	Clayton Bingham, PhD				
Contact Telephone	301-594-5929				
Contact Email	clayton.bingham@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Apr-2025 [Optional][LOI/Pre-App], 25- Sep-2025 , 15-Dec-2025 , 16-Dec-2025 [O Aug-2026 [Optional][LOI/Pre-App], 15-Se 2027	ptional][LOI/Pre-App], 15-Jan-20	026 , 15-Apr-20	026 , 15-May-2026 , 14-Au	g-2026 , 16-
Synopsis	NLM wishes to accelerate access to, and as the basis for transformative biomedica and scope of curation processes are need data being produced from ongoing data s	l discoveries. Innovative at-scale ed for data mining and knowled	computation	al approaches that increase	e the speed
113609 NLM Research Grants in Biomedia Clinical Trial Optional)	cal Informatics and Data Science (R01	National Library of Medicine/NIH/DHHS	PAR-25- 238	07-May-2025	1,000,000 USD
Contact Name	Meryl Sufian, PhD				
Contact Telephone					
·	sufianm@mail.nih.gov				
Sponsor Website					
•	Link to program URL				
-	<u> </u>				

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 07-Sep-2025, 05-Oct-2025, 07-Jan-2026

The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and Synopsis personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domainindependent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects.

127644

NLM Information Resource Grants to Reduce Health Disparities and Promote Health Equity (G08 Clinical Trial Not Allowed)

National Library of Medicine/NIH/DHHS

PAR-24-281

25-Apr-2025 [Optional][LOI/Pre-App] USD

600.000

Contact Name Cristan Smith, PhD

Contact Telephone 304-594-4882

Contact Email cristan.smith@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-Apr-2025 [Optional] [LOI/Pre-App], 25-May-2025, 24-Apr-2026 [Optional] [LOI/Pre-App], 25-May-2026

This Notice of Funding Opportunity Announcement (NOFO) solicits resource grant applications for projects that will provide accurate, useful, usable, and understandable health information to populations that experience health disparities and their health care providers. This NOFO supports the development of resources that can be used to improve health and well-being and that lead to reductions in health disparities. Access to accurate, useful, usable, and understandable health information is Synopsis an important factor when managing health and health care. Proposed projects should harness the capabilities of information technology and medical or health libraries to disseminate clear, evidence-based health-related information in formats used by individuals and their health care providers. Proposed projects should emphasize the development and deployment of new information resources or services, or expand and improve an existing resource or service, to meet the needs of populations experiencing health disparities and to promote health equity.

Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Office of Research Infrastructure PAR-25-119606 Models (R21 Clinical Trial Not Allowed)

Programs/NIH/DHHS 165

07-May-2025

400,000 USD

Contact Name Biao Tian, PhD

Contact Telephone 301-594-5367

Contact Email biao.tian@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 07-Sep-2025

The purpose of this notice of funding opportunity announcement (NOFO) is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of

their residency training but who have at least two years of postdoctoral experience. The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these ESIs to develop new research directions and to position these researchers to be competitive for new research funding (e.g., R01).

Proposed projects must use NHPs as preclinical models for HIV/AIDS research. This funding initiative encompasses all priorities of the fiscal year (FY) 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hivpolicy-and-research/strategic-plan): reduce the incidence of HIV; develop next-generation HIV therapies; conduct research toward HIV cure; address HIV-associated comorbidities, coinfections, and complications; and advance cross-cutting areas of

research.

Limited Competition: National Primate Research Centers (P51) (Clinical 118863 Trials Not Allowed)

Office of Research Infrastructure PAR-23-Programs/NIH/DHHS 126

25-May-2025

Not Specified

Contact Name Stephanie Murphy, VMD, PhD,

Contact Telephone 301-451-7818

Contact Email stephanie.murphy@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 25-May-2025, 25-Sep-2025, 25-Jan-2026, 25-May-2026

This funding opportunity announcement (FOA) encourages grant applications that support the activities of the National

Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers.

Development of Resources and Te 113928 Reproducibility, and Translatabilit Research (R24 Clinical Trials Not A	ry of Animal Models in Biomedical	Office of Research Infrastructure Programs/NIH/DHHS	PAR-23- 039	25-May-2025	Not Specified
Contact Name	Sige Zou, Ph.D.				
Contact Telephone	301-435-0749				
Contact Email	zous@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-May-2025				
Synopsis	The Office of Research Infrastructure Prog developing broadly applicable technologie reproducibility, and translatability of anim this Funding Opportunity Announcement (ICs), explore multiple organ systems, or b to align with ORIP's NIH-wide mission and translatability of animal research through across a broad range of research areas usi technologies impact rigor and reproducibiare not suitable for this FOA.	es, tools, and resources for validational research. Proposed studies, more (FOA) must either address research e applicable to diseases and proce programs. Applications should aim the development of technologies, ng animal models. Applications must be seen and research to the seen and research to	ng animal m dels, resour n interests o sses that im n to enhanc tools, and r ust demons	nodels and enhancing rigories, or technologies submof multiple NIH Institutes an pact multiple organ system the rigor, reproducibilities are the rigor, reproducibilities are the how the proposed retails.	or, nitted under and Centers ems in order y, and icant impact esources and
	d Research Projects for Development of rials (R24 Clinical Trials Not-Allowed)	Office of Research Infrastructure Programs/NIH/DHHS	RFA-OD- 22-013	25-May-2025	Not Specified
Contact Name	Sige Zou, PhD				
Contact Telephone	301-435-0749				
Contact Email	zous@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-May-2025				
Synopsis	The Office of Research Infrastructure Prog improving animal models of human diseas				

models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.

	only peripherally related to the research in	terests of other Institutes and Cer	nters will als	so not be acceptable for th	nis FOA.
115070 RFA-OD-23-001 Animal and Bio (Clinical Trials Not-Allowed)	logical Material Resource Centers (P40)	Office of Research Infrastructure Programs/NIH/DHHS	RFA-OD- 23-001	08-May-2025	Not Specified
Contact Name	Oleg Mirochnitchenko, Ph.D.				
Contact Telephone	301-435-0748				
Contact Email	oleg.mirochnitchenko@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-May-2025 , 28-May-2025 , 09-Sep-2025	5 , 26-Sep-2025 , 08-Jan-2026			
Synopsis	This FOA encourages grant applications for for special colonies of laboratory animals, a tissues, and organs) and genetic stocks tha local, regional, and national basis. The goa optimization and enhancement of scientifi Proposed Animal and Biological Material R (ICs) to align with the ORIP's NIH-wide miss	as well as other resources such as t serve the biomedical research coll of projects supported by this FOA crigor, transparency, and experimesource Centers must have broad	informatics ommunity in a is to provi ental repro application	tools, reagents, cultures (n a variety of research are de research resources tha oducibility of biomedical re to multiple NIH Institutes	(cells, as on a t facilitate esearch. s or Centers

Notice of Special Interest (NOSI): Revision Applications to add a Curation
and Informatics Component to Existing Animal and Biological Material
Resource Centers (P40) (Clinical Trials Not Allowed)

Office of Research Infrastructure NOT-OD-Programs/NIH/DHHS 23-068

application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.

support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an

08-May-2025

Not Specified

Contact Name Oleg Mirochnitchenko, Ph,D.

Contact Telephone 301-435-0748

Contact Email oleg.mirochnitchenko@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-May-2025, 28-May-2025, 09-Sep-2025, 26-Sep-2025

Animal and Biological Material Resource Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, biological materials (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The Division of Program Coordination, Planning and Strategic Initiatives, ORIP encourages current Centers supported by P40 grants awarded under RFA-OD-20-002 or PAR-17-006 that have not yet applied for a P40 competitive renewal application under RFA-OD-23-001 to submit a revision application to add a Curation and Informatics component to existing Animal and Biological Material Resource Centers (P40) as a Curation and Informatics component is a requirement in RFA-OD-23-001. The supplement will provide support to currently funded Centers for a Curation and Informatics component to develop and maintain in-house data management systems, curate stocks of animals and biomaterials, and maintain a searchable web portal with an

Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)

Office of Research Infrastructure PAR-24-Programs/NIH/DHHS 129

07-May-2025

Not Specified

Contact Name Biao Tian, PhD

Contact Telephone 301-594-5367

123616

Contact Email biao.tian@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 07-Sep-2025, 07-Jan-2026, 07-May-2026, 07-Sep-2026, 07-Jan-2027

integrated community-friendly request/ordering system and outreach presentations.

The purpose of this Notice of Funding Opportunity (NOFO) is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-21-089 and PAR-18-669 that support Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research. Breeding colonies are essential to sustain appropriate SPF macaques for research related to HIV/AIDS. Pedigree SPF macaques are free of certain viruses, which may confound the results of HIV/AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major histocompatibility complex (MHC) class I types, because MHC class I genotypes have large effects on macaque immune responses to Simian Immunodeficiency Virus (SIV) that can induce AIDS in nonhuman primates (NHPs) and on human immune responses to HIV.

128780 Development of Animal Models a Research (R21 Clinical Trial Not Al	nd Related Biological Materials for llowed)	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25- 273	07-May-2025	275,000 USD
Contact Name	Sige Zou, Ph.D.				
Contact Telephone	301-435-0749				
Contact Email	sige.zou@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025 , 2026 , 16-Oct-2026 , 07-Jan-2027 , 16-Feb-				•
Synopsis	This notice of funding opportunity (NOFO) animal models as well as animal model relator studies relevant to human health and dof diseases that could confound or interfer applicability to multiple NIH Institutes or Conformation (ORIP). The propose multiple categories of diseases. Application propose studies primarily relevant to a single	ated biological materials, technological materials, technological materials, technologicalse. This NOFO also seeks project with animal use in biomedical references (ICs) to align with the NIH-value sed studies must include animal materials that develop models focused or	gies, and no ects aimed a esearch. The wide mission nodels and e n a specific o	ew approach methodo at improving the diagr e proposed project mu n of the Office of Rese explore multiple body disease or area of rese	ologies (NAMs) nosis and control ust have broad earch systems or earch, or only
128808 Research Career Award (SERCA) K Allowed)	Program for ORIP Special Emphasis O1 Recipients (R03 Clinical Trials Not	Office of Research Infrastructure Programs/NIH/DHHS	PAR-25- 176	07-May-2025	150,000 USD
Contact Name	Stephanie Murphy, VMD, PhD				
Contact Telephone	301-451-7818				
Contact Email	stephanie.murphy@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 16-Jun-2025 , 07-Sep-2025	, 16-Oct-2025 , 07-Jan-2026 , 16-F	eb-2026 , 0	7-May-2026	
Synopsis	The Office of Research Infrastructure Programitiatives announces an opportunity to ap Award (SERCA) K01 recipients who have co	ply for small grant support for ORI	P-supporte	d Special Emphasis Re	search Career

enhance the ability of ORIP SERCA K01 recipients to conduct research as they transition to fully independent investigator status. The RO3 mechanism supports projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support research projects that can realistically be completed in two years and that require limited levels of funding. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

128790

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)

Office of the Director, National Institutes of Health/NIH/DHHS

PA-25-168 07-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email NIATraining@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-May-2025, 25-May-2025, 07-Sep-2025, 25-Sep-2025, 07-Jan-2026, 25-Jan-2026, 07-May-2026, 25-May-2026, 07-Sep-2026, 25-Sep-2026, 07-Jan-2027, 25-Jan-2027, 07-May-2027, 25-May-2027, 07-Sep-2027, 25-Sep-2027, 07-Jan-2028

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to develop and/or enhance predoctoral and postdoctoral research training, including short-term research training, to help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation's biomedical, behavioral, and clinical research agenda. Research training programs are expected to incorporate engaging, didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

124924	Foundations for Digital Twins and Innovation	as Catalyzers of Biomedical Technological	National Science Foundation	24-561	05-May-2025	Not Specified
	Contact Name	Yulia R. Gel				
	Contact Telephone	703-292-7888				
	Contact Email	ygel@nsf.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL					
	Deadline Dates (ALL)	05-May-2025				
	Synopsis	The Foundations for Digital Twins as Catalyzers inherently interdisciplinary research projects the development and use of digital twins and synthedigital, in silico models used in the evaluation of current and emerging challenges affecting the object initiative is to catalyze biomedical tech algorithms relevant to digital twins and synthetic	at underpin the mathematical and etic data in biomedical and health f medical devices and the relevand levelopment and assessment of boological innovation through new	d engineer ncare applic ce of the d iomedical	ing foundations cations, with a p eveloped model technologies. Th	behind the articular focus on s in addressing the goal of the FDT-
126359	Cyber-Physical Systems		National Science Foundation	24-581	31-May-2025	Not Specified
	Contact Name	David Corman				
	Contact Telephone	703-292-8754				
	Contact Email	dcorman@nsf.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-May-2025 , 28-Aug-2025				
	Synopsis	The CPS program aims to develop the core rese dependable, high-confidence, or provable beha machine learning including real-time learning for including human-in- or human-on-the-loop, net abstracting from the particulars of specific syste fundamental scientific and engineering principal	viors. Core research areas of the por control, autonomy, design, Inte tworking, privacy, real-time systen tems and application domains, the	orogram in rnet of Thi ns, safety, CPS progra	clude control, dangs (IoT), mixed security, and versions seeks to reve	ata analytics, and initiatives rification. By eal cross-cutting,

application domains. The program additionally supports the development of methods, tools, and hardware and software components based upon these cross-cutting principles, along with validation of the principles via prototypes and testbeds. This program also fosters a research community that is committed to advancing education and outreach in CPS and accelerating the transition of CPS research into the real world.

115139 Special Emphasis Notice (SEN):Real and Healthcare		Agency for Healthcare Research and Quality/DHHS	NOT-HS-23-006	26-Feb-2025	Not Specified
Contact Name	Brent Sandmeyer, MPH				
Contact Telephone	301-427-1441				
Contact Email	Brent.sandmeyer@ahrq.hh	ns.gov			
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		, 12-Apr-2025 , 25-May-2025 , 12-Jun- c-2025 , 12-Feb-2026 , 12-Jun-2026 , 1		ıg-2025 , 25-Sep-20	25 , 25-Sep-
Synopsis		ce (SEN) announces AHRQ's interest in climate change and healthcare.	receiving health services re	search grant applic	ations that
123859 AHRQ Health Services Research Dissemination Grants (R18)		Agency for Healthcare Research and Quality/DHHS	PA-24-156	25-May-2025	2,000,000 USD
Contact Name					
Contact Telephone	301-427-1025				
Contact Email	kathryn.woolridge@ahrq.h	ihs.gov			
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)		5 , 25-Jan-2026 , 25-May-2026 , 25-Sep ep-2028 , 25-Jan-2029 , 25-May-2029	-2026 , 25-Jan-2027 , 25-M	ay-2027 , 25-Sep-20)27 , 25-Jan-
Synopsis	AHRQ research priorities, in practice improvement, and including the hospital, long Research may involve many	e of Funding Opportunity (NOFO) is to some of Funding improving healthcare quality of enhancing whole-person healthcare of term care, ambulatory care, home he y partners and other groups, including thcare organizations, providers and according	and patient safety, improving lelivery. AHRQ supports res althcare, pharmacy, and ca patients, families, clinicians	ng healthcare delive earch in all healthca re transitions betwe s, non-clinical health	ery and are settings, een settings. occare staff,
114270 Special Emphasis Notice (SEN): In	iterest in Healthcare	Agency for Healthcare Research and	NOT-HS-23-003	25-May-2025	Not

	Associated Infections and Comba	ting Antibiotic Resistant Quality/DHHS	Specified
	Bacteria Research		
	Contact Name	Leyi Lin, MD	
	Contact Telephone	301-427-1333	
	Contact Email	leyi.lin@ahrq.hhs.gov	
	Sponsor Website		
	Program URL	Link to program URL	
	Deadline Dates (ALL)	25-May-2025 , 05-Jun-2025 , 25-Sep-2025 , 25-Jan-2026 , 05-Feb-2026 , 25-May-2026 , 05-Jun-2026 , 25-Sep-2026 , 05-Oct-2026	ep-2026 , 05-Oct-
	Synopsis	The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Research and Quality (AHRQ) continued interest in, and available funding for, supporting innovative research community of the Agency for reduce the burden of healthcare-associated infections (HAIs) and to address the growing threat posed by resistant organisms. HAIs continue to cause significant patient harm and are also associated with conside consequences for healthcare facilities and for patients. Unfortunately, the COVID-19 pandemic has been observed increases of several types of HAIs as well as increases in antimicrobial resistance, highlighting the developing and studying resilient and adaptable countermeasures.	arch seeking to antimicrobial rable financial associated with
107017	Large Health Services Research D Dissemination Projects for Comba Bacteria (CARB)(R18)	Agency for Healthcare Research and	2,500,000 USD
	Contact Name	James Cleeman, MD	
	Contact Telephone	301-427-1330	
	Contact Email	james.cleeman@ahrq.hhs.gov	
	Sponsor Website	<u>Link to sponsor website</u>	
	Program URL	Link to program URL	
	Deadline Dates (ALL)	25-May-2025 , 25-Sep-2025 , 25-Jan-2026 , 25-May-2026 , 25-Sep-2026	
		Agency for Healthcare Research and Quality (AHRQ) invites applications to conduct Large Health Services Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CA use the R18 Research Demonstration and Dissemination Projects award mechanism.	

130097 FCO Critical Orientation of Math Advancements in Science and Sec		Defense Advanced Research Projects Agency/Department of Defense	DARPA-EA-25-02-03	12-May-2025	Not Specified
Contact Name	BAA Coordinator				
Contact Telephone					
Contact Email	COMPASS@darpa.mil				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	12-May-2025				
Synopsis	(i.e., air, land, maritime, s mathematical framework operational environment approximations, resulting future conflicts. In contra profound and wide-reach military discern threats in due to its strong assumpt dynamical systems appro- framework that inherent theory, supporting milital communications and mu- enables transformative D formulate the problem we dynamic, and uncertain of	finational security. A decision-maker's abspace, and cyberspace), and adapt to rapks and effective problem formulations these. Unfortunately, mathematical approach in fragile solutions that severely limit out ast, establishing robust mathematical framing results. For instance, the Wiener filter the air domain from noisy radar observation of signal stationarity, a condition rareach, in 1960 Rudolf Kalman reformulated by addressed non-stationarity. 2 Sixty yearly decisions in autonomous navigation, for more. The combination of a robust mathematical environments, military decisions these challenges. Emerging fields in mathematical environments, military decisions these challenges. Emerging fields in mathematical environments.	at fully encapsulate the cornes in Defense often rely of ur nation's ability to address meworks and properly former was developed during wations. However, the technely satisfied in operational of the filtering problem in a rs later, the Kalman filter relight control systems, sense athematical framework with ever, requires deep mathem challenge at hand. To exceon-makers need richer mat	rapes hinges on robumplexities of real-won "good-enough" as these evolving chanulating problems of World War II to help ology's effectivenes settings. By leverage more robust state-semains a pillar of moor fusion, wireless high the right problem natical insight to problem in increasingly continued to the matical framework.	allenges in an yield the U.S. as was limited ing a space odern control formulation operly aplex,
129381 Accelerating STEM and Space Am	bitions	Department of State	LUXEM-PDS-FY25-02	02-Mar-2025 [LOI/Pre-App]	15,000 USD

Contact Name

Contact Email <u>LuxembourgGrants@state.gov</u>

Contact Telephone

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2025 [LOI/Pre-App], 09-Apr-2025, 04-May-2025 [LOI/Pre-App], 08-Jun-2025

The Public Diplomacy Section (PD) of the U.S. Embassy in Luxembourg, U.S. Department of State, announces an open Synopsis competition for organizations to submit applications to carry out programs strengthening bilateral ties between the United States and Luxembourg on Accelerating STEM and Space Ambitions.

FCO--AMENDMENT--SDA Battle Management Mission 126085 Applications (Program BAA)

Space Development Agency/Department of Defense

FA240124S0002

19-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email ussf.pentagon.sda.mbx.FA240124S0002@mail.mil

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 19-May-2025

The Space Development Agency (SDA) is responsible for defining and developing the Department of Defense threat-driven space architecture and accelerating the development and fielding of new military space capabilities necessary to ensure U.S. technological and military advantage in space. To achieve this mission, SDA will unify and integrate next-generation space capabilities to deliver the Proliferated Warfighter Space Architecture (PWSA), a resilient military sensing and data transport capability in Low Earth Orbit (LEO). The mission to deliver low-latency data transport and develop sensor-to-shooter and direct-to-weapon connectivity is critical to the Joint All Domain Command and Control (JADC2) approach to sense, make sense, and act at all levels and phases of war and across all domains, and to deliver information advantage at the speed of relevance. SDA is constructing satellites and ground stations with a Battle Management Command, Control and Communications (BMC3) capability that will support advanced decision-making from space, enabling the PWSA to react to emerging technology in the ever-evolving threat environment. SDA is dedicated to promptly delivering, from ideation to deployment, mission-specific software solutions, leveraging existing on-orbit systems, and data flows within a matter of months. Objectives for software solutions provided under this BAA include automating numerous processes within current architectures and providing additional capabilities for mission processing and data fusion. The SDA Battle Management Mission Applications Program BAA is attached. For the CUI Bidder's Library, please send an email to ussf.pentagon.sda.mbx.FA240124S0002@mail.mil no later than 27 May 2024 at 12:00 pm EST with the subject line "SDA BMC3 Mission Apps Bidder Library Request." Please include your organization's CAGE code and location in your

request. Requests received from organizations that do not possess a facility clearance of at least Secret will be evaluated on a case-by-case basis. SDA will endeavor to respond to all requests in the order that they are received and within one business day of receipt.

126045	Locally Led Development Annual Program Statement (LLD-	U.S. Agency for International	7200AA24APS000062024	16-May-2025	Not
120045	APS)	Development	7200AA24AP3000062024	10-1VIdy-2025	Specified

Contact Name

Contact Telephone

Contact Email IId-aps@usaid.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 16-May-2025

This Annual Program Statement (APS) offers USAID Operating Units ("OUs" also referred to as Missions, Bureaus, and Independent Offices) a mechanism to advance localization, which calls for intentional changes to USAID's policies, processes, staffing, and funding decisions to support partnerships and programs that equitably empower local actors, strengthen local systems, and facilitate local leadership so that development and humanitarian assistance is more effective and sustainable. It also aligns with USAID's Local Capacity Strengthening Policy, which recognizes USAID's commitment to collaborating with local partners to define their own vision for success; strengthen their ability to be effective and relevant actors within their local communities and contexts; and elevate local ownership in sustaining development results. Furthermore, this APS builds upon Agency policy, guidance, and emerging practice in the areas of systems thinking, collaboration, learning, and adaptive, contextually informed design and management. It prioritizes diversity and encourages approaches that shift decision-making power to local people who have traditionally been marginalized, such as women, youth, religious and ethnic minorities, LGBTQI+, and gender diverse people. It enhances USAID's capability to work with diverse local partners, to learn from these engagements, and to share this learning broadly.

Synopsis

130293 Grant Program	Alliance for Potato Research & Education	17-Mar-2025 [LOI/Pre-App]	Not Specified
Contact Name			
Contact Telephone			
Contact Email	research@apre.org		
Sponsor Website	<u>Link to sponsor website</u>		
Program URL	Link to program URL		
Deadline Dates (ALL)	17-Mar-2025 [LOI/Pre-App], 12-May-2025		
	APRE supports domestic and international health-related research to help expand k properties and health benefits of potatoes (not sweet potatoes or yams) in all forms		
	fried, and frozen. The sponsor supports early career and well-established researche		
Applicant Types			
Applicant Types			
Applicant Types	0.00 see detail		
Applicant Types Funding Limit	0.00 see detail		
Applicant Types Funding Limit Limited Submission	0.00 see detail No Alternatives Research and Development Foundation	rs meeting the requi	rements.
Applicant Types Funding Limit Limited Submission 004889 Annual Open Grant Program	0.00 see detail No Alternatives Research and Development Foundation	rs meeting the requi	rements.
Applicant Types Funding Limit Limited Submission 004889 Annual Open Grant Program Contact Name Contact Telephone	0.00 see detail No Alternatives Research and Development Foundation	rs meeting the requi	rements.

Program URL
Deadline Dates (ALL)

ARDF's Annual Open grant program was established to fund research projects that develop alternative methods to advance science and replace or reduce animal use. Proposals are welcome from any nonprofit educational or research institution worldwide, although there is a preference for U.S. applications to support advancing alternatives here. Proposals are evaluated based on scientific merit and feasibility, and the potential to reduce or replace the use of animals in the near future. Proposals are considered across the fields of research, testing, or education. The maximum award amount is \$50,000, and the historical funding rate is approximately 20%.

Applicant Types
Funding Limit
Limited Submission
No

089843	Alzheimer's Association Clinician Scientist Fellowship (AACSF)	Al-baimanta Assasiation	27-Feb-2025	250,000
	<u>Program</u>	Alzheimer's Association	[LOI/Pre-App]	USD

Contact Name

Contact Telephone 800-272-3900

Contact Email grantsapp@alz.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 27-Feb-2025 [LOI/Pre-App], 01-May-2025

Synopsis The Alzheimer's Association recognizes the need to support the training of clinician scientists in Alzheimer's and all other dementias. For the purpose of this program, a clinician scientist is defined as an individual already trained,

licensed and practicing in a clinical field that includes patient contact (e.g., neurology, psychiatry, geriatrics, psychology) or patient-related diagnostic studies (e.g., neuropathology and radiology). Applicants who are within 15 years of receiving their M.D., D.O. or Ph.D. (or equivalent) and have licensure for clinical practice, including postdoctoral fellows through Assistant Professors, are eligible. Positions higher than Assistant Professor will not be considered.

Applicant Types

Funding Limit 250,000.00 maximum

Limited Submission No

000148	Alzheimer's Association Research Grant to Promote Diversity	Alzheimer's Association	27-Feb-2025	200,000
	(AARG-D)	Alzheimer's Association	[LOI/Pre-App]	USD

Contact Name

Contact Telephone

Contact Email grantsapp@alz.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 27-Feb-2025 [LOI/Pre-App], 01-May-2025

The AARG-D grant program aims to fund early-career investigators who are less than 15 years past their doctoral degree or post-residency (M.D. or D.O.) with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to federal or other funding entities.

Applicant Types

Funding Limit 200,000.00 maximum Limited Submission No

089845	Alzheimer's Association Clinicia Diversity (AACSF-D)	n Scientist Fellowship to Promote Alzheimer's Association		27-Feb-2025 LOI/Pre-App]	250,000 USD
	Contact Name				
	Contact Telephone	800-272-3900			
	Contact Email	grantsapp@alz.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Feb-2025 [LOI/Pre-App], 01-May-2025			
	Synopsis	The Alzheimer's Association recognizes the need to increase the numbe in clinical research. The sponsor anticipates that by providing this fundir underrepresented physicians entering and remaining in clinical careers increase.	ng opportunity, th	he number of	
	Applicant Types				
	Funding Limit	250,000.00 maximum			
	Limited Submission	No			
089988	Alzheimer's Association Resear	ch Grant (AARG) Alzheimer's Association		27-Feb-2025 LOI/Pre-App]	200,000 USD
	Contact Name				

Contact Telephone

Contact Email grantsapp@alz.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 27-Feb-2025 [LOI/Pre-App], 01-May-2025

Synopsis

The Alzheimer's Association Research Grant (AARG) award aims to fund early-career investigators who are less than 18 years past their doctoral degree or post-residency (M.D. or D.O.). The purpose of this program is to provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development that will lay the groundwork for future research grant applications to federal or other funding entities. The mechanism of this award is the individual research grant. The Alzheimer's Association recognizes the need to increase the number of scientists from underrepresented groups in the research enterprise for Alzheimer's and all other dementia. Young scientists from these groups are encouraged to apply. Each AARG award total is limited to \$200,000.

Applicant Types

Funding Limit 200,000.00 maximum

Limited Submission No

089983 Alzheimer's Association Research Fellowship (AARF)

Alzheimer's Association

27-Feb-2025 [LOI/Pre-App]

200,000 USD

Contact Name

Contact Telephone 800-272-3900

Contact Email grantsapp@alz.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 27-Feb-2025 [LOI/Pre-App], 01-May-2025

The AARF grant program is intended to support exceptional researchers who are engaged in their post-graduate work (i.e. postdoctoral fellows) and before they have their first independent faculty positions (i.e. Assistant Professor) and working in diverse areas of research, including basic, translational, clinical, functional and social-behavioral research. Investigators doing clinically-focused research without clinical practice are encouraged to apply. This grant is open to U.S. and international researchers.

Applicant Types

Funding Limit 200,000.00 maximum

Limited Submission No

114239 AACR-Sontag Foundation Brain Cancer Research Fellowship

American Association for Cancer Research

01-May-2025

130,000 USD

Contact Name

Contact Telephone

Contact Email grants@aacr.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

Synopsis The AACR-Sontag Foundation Brain Cancer Research Fellowship represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct brain cancer research and to establish a successful career path in

this field. The proposed project may be in basic, clinical, translational, or population sciences research and must have direct applicability and relevance to brain cancer. Applications from investigators with experience in other areas of cancer or biomedical research who have promising ideas or approaches that can be applied to brain cancer research are especially encouraged. The fellowship provides a two-year grant of \$130,000 to support the salary and benefits of the fellow while working on a mentored brain cancer research project. Funds may also be designated for non-personnel expenses such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

Applicant Types

Funding Limit 130,000.00 maximum

Limited Submission No

005022 Investigator-Initiated Research Grants

American Institute for Cancer Research

16-May-2025

Not Specified

Contact Name

Contact Telephone 202-600-3004

Contact Email research@aicr.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 16-May-2025

Synopsis

The Investigator-Initiated Research Grant Program welcomes proposals from Independent Investigators addressing the impact of modifiable lifestyle exposures on cancer risk and outcomes. AICR's Investigator-Initiated Research Grant Program is dedicated to funding research on cancer prevention, treatment, and survival related to modifiable lifestyle factors including diet, nutrition, body composition, and physical activity but also additional modifiable lifestyle

exposures, such as sleep and stress. There is a new sub-category of the Investigator-Initiated Research Grant Program is intended to support projects from Early Career investigators (within 36 months of first academic appointment). The priority for these awards is to help Early Career Investigators to rapidly address research questions.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission Yes

049768 Investigator-Initiated Research Grant Program

American Institute for Cancer Research

16-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email research@aicr.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 16-May-2025

Investigator-Initiated Research Grant Program welcomes proposals from Independent Investigators addressing the impact of modifiable lifestyle exposures on cancer risk and outcomes. AICR's Investigator-Initiated Research Grant Program is dedicated to funding research on cancer prevention, treatment, and survival related to modifiable lifestyle Synopsis factors including diet, nutrition, body composition, and physical activity but also additional modifiable lifestyle exposures, such as sleep and stress. EARLY CAREER subcategory of Investigator-Initiated Research Grant Program is intended to support projects from Early Career investigators (within 36 months of first academic appointment). The priority for these awards is to help Early Career Investigators to rapidly address research questions.

Applicant Types

Funding Limit 0.00 see detail Limited Submission No

016168 Design Competitions

American Institute of Aeronautics & Astronautics

16-May-2025

Not Specified

Contact Name

Contact Telephone 703-264-2422

Contact Email studentprogram@aiaa.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 16-May-2025

The AIAA Foundation sponsors design competitions every year. These competitions offer a great opportunity for students to participate in a simulated real-world problem, allowing students to gain experience and receive useful and constructive feedback from technical experts who sit on AIAA Technical Committees. Several of the competitions allow students to perform theoretical work and gain real-world insight into the design process. Whether students are Synopsis designing an aircraft, engine, or space vehicle, they will go through all of the primary design steps involved in determining a solution to a Request for Proposal (RFP). This includes determining a hypothetical solution, testing the hypothesis, evaluating its effectiveness, possibly doing some cost analysis, and finally preparing a report that will be submitted in response to the RFP. These responses are reviewed by experts in the field who will provide constructive responses to the students.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

063209 George Klinzing Best PhD Awa	<u>rd</u>	American Institute of Chemical Engineers (AIChE)	31-May-2025	500 USD
Contact Name	Michael Molnar, PTF Vice Chair			
Contact Telephone				
Contact Email	michael.molnar@dow.com			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-May-2025			
Synopsis	outstanding dissertation by an ind	Il Engineers (AIChE) presents the George Klinzing Be ividual who has earned a doctoral degree. The disse neering sciences, with particle science and enginee o tickets to PTF award dinner.	ertation can be in a	any discipline
Applicant Types				
Funding Limit	500.00 see detail			
Limited Submission	No			
002145 Eight and Forty Nursing and Ro	espiratory Therapist Scholarships	American Legion	15-May-2025	1,000 USD
Contact Name				
Contact Telephone				
Contact Email	lasecretaire@8and40.org			

Sponsor Website
Program URL Link to program URL

Deadline Dates (ALL) 15-May-2025 The 8 & 40 is rooted in supporting the medical community, specifically those professionals directly involved in respiratory illnesses in children. Scholarships are available to assist students in furthering their education for a Synopsis position in pediatric related medical care. Applicants must have successfully completed the first year of medical related training. The scholarship amount being offered is \$1,000 per semester, renewable for a second semester. Applicant Types Funding Limit 1,000.00 maximum Limited Submission No American Medical Women's Association 05-May-2025 1,000 USD

058266 Overseas Assistance Grants

Contact Name

Contact Telephone

Contact Email AWHS@amwa-doc.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 05-May-2025, 05-Sep-2025

Synopsis The AWHS Overseas Assistance Grant provides assistance with transportation costs up to \$1,000 connected with pursuing medical studies in an off-campus setting where the medically neglected will benefit.

Applicant Types

Funding Limit 1,000.00 maximum

Limited Submission No

124444 <u>Rocov</u>	rich Research Grant		American Osteopathic Foundation	12-May-2025	5,000 USD
	Contact Name				
	Contact Telephone	312-202-8234			
	Contact Email	info@aof.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-May-2025			
		-	I be given annually to recognize an Osteopathic m scholarly work through research on the biomecha atment (OMT).		
	Applicant Types				
	Funding Limit	5,000.00 maximum			
	Limited Submission	No			
130196 Osteo Grant		cation for Orthopedics (ORE-O)	American Osteopathic Foundation	19-May-2025	Not Specified
	Contact Name				
	Contact Telephone	312-202-8234			
	Contact Email	info@aof.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Deadline Dates (ALL)

AOAO-F/AOF's ORE-O grant supports Osteopathic Orthopedic Residents or Fellows in training who plan to pursue
Osteopathic orthopedic research through this grant, who has demonstrated their contribution to the science and knowledge of the biomechanical, biomedical, and clinical aspects of Osteopathic orthopedic surgery through research and publication.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

107306 Office of International Programs (OIP) Global Experience Award American Phytopathological Society

15-May-2025

4,000 USD

Contact Name

Contact Telephone 651-454-7250

Contact Email apsfoundation@scisoc.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-May-2025

Synopsis

The APS Office of International Programs (OIP) is requesting proposals for the "OIP Global Experience, a program aimed at helping APS plant pathologists work with scientists and extension personnel in developing countries in training and outreach efforts. As agriculture is affected by globalization, it becomes increasingly important to foster and sustain plant pathological research and extension on a global scale.

Applicant Types

Funding Limit 4,000.00 maximum

Limited S	ubmission	No
-----------	-----------	----

	Littlicea Sabitiissioti	110			
045363	Research Grant		American Psychoanalytic Foundation	01-May-2025	40,000 USD
	Contact Name	Tina Faison			
	Contact Telephone	212-752-0450			
	Contact Email	tfaison@apsa.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025			
	Synopsis	Research Grants are awarded for the process and/or outcome of	or a specific project building upon psychoanalytic pr psychoanalytically informed treatments.	inciples or directly in	vestigating
	Applicant Types				
	Funding Limit	20,000.00 per year			
	Limited Submission	No			
072012	David P. Rall Award for Advoca	ncy in Public Health	American Public Health Association	16-May-2025	1,000 USD
	Contact Name	Deborah Dillard			
	Contact Telephone				
	Contact Email	deborah.dillard@apha.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-May-2025			

Synopsis Applicant Types Funding Limit Limited Submission	The David P. Rall Award for Advocacy in Public Health is awarded to an individual who health through science-based advocacy. 1,000.00 see detail No) has contributed t	o public
060378 Avian Health Grant	Association of Avian Veterinarians	01-May-2025	10,000 USD
Contact Name	Elizabeth Mackey, AAV Executive Director		
Contact Telephone	720-458-4111		
Contact Email	grants.awards.scholarships@aav.org		
Sponsor Website	Link to sponsor website		
Program URL	Link to program URL		
Deadline Dates (ALL)	01-May-2025		
Synopsis	The Association of Avian Veterinarians is accepting pre-proposals for research project captive bird health (companion and zoological species). Areas of interest include, but testing, disease treatment, drug pharmacokinetics/pharmacodynamics, and practice to \$10,000.00 US for individual projects.	are not limited to,	diagnostic
Applicant Types			
Funding Limit	10,000.00 maximum		
Limited Submission	No		
080060 Wild Bird Health Grant	Association of Avian Veterinarians	01-May-2025	5,000 USD

Contact Name Elizabeth Mackey, AAV Executive Director

Contact Telephone 720-458-4111

Contact Email grants.awards.scholarships@aav.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

Synopsis The Association of Avian Veterinarians (AAV) is accepting pre-proposals for research projects addressing wild bird health. Grants are limited to \$5,000 US for individual projects.

Applicant Types

Funding Limit 5,000.00 maximum

Limited Submission Yes

011230 BIRD Call for Proposals

Binational Industrial Research and Development 08-May-2025 1,000,000 (BIRD) Foundation [LOI/Pre-App] USD

Contact Name

Contact Telephone 972-3-6988300

Contact Email See notes

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 08-May-2025 [LOI/Pre-App], 08-Jul-2025

Synopsis
Synopsis
The Binational Industrial Research and Development (BIRD) Foundation provides support for projects between U.S.
Applicant Types
Funding Limit
Limited Submission
No

130180 2025 BBSRC Fellowships Scheme

Biotechnology and Biological Sciences Research Council (BBSRC)

07-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email postdoc.fellowships@bbsrc.ukri.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

UK-based early career researchers and research technical professionals are invited to apply for funding to carry out independent research within a host laboratory and gain leadership skills. Applicants must demonstrate appropriate and relevant research, technical or innovation experience and be based at a UK research organisation eligible for BBSRC funding. There is no limit on the value of the grant. BBSRC will fund 80% of the full economic cost. The fellowship will last three years. Fellows can work full time or part time (pro rata).

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

130329 Optum Infusion Pharmacy/Bleen North Carolina Scholarships	eding Disorders Foundation of	Bleeding Disorders Foundation of North Carolina	31-May-2025	3,000 USD
Contact Name				
Contact Telephone	919-319-0014			
Contact Email	scholarships@bleedingdisordersr	nc.org		
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-May-2025			
Synopsis	to be distributed in awards of \$50 been diagnosed with a bleeding of	leeding Disorders Foundation of North Carolina Scho 20 to \$3,000 to persons affected by a bleeding disord disorder; is a caregiver of a child or adult diagnosed vousehold diagnosed with a bleeding disorder.	der including anyo	ne who: has
Applicant Types				
Funding Limit	3,000.00 maximum			
Limited Submission	No			
130327 George D. McCoy Scholarship		Bleeding Disorders Foundation of North Carolina	15-May-2025	1,000 USD
Contact Name				
Contact Telephone	919-319-0014			
Contact Email	scholarships@bleedingdisordersr	nc.org		
Sponsor Website	Link to sponsor website			

Program URL Link to program URL

Deadline Dates (ALL) 15-May-2025

Synopsis The George D. McCoy Scholarship provides a \$1,000 award to persons diagnosed with mild, moderate, or severe hemophilia A. The applicant does not need to be a North Carolina resident.

Applicant Types

Funding Limit 1,000.00 maximum

Limited Submission No

024717 Strategic Research Agreements: Multi Project

Breakthrough T1D

06-May-2025 [LOI/Pre-App]

Not Specified

Contact Name

Contact Telephone

Contact Email <u>preawardsupport@BreakthroughT1D.org</u>

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025 [LOI/Pre-App], 17-Jun-2025

Synopsis JDRF's Strategic Research Agreements are designed to provide research funding for investigators to address critical gaps and challenges and make breakthroughs in type 1 diabetes research.

Applicant Types

Funding Limit 0.00 not provided

Limited Submission No

090492 <u>Travel Awards</u>	British Infection Association	31-May-2025	1,260 USD
Contact Name	Profesor Thushan de Silva		
Contact Telephone			
Contact Email	scientificresearch@britishinfection.org		
Sponsor Website	<u>Link to sponsor website</u>		
Program URL	Link to program URL		
Deadline Dates (ALL)	31-May-2025 , 31-Oct-2025		
Synopsis	The British Infection Association Travel Awards support registration and travel (if aginternational meetings (either in person or on-line), in particular, ASM, ICAAC, IDSA research, where the abstract is already accepted. Accommodation costs may also b limit.	, and ECCMID to pre	sent original
Applicant Types			
Funding Limit	1,000.00 maximum		
Limited Submission	No		
005133 <u>Travel Fund</u>	British Society for Plant Pathology	28-Feb-2025	1,260 USD

Contact Name

Contact Email president@bspp.org.uk
Sponsor Website
Program URL
Link to program URL

Contact Telephone

Deadline Dates (ALL) 28-Feb-2025 , 31-May-2025 , 31-Aug-2025 , 30-Nov-2025

Synopsis

The BSPP Travel Fund is open to members of the Society to assist with expenses for conferences, study tours and visits. Students are particularly encouraged to apply. Awards will be made by a Committee of the Board whose decision shall be final. In judging applications, the Committee will take into consideration the nature of the visit in relation to the work of the applicant and the aims of the Society. All applications will be considered on their merits.

Applicant Types

Funding Limit 1,000.00 maximum

Limited Submission No

001975 Grants Program

Brooks (Gladys) Foundation

31-May-2025

USD

Contact Name Kathy Petry

Contact Telephone 516-746-6103

Contact Email kathy@gladysbrooksfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 31-May-2025

Synopsis The Gladys Brooks Foundation will consider grant proposals with emphasis on innovative projects in the fields of libraries, education, hospitals and clinics.

Applicant Types

Funding Limit 150,000.00 see detail

Limited Submission No

45538 Partnering Opportunity For Clin	nical Trial Stage Projects (CLIN2)	California Institute for Regenerative Medicine	28-Feb-2025	Not Specified
Contact Name				
Contact Telephone	510-340-9101			
Contact Email	Clinical@cirm.ca.gov			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	28-Feb-2025 , 31-Mar-2025 , 30-A	pr-2025 , 30-May-2025 , 30-Jun-2025		
Synopsis	transformative regenerative medi objective of this funding opportur therapy (stem cell-based or genet act not only as a funding agency, be world-class subject matter experts	for Regenerative Medicine (CIRM) is to acceleration treatments in an equitable manner to a divinity is to support completion of a clinical trial for ic therapy) that addresses an unmet medical nebut will also devote significant internal resources to actively advance the project. The result of a nat both accelerates the program and gives it the	erse California and wo a regenerative medic ed. Under this progran s and leverage its exte successful application	orld. The ine-based m, CIRM will ernal team o n will be the
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
15367 Partnering Opportunity for Late	e Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine	28-Feb-2025	6,000,000 USD
Contact Name				

Contact Telephone 510-340-9101

Contact Email clinical@cirm.ca.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 28-Feb-2025, 31-Mar-2025, 30-Apr-2025, 30-May-2025, 30-Jun-2025

Synopsis

The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. The objective of this program announcement is to support late-stage preclinical studies necessary to file and attain an active IND with the Food and Drug Administration (FDA) and initiate start-up activities to prepare for a clinical trial for a regenerative medicine therapy (stem cell-based or genetic therapy). Under this program, CIRM will act not only as a funding agency, but will also devote significant internal resources and leverage its external team of world-class subject matter experts to actively advance the project. The result of a successful application will be the formation of a true partnership that both accelerates the program and gives it the greatest opportunity for success.

Applicant Types

Funding Limit 6,000,000.00 maximum

Limited Submission No

074616 Health and Nutrition Research Grant Program

California Walnut Commission

07-Mar-2025 [LOI/Pre-App] 500,000 USD

Contact Name Dr. Rachel Blaine

Contact Telephone

Contact Email rblaine@walnuts.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 07-Mar-2025 [LOI/Pre-App], 07-May-2025

Synopsis The California Walnut Commission (CWC) is seeking proposals to support human clinical trials and observational studies on priority topics. CWC supports domestic and international health-related research on walnuts.

Applicant Types

Funding Limit 500,000.00 maximum

Limited Submission No

027711 Richard Rowe Research Prize

Canadian Cardiovascular Society

06-May-2025

350 USD

Contact Name

Contact Telephone

Contact Email cpca@ccs.ca

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025

The Canadian Cardiovascular Society presents the Richard Rowe Research Prize annually to an individual for outstanding research in heart disease in children undertaken during training. The winner of the award will be announced at the CCC following the Richard Rowe Session presentations. The winner will receive a \$500 cash award and an honorary plaque.

Applicant Types

Funding Limit 500.00 see detail

Limited Submission	No		
129612 Global Science Scholars	Chan Zuckerberg Initiative	27-May-2025	Not Specified
Contact Name			
Contact Telephone			
Contact Email	sciencegrants@chanzuckerberg.com		
Sponsor Website	<u>Link to sponsor website</u>		
Program URL	Link to program URL		
Deadline Dates (ALL)	27-May-2025		
Synopsis	The Chan Zuckerberg Biohub Network (CZ Biohub Network) and the applications for the Global Science Scholars program, an up to two program between the U.S. and Japan designed to advance exceller supporting early-career researchers to advance their careers and of Japanese research labs.	-year international postdoctoral fellow nce in bioengineering and biomedical r	vship esearch by
Applicant Types			
Funding Limit	0.00 see detail		
Limited Submission	No		
085272 Syringe Access Program Grant	Comer Foundation	01-May-2025	Not Specified
Contact Name Contact Telephone			

Contact Email grants@comerfamilyfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Nov-2025

The Comer Foundation will support syringe services programs and community-based harm reduction programs that Synopsis improve the health and wellness of people who use drugs. These programs provide free safer use supplies, education, and community wraparound services to reduce opioid overdoses and the transmission of HIV and viral hepatitis.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

000055	Research	Fellowship.	Λwarde
000000	IVE3EalCII	I CHOWSHID	-wai us

Crohn's & Colitis Foundation of America

06-May-2025 [LOI/Pre-App]

210,000 USD

Contact Name N'Dea Johnson

Contact Telephone 646-943-7501

Contact Email training awards@crohnscolitisfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025 [LOI/Pre-App], 18-Jul-2025

Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop synopsis skills related to basic research investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.

Applicant Types
Funding Limit 70,000.00 per year

Limited Submission No

01440 <u>Career Development Awards</u>	Crohn's & Colitis Foundation of America	06-May-2025 [LOI/Pre-App]	180,000 USD		
Contact Name	N'Dea Johnson				
Contact Telephone	800-932-2423				
Contact Email	ining_awards@crohnscolitisfoundation.org				
Sponsor Website	<u>Link to sponsor website</u>	k to sponsor website			
Program URL	L <u>Link to program URL</u>) 06-May-2025 [LOI/Pre-App], 18-Jul-2025				
Deadline Dates (ALL)					
Synopsis	Career Development Awards are mentored awards intended to facilitate the development potential to prepare for a career of independent basic research investigation bowel disease (IBD).	•			
Applicant Types					
Funding Limit	60,000.00 per year				
Limited Submission	No				
		06-May-2025			

Contact Name Saleha Hossain

Contact Telephone 800-932-2423

Contact Email SRA@crohnscolitisfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025 [LOI/Pre-App], 18-Jul-2025

Synopsis Senior Research Awards are intended to provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources such as the National Institutes of Health (NIH).

Applicant Types

Funding Limit 130,000.00 per year

Limited Submission No

063869	Litwin	IBD	Pioneers	Initiative
--------	--------	------------	-----------------	-------------------

Crohn's & Colitis Foundation of America

06-May-2025 [LOI/Pre-App]

130,000 USD

Contact Name Saleha Hossain

Contact Telephone

Contact Email litwinprogram@crohnscolitisfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025 [LOI/Pre-App], 18-Jul-2025

The Litwin IBD Pioneers initiative supports innovative clinical and translational research projects with the potential to Synopsis impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds

innovative pilot research so that scientists can test their initial ideas and generate preliminary data. Litwin IBD Pioneers supports researchers who are exploring all possible opportunities for diagnostic and therapeutic improvements, including novel, out-of-the-box ideas, and funds innovative and pioneering ideas that have a clinically relevant focus. Additionally, the program is open to investigators from other disciplines new to the IBD field, as well as countries outside the United States.

Applicant Types

Funding Limit 130,000.00 see detail

Limited Submission Yes

002222	Crohn's & Colitis Foundation/NASPGHAN IBD Young Investigator	Crohn's & Colitis Foundation of America	06-May-2025	Not
083322	Award	Croffin's & Collus Foundation of America	[LOI/Pre-App]	Specified

Contact Name N'Dea Johnson

Contact Telephone

Contact Email training_awards@crohnscolitisfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025 [LOI/Pre-App], 18-Jul-2025

Career Development Awards are mentored awards intended to facilitate the development of individuals with synopsis research potential to prepare for a career of independent basic research investigation in the area of inflammatory bowel disease (IBD).

Applicant Types

Funding Limit 0.00 see detail

Limited Submission	No		
002586 Grants Program	Cure Parkinsons Trust	05-May-2025	315,000 USD
Contact Name			
Contact Telephone	0207 487 3892		
Contact Emai	Research@cureparkinsons.org.uk		
Sponsor Website	<u>Link to sponsor website</u>		
Program URI	Program URL Link to program URL		
Deadline Dates (ALL)	05-May-2025 , 21-Jul-2025 , 03-Nov-2025		
Synopsis	This programme primarily funds preclinical and clinical research focused on slowing, Parkinson's. For preclinical research, projects that could lead to clinical trials in Parki prioritised. The sponsor only funds clinical research in people with Parkinson's.		-
Applicant Types			
Funding Limit	250,000.00 see detail		
Limited Submission	No		
130294 Grant Programs	Cure Sanfilippo Foundation	28-Mar-2025 [LOI/Pre-App]	Not Specified
Contact Name	Kassidie Reynolds		

Contact Telephone

Contact Email Research@CureSanfilippoFoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 28-Mar-2025 [LOI/Pre-App], 30-May-2025

Cure Sanfilippo Foundation seeks to support research that fills critical gaps in current knowledge and access to treatment across basic and translational science, clinical care, and therapeutic interventions in clinical trials. The sponsor's overarching goal is to advance a pipeline of scientific discovery which will improve the lives of children with Sanfilippo syndrome. Scientist-clinician-patient collaborations are highly encouraged and an area of active engagement for the Foundation. Proposals will be considered under the following mechanisms: Pilot Awards ADVANCE Awards All funding awards are contingent upon alignment with the Foundation's goals and priorities as informed by recognized gaps in clinical care and/or scientific knowledge which present significant barriers to the development of beneficial therapies and improved quality of life for affected individuals. Funding levels and award categories may vary over time to adapt to the ongoing funding commitments by the Foundation and availability of resources. Award funding is milestone driven and proposals should be written with clear milestones.

Synopsis

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

Department of Urology - Endourology Fellowship at 019022 Northwestern

Endourological Society

16-May-2025

Not Specified

Contact Name Debra Caridi, Fellowship Coordinator

Contact Telephone 516-520-1226

Contact Email debra@endourologysociety.com

Sponsor Website Link to sponsor website

	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-May-2025 , 24-Jun-2025			
	The Endourological Society facilitates one and two year clinical fellowships around the world. The training is focuse on developing advanced knowledge, experience, and technical skills in endourologic and laparoscopic and/or robot assisted surgery. Fellows also receive training in translational research, as an underlying goal is the training of futur academicians and potential national and international leaders in their specialty.				
Applicant Types					
Funding Limit 0.00 not provided					
	Limited Submission	No			
130304	Francis Fontan Fund - Nurses a Fellowship in Partnership with		European Association for Cardio-Thoracic Surgery (EACTS)	01-May-2025	5,460 USD
	Contact Name	Natasha Smith-Jones			
	Contact Telephone	+44 (0)1753 832 166			
	Contact Email	natasha.smithjones@eacts.co.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025			
	Synopsis This fellowship will be awarded to nursing and allied health professionals that would like to visit a centre of excellence specialised in cardiac and/or thoracic surgery in Europe.			e of	
	Applicant Types				
Funding Limit 5,200.00 see detail					

	Limited Submission	No			
126870	Francis Fontan FundOBCAB E with Medtronic	extended Fellowship in Partnership	European Association for Cardio-Thoracic Surgery (EACTS)	01-May-2025	6,300 USD
	Contact Name				
	Contact Telephone				
	Contact Email	info@eacts.co.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025			
	Synopsis	depth understanding of cardiothor understanding of cardiothoracic su acquire theoretical and practical k	in partnership with Medtronic, will provide the succeracic surgical outcomes. The 1 1/2 month OPCAB Felurgical outcomes, providing an opportunity for a youn nowledge in the surgical and anaesthesiologic manacial interest in off-pump (OPCABG) techniques.	llowship will enha ung cardiothoracio	nce clinical surgeon to
	Applicant Types				
	Funding Limit	6,000.00 maximum			
	Limited Submission	No			
126860	Francis Fontan FundAdvance Fellowship	d Intensive Postoperative Care	European Association for Cardio-Thoracic Surgery (EACTS)	01-May-2025	Not Specified
	Contact Name				
	Contact Telephone				

Contact Email
Sponsor Website
Program URL
Deadline Dates (ALL)

This Fellowship provides a chance to gain experience in the postoperative management in adult cardiovascular surgery, as well as a wide exposure to minimally invasive and other advanced techniques in cardiovascular surgery.

Synopsis
The successful Fellow will have the opportunity to attend existing relevant courses held at the world-renowned Department of Cardiovascular Surgery at Hospital Clinic de Barcelona (University of Barcelona), and attend symposia, Wetlabs, Congresses, Heart Team meetings, multidisciplinary meetings and simulations.

Applicant Types
Funding Limit

0.00 see detail

130297 Francis Fontan Fund--Pulmonary Thromboendarterectomy Fellowship

European Association for Cardio-Thoracic Surgery (EACTS) 01-N

01-May-2025 4,200 USD

Contact Name

Limited Submission No

Contact Telephone

Contact Email info@eacts.co.uk

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

	Synopsis	Synopsis This Fellowship offers a one month stay in a European chronic thromboembolic pulmonary hypertension (CTEPH) centre. Possible centres: Papworth, Leuven, Hannover, Paris.			
	Applicant Types				
	Funding Limit	4,000.00 maximum			
	Limited Submission	No			
130290	Francis Fontan FundTranscatt (TAVI) Fellowship	heter Aortic Valve Implantation European Association for Cardio-Thoracic Surgery (EACTS) 01-May-2025 6,930 USE			
	Contact Name				
	Contact Telephone				
	Contact Email	info@eacts.co.uk			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025			
		The transcatheter fellowship is designed for cardiac surgery trainees who want to learn how to differently approach the treatment of all heart valves diseases percutaneously.			
	Applicant Types				
	Funding Limit	6,600.00 maximum			
	Limited Submission	No			
126867	Francis Fontan FundOff-Pump Fellowship in Partnership with	UI-May-2025 5 460 USI			

Contact Name

Contact Telephone

Contact Email info@eacts.co.uk

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

Synopsis

The Off-Pump Coronary Artery Bypass Fellowship, in partnership with Medtronic, supports a newly graduated cardiothoracic surgeon to acquire theoretical and practical knowledge in the surgical management of patients with coronary artery disease, with special interest in off-pump and minimal invasive techniques. A Fellow will have an exciting opportunity to work under the guidance of leading surgeon-educators in this field. Specifically, the fellow will gain foundational knowledge of the pathophysiology of coronary artery disease, the rationale for its surgical treatment and first-hand experience in OPCAB.

Applicant Types

Funding Limit 5,200.00 maximum

Limited Submission No

126868

Francis Fontan Fund--MiCS Coronary Artery Bypass Graft (MiCS-CABG) Fellowship in Partnership with Medtronic

European Association for Cardio-Thoracic Surgery (EACTS)

01-May-2025

5,460 USD

Contact Name

Contact Telephone

Contact Email info@eacts.co.uk

Sponsor Website Link to sponsor website

	Program URL Deadline Dates (ALL) Synopsis	The MICS-CABG Fellowship, in part acquire theoretical and practical ki with special interest in off-pump a under the guidance of leading surg	tnership with Medtronic, supports newly graduated nowledge in the surgical management of patients wind minimal invasive techniques. A Fellow will have a geon-educators in this field. Specifically, the Fellow was presented to the second seco	ith coronary artery an exciting opportu will gain foundation	disease, unity to work nal
		experience in MICS CABG.	of coronary artery disease, the rationale for its surg	5.0a. v. 0a	
	Applicant Types				
	Funding Limit	5,200.00 maximum			
	Limited Submission	No			
084682	<u>Francis Fontan Fund - Atrial Fib</u> <u>with AtriCure</u>	orillation Fellowship in Partnership	European Association for Cardio-Thoracic Surgery (EACTS)	01-May-2025	Not Specified
	Contact Name	Natasha Smith-Jones			
	Contact Telephone	+44 (0)1753 832 166			
	Contact Email	natasha.smithjones@eacts.co.uk			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025			
	Synopsis	The Atrial Fibrillation Fellowship is patients with atrial fibrillation (AF)	designed to enhance clinical understanding and sur . The Fellowship supports cardiothoracic surgeons v	gical proficiency in vorking towards a	treating leadership

role in surgical AF treatment. This Fellowship gives Fellows an opportunity to acquire the foundational knowledge of the pathophysiology of atrial fibrillation, the rationale for its surgical treatment and to gain first-hand experience in AF correction procedures through a range of surgical approaches.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

126866 Francis Fontan Fund--Aortic Root And Valve Repair Fellowship

European Association for Cardio-Thoracic Surgery (EACTS)

01-May-2025

6,510 USD

Contact Name

Contact Telephone

Contact Email info@eacts.co.uk

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

The Aortic Root and Valve Repair Fellowship provides an opportunity to acquire theoretical and practical knowledge Synopsis in the surgical management of patients with a rtic root dilatation and a ortic regurgitation, with special interest in the sparing of the aortic valve.

Applicant Types

Funding Limit 6,200.00 maximum

Limited Submission No

130298 Francis Fontan FundExtracor Fellowship	poreal Life Support (ECLS)	European Association for Cardio-Thoracic Surgery (EACTS)	01-May-2025	6,825 USD
Contact Name				
Contact Telephone				
Contact Emai	info@eacts.co.uk			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL)	01-May-2025			
Synopsis	in post-cardiotomy mechanical c three fellowship centres (Three of simulation sessions, together with Fellowship also includes participal further exposed to all the aspect	entre (MUMC), in collaboration with two European ce irculatory support (PC-MCS). The Fellowship will const one-week placements), providing the possibility to ha th case discussion and presentation by the teams invo- ation to the EACTS MCS Summit (November 2026) du s of the project topics, being able to meet and listen to eld, and attend further simulation sessions, usually or	ist of one-week vive access to clinicolyed in these progring which the care to the most advan	sits to the al and grams. The adidate will be ced
Applicant Types	5			
Funding Limit	6,500.00 maximum			
Limited Submission	No			
003157 Clinical Visit (CV)		European Association of Urology	01-May-2025	3,150 USD
Contact Name				

Contact Telephone

Contact Email eusp@uroweb.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Sep-2025

This program is for a duration of 6 to 12 weeks at a reputable European institution abroad. Recipients will immerse Synopsis themselves in the best practices by observing experts in the field. Together, they will work on a structured project to achieve an international peer-reviewed publication.

Applicant Types

Funding Limit 3,000.00 maximum

Limited Submission No

009740 ECCO Fellowship

European Crohn's and Colitis Organisation

05-May-2025

63,000 USD

Contact Name

Contact Telephone +43-(0)1-710 2242-0

Contact Email ecco@ecco-ibd.eu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 05-May-2025

Synopsis The European Crohn's and Colitis Organisation (ECCO) offers Fellowships to encourage and support early career individuals and promote innovative scientific research in the area of Inflammatory Bowel Diseases (IBD) in Europe.

Applicant Types

Funding Limit 60,000.00 see detail

Limited Submission Yes

048728 N-ECCO Travel Award European Crohn's and Colitis Organisation 05-May-2025 1,575 USD

Contact Name

Contact Telephone +43-01-710 2242-0

Contact Email ecco@ecco-ibd.eu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 05-May-2025

The European Crohn's and Colitis Organisation (ECCO) offers the N-ECCO Travel Award as an opportunity for IBD nurses to visit a different Inflammatory Bowel Disease (IBD) centre in Europe and to observe and learn from IBD nursing services of another centre. This travel award aims to enhance the opportunity for IBD nurses to visit European centres. They are not designed to support travel to congresses or meetings. A total amount of EUR 1,500 will be awarded per N-ECCO Travel Award.

Applicant Types

Funding Limit 1,500.00 maximum

Limited Submission No

117091 <u>D-ECCO Research Grants</u> European Crohn's and Colitis Organisation 05-May-2025 84,000 USD

Contact Name

Contact Telephone 43 0 1 710 22 42-0

Contact Email ecco@ecco-ibd.eu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 05-May-2025

The European Crohn's and Colitis Organisation (ECCO) offers D-ECCO Research Grants for IBD dietitians to promote innovative scientific research in the area of nutrition across Europe. D-ECCO Research Grants enhance the opportunity for dietitians to be involved in international research projects. The aim is to engage dietitians who are Synopsis less experienced in carrying out research, to conduct proper systematic research under the mentorship of a senior researcher. Typically, research for a D-ECCO Grant project is coordinated by a senior researcher and conducted by IBD dietitian(s) with less research experience in other European centres. The coordinator acts as the Principal Investigator

Applicant Types

Funding Limit 80,000.00 maximum

and will be responsible for the accomplishment of the study.

Limited Submission Yes

014087 Small Research Grant

Fisheries Society of the British Isles

01-May-2025

9,450 USD

Contact Name

Contact Telephone 02039253449

Contact Email theteam@fsbi.org.uk

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

The FSBI funds a number of small research projects each year to support members of the Society to undertake novel Synopsis research into any aspect of fish biology and fisheries science that is relevant to the Society's objectives. Applicants can bid for up to £7,500 to support their projects.

Applicant Types

Funding Limit 7,500.00 maximum

Limited Submission No

010950 General Request for Applications (RFA)

Foundation for Prader-Willi Research

28-Feb-2025 [LOI/Pre-App] 150,000 USD

Contact Name Jessica Bohonowych

Contact Telephone 888-322-5487

Contact Email jessica.bohonowych@fpwr.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 28-Feb-2025 [LOI/Pre-App], 16-May-2025, 05-Sep-2025 [LOI/Pre-App], 14-Nov-2025

The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to

Synopsis

advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS. Applicants may request up to \$150,000 USD in direct costs for the initial 18 months of support, with the possibility of a second grant period of 18 months of funding upon competitive renewal.

Applicant Types Funding Limit 150,000.00 maximum Limited Submission No Personalized Approaches for Understanding, Assessing and Fox (Michael J.) Foundation for Parkinson's 2,000,000 06-May-2025 128032 Improving Gait in Parkinson's Disease Research Program Research USD Contact Name Contact Telephone 212-509-0995 x261 Contact Email grants@michaelifox.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 06-May-2025 MJFF is issuing a Request for Applications (RFA) to fund clinical testing on personalized approaches for understanding, Synopsis assessing and improving gait in Parkinson's disease (PD) to address the wide variances of gait challenges across the continuum of the disease. **Applicant Types** Funding Limit 2,000,000.00 maximum Limited Submission No 250,000 001921 Bower Award and Prize for Achievement in Science 30-May-2025 Franklin Institute USD

Contact Name Beth Scheraga

Contact Telephone 215-448-1329

Contact Email bscheraga@fi.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 30-May-2025

Synopsis

The Franklin Institute seeks nominations for the 2026 Bower Award and Prize for Achievement in Science of individuals who have made significant contributions to the development of the field of human gene therapy. Since the concept of gene therapy was proposed more than 50 years ago, the development of therapeutic approaches using directed modification of DNA or cells has made significant progress in tackling challenges of biological complexity. Applications of gene editing systems, novel delivery platforms, and immunotherapies now have the potential to be 'game-changers' in the treatment of diseases ranging from in-born errors of metabolism to cancers. Nominations should recognize fundamental contributions to the development of strategies for engineering genetic alterations to cells for the treatment of human disease.

Applicant Types

Funding Limit 250,000.00 see detail

Limited Submission No

117549 Transformative Research Award Program

Hereditary Disease Foundation

01-May-2025

Not Specified

Contact Name Sarah Hernandez, PhD

Contact Telephone 212-928-2121

Contact Email sarahhernandez@hdfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

The Hereditary Disease Foundation (HDF) Transformative Research Award program will make funds available to advance transformational collaborative projects that will provide new insights into disease mechanisms or create or Synopsis implement tools and technologies not previously applied to Huntington's disease (HD) research for the advancement of therapeutics. Awards will range fro \$300,000 to 500,000 per award per year for up to a two-year period. Awardees should plan to start their projects by August-September, 2025.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

003805 Long-Term Fellowships (LTF)

Human Frontier Science Program Organization

07-May-2025 [LOI/Pre-App] Not **Specified**

Contact Name

Contact Telephone +1 703 964 5840

Contact Email fellow@hfsp.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025 [LOI/Pre-App], 15-May-2025 [LOI/Pre-App], 25-Sep-2025

Synopsis The HFSP fellowship program supports proposals for frontier, potentially transformative research in the life sciences. Applications for high-risk projects are particularly encouraged. The projects should be interdisciplinary in nature and

should challenge existing paradigms by using novel approaches and techniques. Scientifically, they should address an important problem or a barrier to progress in the field. Long-Term Fellowships are for applicants with a PhD on a biological topic who want to embark on a novel and frontier project focussing on the life sciences.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

019869 Sidney & Joan Pestka Graduate and Post-Graduate Awards in Interferon & Cytokine Research

International Cytokine and Interferon Society

15-May-2025

7,500 USD

Contact Name Joan Oefner, Managing Director

Contact Telephone 800-947-1960

Contact Email joefner@cytokinesociety.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-May-2025

The Sidney & Joan Pestka Graduate and Post-Graduate Awards, generously sponsored by PBL Assay Science, are Synopsis targeted to graduate students and post-doctoral fellows who have begun to make an impact in interferon and cytokine research.

Applicant Types

Funding Limit 7,500.00 see detail

Limited Submission No

116536 Amanda Proudfoot Tribute Award for Ad Biology by a Trainee	Vances in Chemokine International Cytokine and Interferon Socie	ety 15-May-2025	Not Specified
Contact Name Stephanie	e Flores		
Contact Telephone 800-947-2	1960		
Contact Email sflores@c	cytokinesociety.org		
Sponsor Website Link to sp	onsor website		
Program URL <u>Link to pr</u>	ogram URL		
Deadline Dates (ALL) 15-May-2	025		
Synopsis This ICIS t	rainee award is dedicated to the memory of Amanda Proudfoot (194	9-2019), who is internation	onally
	d for her important contributions to the field of chemokine biology.		
	d for her important contributions to the field of chemokine biology.		
recognize	·		
Applicant Types	·		
Applicant Types Funding Limit 0.00 see o	detail	ety 15-May-2025	Not Specified
Applicant Types Funding Limit 0.00 see of Limited Submission No ICIS-Regeneron New Investigator Awards	detail <u>s for Excellence in</u> International Cytokine and Interferon Socie	ety 15-May-2025	
Applicant Types Funding Limit 0.00 see of Limited Submission No 130118 ICIS-Regeneron New Investigator Awards	detail Solution for Excellence in International Cytokine and Interferon Socie E Flores	ety 15-May-2025	
Applicant Types Funding Limit 0.00 see of Limited Submission No 130118 CIS-Regeneron New Investigator Awards	detail Solution of the second	ety 15-May-2025	
Applicant Types Funding Limit 0.00 see of Limited Submission No 130118 ICIS-Regeneron New Investigator Awards Cytokine & Interferon Research Contact Name Stephanie Contact Telephone 800-947-2	detail s for Excellence in International Cytokine and Interferon Socie Flores 1960 cytokinesociety.org	ety 15-May-2025	

Deadline Dates (ALL)

Up to four awards will be granted to individuals who have made notable contributions to either basic or clinical research. ICIS members must be nominated by other eligible members for these Awards or can self-apply, but must include a letter(s) of nomination from their mentor(s) or other colleagues. All Awardees will be invited for an Oral presentation during the Meeting.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

026756 Research Grant International Pain & Spine Intervention Society 01-May-2025 Not Specified

Contact Name

Contact Telephone 630-203-2252

Contact Email grants@ipsismed.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025

The International Pain & Spine Intervention Society (IPSIS) is proud to provide funding for high quality research to Synopsis help generate definitive evidence and support the interventional pain medicine field. IPSIS has supported research in the field since 1990, yet much more needs to be accomplished in order to sustain our specialty.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission	No			
081727 Therapeutic Area Contribution	s - Neuroscience Program	Janssen Pharmaceuticals, Inc.	31-May-2025	Not Specified
Contact Name				
Contact Telephone	215-325-2599			
Contact Email				
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-May-2025 , 30-Sep-2025			
	health equity and strengthen for disease awareness efforts,	ams and initiatives that improve patient access frontline health workforces within the area of , patient empowerment and advocacy, and link health system improvement with measurable	Neuroscience. Support will cages to care. There is a pre	be provided ference to
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
001692 Grant Programs - Science and	Engineering Research	Keck (W. M.) Foundation	01-May-2025 [LOI/Pre-App]	5,000,000 USD
Contact Name				
Contact Telephone	213-612-2000			

Sponsor Website
Program URL
Deadline Dates (ALL)

O1-May-2025 [LOI/Pre-App], 15-Aug-2025

The W. M. Keck Research Program seeks to benefit humanity by supporting Medical Research and Science & Engineering projects that are distinctive and novel in their approach, question the prevailing paradigm, or have the potential to break open new territory in their field. Grants range from \$1 million to \$5 million and are typically \$2

Applicant Types

Funding Limit 5,000,000.00 maximum

million or less.

Contact Email research@wmkeck.org

Limited Submission No

129850 Mid-Career "Bridge to Breathe" Research Awards

LUNGevity Foundation

12-May-2025

150,000 USD

Contact Name Jody Roosevelt

Contact Telephone

Contact Email <u>mjacobson@LUNGevity.org</u>

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025

Synopsis Mid-Career "Bridge to Breathe" Research Awards support mid-career physician-scientists with a successful track record (as evidenced by publications and previous grant funding) who are seeking bridge funding to sustain their

research program while resubmitting a grant application for major federal funding or its equivalent. Applicants must have a track record of success as demonstrated by holding the rank of associate professor with tenure or its equivalent, previous research funding (NIH R01 or equivalent), and a strong publication history.

Applicant Types

Funding Limit 75,000.00 per year

Limited Submission No

026029 LUNGevity Career Development Awards

LUNGevity Foundation

12-May-2025

300,000 USD

Contact Name

Contact Telephone 312-407-6100

Contact Email info@lungevity.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025

LUNGevity Career Development Awards support future research leaders who will keep the field of lung cancer research vibrant with new ideas. LUNGevity's Career Development Award program was created with one goal: to Synopsis support future research leaders who will keep the field of lung cancer research vibrant with new ideas. This is a mentored award and a mentoring plan will be required as part of the application package. The awards may be for a maximum of \$100,000 (direct and indirect) per year for three years, for a maximum award of \$300,000.

Applicant Types

Funding Limit 100,000.00 per year

Limited Submission	No			
129842 Health Equity and Inclusivenes	s Research Fellow Award	LUNGevity Foundation	12-May-2025	100,000 USD
Contact Name	Jody Roosevelt			
Contact Telephone				
Contact Email	mjacobson@LUNGevity.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	12-May-2025			
Synopsis	conducting lung cancer clinic underrepresented minorities lung cancer or on the outcon	d Inclusiveness Research Fellow Awards support all research and bridging health disparities by engoness. Projects funded in 2025 are expected to have an es of lung cancer, or to provide a clear conceptuods for early detection and/or individualized treats.	gaging underserved commo direct impact on the early ual or experimental founda	unities or detection of tion for the
Applicant Types				
Funding Limit	50,000.00 per year			
Limited Submission	No			
070855 Pilot Award		Lymphatic Malformation Institute	21-Mar-2025 [LOI/Pre-App]	75,000 USD
Contact Name	Mike Dellinger			

Contact Telephone

Contact Email mdellinger@lmiresearch.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 21-Mar-2025 [LOI/Pre-App], 30-May-2025

Synopsis Pilot awards are intended to test new hypotheses or technologies that have the potential to significantly advance our understanding and/or treatment of CCLA, GLA, GSD, or KLA. Preliminary data are required.

Applicant Types

Funding Limit 75,000.00 maximum

Limited Submission No

038045 Research Grants Ménière's Society 01-May-2025 Not Specified

Contact Name

Contact Telephone +44 0 1306 876883

Contact Email research@menieres.org.uk

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 01-Nov-2025, 01-Feb-2026

Synopsis The Ménière's Society is the only registered charity in the UK dedicated solely to supporting people with vestibular disorders causing dizziness and imbalance. The overall aims of research funded by the Ménière's Society are

therefore: to improve the diagnosis and treatment of Ménière's disease and other vestibular disorders. The ultimate aim is to contribute towards finding a cure.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

037398 Research Associateship Program (RAP)

National Academies

01-May-2025

Not Specified

Contact Name

Contact Telephone

Contact Email RAP@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025 , 01-Aug-2025 , 01-Nov-2025

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and Synopsis affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-

the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

089862 <u>3Rs Prize</u>		National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)	01-May-2025	Not Specified
Contact Name				
Contact Telephone	020 7611 2233			
Contact Email	3rsprize@nc3rs.org.uk			
Sponsor Website	<u>Link to sponsor website</u>			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-May-2025			
	annual prize for a paper that des	lacement, Refinement and Reduction of Animals in Re scribes outstanding and original work that has or could ement of the use of animals in research. This award co	l have major impa	icts on the
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
114729 Blind Educator of the Year Awa	<u>ird</u>	National Federation of the Blind	01-May-2025	1,000 USD
Contact Name Contact Telephone Contact Email				

Sponsor Website
Program URL
Link to program URL

Deadline Dates (ALL) 01-May-2025 The National Federation of the Blind (NFB) offers the Blind Educator of the Year Award to recognize outstanding blind teachers. Every year, the award pays tribute to a blind teacher whose exceptional classroom performance, notable Synopsis community service, and uncommon commitment to the NFB merit national recognition. The recipient of the Blind Educator of the Year Award must advance the cause of blind people in the spirit and philosophy of the NFB. **Applicant Types** Funding Limit 1,000.00 see detail Limited Submission No Research Associateship Programs -- Army Aviation and Missile Not 058592 National Research Council 01-May-2025 Research, Development, and Engineering Center (AMRDEC) Specified

Contact Name Dr. Tom Jurkiw, NRC Program Administrator

Contact Telephone

Contact Email rap@nas.edu

Synopsis

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025 , 01-Aug-2025 , 03-Nov-2025

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the Army Aviation and Missile Research, Development, and Engineering Center (AMRDEC).

	Funding Limit	0.00 see detail			
	Limited Submission	No			
118194	Research Associateship Progra Weapons Division	ms Naval Air Warfare Center	National Research Council	01-May-2025	Not Specified
	Contact Name	Dr. Stephen Fallis			
	Contact Telephone	760-939-1602			
	Contact Email	stephen.fallis@navy.mil			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025 , 01-Aug-2025 , 03-N	Nov-2025		
	Synopsis	provide promising scientists and e	Programs (RAP) are prestigious postdoctoral and sen Engineers with high-quality research opportunities at ir Warfare Center Weapons Division (NAWCWD) off	t federal laboratorio	es and
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
058602	Research Associateship Progra and Materiel Command	ms U.S. Army Medical Research	National Research Council	01-May-2025	Not Specified

Applicant Types

Contact Name Dr. Tom Jurkiw, NRC Program Administrator

Contact Telephone

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 03-Nov-2025

Synopsis

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-ofthe-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the U.S. Army Medical Research and Materiel Command.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

070292

Research Associateship Programs -- Environmental Protection Agency Faculty Fellowship Program (EPA/FFP)

National Research Council

01-May-2025

Not Specified

Contact Name

Contact Telephone 202-334-2760

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

	Program URL	ink to program URL					
	Deadline Dates (ALL)	01-May-2025 , 01-Aug-2025 , 01-Nov-2025					
	Synopsis	e NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research inducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and nior level research opportunities at sponsoring federal laboratories and affiliated institutions. This opportunity is the Environmental Protection Agency Faculty Fellowship Program (EPA/FFP).					
	Applicant Types						
	Funding Limit 0.00 see detail						
	Limited Submission	No					
058601	Research Associateship Progra Biological Center (CCDC CBC)	ms U.S. Army CCDC Chemical National Research Council	01-May-2025	Not Specified			
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator					
	Contact Telephone						
	Contact Email	rap@nas.edu					
	Sponsor Website	<u>Link to sponsor website</u>					
Program URL Link to program URL Deadline Dates (ALL) 01-May-2025 , 01-Aug-2025 , 03-Nov-2025							
						Synopsis	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-

the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career

development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the U.S. Army CCDC Chemical Biological Center (CCDC CBC).

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

Research Associateship Programs -- National Oceanic and 058545 Atmospheric Administration (NOAA)

National Research Council

01-May-2025

Not **Specified**

Contact Name Dr. Tom Jurkiw, NRC Program Administrator

Contact Telephone

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 01-Nov-2025

Synopsis

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-ofthe-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the National Oceanic and Atmospheric Administration (NOAA).

Applicant Types

Funding Limit 0.00 see detail

	Limited Submission	No			
058603	Research Associateship Progra Center (CCDC SC)	ms U.S. Army CCDC Soldier N	lational Research Council	01-May-2025	Not Specified
	Contact Name	Dr. Tom Jurkiw, NRC Program Admin	istrator		
	Contact Telephone				
	Contact Email	rap@nas.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025 , 01-Aug-2025 , 03-Nov	<i>y-</i> 2025		
	Synopsis	provide promising scientists and eng affiliated institutions. These program the-art facilities, and opportunities to	grams (RAP) are prestigious postdoctoral and sen ineers with high-quality research opportunities are offer a comprehensive experience, including most influence government policy, all geared toward ates. This opportunity is for the NRC Research Associated.	t federal laboratorion entorship, access to enhancing the rese	es and o state-of- earch career
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
058572	Research Associateship Progra	ms Naval Postgraduate School N	lational Research Council	01-May-2025	Not Specified

Contact Name Dr. Tom Jurkiw, NRC Program Administrator

Contact Telephone

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 03-Nov-2025

Synopsis

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-ofthe-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the Naval Postgraduate School (NPS).

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

Research Associateship Programs -- U.S. Army Research, 058596 Development & Engineering Command, NVESD (RDEC/NVESD)

National Research Council

01-May-2025

Not Specified

Contact Name Dr. Tom Jurkiw, NRC Program Administrator

Contact Telephone

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 03-Nov-2025

Synopsis

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the U.S. Army Research, Development & Engineering Command, NVESD (RDEC/NVESD).

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

058604 Research Associateship Programs -- U.S. Army Research Laboratory (ARL)

National Research Council

01-May-2025

Not Specified

Contact Name Dr. Tom Jurkiw, NRC Program Administrator

Contact Telephone

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 03-Nov-2025

Synopsi

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career

Army Research Laboratory (ARL). **Applicant Types** Funding Limit 0.00 see detail Limited Submission No Research Associateship Programs -- Air Force Research National Research Council 01-May-2025 80,000 USD Contact Name Tom Jurkiw **Contact Telephone** Contact Email rap@nas.edu

development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the U.S.

058542

Laboratory

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 03-Nov-2025

Synopsis

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-ofthe-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the Air Force Research Laboratory.

Applicant Types

Funding Limit 80,000.00 see detail

Sponsor Website Link to sponsor website Program URL Link to program URL

	Limited Submission	No			
058607	Research Associateship Progra Protection Agency (EPA)	ms U.S. Environmental National Research Council 02	1-May-2025	Not Specified	
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator			
	Contact Telephone				
	Contact Email	rap@nas.edu			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	1-May-2025 , 01-Aug-2025 , 03-Nov-2025			
	Synopsis	The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior of provide promising scientists and engineers with high-quality research opportunities at few affiliated institutions. These programs offer a comprehensive experience, including mento the-art facilities, and opportunities to influence government policy, all geared toward enhanced development of the Research Associates. This opportunity is for the NRC Research Associates Environmental Protection Agency (EPA).	deral laboratorie orship, access to nancing the rese	es and state-of- arch career	
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
058605	Research Associateship Progra (ARO)	ms U.S. Army Research Office National Research Council 03	1-May-2025	Not Specified	
	Contact Name	Dr. Tom Jurkiw, NRC Program Administrator			

Contact Telephone

Contact Email rap@nas.edu

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Aug-2025, 03-Nov-2025

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to

Synopsis

provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. These programs offer a comprehensive experience, including mentorship, access to state-of-the-art facilities, and opportunities to influence government policy, all geared toward enhancing the research career development of the Research Associates. This opportunity is for the NRC Research Associateship Program at the U.S. Army Research Office (ARO).

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

118195 Research Associateship Programs -- National Security Agency

National Research Council

01-May-2025

Not Specified

Contact Name Dr. Thomas Steven Salter Jr.

Contact Telephone 301-935-6474

Contact Email tsalter@lps.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025 , 01-Aug-2025 , 03-Nov-2025

Synopsis

The NRC Research Associateship Programs (RAP) are prestigious postdoctoral and senior research awards designed to provide promising scientists and engineers with high-quality research opportunities at federal laboratories and affiliated institutions. The National Security Agency (NSA) offers a research opportunity for Postdoctoral and Senior applicants.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

116098 Request for Proposals -- Special Projects Fund

New York Health Foundation

04-Mar-2025 [LOI/Pre-App] Not Specified

Contact Name

Contact Telephone 212-664-7656

Contact Email specialprojectsfund@nyhealthfoundation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 04-Mar-2025 [LOI/Pre-App], 15-May-2025

The New York Health Foundation's Special Projects Fund awards are one-time, nonrenewable funding opportunities supporting projects that address important and emerging health care and public health issues that fall outside the Foundation's priority areas of: Healthy Food, Healthy Lives; Primary Care; or Veterans' Health.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission	No		
	I	42 May 2025	E 000 HCD
129577 Graduate Research Grant Seed	North American Spine Society	12-May-2025	5,000 USD
Contact Name			
Contact Telephone	630-230-3694		
Contact Email	research@spine.org		
Sponsor Website	<u>Link to sponsor website</u>		
Program URL	Link to program URL		
Deadline Dates (ALL)	12-May-2025		
Synopsis	In an effort to further promote the development of aspiring spine researche new Graduate Research Seed Grant to award funding up to \$5,000 each to pure credentialed graduate program, pursuing spine-related research. Applicants graduate study program at the time of application, with confirmed mentor/in good-standing. Acceptable graduate and doctoral programs include: MD, spine-related).	promising student(s) enrolle must be enrolled in a crede faculty supervision from a N	d in a ntialed ASS member
Applicant Types			
Funding Limit	5,000.00 maximum		
Limited Submission	No		
088606 Young Investigator Grants	North American Spine Society	12-May-2025	Not Specified
Contact Name Contact Telephone			

Contact Email research@spine.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025

The North American Spine Society (NASS) awards funding to promising Young Investigators to encourage and Synopsis promote quality spine-related research. It is recommended that approved grant budgets range between \$ 20,000-\$ 40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$ 50,000 per year.

Applicant Types

Funding Limit 50,000.00 per year

Limited Submission No

088605 Research Grants

North American Spine Society

12-May-2025 Not
Specified

Contact Name

Contact Telephone 630-230-3694

Contact Email research@spine.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025

The North American Spine Society (NASS) research grants provide funding for promising research projects by qualified Synopsis investigators in the field of spine. It is recommended that approved grant budgets range between \$ 20,000-\$ 40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$ 50,000 per year.

Applicant Types

Funding Limit 50,000.00 per year

Limited Submission No

088607 Nontraditional Nonsurgical Treatment Grants

North American Spine Society

12-May-2025

Not Specified

Contact Name

Contact Telephone 630-230-3694

Contact Email research@spine.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025

The North American Spine Society (NASS) offers the Nontraditional, Nonsurgical Treatment Grant to support research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such back and neck pain and radiculopathy. If TNF-inhibitors other than etanercept are used in research and/or treatment funded, comparison studies using perispinal etanercept in at least as many research subjects or patients should be done. It is recommended that approved grant budgets range between \$ 20,000-\$ 40,000 per year. In rare cases and at the discretion of the committee, each year may be up

Applicant Types

Funding Limit 50,000.00 per year

to \$ 50,000 per year.

Limited Submission No

078645 Research Traveling Fellowship	North American Spine Society	12-May-2025	7,000 USD
Contact Name			
Contact Telephone	630-230-3694		
Contact Email	research@spine.org		
Sponsor Website	<u>Link to sponsor website</u>		
Program URL	Link to program URL		
Deadline Dates (ALL)	12-May-2025		
Synopsis	The Research Traveling Fellowship spans at least five months at one medical centhe applicant currently practices) to participate in a research project.	ter (other than the faci	lity at which
Applicant Types			
Funding Limit	7,000.00 see detail		
Limited Submission	No		
088608 Clinical Traveling Fellowship	North American Spine Society	12-May-2025	7,000 USD
Contact Name			
Contact Telephone	630-230-3691		
Contact Email	research@spine.org		
Sponsor Website	<u>Link to sponsor website</u>		

Program URL Link to program URL

Deadline Dates (ALL) 12-May-2025

Synopsis

The North American Spine Society (NASS) offers the Clinical Traveling Fellowship which spans at least one month to be spent in three to five different medical centers studying spine techniques. The centers selected by the applicant should agree in writing to accept the applicant if he/she receives the Fellowship. The Fellowship primarily covers the costs of travel and housing and typically ranges from \$3,000-\$7,000.

Applicant Types

Funding Limit 7,000.00 see detail

Limited Submission No

SPIN ID	Program Title	I Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
018980	Department of Radiology - Neuroradiology Fellowship	Northwestern University Feinberg School of Medicine		31-May-2025	Not Specified

Contact Name Michelle Bolivar, Program Coordinator

Contact Telephone 312-695-1292

Contact Email michelle.bolivar@nm.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 31-May-2025

The Neuroradiology Fellowship training program at McGaw Medical Center of Northwestern University is an ACGME-Synopsis approved, one-year program based at Northwestern Memorial Hospital (NMH) and the main campus of

Northwestern University Feinberg School of Medicine in the heart of Chicago between North Michigan Avenue and

Lake Michigan. Fellows also rotate at the Ann & Robert H. Lurie Children's Hospital of Chicago. The program is offered to physicians who have completed their radiology residency and are American Board of Radiology boardcertified/eligible. A total of six positions are available.

Applicant Types

Funding Limit 0.00 not provided

Limited Submission No

Infectious Diseases – Catalyst Grants 126442

Novo Nordisk Fonden

07-May-2025

Not Specified

Contact Name Fiona Goldizen

Contact Telephone +45 2061 4825

Contact Email fgo@novo.dk

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

Synopsis

The purpose of the "Infectious Diseases - Catalyst Grants" programme is to provide catalytic funding for exploratory research projects within the thematic research areas pathogenic fungi, novel antimicrobial resistance (AMR) tools, and harnessing innate immunity. Within these thematic areas, the aim is to stimulate Danish research, strengthen international collaborations, and to initiate innovative research projects with exceptional potential for future direct impact on global challenges. Up to DKK 3.5 million per grant for projects with a single applicant (one PI) and up to DKK 6.5 million per grant for collaborative projects (one PI plus one co-PI) may be requested.

Applicant Types

Funding Limit 0.00 see detail

Limitad	Submission	NIA
Limited	Submission	No

	Little a Subitiission		
120814	Ono Pharma Breakthrough So Program	ience Initiative Awards Ono Pharma Foundation	08-May-2025 Not Specified
	Contact Name		
	Contact Telephone		
	Contact Email		
	Sponsor Website	Link to sponsor website	
	Program URL	Link to program URL	
	Deadline Dates (ALL)		
	Synopsis	Annually, the Ono Pharma Foundation considers proposals from P human health.	Is for research that could ultimately transform
	Applicant Types		
	Funding Limit	0.00 see detail	
	Limited Submission	No	
127612	Advanced Research Traineesh	ip Osteology Foundation	01-May-2025 Not Specified
	Contact Name		
	Contact Telephone		
	Contact Email	grants@osteology.org	
	Sponsor Website	Link to sponsor website	
	Program URL	Link to program URL	

Deadline Dates (ALL) 01-May-2025

Synopsis

The Advanced Research Traineeship aims to strengthen the link between research and education through a shortterm, research-based training and learning approach. The core values of this programme are knowledge transfer, collaboration and network building. The objectives are to teach and train individuals on the use of a certain technique, method or model as part of their professional development. A mentor at the receiving organisation provides guidance and shares expertise with the applicant, fostering collaboration at an individual but also institutional level. Overall, the programme shall facilitate transnational and transdisciplinary exchange of knowledge and good practices, and lead to the development of new skills and competencies that the applicant transfers to their home institution and own research projects.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

Broad Pragmatic Studies Funding 038162

Patient-Centered Outcomes Research Institute (PCORI)

06-May-2025

Not Specified

Contact Name

Contact Telephone 202-827-7700

Contact Email pfa@pcori.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025

Synopsis The Patient-Centered Outcomes Research Institute (PCORI) has issued a PCORI Funding Announcement (PFA) inviting applications for high-quality comparative clinical effectiveness research projects. All applications must align the

proposed research with at least one of the National Priorities for Health National Priorities for Health described within the PFA (Increase Evidence for Existing Interventions and Emerging Innovations in Health; Accelerate Progress Toward an Integrated Learning Health System; Achieve Health Equity; or Advance the Science of Dissemination, Implementation and Health Communication). Through this funding opportunity, PCORI intends to commit up to \$160 million for projects of up to 5 years.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

Improving Methods for Conducting Patient-Centered 038157 Comparative Clinical Effectiveness Research

Patient-Centered Outcomes Research Institute (PCORI)

06-May-2025

750,000 USD

Contact Name

Contact Telephone 202-827-7700

Contact Email pfa@pcori.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025

The Patient-Centered Outcomes Research Institute (PCORI) has issued a PCORI Funding Announcement (PFA) with the aim of funding studies that address high-priority methodological gaps in patient-centered comparative clinical Synopsis effectiveness research (CER). PCORI has \$12 million to support successful proposals. They will provide up to \$750,000 for a period of 3 years.

Applicant Types

Funding Limit	750,000.00 maximum
Limited Submission	No

PCORI Funding Announcement (PFA) - Advancing the Patient-Centered Outcomes Research 112400 06-May-2025 Not Specified Science of Engagement (SoE)--Cycle 1 2025 Institute (PCORI) Contact Name Contact Telephone 202-827-7700

> Contact Email sciencequestions@pcori.org Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025

This PCORI Funding Announcement (PFA) seeks to fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research. Techniques that lead to effective engagement in research. How effective engagement techniques should be modified and resourced for different contexts, settings, and communities to ensure equity in engagement and research.

Synopsis PCORI's Science of Engagement in Research PFA will solicit applications that focus on: Development and validation of measures to capture structure/context, process, and outcomes of engagement, for both stakeholders and investigators. Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement in research, particularly for underrepresented populations, and how effectiveness varies by context.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

129138	Topical PCORI Funding Annou	uncement: Managing Pain	Patient-Centered Outcomes Research Institute (PCORI)	06-May-2025	12,000,000 USD
	Contact Name				
	Contact Telephone	202-827-7700			
	Contact Email	info@pcori.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	06-May-2025			
	Synopsis	s to fund high-quality patie interventions to improve p particularly interested in ap and pelvic pain, pain in indicell disease and neuropath allotted up to approximate effectiveness studies that r	comes Research Institute (PCORI) has issued a PCORI ent-centered comparative clinical effectiveness reseatient-centered outcomes for individuals living with pplications focusing on the following Special Areas of ividuals living with limitations in cognitive functioning ic pain. However, eligible applications are not limitedly \$100 million under this PFA to fund high-quality, prespond to research questions of interest. The proposition in direct costs. The maximum allowable	rch (CER) projects that acute and/or chronic pf Emphasis (SAEs): urogg, pain in individuals lid to only these areas. Foatientcentered compased budget for studies	t focus on pain. PCORI is gynecological ving with sickle PCORI has arative clinical under this
	Applicant Types				
	Funding Limit	12,000,000.00 maximum			
	Limited Submission	No			

129276	Topical PCORI Funding Announcement (PFA): Improving Mental and Behavioral Health	Patient-Centered Outcomes Research Institute (PCORI)	06-May-2025	12,000,000 USD
--------	--	--	-------------	-------------------

Contact Name

Contact Telephone 202-827-7700

Contact Email info@pcori.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 06-May-2025

The Patient-Centered Outcomes Research Institute (PCORI) has approximately \$100 million to award up \$12 million over a period of 5 years for high-quality patient-centered comparative clinical effectiveness research (CER) projects that focus on improving mental and behavioral health. This opportunity aims to fund studies comparing two or more approaches for prevention, diagnosis, treatment or care delivery related to mental and behavioral health conditions. Studies should address a critical clinical or care delivery problem. Proposed comparators must have well documented evidence of efficacy and/or widespread use, as demonstrated by prior research, systematic reviews and/or clinical guidelines. Studies should include evidence-based, impactful, patient-centered outcomes as indicated by patients, families and caregivers (particularly those with lived experience) from the population of interest, as well as relevant members of the broader health and healthcare community. At least one primary outcome should be a mental health outcome. Clinically meaningful outcomes (e.g., no longer meeting diagnostic criteria or using patient-centered minimum clinically important differences) are encouraged, as well as longer-term follow-up (e.g., 12 months) that allows for the measurement of recovery from and recurrence of mental health symptoms. Applicants should consider, as appropriate, the full range of clinical and patient-centered outcomes data related to mental and behavioral health that are relevant to patients and other stakeholders. PCORI's Principles for the Consideration of the

Synopsis

		_	ata in PCORI-Funded Research inform the expect of applications submitted in response to this PFA	• • •	the
	Applicant Types				
	Funding Limit	12,000,000.00 maximum			
	Limited Submission	No			
036538	Postdoctoral Fellowships - De	epartment III	Planck (Max) Institute for the History of Science	01-May-2025	Not Specified
	Contact Name				
	Contact Telephone	(+4930) 22667-0			
	Contact Email	career@mpiwg-berlin.mp	<u>g.de</u>		
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-May-2025 , 01-Nov-20	25		
			for the History of Science, Berlin, Department III: seeks one Postdoctoral Fellow for three years, w 024.		-
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
007309	Prince Mahidol Award		Prince Mahidol Award Foundation	31-May-2025	100,000 USD

Contact Name

Contact Telephone 662-418-2568

Contact Email pmaf@mahidol.ac.th

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 31-May-2025

The Prince Mahidol Award is presented to individual(s) or institution(s) for their outstanding performance and/or synopsis research that contributes directly to the betterment of society. Two Prince Mahidol Awards will be conferred on an annual basis, one in medicine and one in public health, each prize consists of a medal, a certificate, and \$US 100,000.

Applicant Types

Funding Limit 100,000.00 see detail

Limited Submission No

117570 Innovation in PH Research Award

Pulmonary Hypertension Association

07-May-2025

120,000 USD

Contact Name

Contact Telephone

Contact Email Research@PHAssociation.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025

	Synopsis	The award supports new areas of PH research that couldn't have been innovative pulmonary hypertension research will be accepted. Up to \$6	explored without PHA fundin 60,000 a year for two years is	ig. Any areas of available.
	Applicant Types			
	Funding Limit	60,000.00 per year		
	Limited Submission	No		
037845	Early Career Research Grant S	cheme Regional Studies Association	12-May-2025 [LOI/Pre-App]	12,600 USD
	Contact Name			
	Contact Telephone	+44 (0)1273 698 017		
	Contact Email	ecgrant@regionalstudies.org		
	Sponsor Website	Link to sponsor website		
	Program URL	Link to program URL		
	Deadline Dates (ALL)	12-May-2025 [LOI/Pre-App]		
	Synopsis	The Regional Studies Association Early Career Awards are provided to sand/or regional science research. This scheme is only available to post-certificate on the date of Expression of Interest deadline at the latest.	doctoral researchers who ha	ve received their
	Applicant Types			
	Funding Limit	10,000.00 maximum		
	Limited Submission	No		
063215	Lawren H. Daltroy Preceptors Communciation	Rheumatology Research Foundation	01-May-2025	15,000 USD

Contact Name

Contact Telephone 404-365-1373

Contact Email foundation@rheumatology.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 01-May-2025, 01-Nov-2025

Synopsis The Lawren H. Daltroy Preceptorship in Health Communication was established with the aim of improving patient-clinician interactions and communications.

Applicant Types

Funding Limit 15,000.00 maximum

Limited Submission No

104673 Health Professional Online Education Grant

Rheumatology Research Foundation

03-May-2025

Not Specified

Contact Name

Contact Telephone 404-365-1373

Contact Email Foundation@rheumatology.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 03-May-2025, 01-Aug-2025, 01-Nov-2025

Synopsis The Rheumatology Research Foundation offers a Health Professional Online Education Grant for non-physician rheumatology health professionals to complete the Advanced Rheumatology Course.

Applicant Types

Funding Limit 0.00 see detail

Contact Telephone 414-289-9107

Limited Submission No

053501	First Year Graduate Fellowshi	P. Rho Chi Society	01-May-2025	7,500 USD
	Contact Name			
	Contact Telephone	734-615-4898		
	Contact Email	RhoChiSociety@umich.edu		
	Sponsor Website	<u>Link to sponsor website</u>		
	Program URL	Link to program URL		
	Deadline Dates (ALL)	01-May-2025		
	Synopsis	Generally, one First Year Graduate Fellowship is awarded annually to a stude study. It shall be the policy of The Rho Chi Society to award on an annual bas AFPE First-Year Graduate Fellowship, a cash award of \$7,500.		
	Applicant Types			
	Funding Limit	7,500.00 maximum		
	Limited Submission	No		
117571	SRS-Cotrel Foundation Resea	Scoliosis Research Society	15-Mar-2025 [LOI/Pre-App]	50,000 USD
-	Contact Name	Laura Pizur		

Contact Email | Ipizur@srs.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-Mar-2025 [LOI/Pre-App], 15-May-2025

Synopsis The SRS-Cotrel Foundation basic science research grant is conceived to support projects that will be performing work in Pediatric Scoliosis. Awards of up to \$25,000 per year for a maximum of two years may be requested.

Applicant Types

Funding Limit 25,000.00 per year

Limited Submission No

089202 <u>Standard Research Grant</u> Scoliosis Research Society 15-Mar-2025 [LOI/Pre-App]

Contact Name

Contact Telephone 414-289-9107

Contact Email info@srs.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-Mar-2025 [LOI/Pre-App], 15-May-2025

The expectation for a standard research grant is that the successfully completed project would be of a quality of a well-received podium presentation at the SRS Annual Meeting. The Society expects that these grants will lay the foundation for a sustained avenue of investigation and allow the investigator(s) to seek larger grants from sources such as the NIH or OREF. Investigators and consortia that have an ongoing study in this category will not be

considered for additional funding until their funded project is complete, regardless of whether or not their new application is for a different avenue of investigation. Up to 2 years will be supported. Up to \$37,500 per year may be requested (max \$75,000 total). Applications requesting more than \$25,000 per year should spend additional effort to justify the request. Up to 2-3 grants will be awarded each cycle.

Applicant Types

Funding Limit 37,500.00 per year

Limited Submission No

026705 PhD in Agrobiodiversity Scuola Superiore Sant'Anna

15-May-2025

Not Specified

Contact Name

Contact Telephone +39 050 882604

Contact Email info-phdlifesciences@santannapisa.it

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 15-May-2025

The goal of this four-year PhD Programme is to enhance human resource capacities in the use and management of Synopsis genetic variation in agricultural and natural systems, to improve the sustainability of agricultural systems and the conservation of genetic resources for the well-being of present and future generations. The annual budget for each student includes a scholarship and an additional housing contribution.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

023638	Janett Rosenburg Trubatch Co	areer Development Award	Society for Neuroscience	08-May-2025	2,000 USD
	Contact Name				
	Contact Telephone	202-962-4000			
	Contact Email	awards@sfn.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-May-2025			
		_	atch Career Development Award recognizes origin cademic transitions prior to tenure. Two recipient to SfN's annual meeting.	·	
	Applicant Types				
	Funding Limit	2,000.00 see detail			
		No			
	Limited Submission	110			
082867	Changemakers in Family Plan	l	Society of Family Planning	20-May-2025	Not Specified
082867		ning	Society of Family Planning	20-May-2025	Not Specified
082867	Changemakers in Family Plan	ning	Society of Family Planning	20-May-2025	Not Specified
082867	Changemakers in Family Plan Contact Name Contact Telephone	ning	Society of Family Planning	20-May-2025	Not Specified
082867	Changemakers in Family Plan Contact Name Contact Telephone Contact Email	ning	Society of Family Planning	20-May-2025	Not Specified
082867	Changemakers in Family Plan Contact Name Contact Telephone Contact Email Sponsor Website	ning Grants@SocietyFP.org	Society of Family Planning	20-May-2025	Not Specified

Synopsis

The Society of Family Planning is seeking to convene a diverse, equitable, inclusive, and multidisciplinary community of all engaged in the science of abortion and contraception. Underlying this strategy is the knowledge that the full participation of scholars of color is essential to pursuing the ambitious vision of just and equitable abortion and contraception informed by science.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

029965 Conferences Support

Thyssen (Fritz) Foundation

28-Feb-2025

Not Specified

Contact Name

Contact Telephone +49 221 27 74 96 0

Contact Email fts@fritz-thyssen-stiftung.de

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 28-Feb-2025, 21-May-2025, 31-Aug-2025, 30-Nov-2025

The Fritz Thyssen Foundation supports scholarly events, in particular national and international conferences with the Synopsis aim of facilitating the discussion and analysis of specific scholarly questions as well as fostering cooperation and networking of scholars working in the same field or on interdisciplinary topics.

Applicant Types

Funding Limit 0.00 see detail

Limited Submission No

017055	Neuroradiology Fellowship	Weill (Joan and Sanford I.) Medical College of Cornell University	31-May-2025	123,000 USD
	Contact Name	Karishma Patel, Program Coordinator and Education Specialist		
	Contact Telephone			
	Contact Email	kap4015@med.cornell.edu		
	Sponsor Website	<u>Link to sponsor website</u>		
	Program URL	Link to program URL		
	Deadline Dates (ALL)	31-May-2025		
	Synopsis	The Neuroradiology division offers a one-year ACGME-accredited diagnostic N Presbyterian Hospital/Weill Cornell Medicine (NYPH/WCM) with an option for training. NewYork-Presbyterian Hospital is the top hospital in New York and or ranked by US News and World Report. Furthermore, the hospital is ranked #4 Neurosurgery research and clinical care. Weill Cornell Medicine is a top 10 me one of the premier radiology training programs in the country.	a secondary-year of s ne of the top hospital nationally for Neurolo	ubspecialty s nationally as ogy and
	Applicant Types			
	Funding Limit	123,000.00 see detail		
	Limited Submission	No		